





Novel insights into the clinical 
heterogeneity and treatment of 
chronic lymphocytic leukaemia 
 
 
Marwan Cheng Kuang Kwok 
BSc (Hons) Lond, MB ChB Leeds, MRCP (UK) 
 
 
A thesis submitted to the 
University of Birmingham for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
Institute of Cancer and Genomic Sciences 
College of Medical and Dental Sciences 
University of Birmingham 















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 











Chronic lymphocytic leukaemia (CLL) is characterised by marked disease 
heterogeneity and is currently incurable. While clinical outcome has improved with 
chemoimmunotherapy, B cell receptor (BCR) signalling inhibitors and Bcl-2 inhibitors, some 
patients, particularly those with poor-risk features such as TP53 or ATM defects, eventually 
relapse from these agents and die from CLL. Hence, the development of new CLL treatment 
approaches is still needed. This thesis presents work undertaken to discover novel biological 
and therapeutic insights through the characterisation of patients with spontaneous CLL 
regression, the evaluation of ATR inhibition as a therapeutic strategy, and the assessment of 
the impact of post-treatment minimal residual disease (MRD) in CLL.  
Spontaneous regression occurs in less than 2% of CLL cases and the features that 
underpin this rare event remain largely unknown. The first part of this thesis describes an 
investigation into the features of 19 individuals who underwent spontaneous CLL regression. 
CLL tumours that have undergone spontaneous regression express somatically mutated 
immunoglobulin genes, demonstrate short telomeres and a phenotype of clonal anergy with 
unresponsiveness to both IgM and IgD BCR stimulation. Other phenotypic features include 
reduced CD49d and ROR1 expression, and increased FasR expression. This profile 
suggests a model in which the CLL clone undergoes an initial period of proliferation which 
subsequently subside into a state of anergy and low proliferation. Genomic analysis 
revealed that spontaneous regression can occur in the presence of genomic alterations 
including TP53 mutations. These findings identify spontaneous CLL regression as a unique 
subset of CLL and support the use of BCR signalling inhibition for the treatment of CLL. 
TP53 and ataxia telangiectasia mutated (ATM) defects are associated with genomic 
instability and chemoresistance in CLL, and therapies capable of providing durable 
remissions in refractory TP53 or ATM defective CLL are limited. The second part of this 
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thesis describes a study investigating ataxia telangiectasia and Rad3 related (ATR) inhibition 
as a synthetically lethal strategy to target CLL cells with TP53 or ATM defects, using a 
highly-specific ATR inhibitor AZD6738. Irrespective of TP53 or ATM status, induction of CLL 
cell proliferation upregulated ATR protein, which then became activated in response to 
replication stress. In TP53 or ATM defective CLL cells, inhibition of ATR signalling led to an 
accumulation of unrepaired DNA damage, which was carried through into mitosis due to 
defective cell cycle checkpoints, resulting in cell death by mitotic catastrophe. Consequently, 
ATR inhibition was selectively cytotoxic to both TP53 and ATM defective CLL cell lines and 
primary cells. This was confirmed in vivo using primary xenograft models of TP53 or ATM 
defective CLL, where treatment with ATR inhibitor resulted in decreased tumour load and 
reduction in the proportion of CLL cells with such defects. Moreover, ATR inhibition 
sensitised TP53 or ATM defective primary CLL cells to chemotherapy and ibrutinib. These 
findings suggest that ATR is a promising therapeutic target for TP53 or ATM defective CLL 
that warrants clinical investigation. 
The long-term prognostic value of MRD status in therapeutic settings other than 
frontline chemoimmunotherapy is unclear. The final part of this thesis presents a 
retrospective analysis of all patients from a single institution who achieved at least a partial 
response with various therapies between 1996 and 2007, and received a bone marrow MRD 
assessment at the end of treatment. MRD negativity correlated with both progression-free 
survival (PFS) and overall survival (OS) independent of the type and line of treatment, as 
well as known prognostic factors including adverse cytogenetics. The greatest impact of 
achieving MRD negativity was seen in patients receiving frontline treatment, with 10-year 
PFS of 65% vs 10% and 10-year OS of 70% vs 30% for MRD-negative vs positive patients. 
These results demonstrate the long-term benefit of achieving MRD negativity regardless of 
the therapeutic setting and treatment modality, and support its use as a prognostic marker 
for long-term PFS and as a potential therapeutic goal in CLL.  
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EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
ETAA1 Ewing’s tumor-associated antigen 1 
FANCM Fanconi anaemia complementation group M protein 
FBS foetal bovine serum 
FC fludarabine and cyclophosphamide 
FCMR FCR plus mitoxantrone 
FCR fludarabine, cyclophosphamide and rituximab 
FISH fluorescent in situ hybridisation 
FOXO forkhead box O 
FSC forward scatter 
FSC-A FSC-area 
FSC-H FSC-height 
GATK Genome Analysis Tool Kit 
GlyCAM-1 glycosylation dependent cell adhesion molecule 1 
HLA histocompatibility leukocyte antigen 
HR hazard ratio 
HRR homologous recombination repair 
HU hydroxyurea 
ICGC International Cancer Genome Consortium 
IGH immunoglobulin heavy chain 
IGHV immunoglobulin heavy chain variable region 
indel small insertions and deletions 
IP3 inositol-1,4,5-triphosphate 
IR ionising radiation 
IWCLL International Workshop on CLL 
Jnk c-Jun N-terminal kinase 
LAIR1 leucocyte associated immunoglobulin like receptor 1 
mAb monoclonal antibodies 
MACS magnetic-activated cell sorting 
MAdCAM-1 mucosal vascular addressin cell adhesion molecule 1 
MBL monoclonal B cell lymphocytosis 
M-CLL CLL with mutated IGHV 
MDM2 mouse double minute 2 homologue 
MDR minimally deleted region 
MEK mitogen activated protein kinase kinase 
MHC major histocompatibility complex 
MRD minimal residual disease 
MRN MRE11-RAD50-NBS1 complex 
mRNA messenger RNA 
mTOR mechanistic target of rapamycin 
NBS1 nibrin 
NFAT nuclear factor of activated T cells 
NGS next generation sequencing 
NHEJ non-homologous end joining 
NHS National Health Service (UK) 
NOG NOD/Shi-scid/IL-2Rγ 
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nPR nodular PR 
OS overall survival 
PARP poly (ADP-ribose) polymerase 
PBMC peripheral blood mononuclear cell 
PBS phosphate-buffered saline 
PCR polymerase-chain reaction 
PD-L1 programmed death-ligand 1 
PECAM-1 platelet endothelial cell adhesion molecule 1 
PFS progression-free survival 
pH3 phosphohistone H3 ser-10 
PI3K phosphoinositide 3-kinase 
PIKK phosphoinositide 3-kinase related kinase 
PKC protein kinase C 
PLCγ2 phospholipase C-γ2 
PR partial response 
Rb retinoblastoma 
REC research ethics committee 
RIC reduced intensity conditioning 
RPA Replication protein A 
RS Richter syndrome 
SCT haematopoietic stem cell transplantation 
SDS sodium dodecyl sulphate 
SHIP1 SH2 domain inositol 5-phosphatase 1 
SHM somatic hypermutation 
SHP-1 SH2-containing tyrosine phosphatase-1 
sIgD surface IgD 
sIgM surface IgM 
SMC1 structural maintenance of chromosomes protein 1 
SNP single nucleotide polymorphism 
SNV single nucleotide variants 
SSC side scatter 
ssDNA single-stranded DNA 
Syk spleen tyrosine kinase 
TCR T cell receptor 
TEMED tetramethylethylenediamine 
TFS treatment-free survival 
TLR toll-like receptor 
TOPBP1 topoisomerase 2-binding protein 1 
TRAP telomeric repeat amplification protocol 
TTFT time to first treatment 
U-CLL CLL with unmutated IGHV 
UTB urea/Tris buffer 
VCAM-1 vascular cell adhesion protein 1 
VEP variant effect predictor 
VAF variant allelic fraction 
VLA-4 very late antigen-4 
WES whole exome sequencing 
WGS whole genome sequencing 
WRN Werner syndrome ATP-dependent helicase 
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1.1. Chronic Lymphocytic Leukaemia  
 
1.1.1. Epidemiological features 
 Chronic lymphocytic leukaemia (CLL) is a clonal lymphoproliferative disorder of 
mature B lymphocytes (Chiorazzi et al., 2005; Fabbri and Dalla-Favera, 2016). As the most 
common haematological malignancy in the Western world, CLL has an incidence of 3,515 
cases in the United Kingdom in 2011, contributing to 37% of all new cases of leukaemia 
diagnosed that year (Cancer Research UK). The aetiology of CLL, like many other 
haematological malignancies, is not clearly defined, although a combination of genetic and 
environmental factors are likely to be involved. Up to 10% of CLL cases have a familial 
association, suggesting a strong genetic role in the pathogenesis of this disease (Slager et 
al., 2013).  
CLL has a predilection for elderly individuals with the median age of diagnosis being 
around 70 and the majority of patients diagnosed between 60 to 80 years of age. It is 
uncommon in individuals aged 40 or below, with incidence rising with increasing age beyond 
the 45-49 year age group. CLL is more prevalent in males, with a male:female ratio of 
approximately 2:1. For reasons as yet unclear, CLL is most common among Caucasians, 
less prevalent in Afro-Caribbean or South Asian populations, and rare in East Asia. It has 
been postulated that a combination of genetic susceptibility and immune predisposition may 
potentially account for such a difference, with a lower incidence in Asian populations of 
single nucleotide polymorphisms (SNP) within gene susceptibility loci associated with CLL, 
and substantial differences in immunoglobulin heavy chain (IGHV) gene usage in these 
populations compared to Caucasians (Yang et al., 2015).  
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1.1.2 Clinical Features  
 CLL is a clinically heterogeneous disease with clinical course varying greatly among 
patients. The majority of patients are referred with incidental findings of unexplained 
lymphocytosis. Others may present with lymphadenopathy and/or hepatosplenomegaly due 
to infiltration of CLL cells in these lymphoreticular organs. Patients with more progressive 
disease might experience B-symptoms, characterised by night sweats, fever and weight 
loss. Infiltration of bone marrow with malignant lymphocytes would result in bone marrow 
failure with consequential development of anaemia, thrombocytopenia (leading to 
haemorrhage or bruising) and/or neutropenia (leading to enhanced susceptibility to 
infection). Finally, autoimmune haemolytic anaemia, or less commonly, thrombocytopenia, is 
also a feature of CLL. Whereas many individuals experience an indolent course for many 
years without the need for treatment, others have a rapidly progressive course with poor 
response to therapy.  
 Diagnosis of CLL relies on examination of the peripheral blood film, which typically 
reveals the accumulation of small, round lymphocytes with scant cytoplasm and the 
presence of smear cells. The diagnosis is then confirmed by assessment of the peripheral 
blood immunophenotype using multiparameter flow cytometry. In CLL, this would reveal a 
monoclonal (light-chain restricted) population of CD19, CD5 and CD23 positive cells, with 
low expression of CD20 and CD79b, and negativity for FMC7 and CD10 (Rawstron et al., 
2017). In accordance with the International Workshop on CLL (IWCLL) guidelines, a 
diagnosis of CLL mandates the presence of at least 5 x 109 lymphocytes per litre in the 
peripheral blood, together with the appropriate immunophenotype and evidence of clonality 
established by flow cytometry (Hallek et al., 2008).  
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1.1.3. Natural history and clinical heterogeneity of CLL 
 It is now recognised that CLL is invariably preceded by monoclonal B cell 
lymphocytosis (MBL), defined as the asymptomatic expansion of a monoclonal B 
lymphocyte population to a maximum of 5 x 109 B cells/L in the peripheral blood (Landgren 
et al., 2009). The prevalence of MBL is estimated to be in the range of 3-5% among the 
general population aged 50 years or above, and rises with increasing age. The prevalence 
of MBL is also substantially higher among first-degree relatives of patients with familial or 
sporadic CLL (Strati and Shanafelt, 2015).  
In a previous study I contributed to where we monitored a cohort of 185 individuals 
with CLL-phenotype MBL, we discovered that the risk of progressive lymphocytosis was 
dependent on the presentation B cell count. Progressive lymphocytosis was unlikely in 
subjects having a presentation B lymphocyte count below 1.9 x 109/L, and much more 
commonly among those with >4 x 109 B cells/L, where the 5-year risk was >30%. The risk of 
progression to CLL in individuals with MBL presenting with lymphocytosis was estimated to 
be 1-2% per year (Rawstron et al., 2008). Further studies led to segregation of MBL cases 
into distinct low count (<0.5 x 109 B cells/L) and high count (0.5-5 x 109 B cells/L) groups, 
where progression from low-count MBL to CLL is very unusual (Strati and Shanafelt, 2015). 
High-count MBL, on the other hand, display the full spectrum of cytogenetic aberrations 
seen in CLL, and more recently has been shown to harbour mutations commonly found in 
CLL. Moreover, subclonal expansion of CLL driver mutations was found in a proportion of 
high-count MBL cases, indicating evolution from MBL into CLL (Barrio et al., 2017).  
 Among patients who progress from MBL to CLL, the subsequent clinical course is 
heterogeneous. The majority of patients with CLL display an indolent disease course, 
characterised by blood lymphocyte counts that remain largely unchanged (Figure 1.1A) or 
increasing slowly over time (Figure 1.1B). These individuals are often asymptomatic, and 
typically do not require treatment. Many of these individuals lead a normal life expectancy,







The clinical heterogeneity of CLL.  The majority of patients with CLL have stable (A) or 
slowly progressing (B) disease that does not require treatment at diagnosis. A substantial 
minority have relapse/refractory disease (C). Spontaneous CLL regression (D) occurs very 
rarely. The percentages quoted are rough estimates of the proportion of within each 
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and eventually succumb to other acute illnesses or co-morbidities. On the other hand, a 
substantial proportion of patients develop progressive CLL. This is characterised by rapidly 
rising peripheral blood lymphocyte count, typically doubling within 6 months or less, together 
with features such as progressive B-symptoms and/or adenopathy, and the development of 
cytopenias resulting from bone marrow infiltration. These patients typically require imminent 
treatment. While most respond to first-line therapies, many eventually relapse. Those who 
relapse proceed to second-line treatments, but the durability of remission often decreases 
with each additional treatment. Most of these patients eventually die from a CLL-related 
cause, either from CLL itself, from its complications such as infections exacerbated by 
disease-related immunosuppression, or from treatment-related toxicities (Figure 1.1C). Very 
rarely, patients with CLL undergo spontaneous disease regression, characterised by a 
sustained reduction or resolution of lymphocytosis and adenopathy over time without 
treatment (Figure 1.1D). Spontaneous disease regression is estimated to occur in less than 
1-2% of patients with CLL.  
   This clinical heterogeneity of CLL is reflected in the clinical staging systems 
devised by Kanti Rai in 1975 and Jacques-Louis Binet in 1981 which remain in routine use 
today (Binet et al., 1981; Rai et al., 1975). In the Rai staging system, patients are 
categorised into 5 stages (0 to IV) of increasing risk of disease progression. Differentiation 
into the 5 stages are based on the presence, or otherwise, of lymphadenopathy (stage I) and 
splenomegaly (stage II), as well as anaemia (stage III) and thrombocytopenia (stage IV), 
with stage 0 characterised by the absence of any of these features The Binet staging system 
utilises a similar criteria. Patients are classified into three stages (A, B and C) of worsening 
prognosis, according to the extent of adenopathy and the presence or absence of 
cytopenias. Stage A and B patients have adenopathy involving <3 or ≥3 anatomical areas, 
respectively, and no cytopenias, whereas those with stage C disease have anaemia and/or 
thrombocytopenia. At the time of publication, the median overall survival (OS) was not 
reached at 10 years of follow up for stage A patients, and 7 years and 2 years respectively 
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for those in stage B and C. Although survival figures have vastly improved over the ensuing 
years, the differences in outcomes of these patients serve as a reminder of the disease 
heterogeneity of CLL.  
  Finally, disease transformation from CLL to an aggressive lymphoma, known as 
Richter syndrome (RS), is a recognised sequelae of CLL, and occurs in 5-10% of CLL 
patients. The majority of these patients transform to diffuse large B-cell lymphoma (DLBCL), 
although occasionally patients can transform into Hodgkin’s lymphoma. DLBCL arising in 
this context can either be clonally related to the pre-existing CLL, or unrelated (de novo). 
Patients progressing to Richter’s syndrome with clonally-related DLBCL transformations 
have universally poor prognosis, with a median survival of 8-14 months (Parikh et al., 2014). 
Despite recent therapeutic advances in CLL, effective treatment options for this category of 
patients are currently limited.    
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1.2. The Biological Basis of Disease Heterogeneity in CLL 
 
1.2.1. An overview of CLL pathogenesis 
1.2.1.1. CLL cellular origin and pathogenesis 
 Healthy B cells originate from pluripotent haematopoietic stem cells, which 
differentiate into committed common lymphoid progenitors and thence into pro-B cells. In the 
bone marrow, pro-B cells develop through the pre-B cell stage into immature B cells. During 
this developmental process, pro-B cells undergo recombination of specific gene segments 
encoding the immunoglobulin variable regions. For instance, within the gene locus encoding 
the immunoglobulin heavy chain, this involves recombining a VH, a DH and a JH segment 
from multiple VH, DH and JH segments to enable generation of B cell receptors (BCR) of 
diverse specificities (i.e. V(D)J recombination). Immature B cells with BCR that recognise 
foreign antigens are positively selected, whereas self reactive B cells undergo receptor 
editing, or are eliminated through clonal deletion. Immature B cells subsequently exit the 
bone marrow into the peripheral blood, initially as transitional (naïve) B cells expressing both 
IgM and IgD (Cooper, 2015).  
Following exposure to antigen, naïve B cells become activated, migrate to lymph 
nodes, and mature to become follicular or marginal zone B cells. The generation of memory 
and antibody-producing plasma cells from follicular B cells occur through a T-cell and 
germinal centre dependent pathway. Upon receiving co-stimulatory signals from antigen-
activated T cells, B cells proliferate and differentiate into memory cells and plasma cells of 
different isotypes. A substantial proportion of these B cells enter germinal centres within 
lymph nodes where they undergo somatic hypermutation (SHM) of their immunoglobulin 
variable region genes to enable further BCR diversification. Upon an additional T-cell 
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mediated selection process known as affinity maturation, selected B cell clones with the 
highest antigenic affinity undergo differentiation into memory and plasma cells. On the other 
hand, memory cells and plasma cells are generated from marginal zone B cells through an 
alternative pathway that is independent of germinal centre reaction and interaction with T 
cells (De Silva and Klein, 2015; Kurosaki et al., 2015).  
 Analysis of genes encoding the immunoglobulin heavy chain variable region (IGHV) 
in CLL cells revealed that in some patients the IGHV genes have undergone SHM, whereas 
in others they have not (Damle et al., 1999; Fais et al., 1998; Hamblin et al., 1999). This 
indicates that in patients with hypermutated IGHV (M-CLL), the likely normal counterpart to 
the CLL cell would be a post-germinal centre B cell, whereas in patients with unmutated 
IGHV (U-CLL), this would be a pre-germinal centre B cell. In an attempt to identify the 
cellular origin of CLL cells, studies were conducted to compare the gene expression profiles 
of patients with M-CLL and U-CLL against those of different normal human B cell subsets. 
The gene expression profiles of M-CLL and U-CLL were found to be largely similar, and 
displayed the highest similarity to memory B cells (Klein et al., 2001; Rosenwald et al., 
2001). A subsequent gene expression study showed that both M-CLL and U-CLL are likely 
to be derived from normal mature CD5+ B cells (Seifert et al., 2012). On the other hand, 
work comparing the methylomes of CLL cells with healthy B cell subsets indicates that M-
CLL and U-CLL are epigenetically distinct, with methylome of M-CLL and U-CLL being 
related to memory B cells and naïve B cells respectively (Kulis et al., 2012). Thus, the exact 
cellular derivation of CLL remains contentious, with M-CLL likely originating from germinal 
centre dependent memory B cells, and U-CLL either from naïve B cells or germinal centre 
independent memory B cells.  
 Whereas CLL is seen as a malignancy of mature B cells (either memory or naïve) 
based on shared immunophenotypes, gene expression profiles and methylomes as outlined 
above, evidence from two recent studies have provided speculation that the CLL initiating 
event could occur much earlier in the B cell developmental process, possibly at the level of 
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the haematopoietic stem cell. In one study, CD34+ haematopoietic stem cells were isolated 
from the bone marrow of patients with CLL, and then engrafted into immunodeficient mice. 
These xenografts displayed increased B lymphoid haematopoiesis, eventually developing 
into a condition akin to MBL. This was characterised by B cell monoclonality or oligoclonality, 
CD5 expression, IGHV SHM and the usage of VH, DH and JH gene segment combinations 
commonly seen in high-count MBL and CLL, but distinct from that of the original CLL clone 
from which these xenografts were derived (Kikushige et al., 2011). Although no CLL-
associated cytogenetic abnormality was detected in the CD34+ haematopoietic stem cell 
compartment in these CLL patients, a second study utilising deep targeted next generation 
sequencing (NGS) demonstrated that mutations present in the CLL clone were also present 
in CD34+ cells, albeit at a much lower mutant allelic frequency (Damm et al., 2014). 
These observations suggest that CLL pathogenesis could begin early during 
lymphoid development. However, the subsequent development of MBL and the progression 
from MBL to CLL is contingent on the acquisition of the various cancer hallmarks, 
particularly that of apoptotic resistance and enhanced proliferation of the malignant lymphoid 
cells (Hanahan and Weinberg, 2011). In CLL, a large body of evidence suggests that this is 
dependent on several factors: (1) antigen-driven BCR signalling; (2) the interaction of CLL 
cells with different components of the microenvironment; and (3) the progressive 
accumulation of genetic lesions (Figure 2). The nature of BCR signalling (section 1.2.2), 
microenvironmental interactions (section 1.2.3) and genetic aberrations (section 1.2.4) not 
only influence the development of CLL but also dictate its subsequent clinical course, and 
account for the enormous disease heterogeneity that is characteristic of this malignancy.  
 
1.2.1.2. CLL as a disease of failed apoptosis 
 Historically, CLL is viewed as a pathological accumulation of non-proliferative B-
lymphocytes due a failure to undergo apoptosis. Apoptosis is mediated through either the






Drivers of CLL pathogenesis and progression.  The determinants of CLL pathogenesis 
and subsequent disease progression are summarised in this schematic diagram. These 
include BCR signalling, overexpression of anti-apoptotic proteins (e.g. Bcl-2), 
microenvironmental interactions and genomic aberrations (e.g. TP53 or ATM defects).     
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extrinsic pathway or the intrinsic pathway, both resulting in caspase activation which leads to 
cell death. The extrinsic pathway is activated through the binding of death ligands (e.g. Fas 
ligand, TRAIL and TNFα) to their respective cell surface receptors (i.e. Fas/CD95, TRAIL 
receptor/DR4 and TNFα receptor), leading to caspase activation. The intrinsic pathway, on 
the other hand, is regulated through antiapoptotic proteins (e.g. Bcl-2, Bcl-XL and Mcl-1) and 
proapoptotic proteins (e.g. Bim, Bid and Puma). Proapoptotic proteins are activated in the 
presence of cellular stress such as DNA damage. Once activated, proapoptotic proteins bind 
to and inactivate antiapoptotic proteins, the latter of which constrain the activity of two 
essential mediators of the intrinsic apoptotic pathway: Bax and Bak. The balance between 
the activity of antiapoptotic and proapoptotic proteins determines the outcome of this 
apoptotic pathway. When a threshold of proapoptotic activity is exceeded, Bax and Bak 
together induce the permeabilisation of mitochondrial membrane, allowing efflux of 
cytochrome c from the mitochondria to the cytoplasm. Cytochrome c in turn triggers a 
cascade of caspase activation (Taylor et al., 2008).   
 Indeed, a high level of Bcl-2 expression, relative to normal B cells, is a 
characteristic of most CLL cells (Faderl et al., 2002). The mechanism through which Bcl-2 is 
overexpressed in CLL cells, however, has not been thoroughly elucidated. An early study of 
the methylation status of BCL2 showed widespread demethylation of both copies of the 
BCL2 gene in 20 cases of CLL, indicating that epigenetic derepression of BCL2 could 
contribute to an overexpression of the Bcl-2 protein in CLL cells (Hanada et al., 1993). In 
addition, there have been suggestions that Bcl-2 overexpression might be due to the loss of 
the microRNA miR15a/16-1. In two-thirds of CLL cases, miR15a/16-1 expression has been 
shown to be downregulated due to a deletion of chromosome 13q14.2 where miR15a/16-1 is 
located (discussed in section 1.2.4.3), or to an inactivating mutation of miR15a/16-1 (Calin et 
al., 2002; Calin et al., 2005). MicroRNAs are small non-coding RNA molecules that post-
transcriptionally regulate gene expression by binding to and silencing specific mRNAs. In 
human megakaryocytic cell lines, transfection of miR15a/16-1 was shown to suppress Bcl-2 
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levels, suggesting the reverse could possibly occur in CLL cells, leading to apoptotic 
resistance (Cimmino et al., 2005).   
 In addition to Bcl-2 overexpression, recent studies have shown that Mcl-1 can also 
be overexpressed in CLL (Awan et al., 2009; Pepper et al., 2008). Furthermore, the 
acquisition of inactivating TP53 mutations provides yet another means through which CLL 
cells can evade apoptosis (Zenz et al., 2010a). Nuclear p53 transcriptionally activates 
proapoptotic proteins and represses antiapoptotic proteins in response to DNA damage. 
Cytoplasmic p53 also induces Bax/Bak activation and suppresses Bcl-2 and Bcl-XL activity 
(Amaral et al., 2010). Thus, the loss of p53 function enables CLL cells to continue to survive 
despite acquisition of deleterious and genomically destabilising DNA lesions. Finally, CLL 
cells engage in BCR signalling (section 1.2.2) and interact with accessory cells in the 
microenvironment (section 1.2.3), both of which play an important role in supporting CLL cell 
survival.     
 
1.2.1.3. CLL as a proliferative malignancy 
 To view CLL merely as a disease arising from the accumulation of lymphocytes that 
have failed apoptosis, however, ignores the substantial level of CLL proliferative activity 
seen in many patients with this condition, as well as the importance of CLL proliferation in 
shaping their clinical course. The proliferative activity of CLL is most vividly captured by in 
vivo isotope labelling studies. In an important study by Messmer and colleagues, patients 
with CLL were given daily deuterated water, allowing incorporation of deuterium into newly 
synthesised DNA within dividing cells, which can then be measured through regular blood 
sampling. In a cohort of 19 CLL patients, CLL cells were found be born at a rate of 0.11% to 
1.76% per day. The highest birth rates were found among patients with progressive CLL, 
particularly those who have been treated previously (Messmer et al., 2005). Subsequent in 
vivo isotope labelling studies in a larger cohort of recently diagnosed CLL patients confirmed 
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the association between higher proliferation rate and disease progression, as evidenced by 
a shorter time to first treatment (TTFT). Additionally, higher proliferation rates were 
associated with U-CLL, as well as with other adverse prognostic markers such as CD38 and 
ZAP-70 positivity, and adverse cytogenetics (e.g. del(11q)) (Murphy et al., 2017).  
These in vivo isotope labelling studies also captured the rates of CLL cell death, 
reflecting a natural process of cell turnover (Messmer et al., 2005). It is likely that the 
balance between CLL cell proliferation and cell death dictates the absolute disease burden 
at any one time, as well as the clinical course of each individual patient with CLL. CLL cell 
proliferation is driven by BCR signalling and a number of other important cellular pathways. 
These drivers of CLL proliferation will be discussed in subsequent sections. In addition, two 
biomarkers, namely telomere length and CD38 expression, may reflect, respectively, the 
proliferation history and the proliferation potential of CLL cells.  
Telomere length.  The early proliferation history of individual patients’ CLL cells 
may be deciphered from analyses of telomere length. Telomeres are protective structures 
found within either ends of each chromosome. They are progressively shortened with each 
cell division owing to the end-replication problem of DNA polymerase. When telomeres are 
shortened beyond a threshold, cells undergo senescence or apoptosis. CLL cells, like other 
tumour cells, are able to overcome replicative senescence by expressing telomerase, an 
enzyme that extends telomere length by adding hexameric TTAGGG repeats to telomere 
ends. In CLL, short telomeres and high telomerase expression or activity predict for disease 
progression and a more aggressive clinical course. Moreover, short telomeres and high 
telomerase activity have been associated with U-CLL and adverse cytogenetics across 
several studies (Damle et al., 2004; Rampazzo et al., 2012; Roos et al., 2008; Terrin et al., 
2007). Although telomerase activity may allow CLL cells with short telomeres to continue to 
replicate, further shortening of telomeres beyond the threshold for replicative senescence 
leads to a loss of the protective effects of telomeres, leading to DNA double-strand breaks 
(DSBs) and telomeric fusions, and giving rise to genomic instability (Lin et al., 2010).     
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 CD38 expression.  CD38 is a transmembrane glycoprotein that binds platelet 
endothelial cell adhesion molecule 1 (PECAM-1; CD31). It has multiple cellular functions, 
supporting the cell-cell interactions that are essential for the activation, survival and 
migration of immune cells (Brachtl et al., 2014). CD38 is perhaps the most established and 
widely used CLL prognostic marker in clinical practice. Studies have consistently shown that 
CD38 positivity in ≥20% or ≥30% of CLL cells is associated with inferior prognosis (Del 
Poeta et al., 2001; Hamblin et al., 2002; Ibrahim et al., 2001). However, CD38 may also be 
viewed as a marker of proliferative potential in CLL. The CD38 positive fraction within a CLL 
clone is enriched for proliferating cells that are Ki-67 positive, and exhibit higher telomerase 
activity compared to the CD38 negative fraction (Damle et al., 2007). Furthermore, in an in 
vivo deuterium labelling study, the CD38 positive CLL fraction was shown to contain a 
greater proportion of deuterium labelled cells. Since the deuterium labelled CLL cells 
represent newly divided cells during the labelling period, this indicates that the CD38 positive 
CLL fraction had a higher proliferation rate compared to their CD38 negative counterpart 
(Calissano et al., 2009).    
 
1.2.1.4. CLL as a disease of immune dysfunction 
 CLL as a disease is also characterised by a state of impaired immunity (Forconi and 
Moss, 2015). T cell dysfunction, in particular, has been extensively investigated. The 
development of CLL is often accompanied by an increase in T cell numbers, particularly an 
expansion of CD8+ T cells, resulting in an inversion of the CD4:CD8 ratio (CD4:CD8 < 1) in 
some patients (Christopoulos et al., 2011). Within each of the CD4+ and CD8+ T cell 
compartments, the preferential expansion of antigen-experienced memory T cells over naïve 
T cells leads to a skewing of the T cell subset distribution towards memory cells (Hofbauer et 
al., 2011; Nunes et al., 2012; Tinhofer et al., 2009; Walton et al., 2010).  
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Both CD4+ and CD8+ T cells have been shown to exhibit features of T cell 
exhaustion. Exhausted T cells can be identified by the surface expression of T cell 
exhaustion markers such as PD-1, CD160 and CD244, and display impaired proliferation. In 
the case of exhausted CD8+ T cells, impaired cytotoxic activity is also apparent due to 
defective granzyme localisation to the immunological synapse (Riches et al., 2013). 
Moreover, the formation of immunological synapse is impaired due to defective actin 
polymerisation, resulting in curtailed recruitment of key regulatory proteins to the synapse 
required for effective cytotoxic (in case of CD8+ T cells) or co-stimulatory (in case of CD4+ T 
cells) activity (Ramsay et al., 2008). CLL cells may exert a direct inhibitory effect on 
autologous T cells, leading to their functional impairment. This is evidenced by changes in 
the gene expression profile in healthy T cells, upon co-culturing with CLL cells, to that seen 
in T cells derived from CLL patients (Gorgun et al., 2005). This inhibitory effect on T cells is 
also evidenced from the observation that defects in the formation of immunological synapse 
are seen in healthy T cells upon exposure to CLL cells (Ramsay et al., 2008). Finally, 
studies have been conducted to sequence T cell receptors (TCR) from CLL patients. These 
studies revealed restriction in the TCR repertoire among CLL patients compared to healthy 
individuals, and evidence of TCR oligoclonality in these patients (Vardi et al., 2016; Vardi et 
al., 2017). This suggests the possibility of an antigen-driven selection process for specific 
TCR, similar in nature to the selection of stereotyped BCR by antigens in CLL (to be 
discussed in section 1.2.2.2).  
 Natural killer (NK) cell numbers are also increased in CLL, and like T cells, 
functional defects are evident (Huergo-Zapico et al., 2014; Parry et al., 2016). On the other 
hand, healthy B cell numbers, and possibly also function, is markedly suppressed in CLL. 
This is reflected by hypogammaglobinaemia involving one or more of the three 
immunoglobulin classes (IgG, IgA and IgM) which a frequent occurrence in CLL patients, 
and contributes to an increased susceptibility to infections (Rozman et al., 1988). Finally, 
there is also evidence pointing to defects in the activity of neutrophils and other components 
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of the innate immune system such as the complement system (Kontoyiannis et al., 2013; 
Schlesinger et al., 1996). Together, these defects result in a state of impaired immunity in 
patients with CLL. Given the increasingly recognised roles of the immune system in 
countering tumour growth, as well as infection, it is likely that these immune defects play a 
role in the pathogenesis and progression of CLL.  
 
1.2.2. B cell receptor signalling 
1.2.2.1. The BCR signalling pathway  
 Several pieces of experimental evidence have underscored the central importance 
of B cell receptor (BCR) signalling in the pathogenesis of CLL. Firstly, through V(D)J 
recombination, receptor editing and SHM, the human body is physiologically capable of 
producing a diverse BCR repertoire (of up to 2 x 1012 unique specificities) (Langerak et al., 
2012). It would therefore be uncommon to find any two B lymphocyte clones carrying 
identical BCR in a healthy individual. However, up to one-third of CLL patients exhibit 
stereotyped BCR usage, whereby specific combinations of IGHV genes are utilised at much 
higher frequencies than expected. Patients whose CLL BCR belonging to one of the 
stereotyped BCR subsets would have very similar BCR specificities. This implicates a role 
for the recognition of antigens by BCR, and the resultant selection of the B lymphocyte 
carrying the corresponding BCR specificity, in the pathogenesis of CLL (Messmer et al., 
2004; Widhopf et al., 2004). Secondly, patients with CLL belonging to different stereotyped 
BCR subsets can have markedly different clinical course (Murray et al., 2008). Likewise, 
there is a marked difference in the prognosis of patients with U-CLL and M-CLL, providing 
further evidence for an antigen-driven process in the development and progression of CLL 
(Hamblin et al., 1999). Finally, BCR signalling inhibitors such as ibrutinib, idelalisib and 
acalabrutinib have shown clinical efficacy both within and outside clinical trials, further 
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highlighting the importance of BCR signalling in CLL pathogenesis (Byrd et al., 2013; 
Furman et al., 2014). 
 BCR signalling is initiated by the binding of an antigen to the BCR expressed on the 
B lymphocyte cell surface. In CLL, these antigens are usually either autoantigens or foreign 
antigens, such as bacterial and viral antigens (Hoogeboom et al., 2013; Rosen et al., 2010; 
Steininger et al., 2012), although CLL has also shown capacity for antigen-independent 
autonomous BCR signalling (Duhren-von Minden et al., 2012). The BCR is a 
transmembrane complex composed of a membrane immunoglobulin attached to two 
proteins, CD79a and CD79b. Upon binding of an antigen to the membrane immunoglobulin, 
the following events occur in chronological order in a positive signalling event (Stevenson et 
al., 2011; Woyach et al., 2012):  
First, a BCR signalosome is formed which is required for signal initiation 
(Figure 1.3A). This begins with the phosphorylation of the intracellular portion of CD79a and 
CD79b by the kinase Lyn. This results in the recruitment of other proteins, including spleen 
tyrosine kinase (Syk), Bruton tyrosine kinase (BTK), phospholipase C-γ2 (PLCγ2) and the 
adaptor protein B-cell linker (BLNK), to CD79a and CD79b in order to form a complex known 
as the BCR signalosome. Syk mediates the dual phosphorylation of CD79a and CD79b 
required for positive BCR signal transduction. BLNK, on the other hand, provides a scaffold 
onto which other proteins, notably BTK and PLCγ2, bind to and exert their effect. The 
binding of antigens to the BCR also results in the aggregation of these BCR on the cell 
membrane, resulting in the formation of microclusters known as lipid rafts.  
Second, the signal is propagated from the BCR signalosome through BTK, 
PLCγ2 and PI3K (Figure 1.3A-B). Once the BCR signalosome is formed, BTK and PLCγ2 
become activated through phosphorylation. BTK can self-phosphorylate, and can also be 
phosphorylated by Syk and Lyn. On the other hand, PLCγ2 is phosphorylated by BTK and 
Syk. PLCγ2, once phosphorylated, exerts its action through two pathways, the protein 





B cell receptor signalling in CLL.  Reproduced with minor modifications from Stevenson et 
al (2011). B-cell receptor signaling in chronic lymphocytic leukemia.  Blood. 118, 4313-4320.  
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kinase C (PKC) pathway and the inositol-1,4,5-triphosphate (IP3) pathway, the latter of 
which mediates calcium flux from the endoplasmic reticulum. Phosphoinositide 3-kinase 
(PI3K), although not part of the initial signalosome, is subsequently recruited and 
phosphorylated by Lyn. Upon binding to the positive BCR co-receptor CD19, phosphorylated 
PI3K mediates downstream signalling through the PI3K/Akt pathway.    
Third, signalling through downstream pathways leads to modulation of 
transcriptional activity to enhance cell survival and proliferation (Figure 1.3B). 
Signalling through the PKC pathway, and calcium flux, lead to phosphorylation and 
activation of intermediates such as Erk, c-Jun N-terminal kinase (Jnk) and p38. These 
intermediates in turn activates the transcription factors Myc, Jun and AFT2 respectively. In 
addition, calcium flux directly activates the transcription factor nuclear factor of activated T 
cells (NFAT). Furthermore, signalling through the PKC and Akt pathways results in 
phosphorylation and subsequent proteasomal degradation of the NF-κB inhibitory molecule 
I-κB. This activates NF-κB and allows its translocation to the nucleus where it performs its 
transcriptional modulatory activities. Akt also activates other growth pathways such as 
mechanistic target of rapamycin (mTOR) and inhibits proapoptotic proteins such as 
Forkhead Box O (FOXO). Finally, Lyn can signal through the Ras/Raf pathway, leading to 
Erk and Myc activation. Therefore, positive BCR signalling converges onto a number of 
transcription factors which modulates transcriptional activity to promote cell survival, 
migration and proliferation. In CLL, these activities occur within CLL cells, and are required 
for disease maintenance and progression.  
 Positive signalling through the BCR also results in downstream effects beyond 
transcriptional modulation (Spaargaren et al., 2003). In particular, positive BCR signalling 
has been shown to modulate integrin activity through “inside-out” integrin signalling. For 
instance, the activation of CD49d through “inside-out” signalling requires the activation 
specifically of Lyn, Syk, PI3K, BTK, IP3-mediated calcium release and PKC. Moreover, the 
promotion of B cell migration by chemokines such as CXCL12, which binds to the cell 
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surface receptor CXCR4, is also dependent on BCR signalling pathways. Subsequent to the 
engagement of CXCR4 by CXCL12, integrin-mediated migration of B cells is dependent on 
the activation of BTK and PLCγ2 in an “outside-in” signalling process (de Gorter et al., 
2007). Thus, in these ways, positive BCR signalling and pathways regulating cell adhesion 
and trafficking are tightly coupled, and together promote the homing of CLL cells to lymph 
nodes where proliferation takes place. Finally, BCR signalling also appears to modulate the 
expression of the antiapoptotic protein Mcl-1. In CLL cells, BCR signalling triggered by 
immobilised anti-IgM, but not soluble anti-IgM, was shown to increase the level of Mcl-1 
expression and protect CLL cells from chemotherapy-induced (but not spontaneous) 
apoptosis (Petlickovski et al., 2005).     
 With few exceptions, CLL cells express IgM and IgD BCR of the same specificity on 
their cell surface, albeit at different densities in different patients. The few exceptions to this 
are in CLL cells with class-switched BCR, which express IgG (Potter et al., 2006). Positive 
signalling events are largely identical whether occurring through IgM or IgD BCR, but the 
end result might differ. IgM stimulation promotes CLL cell cycle progression and 
proliferation, with limited effect on cell survival (Guarini et al., 2008). IgD stimulation, in 
contrast, has been shown to enhance CLL cell survival, but does not induce proliferation 
(Zupo et al., 2000). The latter has been attributed, in part, to significantly lower levels of Myc 
induction following IgD BCR signalling, in comparison with IgM BCR signalling (Krysov et al., 
2012). However, a recent study has suggested the contrary: that IgM but not IgD signalling 
promotes CLL cell survival. This study also showed that IgM stimulation, in comparison to 
IgD stimulation, led to more prolonged downstream activation resulting in enhanced levels of 
chemokine secretion (Ten Hacken et al., 2016). Overall, the functional roles and relative 
contribution of IgM and IgD BCR signalling in CLL pathogenesis remain incompletely 
understood.  
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1.2.2.2. CLL anergy and negative regulation of BCR signalling  
 Anergy, in B lymphocytes, refers to a state of unresponsiveness to BCR stimulation. 
In healthy B cells, this occurs following chronic antigenic stimulation of BCR in the absence 
of a co-stimulatory signal from antigen-activated T cells. Physiologically, anergy exists as a 
mechanism through which autoreactive lymphocytes that have evaded clonal deletion during 
their developmental process are silenced in the peripheral circulation. Studies have shown 
that B cell anergy is a dynamic and reversible process, and that maintenance of anergy 
requires constant BCR occupancy and signalling. Indeed, BCR occupancy must exceed a 
threshold in order for anergy to occur, whereas removal of the occupying antigens results in 
recovery of response to BCR stimulation within minutes (Gauld et al., 2005). Mechanistically, 
anergy occurs as a consequence of signalling through a negative BCR signalling pathway 
(Figure 1.3A). This regulatory pathway is mediated by negative transmembrane co-
receptors, such as FcγRIIb, CD5, CD22, CD72 and leucocyte associated immunoglobulin 
like receptor 1 (LAIR1) (Perbellini et al., 2014; Stevenson et al., 2011; Woyach et al., 2012). 
These inhibitory co-receptors may be activated through co-ligation with BCR and 
subsequent phosphorylation by Lyn. Once activated, these co-receptors recruit a number of 
downstream phosphatases, notably SH2 domain inositol 5-phosphatase 1 (SHIP1) and/or 
SH2-containing tyrosine phosphatase-1 (SHP-1). SHIP1 and SHP-1 inhibit positive BCR 
signalling in different ways. SHIP1 has been shown to suppress the PI3K pathway (Getahun 
et al., 2016). SHP-1, on the other hand, dephosphorylates several proteins involved in 
positive BCR signalling, including Syk (Adachi et al., 2001). The maintenance of B cell 
anergy necessitates continuous inhibitory signalling through both SHIP1 and SHP-1  
pathways (Getahun et al., 2016).        
CLL cells are variably stimulated and anergised in vivo. Anergic CLL cells are 
unresponsive to BCR stimulation. More specifically, anergic CLL cells display a lack of 
responsiveness to IgM BCR crosslinking by anti-IgM antibodies. CLL cells that fail to 
respond to IgM receptor stimulation often, but not always, retain responsiveness to IgD 
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receptor stimulation (Lanham et al., 2003). Anergic CLL cells downregulate cell surface IgM 
expression, but spontaneous recovery of surface IgM expression and responsiveness can 
become apparent following incubation of these cells in vitro in media deplete of antigen 
(Mockridge et al., 2007). The latter observation substantiates the notion that chronic 
antigenic stimulation is required for the maintenance of anergy, and that IgM BCR 
endocytosis following antigenic stimulation may account for the low surface IgM expression 
in anergic CLL cells. Other features displayed by anergic CLL cells include constitutive 
phosphorylation of Erk as well as mitogen activated protein kinase kinase (MEK) that is 
upstream of Erk, and increased basal NFAT activation (Muzio et al., 2008).  
 
1.2.2.3. Determinants of the heterogeneity of BCR signalling responses in CLL 
There is substantial heterogeneity of BCR signalling activity among patients with 
CLL. In addition, within an individual patient, there can be considerable intraclonal variability 
in the signalling capacity of CLL cells, with some cells exhibiting features of anergy, and 
others displaying much higher propensity for positive BCR signalling (Coelho et al., 2013). 
Inter-patient variability in BCR signalling is a recognised contributor to the clinical 
heterogeneity of CLL. The factors influencing BCR signalling capacity and their clinical 
impact will be discussed here: 
IGHV mutational status.  As alluded to previously in section 1.2.1.1., M-CLL and 
U-CLL may reflect different B cell maturation stages during which differentiation arrest and 
malignant transformation to CLL occurs. This results in differences in IGHV SHM that can be 
detected upon IGHV gene sequencing using DNA extracted from CLL cells. A convention is 
generally adopted whereby CLL IGHV sequences of <98% homology to germline IGHV 
sequences denotes U-CLL, whereas ≥98% homology to germline sequences represents M-
CLL (Rosenquist et al., 2017). Clinically, IGHV mutational status identifies two subgroups of 
CLL patients with different prognosis: M-CLL which is usually associated with more indolent 
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disease, and therefore good prognosis; and U-CLL which is associated with a more 
aggressive clinical course, and hence poorer prognosis (Damle et al., 1999; Hamblin et al., 
1999). Subsequent studies have revealed that U-CLL cases are generally responsive to IgM 
BCR ligation. On the other hand, many, but not all, M-CLL patients display features of 
anergy to varying degrees. They generally possess lower CLL surface IgM expression, and 
reduced responsiveness to BCR stimulation compared to U-CLL cases (Lanham et al., 
2003; Mockridge et al., 2007).  
IGHV stereotypy.  BCR belonging to a particular stereotyped subset have three 
features in common. Firstly, with few exceptions, they must have the same IGHV mutational 
status. Secondly, the IGHV gene used must be phylogenetically related, as evidenced by 
belonging to the same clan, with IGHV1/5/7 genes forming clan 1, IGHV2/4/6 genes clan 2 
and the IGHV3 gene clan 3. Finally, they must have similar complementarity-determining 
region 3 (CDR3): the sequence located at the junction between the recombined VH, DH and 
JH gene segments responsible for the unique specificity of the BCR (Agathangelidis et al., 
2012; Bystry et al., 2015). In CLL, 19 major stereotyped subsets have been identified. Four 
of these subsets are particularly well characterised. Subset 1 contains U-CLL cases utilising 
IGHV1/5/7, IGHD6-19 and IGHJ4, and has a 13 amino acid CDR3 sequence. Subset 2 
cases utilise IGHV3-21 and IGHJ6, with a CDR3 of 9 amino acids, and can either be M-CLL 
or U-CLL. Subset 4 consists of M-CLL cases with IGHV4-34/IGHD5-18/IGHJ6 and a CDR3 
of 20 amino acid, while subset 8 comprises U-CLL cases with IGHV4-39/IGHD6-13/IGHJ5 
and a CDR3 of 19 amino acids (Stamatopoulos et al., 2017). Subsets 1, 2 and 8 are 
associated with an aggressive clinical course, with subset 8 being additionally linked to a 
high risk of transformation to RS. Subset 4 CLL cases, on the contrary, display a very 
indolent clinical course (Baliakas et al., 2014). The variation in clinical behaviour among 
these stereotyped subsets may be explained, in part, by differences in BCR signalling 
responses. Subsets 1 and 8 CLL cells respond strongly to BCR stimuli, especially subset 8 
cases which exhibit a distinct avidity to a broad range of antigens (Del Giudice et al., 2014; 
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Gounari et al., 2015). In contrast, subset 4 CLL cells manifest features of B cell anergy 
(Gounari et al., 2015). 
ZAP-70 expression.  ZAP-70, alongside IGHV mutational status, is one of the 
more commonly used prognostic biomarkers in CLL. ZAP-70 is primarily involved in TCR 
signalling by acting as a signalling intermediate, with a role similar to that of Syk in BCR 
signalling. ZAP-70 is not ordinarily expressed in healthy B cells. However, it is variably 
expressed in a proportion of CLL cases. ZAP-70 expression is associated with U-CLL, with 
ZAP-70 positive CLL cells displaying enhanced BCR signalling upon IgM ligation, as 
evidenced by higher levels of Syk and PLCγ2 phosphorylation, as well as calcium flux, in 
comparison to ZAP-70 negative cells (Chen et al., 2005; Chen et al., 2002). Recently, 
evidence has emerged that the Toll-like receptor (TLR) signalling pathway also activates 
Syk, and collaborates with the BCR signalling pathway in driving CLL proliferation. However, 
TLR-mediated Syk activation in CLL cells is highly dependent on ZAP-70 (Wagner et al., 
2016). This may provide an explanation for the enhanced BCR signalling activity in ZAP-70 
positive CLL cells. As such, ZAP-70 positivity, using 20% positive cells as cut-off, was 
shown to confer more rapid CLL progression and poorer OS (Crespo et al., 2003).   
 
1.2.3. Microenvironmental interactions 
1.2.3.1. CLL cell homing and trafficking 
 CLL cells betray a dependence on the tumour microenvironment. This is evident 
from prolonged in vitro culture of these cells without stromal support, which inevitably results 
in cell death. Within the in vivo tumour microenvironment, CLL cells interact with a number of 
other cell types. These include mesenchymal stromal cells, monocyte-derived nurse-like 
cells, follicular dendritic cells and T cells. These accessory cells are located mostly within 
lymphoid tissues such as the lymph nodes and bone marrow, and provide prosurvival and 
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proliferative signals to CLL cells. Together, they form a niche within which CLL cells are 
protected from apoptosis, and support CLL cell growth and proliferation (Burger, 2011). 
Positive BCR signalling in CLL cells, for instance, occurs almost exclusively in proliferation 
centres within lymph nodes, and to a much lesser extent in the bone marrow (Herishanu et 
al., 2011).  
 However, not all CLL cells reside in these niches. Instead, the vast majority are 
circulating within the peripheral blood. CLL cells in the peripheral blood are mostly 
quiescent, and are less protected from cell death. The difference in the characteristic of CLL 
cells within the lymphoid tissue and peripheral blood compartments is apparent from the 
gene expression differences of CLL cells obtained from these two sites. CLL cells resident 
within lymph nodes have higher expression of genes associated with BCR positive 
signalling, including Myc and NF-κB activation, which promote cell survival and proliferation 
(Herishanu et al., 2011). Hence, in vivo, there is a constant traffic of CLL cells between 
proliferation niches and the peripheral blood. CLL cells move into lymph nodes to receive 
survival signals and to proliferate, following which they exit into the peripheral circulation, to 
return at a later time.  
   Such a process of CLL cell trafficking is essential for the development and 
progression of CLL, and is facilitated by a number of pathways and microenvironmental 
interactions. The most important among these are interactions between chemokines and 
chemokine receptors, and those between adhesion molecules and their ligands. These 
interactions will be explained in more detail below:  
 Chemokine-chemokine receptor interactions.  CLL cells express on their cell 
surface multiple chemokine receptors, including CXCR4, CXCR5, CCR6 and CCR7 (Durig 
et al., 2001). CXCR4 and CXCR5 are both expressed at a high level on CLL cells, whereas 
the expression of CCR6 is intermediate and more variable. CXCR4 binds CXCL12, a 
chemokine that is produced by various cell types including nurse-like cells and bone marrow 
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mesenchymal stromal cells within lymphoid tissues. The CXCR4-CXCL12 interaction 
confers a prosurvival effect on CLL cells, and allows peripheral blood CLL cells to migrate 
along a CXCL12 chemokine gradient towards, and, through the endothelium, into these
lymphoid tissues (Burger et al., 2000; Mohle et al., 1999). CXCL12 binding to CXCR4 is also 
likely to play a role in retaining CLL cells within lymph nodes. This can be inferred from an in 
vivo isotope labelling study which shows that CLL cells with delayed exit from lymph nodes 
possess higher levels of CXCR4 expression (Calissano et al., 2009). Nevertheless, CXCR4 
is downregulated following BCR ligation, allowing newly proliferated CLL cells to exit from 
lymph nodes into the circulation (Vlad et al., 2009). Thus, the CLL population that has 
recently divided can be identified by its low level of CXCR4 expression. Over time, these 
cells recover CXCR4, permitting eventual re-entry into lymph nodes (Calissano et al., 2011; 
Coelho et al., 2013), as illustrated in Figure 1.4. CXCR5 has also been shown to be 
important in the homing of CLL cells into lymph nodes through binding to the chemokine 
CXCL13, which is secreted by nurse-like cells (Burkle et al., 2007). In comparison with 
CXCR4 and CXCR5, the role of CCR6 in CLL has been less extensively studied. However, 
its ligand, CCL20, is highly expressed in lymph nodes, thus supporting a potential role for 
CLL cell homing (Rossi et al., 1997). Interestingly, like CXCR4, the expression of CCR6 on 
B lymphocytes and CXCR5 on CLL cells is also markedly reduced following BCR 
engagement (Krzysiek et al., 2000; Saint-Georges et al., 2016). Finally, CCR7 is also high 
expressed on CLL cells and may also play a role in cell homing (Till et al., 2002).  
  Adhesion molecules.   Transendothelial migration requires CLL cells to adhere to 
and roll on the vascular endothelium. This is facilitated by adhesion molecules expressed on 
the CLL cell surface. Two of the functionally most important adhesion molecules in CLL are 
CD49d and CD62L. CD49d is an α4 integrin that associates with CD29, a β1 integrin, to 
form a heterodimer known as very late antigen-4 (VLA-4). CD49d binds to vascular cell 
adhesion protein 1 (VCAM-1), expressed on the surface of endothelial cells and bone 
marrow stromal cells, as well as fibronectin within the extracellular matrix 





Trafficking of CLL cells between the proliferative and peripheral blood compartments. 
CLL cells traffic continuously between the proliferative compartment in the lymph nodes and 
the peripheral blood circulation. (1) Newly proliferated CLL cells downregulate CXCR4 
expression to allow their exit from the lymph nodes into the peripheral circulation. They also 
have high CD38 and CD5 expression.  (2) Over time, these CLL cells recover CXCR4 
expression and downregulate CD38 and CD5 expression.  (3)  Circulating CLL cells with 
high CXCR4 expression home to the lymph nodes along the CXCL12 chemokine gradient 
where they re-enter the proliferative compartment for further proliferation. Reproduced from 
Calissano et al (2011). Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions 
Enriched in Recently Born/Divided and Older/Quiescent Cells.  Mol Med. 17, 1374-1382. 
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(Brachtl et al., 2014). CD49d was shown to be crucial for the transendothelial migration of 
CLL cells across a CXCL12 chemokine gradient, and blocking CD49d inhibited this (Till et 
al., 2005). The importance of CD49d for CLL cell trafficking into lymph nodes was 
demonstrated by a positive association between CD49d expression levels and 
lymphadenopathy (Till et al., 2002). CD49d was also shown to facilitate homing of CLL cells 
to the bone marrow (Brachtl et al., 2011). Clinically, patients with ≥30% CLL cells expressing 
CD49d had poorer OS and treatment-free survival (TFS) in a meta-analysis of published 
studies, supported by a validation cohort (Bulian et al., 2014). On the other hand, CD62L, 
also known as L-selectin, is a member of the selectin family of adhesion molecules. CD62L 
binds to such ligands as CD34, glycosylation dependent cell adhesion molecule 1 (GlyCAM-
1) and mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) expressed on 
endothelial cell surface to facilitate CLL entry into lymph nodes. Low CD62L expression has 
been linked to an impaired transendothelial migration of CLL cells, and CD62L inhibition may 
result in cell death (Burgess et al., 2013; Gu et al., 2001). Similar to CXCR4, BCR triggering 
can also result in the downregulation of CD62L expression to facilitate the exit of recently 
proliferated CLL cells from lymph nodes (Vlad et al., 2009).          
 
1.2.3.2. CLL interactions with T cells 
  Co-stimulatory signals from CD4+ T helper cells are indispensable for the 
differentiation and proliferation of healthy B lymphocytes in response to antigenic 
stimulation. Conversely, the failure to receive a co-stimulatory signal upon BCR ligation 
results in B cell anergy (section 1.2.2.2). In healthy B lymphocytes, BCR activation is usually 
followed by the internalisation of the BCR-bound antigen and its presentation on class II 
major histocompatibility complexes (MHC). Simultaneously, two co-stimulatory molecules, 
CD80 and CD86, are upregulated on the B lymphocyte. Presentation of the MHC-bound 
antigen to a CD4+ T cell, facilitated by a co-stimulatory signal mediated through the binding 
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of CD80/CD86 on the B lymphocyte to CD28 on the T cell, leads to activation of that T cell. 
The activated CD4+ T cell then reciprocates by activating the B lymphocyte. This is 
facilitated by the upregulation of CD40L on the T cell, which binds CD40 that is constitutively 
expressed on the B lymphocyte, to create a second co-stimulatory signal. The activated T 
cell also releases multiple cytokines that support the proliferation of the B lymphocyte.  
 In CLL cells, although in vitro ligation of BCR by anti-IgM triggers modulation of 
transcription in favour of enhanced proliferation (Guarini et al., 2008), the actual increase in 
proliferation was modest in the absence of co-stimulation (Balakrishnan et al., 2015). In 
contrast, a high level of CLL cell proliferation was seen in patient lymph nodes (Herishanu et 
al., 2011). This indicates that additional signals are required for CLL proliferation in vivo in 
addition to BCR activation. Indeed, CLL cells were demonstrated to be capable of presenting 
antigens to autologous CD4+ T cells or allogenic T cells with the same histocompatibility 
leukocyte antigen (HLA) restriction, and that these T cells in turn induced the activation and 
proliferation of CLL cells (Os et al., 2013). Further evidence of a requirement for T cell co-
stimulatory signals emerged from primary CLL xenotransplantation studies on immune 
deficient murine models. Transplanted human CLL cells do not engraft in mice in the 
absence of T cells. However, when autologous CD34+ haematopoietic progenitor cells were 
co-transplanted with CLL cells, which differentiated in vivo into T cells, the transplanted CLL 
cells were able to engraft and proliferate in mice (Bagnara et al., 2011). Similarly, co-
transplantation of human CLL cells into mice, alongside autologous T cells that were 
activated ex vivo, enabled engraftment and proliferation of the CLL clone (Patten et al., 
2015). Finally, CLL cells proliferated robustly in vitro upon co-culturing with CD40L 
expressing cells, especially in the presence of cytokines such as IL-21 or IL-4, further 
substantiating the role of co-stimulatory signals in CLL proliferation (Balakrishnan et al., 
2015; Pascutti et al., 2013).   
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1.2.4. Genomic aberrations 
1.2.4.1. Spectrum of copy number aberrations in CLL 
 Like all other malignancies, genomic aberrations contribute to the pathogenesis and 
subsequent development of CLL. However, unlike other malignancies such as chronic 
myeloid leukaemia (CML), there is no recognised initiating lesion in CLL responsible for its 
malignant transformation. Rather, genomic aberrations in CLL tend to accumulate 
throughout the natural history of the disease. The combination of acquired lesions and the 
sequence of acquisition of these lesions differ from one patient to another, helping to shape 
the unique clinical course of each individual.    
Cytogenetic analysis of CLL began in the late 1980s and continued into the 1990s, 
culminating in the Döhner hierarchical classification system of cytogenetic lesions that is still 
in use today (Dohner et al., 2000). Among the cytogenetic abnormalities in CLL, del(13q14) 
is the most prevalent, and is present in approximately 55% of individuals with the condition. 
This is followed by del(11q22-23), trisomy 12, del(17p) and del(6q15-21), reported in 18%, 
16%, 7% and 6% respectively of the Döhner cohort. Of note, the Döhner cohort comprised 
predominantly of treatment naïve CLL patients. Among relapsed/refractory patients, the 
frequencies of del(11q), trisomy 12 and del(17p) would generally be higher, reflecting the 
functional impact of these lesions on disease biology. When the clinical impact of these 
lesions was considered, del(13q14) as the sole abnormality conferred the best prognosis, 
followed by no abnormality. Trisomy 12 appeared next, and conferred intermediate risk. 
Del(11q) then followed, with del(17p) being associated with the worst TFS and OS outcomes 
(Dohner et al., 2000).    
 Our knowledge of copy number aberrations (CNAs) in CLL has expanded in the 
ensuing years, due to newer technologies such as single nucleotide polymorphism (SNP) 
arrays and next generation sequencing (NGS). SNP arrays utilise a library of probes 
complementary to different possible allelic variations within each genomic region. This 
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allows determination of copy number and the allelic composition within each genomic locus 
from which the presence of CNAs could be inferred (see section 2.5.1 for further detail) 
(Nowak et al., 2009). Unlike FISH, SNP arrays permit a comprehensive analysis of CNAs 
across the entire genome. Such an unbiased genome-wide discovery of CNAs can also be 
achieved through whole genome sequencing (WGS) or whole exome sequencing (WES), 
although CNA analysis from WES data is limited by coverage of only the coding regions 
which comprise a small fraction of the genome.  
Application of these technologies on large patient cohorts has provided insight into 
the spectrum of CNAs in CLL. Firstly, the range of recurrent CNAs in CLL is small, with only 
9 CNAs found at a frequency of >3% by WGS in a cohort of 452 individuals with stable or 
progressive CLL. These are del(13q14), trisomy 12, del(11q), del(14q), amp(2p), del(17p), 
del(18p), del(6q) and amp(8q) (Puente et al., 2015). In another study of 538 mainly 
progressive individuals by WES, only del(13q14), trisomy 12, del(11q), del(17p), del(6q), 
amp(2p) and del(8p) was found in >3% of the cohort (Landau et al., 2015) (Figure 1.5). 
Secondly, whereas some CNAs are predominantly clonal, for example del(13q14) and 
trisomy 12, others such as del(11p) and del(17p) may be present only in a fraction of CLL 
cells within an individual, and therefore subclonal (Landau et al., 2015). Clonal lesions are 
likely to have arisen early during CLL development, whereas subclonal lesions may have 
been acquired during subsequent disease evolution (Landau et al., 2013).     
 
1.2.4.2. Spectrum of driver mutations in CLL 
 In addition to structural DNA lesions such as CNAs, gene mutations constitute a 
major source of genomic aberrations in CLL. Studies have found that a proportion of CLL 
cases carry mutational signatures consistent with apolipoprotein B mRNA editing catalytic 
subunit (APOBEC) activity (Alexandrov et al., 2013; Kasar et al., 2015). APOBEC proteins 
are cytidine deaminases that generate targeted DNA damage. Activation-induced





The genomic landscape of CLL. Copy number aberrations are displayed on the left and 
putative driver mutations are displayed on the right. Reproduced with minor modifications 
from Wu et al (2017). Clinical Implications of Novel Genomic Discoveries in Chronic 
Lymphocytic Leukemia. J Clin Oncol. 35, 984-995.  
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deaminase (AID) is an APOBEC protein that is involved in the SHM process within germinal 
centres during B cell development (Patten et al., 2012). Therefore, it is plausible that some 
of the gene mutations may arise, in part, from AID activity during the development of CLL.  
 Numerous WES and WGS studies have been carried out over the past decade to 
comprehensively catalogue somatic mutations in CLL, including single nucleotide variants 
(SNVs) and small insertions and deletions (indels). Effort has also been made within these 
studies to identify putative genomic drivers: recurrent genes mutations that are likely 
functional significance and confer growth advantage on CLL cells. Two of the largest such 
studies are the Spanish International Cancer Genome Consortium (ICGC) study and the 
Dana Farber Cancer Institute (DFCI) study on patients from the German CLL study group 
CLL8 trial (Landau et al., 2015; Puente et al., 2015). Combining data from these two studies 
(n=990), a total of 75 significantly mutated genes were found, of which 28 were common to 
both studies (Figure 1.5). The most frequently mutated genes are SF3B1, ATM, NOTCH1, 
TP53, BIRC3, CHD2, POT1, XPO1 and MYD88. These genes are involved in a wide range 
of cellular processes including DNA damage response (DDR), cell cycle regulation, RNA 
processing, NOTCH signalling as well as other growth and inflammatory signalling pathways 
(Lazarian et al., 2017). Thus, through acquiring a spectrum of genetic mutations, CLL cells 
are able to co-opt diverse cellular functions to enhance their own survival and proliferation.  
The following section will discuss the functional and clinical consequences of a 
select few of the most frequent and significant genomic aberrations in CLL.  
 
1.2.4.3. Functional significance of genomic aberrations in CLL 
 13q14 deletion.  Del(13q14) is the single most frequent genomic event in CLL. The 
majority of 13q deletions in CLL involve a minimally deleted region (MDR) on 13q14.2 which 
contains the DLEU2 gene. DLEU2 encodes for a long non-coding RNA with unknown 
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function. However, located within an intron of DLEU2 is the miR15a/16-1 cluster, discussed 
earlier in section 1.2.1.2. In an important study by Klein and colleagues, deletion of the 
13q14 MDR or of miR15a/16-1 itself led to the development of CLL in mice. Moreover, 
deletion of miR15a/16-1 resulted in enhanced proliferation of murine B cells. In human CLL 
cells with del(13q14), re-expression of miR15a/16-1 led to a downregulation of genes 
essential for cell cycle progression, and suppressed CLL cell proliferation (Klein et al., 2010). 
The importance of the miR15a/16-1 cluster in controlling cell proliferation is confirmed in 
another study employing a human megakaryocytic cell line, wherein transfection of 
miR15a/16-1 resulted in downregulation of cell cycle genes (Calin et al., 2008).  
As discussed in section 1.2.1.2, experiments on these megakaryocytic cells also 
suggested a potential role for miR15a/16-1 in regulating Bcl-2 expression (Calin et al., 2008; 
Cimmino et al., 2005). However, this could not be validated in two other studies, including in 
CLL primary cells, where no correlation was observed between miR15a/16-1 and Bcl-2 
expression levels (Fulci et al., 2007; Linsley et al., 2007). In the study by Klein et al, only 
modest effect on Bcl-2 expression was observed upon re-introduction of miR15a/16-1 in 
del(13q14) CLL cells (Klein et al., 2010). Finally, it is important to note that in many cases of 
del(13q14), the deletion encompasses other genes that surround the MDR, including known 
tumour suppressors such as the retinoblastoma (Rb) gene, and other putative tumour 
suppressors such as DLEU7 and RNASEH2B. Although del(13q14) CLL as a group is 
associated with a better prognosis, larger deletions that extend beyond the MDR are linked 
to the development of more aggressive CLL in murine models (Lia et al., 2012). This 
correlated with comparatively poorer clinical outcomes in patients with a larger del(13q14) 
compared to those with a smaller del(13q14) (Ouillette et al., 2011; Parker et al., 2011).  
  17p deletion and TP53 mutation.  The TP53 gene is located within 17p13, and 
encodes for the transcription factor p53 which plays a crucial tumour suppressor role in 
regulating cell cycle arrest (see section 1.4.1) and apoptosis (see section 1.2.1.2) in 
response to DNA damage, thereby contributing to the maintenance of genome integrity 
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(Bieging et al., 2014). Like many other malignancies, the majority of TP53 lesions in CLL are 
loss-of-function mutations or deletions, acquired by CLL cells as a means to promote 
survival and unperturbed proliferation. Del(17p) occurs in 8-10% of untreated CLL cases, but 
is enriched in patients relapsing from cytotoxic chemotherapy, affecting 40-50% of these 
individuals (Pospisilova et al., 2012). Over 80% of CLL patients with del(17p) have an 
inactivating mutation in their remaining TP53 allele. On the other hand, a smaller proportion 
of patients (about 5% of an untreated CLL cohort) have monoallelic or biallelic TP53 
mutation in the absence of del(17p) (Malcikova et al., 2009). Many of these are missense 
mutations, with the majority occurring within exons 5-8 of the TP53 gene, which encodes for 
the DNA binding domain of p53. These mutations may cause conformational change in p53 
or disrupt its binding to DNA, thus hampering the transcriptional regulation of p53 target 
genes (Marinelli et al., 2013; Zenz et al., 2008; Zenz et al., 2010c). A minority of TP53 
missense mutations, in contrast, may have gain-of-function effects, possibly through the 
transactivation of other transcription factors such as NF-κB (Trbusek et al., 2011).  
Patients with monoallelic TP53 aberrations have poor prognosis, and display 
chemorefractoriness (Zenz et al., 2008). However, biallelic TP53 inactivating lesions carry 
even poorer prognosis compared to del(17p) alone since the latter might possess some 
residual DDR activity whereas the former would not (Malcikova et al., 2009; Zenz et al., 
2010a). The observation that >80% of del(17p) patients acquire concomitant TP53 mutation 
could be explained by a selective effect, whereby biallelic TP53 inactivated CLL cells with 
survival and proliferative advantage are selected in favour of those with monoallelic TP53 
loss (Malcikova et al., 2009).    
  11q deletion and ATM mutation.  The ATM gene encodes for ataxia 
telangiectasia mutated (ATM) which is another important component of the DDR. ATM is a 
protein kinase that is activated in response to DSBs, and mediates repair of these breaks 
through homologous recombination. It also plays a role in cell cycle regulation and the 
induction of apoptosis through activating p53, which is downstream of ATM (Marechal and 
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Zou, 2013; Shiloh and Ziv, 2013). The ATM gene is located on chromosome 11q22-23, and 
similar to TP53, ATM may be disrupted through inactivating mutations or deletions. Unlike 
the TP53 gene, however, the ATM gene spans more than 60 exons, and mutations within 
ATM are distributed throughout these exons, with no mutation hotspot (Stankovic and 
Skowronska, 2014). Previous work undertaken by our group provided demonstration that 
DDR is impaired in CLL cells with ATM mutation. This was demonstrated through reduced or 
absent phosphorylation of ATM and ATM downstream targets such as structural 
maintenance of chromosomes protein 1 (SMC1), nibrin (NBS1) and p53 upon exposure to 
ionising radiation (IR), which induces DSBs. In addition, the loss of ATM function was 
marked by a failure to induce apoptosis in response to DNA damaging agents (Austen et al., 
2005).  
CLL patients with the loss of one ATM allele through del(11q) may subsequently 
acquire an inactivating mutation in the remaining ATM allele. Indeed, 35-50% of del(11q) 
patients also harbour an ATM mutation (Austen et al., 2007; Skowronska et al., 2012). 
Whereas residual ATM activity is typically seen in individuals with del(11q) alone, complete 
functional inactivation of ATM occurs in those with biallelic loss. Complete inactivation of 
ATM is also observed in individuals with a dominant negative ATM mutation in the absence 
of del(11q), whereby the mutant ATM inhibits the activity of the functional ATM derived from 
the wild-type ATM allele (Austen et al., 2005). Consequently, patients with complete 
functional loss of ATM display particularly adverse prognosis (Austen et al., 2007). This was 
demonstrated within the UK CLL4 trial where patients were treated with chemotherapy-
based regimens. Compared to patients with a sole del(17p) defect, those with del(11q) alone 
comparatively better progression-free survival (PFS) and OS, while those with del(11q) and 
an ATM mutation had inferior PFS and OS (Skowronska et al., 2012).             
 BIRC3 mutation.  Deletions of 11q can be of variable sizes, and larger deletions 
may disrupt other genes within 11q including BIRC3. BIRC3 is deleted in up to 80% of 
patients with del(11q), and BIRC3 deletion may co-occur with up to 40% of patients with an 
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ATM mutation (Rose-Zerilli et al., 2014). Functionally, BIRC3 negatively regulates 
MAP3K14, an activator of NF-kB signalling. Thus, in CLL cases where BIRC3 is mutated, 
NF-kB signalling is rendered constitutionally active. The clinical importance of this gene is 
corroborated by the inferior outcome demonstrated in CLL patients with a BIRC3 mutation, 
where the adverse impact of BIRC3 mutations on OS and TFS was found to be similar to 
that of TP53 mutations (Rossi et al., 2012a; Rossi et al., 2013). In patients with del(11q) who 
possess both ATM or BIRC3 mutations, however, ATM mutation but not BIRC3 mutation 
confers additional adverse prognosis over and above that associated with monoallelic 
del(11q) (Rose-Zerilli et al., 2014).  
  SF3B1 mutation.  The SF3B1 gene encodes for core components of the 
spliceosome, a protein complex essential for removing introns from messenger RNA 
(mRNA) precursors in a process known as splicing. Mutations of the SF3B1 gene occur in 
up to 15% of previously untreated CLL patients, and are associated with adverse prognosis 
(Rossi et al., 2013). Interestingly, SF3B1 mutations frequently occur with del(11q) or ATM 
mutations, and that del(11q) patients carrying an SF3B1 mutation have poorer outcomes 
compared to those with del(11q) alone (Jeromin et al., 2014; Wang et al., 2011). This 
suggests the possibility that SF3B1 might act synergistically with ATM. Although ATM kinase 
activity remains normal in CLL patients with sole SF3B1 mutation, transcriptional and 
apoptotic response to DNA damaging agents is impaired, implicating a potential role of 
SF3B1 in DDR (Te Raa et al., 2015). More recently, a transcriptomic analysis comparing 
SF3B1 wild-type and mutant CLL cells indicates that multiple pathways could be deregulated 
by SF3B1 mutations, including DDR, telomere maintenance and Notch signalling (Wang et 
al., 2016).  
 NOTCH1 mutation.  The NOTCH1 gene encodes for a transmembrane receptor 
that mediates a signalling cascade leading to the transcriptional activation of genes essential 
for cell survival, apoptotic resistance and proliferation (Lobry et al., 2011). NOTCH1 
mutations, occurring in about 10% of CLL patients, lead to impaired degradation of the 
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receptor and constitutional activation of the Notch signalling pathway. Like SF3B1 mutations, 
NOTCH1 mutations confers adverse prognosis (Baliakas et al., 2015; Rossi et al., 2012b).  
 
1.2.5. Spontaneous disease regression in CLL 
 In the above sections, the important enablers of CLL development and progression 
have been discussed. BCR signalling activity, microenvironmental interactions and genomic 
aberrations converge to drive CLL cell proliferation and apoptotic resistance, facilitated by a 
state of impaired tumour immunity. However, the nature of the BCR signalling activity, 
microenvironmental interactions and genomic aberrations is inevitably different in different 
individuals, as is the balance between CLL cell proliferation and cell death. Variation in these 
processes across patients underlies the enormous disease heterogeneity seen in CLL, and 
account for the patients’ disparate clinical course, with some progressing rapidly and others 
much more slowly or not at all. Indeed, a multitude of prognostic biomarkers have been 
discovered to predict the likely clinical outcome of individual CLL patients (Table 1.1).  
Of particular interest is a group of patients whose CLL decreases or disappears 
over time without treatment. Spontaneous tumour regression, manifested by a reduction or 
disappearance of the malignant clone without treatment, is an intriguing phenomenon. 
Although uncommon, spontaneous disease regression has been described in solid tumours 
such as neuroblastoma (Brodeur and Bagatell, 2014; Diede, 2014). Among haematological 
malignancies, spontaneous disease regression was reported in acute myeloid leukaemia 
(Daccache et al., 2007; Paul et al., 1994), chronic myeloid leukaemia (Musashi et al., 1997), 
myeloma and lymphoma (Kaufmann et al., 1995; Puig et al., 2009), as well as in CLL (Del 
Giudice et al., 2009; Herishanu et al., 2012; Nakhla et al., 2013; Thomas et al., 2002). In 
some cases, spontaneous tumour regression was linked to infections, blood transfusions or 
second malignancies that can be associated with a pro-inflammatory state (Paul et al., 1994; 
Schmidt et al., 1995). Alternatively, spontaneous regression has been variously attributed to 
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Table 1.1.   Prognostic factors in chronic lymphocytic leukaemia.  
 
Established prognostic factors 
 
Clinical stage (Binet et al., 1981; Rai et al., 1975) 
CD38 
(Del Poeta et al., 2001; Hamblin et al., 2002; 
Ibrahim et al., 2001) 
ZAP-70 (Crespo et al., 2003) 
IGHV mutational status (Damle et al., 1999; Hamblin et al., 1999) 
Cytogenetics (17p-, 11q-, 12+, 13q-) (Dohner et al., 2000) 
TP53 mutations 
(Malcikova et al., 2009; Zenz et al., 2010a; 





Novel prognostic factors 
 
CD49d (Bulian et al., 2014) 
ROR1 (Cui et al., 2016) 
Telomere length 
(Damle et al., 2004; Rampazzo et al., 2012; 
Roos et al., 2008) 
IGHV stereotypy (Baliakas et al., 2014) 
Complex karyotype (Herling et al., 2016; Thompson et al., 2015) 
Putative driver mutations (e.g. ATM, 
SF3B1, NOTCH1, BIRC3, NFKBIE) 
(Landau et al., 2015; Mansouri et al., 2015; 
Rossi et al., 2013; Skowronska et al., 2012; 
Stilgenbauer et al., 2014) 
MRD negativity Table 1.2 & Chapter 5  
 
 
Established prognostic factors refer to those that are widely used in clinical practice, 
whereas novel prognostic factors are those that have been reported recently and not yet 
widely used in routine practice. MRD; minimal residual disease.  
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the spontaneous apoptosis of malignant cells and clonal evolution in a case of mantle cell 
lymphoma (Kaufmann et al., 1995), and neurotrophin deprivation, epigenetic changes, 
telomere shortening and cellular senescence in neuroblastoma (Brodeur and Bagatell, 
2014).  
In CLL, spontaneous disease regression is indicated by a sustained reduction or 
resolution of lymphocytosis, adenopathy, cytopenias and disease-related symptoms, in the 
absence of treatment or other plausible clinical explanations (Del Giudice et al., 2009; 
Thomas et al., 2002). Spontaneous disease regression is estimated to occur in 1-2% of CLL 
patients. A single case of spontaneous CLL regression resulting in absent minimal residual 
disease has been reported (Herishanu et al., 2012). However, in the majority of cases 
residual CLL cells remain detectable in the peripheral blood by flow cytometry despite 
clinical disease remission (Del Giudice et al., 2009; Nakhla et al., 2013; Thomas et al., 
2002). There are few studies in the literature on CLL spontaneous regression. They 
comprise entirely of single case reports or small case series, with limited laboratory 
correlates. To date, there are two published series containing more than five cases.  
The first series is a collection of 10 cases from a UK group (Thomas et al., 2002). In 
these patients, spontaneous CLL regression occurred over a course of two to 20 years, with 
the highest lymphocyte count ranging from 5.7 x 109/L to 124 x 109/L, falling to 1.2 x 109/L to 
27 x 109/L at the time of study. This was accompanied by a reduction or disappearance of 
adenopathy without treatment. Interesting, two of the patients had trisomy 12 on cytogenetic 
analysis. However, no other biological studies were carried out.  
The second series consists of 9 cases from an Italian group (Del Giudice et al., 
2009). In these patients, spontaneous regression occurred over a median of 9 years (range 
3-24 years), with a reduction of lymphocytosis to below 4 x 109/L and resolution of 
adenopathy. No evident clinical conditions, autoimmune disease, drug intake or viral 
infections were able to account for the disease regression. In all 9 cases, CD38 and ZAP-70 
expression were negative. In addition, of the 7 cases where IGHV sequencing was 
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performed, all were IGHV mutated, with the use of IGVH3 genes in 6 of 7 cases. 
Furthermore, a microarray analysis was carried out on the residual CLL population, 
comparing 4 of these individuals against 12 others with stable or progressive disease. A 
diverse range of genes were found to be differentially expressed among the spontaneous 
regressors in comparison with non-regressing CLL patients, including those involved in 
signal transduction, RNA metabolism, transcriptional regulation, lipid metabolism, apoptosis 
and cell cycle regulation. No clear mechanism of spontaneous regression was found, 
although a number of potential contributors, such as BCR signalling and immune control, 
were suggested.  
 In summary, with the exception of the two individuals with trisomy 12 from the UK 
series, all other previously reported individuals with spontaneous CLL regression had good 
risk biological features. However, few published studies on CLL spontaneous regression are 
available, reflecting the rarity of this event. Within the few published studies, biological 
characterisation has been limited in scope, and the mechanism of spontaneous regression 
remains elusive.  
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1.3. Current therapeutic approaches in CLL 
 
1.3.1. Chemotherapy-based treatment approaches 
1.3.1.1. Chemotherapy-based treatments in CLL (Figure 1.6) 
 Therapeutic options for CLL have historically been rather limited. Alkylating agents 
such as chlorambucil was the primary agent used for CLL in the 1970s and 1980s. While 
substantial cytoreduction and symptomatic relief was afforded by chlorambucil, complete 
remissions were uncommon. The purine analogue fludarabine was introduced in the 1990s, 
and its use, either alone or in combination with cyclophosphamide, led to higher remission 
rates (Catovsky et al., 2007; Rai et al., 2000). 
 The addition of monoclonal antibodies (mAb) to chemotherapy represents the first 
major therapeutic advance in CLL. The monoclonal antibody rituximab targets CD20, which 
is expressed on CLL cells at low levels. Upon binding to CD20, rituximab mediates cell 
death by direct signalling through CD20, or by activating complement and other immune 
cells (Weiner, 2010). In the multicentre phase III randomised study of the German CLL 
group CLL8 trial comparing fludarabine and cyclophosphamide (FC) versus fludarabine, 
cyclophosphamide and rituximab (FCR) where 817 patients were randomly assigned to 
either groups, FCR demonstrated superiority compared to FC (Hallek et al., 2010). 
Cytogenetic subgroup analyses in the study showed that the addition of rituximab resulted in 
better outcomes in del(11q) but not del(17p) CLL. Moreover, extended follow-up revealed 
long-term treatment-free remission among a proportion of M-CLL patients following FCR 
(Thompson et al., 2016). Currently, chemoimmunotherapy remains a standard CLL 
treatment in the frontline setting. 
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Current treatment approaches in CLL.  (A) Timeline summarising the major historical 
advances in CLL treatment.  (B) Mechanism of action of the BCR signalling inhibitors 
ibrutinib and idelalisib.  (C) Mechanism of action of the Bcl-2 inhibitor venetoclax (ABT-199). 
Ab. Antibody; Ig, immunoglobulin.   
A 
B C 
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1.3.1.2. Limitations of chemotherapy-based CLL treatments 
 Despite the effectiveness of chemoimmunotherapy in a substantial proportion of 
CLL patients, major problems exist. These relate to toxicity, long-term effects and 
chemoresistance. The myelosuppressive effects of FCR are well described, and are not 
always well-tolerated, especially in older or frailer individuals (Hallek et al., 2010). In 
addition, secondary malignancies such as myelodysplastic syndrome and acute myeloid 
leukaemia may subsequently arise from previous treatment with chemoimmunotherapy 
(Tam et al., 2008).  
 Clonal evolution is an important mechanism driving disease progression in cancer, 
and may be spontaneous, accelerated by treatment or treatment-induced (Davies et al., 
2017). The idea of therapy-driven clonal expansion was supported by the observation, in 
paired pre-treatment and post-treatment samples, that the allelic fraction of subclonal driver 
mutations may increase over time during the course of treatment, eventually becoming 
clonal. Of note, not all treated cases result in clonal evolution, with some patients 
maintaining clonal equilibrium. However, clonal evolution predicts for shorter PFS and TFS 
(Landau et al., 2013). In patients receiving chemotherapy-based treatments, 
chemoresistance and disease relapse coincides with an expansion of TP53 mutant 
subclones. Moreover, the presence of detectable TP53 mutations at the time of FCR 
treatment, even within a small fraction of CLL cells, confers adverse treatment outcome 
(Landau et al., 2015; Rossi et al., 2014). While FCR-based treatments do not appear to 
specifically select for ATM mutations or deletions, del(11q) as well as del(17p) are frequent 
in relapsed cases, possibly reflecting their underlying genomic instability through the loss of 
DDR function (Tam et al., 2014).   
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1.3.2. Chemotherapy-free treatment approaches 
1.3.2.1. Chemotherapy-free treatments in CLL (Figure 1.6) 
 The problems with chemotherapy with respect to toxicity and chemoresistance have 
propelled the development of novel chemotherapy-free CLL treatments. The clinical 
discovery and translation of small molecule inhibitors targeting BCR signalling and Bcl-2 
represent the second major therapeutic advance in CLL.  
Ibrutinib and acalabrutinib are inhibitors of BTK. Idelalisib, on the other hand, 
inhibits the p110δ isoform of PI3K, one of the two PI3K isoforms utilised by B cells. Clinical 
trials have confirmed the efficacy of ibrutinib in relapsed/refractory CLL. Consistent with its 
p53-independent mechanism of action, administration of ibrutinib in heavily pre-treated 
del(17p) CLL patients yielded comparable response rates to those with no detectable 
del(17p) (Byrd et al., 2013). Moreover, the PFS outcome with ibrutinib was superior to that of 
the CD20 mAb ofatumamab, as well as to historical PFS data on the CD52 mAb 
alemtuzumab, the latter of which has hitherto been the standard treatment for del(17p) CLL 
(Burger et al., 2014; Byrd et al., 2014; Pettitt et al., 2012). Likewise, acalabrutinib and 
idelalisib have respectively shown efficacy in relapsed/refractory CLL (Byrd et al., 2016).   
 Venetoclax is a selective inhibitor of Bcl-2. In patients with relapsed/refractory CLL, 
venetoclax treatment produced an overall response rate of 79%, and a complete response 
(CR) rate of 20%. Consistent with its p53-independent activity, response rates did not differ 
substantially between patients with del(17p) and those without (Roberts et al., 2016).  
 
1.3.2.2. Limitations of current chemotherapy-free CLL treatments 
 Despite the excitement surrounding these novel small molecule inhibitors, and their 
remarkable efficacy in poor-risk CLL compared to existing therapies, these agents are not 
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without their limitations. Firstly, while myelosuppression is less common in patients treated 
with BCR signalling inhibitors and Bcl-2 inhibitors, each of these inhibitors has its own 
unique toxicity profile that may make them unsuitable for certain patients. For instance, 
ibrutinib may be associated with cardiovascular toxicity and a bleeding risk in some 
individuals. Idelalisib, on the other hand, may cause colitis, pneumonitis and hepatotoxicity 
(Lampson et al., 2016). Indeed, several clinical trials of idelalisib have recently been 
terminated because of drug-related adverse events. Secondly, these treatments are not 
curative. In particular, BCR signalling inhibitors do not produce deep remissions, and CRs 
are uncommon (Byrd et al., 2013; Byrd et al., 2016). As a result, patients are generally on 
long term treatment with these drugs, with associated cost and patient compliance 
implications. Finally, therapeutic resistance to these inhibitors is an important and growing 
concern.  
 Notwithstanding the high ibrutinib response rates in del(17p) patients, patients on 
ibrutinib harbouring del(17p) or del(11q) in their CLL clone have inferior PFS compared to 
individuals without these cytogenetic aberrations. Indeed, a 3-year follow-up study of 
patients on ibrutinib treatment shows that only 48% of del(17p) patients and 74% of del(11q) 
patients remained in remission at 30 months, compared to 87% of those without del(17p) or 
del(11q) (Byrd et al., 2015). Most patients relapse from ibrutinib with a BTK or PLCγ2 
mutation, while others undergo clonal evolution and acquire other genomic aberrations. In 
addition, a small group of patients experience transformation to RS while on ibrutinib. The 
majority of these patients were found to carry del(17p), del(11q) and/or a complex karyotype 
(Burger et al., 2016; Maddocks et al., 2015; Woyach et al., 2014a). In addition, complex 
karyotype predicted for an increased risk of clinical progression while on venetoclax 
(Anderson et al., 2017).  
These observations may reflect a heightened level of genomic instability within the 
CLL cells from relapsing patients, as a result of DDR impairment from a loss of functional 
p53 or ATM. This could be exacerbated by the use of BCR signalling inhibitors. Indeed, it 
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has recently been shown that BCR signalling inhibitors, particularly PI3K inhibitors such as 
idelalisib, increase genomic instability in B lymphocytes by upregulating their expression of 
AID. This consequently results in increased SHM and chromosomal translocation frequency, 
both within the IGH gene locus, and in other parts of the genome that could be due to off-
target effects of AID (Compagno et al., 2017). Patients relapsing from BCR signalling 
inhibitors have limited salvage options and poor clinical outcome, with a median survival of 
3.1 months following discontinuation of ibrutinib as reported recently (Jain et al., 2015). For 
all the above reasons, additional CLL treatment strategies and therapeutic combinations are 
still needed.   
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1.4. The ATR pathway as a novel therapeutic target 
 
1.4.1. The DNA damage response  
The DDR is an essential cellular mechanism for the maintenance of genome 
integrity. This is accomplished through a network of intricately connected pathways, resulting 
in a dichotomous outcome: either repair and resolution of the incipient DNA lesion, or 
apoptotic cell death, depending on the nature and severity of the afflicting lesion.  
ATM and ataxia telangiectasia and Rad3 related (ATR) are the two master 
regulators of DDR. ATM and ATR respond to different types of DNA lesions. ATM is a 
member of the phosphoinositide 3-kinase related kinase (PIKK) family of proteins. ATM 
responds primarily to DNA DSBs that can arise from physiological processes such as 
meiotic recombination and V(D)J recombination, or from exogenous genotoxic agents such 
as IR. The ATM signalling pathway (Figure 1.7) is initiated by docking of the MRE11-
RAD50-NBS1 (MRN) complex to the DSB which stabilises DSB ends. ATM is then recruited 
to the MRN complex.  At the MRN complex, ATM autophosphorylates, leading to its 
conversion from an inactive dimer form to active monomers. Activated ATM in turn 
phosphorylates a large number of substrates. Among these is the histone H2AX, yielding 
γH2AX. The phosphorylated histone γH2AX provides a platform for the recruitment and 
activation of downstream molecules. These include BRCA1 and 53BP1. They commit cells 
to homologous recombination repair (HRR) and non-homologous end joining (NHEJ) 
respectively, which are the two main pathways for DSB repair (Awasthi et al., 2016; 
Cremona and Behrens, 2014).  
Cell cycle regulation is also an important ATM function. The cell cycle is divided into 
four sequential phases: G1, S, G2 and M. During the S phase DNA synthesis occurs, and 
within the M phase cells undergo mitosis. These two phases are separated by gap phases 








The ATM signalling pathway.  (1) The MRE11-RAD50-NBS1 (MRN) complex is recruited 
to the site of the DSB which stabilises DSB ends. (2) ATM is recruited to the MRN complex 
and is activated by autophosphorylation and dimerisation. (3) ATM phosphorylates the 
histones H2AX to form γH2AX. (4) MDC1 binds to γH2AX. (5) MDC1 recruits the ubiquitin 
ligases RNF8 and RNF168, which ubiquitylates γH2AX and promotes the recruitment of 
53BP1 and BRCA1. (6) BRCA1 mediates homologous recombination repair (HRR) whereas 
53BP1 mediates non-homologous end joining (NHEJ). (7) ATM also mediates G1/S cell 
cycle arrest and apoptosis by activating Chk2 and p53. Reproduced with modifications from 
Anacker & Moody (2017). Modulation of the DNA damage response during the life cycle of 
human papillomaviruses. Virus Res. 231, 41-49.  
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(G1 and G2), which allow additional time for cell growth and to ensure conditions are 
suitable for commencing DNA replication or mitosis. There are two major checkpoints that 
control cell cycle progression: the G1/S checkpoint that regulates cell cycle entry and the 
initiation of DNA replication, and the G2/M checkpoint that regulates entry into mitosis.  
ATM controls principally the G1/S checkpoint through its downstream effector Chk2 
and the transcription factor p53. Firstly, ATM upregulates and activates p53. The latter is 
achieved by directly phosphorylating p53 and by promoting the proteasomal degradation of 
mouse double minute 2 homologue (MDM2), a negative regulator of p53. Active p53 induces 
the expression of p21, which suppresses the activity of the cyclin dependent kinase Cdk2 
required for entry into S phase, leading to G1/S cell cycle arrest. Secondly, ATM 
phosphorylates and activates Chk2. In turn, Chk2 activates p53 and inhibits the 
phosphatase Cdc25A essential for Cdk2 activation. This results in G1/S cell cycle arrest. 
Hence, ATM induces G1/S arrest through both p53 dependent and independent 
mechanisms, allowing time for DNA repair (Abraham, 2001). However, in cells with 
irreparable DNA damage, ATM signalling promotes their apoptosis through its activation of 
p53 (section 1.2.1.2).  
ATR is also a PIKK. However, in contrast to ATM, ATR has wide-ranging roles in 
the regulation of DNA replication and response to single-stranded DNA (ssDNA) 
perturbations during this process (Cimprich and Cortez, 2008). In addition, similar to ATM 
and p53, ATR also plays an important role in cell cycle regulation. The following sections will 
describe the functions of ATR and the ATR signalling pathway, and illustrate how targeting 
this pathway could potentially be useful in treating cancers including CLL, particularly in 
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1.4.2. Functional roles of ATR and the ATR signalling cascades 
1.4.2.1. Regulation of DNA replication initiation 
 DNA replication (Figure 1.8A) begins with the unwinding of the DNA double helix. 
This process is mediated by DNA helicase, which separates the two DNA strands as it 
moves along the DNA double helix. The position at which the DNA double helix first opens 
up is known as the replication origin. Opening up of the DNA double helix exposes the two 
parental DNA strands, which act as templates for the synthesis of two daughter strands. 
Synthesis of the two daughter strands is catalysed by DNA polymerase, which recognises 
each nucleotide on the two parental strands, and pairs it with a complementary nucleotide to 
form the daughter strands. DNA strands can only be synthesised in one direction, from 5’ to 
3’. Therefore, while one of the daughter strands (5’ to 3’) can be synthesised continuously in 
the forward direction, the other daughter strand (3’ to 5’) has to be synthesised in the 
reverse direction to the overall direction of DNA synthesis. The 3’ to 5’ daughter strand is 
synthesised as short DNA fragments called Okazaki fragments that are then joined together. 
The localised region of DNA synthesis is called the replication fork, which moves along the 
parental DNA double helix, and in doing so elongating the two daughter strands. This 
movement is known as replication fork progression. From the replication origin, two 
replication forks are formed, progressing in the opposite direction from each other. 
Therefore, daughter strands are elongated in both directions from the replication origin 
(Frouin et al., 2003).  
      In human cells, replication origins can arise simultaneously at multiple sites 
throughout the genome. Multiple replication origins, about 14 on average, are replicated 
together in clusters called replication factories. An important function of ATR is its ability to 
protect replication forks by acting as a negative regulator of replication origin initiation. This 
limits the activation of new replication factories, thereby directing replication towards already 
active factories (Chen et al., 2015; Ge and Blow, 2010). Such negative regulation of










Normal and aberrant DNA replication. (A) Replication is initiated at replication origins and 
involves the opening of the DNA double helix (by DNA helicase) and the synthesis of 
daughter strands (by DNA polymerase). The leading strand is synthesised continuously in 
the forward direction, whereas the lagging strand is synthesised as Okazaki fragments that 
are joined together. From the replication origin, two replication forks are formed, travelling in 
the opposite direction from each other. (B) Replication stress occurs when replication fork 
progression is disrupted, e.g. due to a DNA lesion. Continued unwinding of the DNA double 
helix by DNA helicase, despite stalled DNA polymerase, leads to exposed ssDNA that is 
prone to breakage. Reproduced with modifications from Mechali (2010). Eukaryotic DNA 
replication origins: many choices for appropriate answers. Nat Rev Mol Cell Biol. 11, 728-
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replication initiation is important in preventing the depletion of cellular pools of nucleotides 
and replication proteins, which would otherwise result in replication fork breakage and 
genomic instability.  
 
1.4.2.2. Maintenance of replication fork stability 
 During DNA replication, replication fork progression can slow or stall due to 
replication obstacles such as DNA damage. This may lead to continued unwinding of the 
DNA double helix despite stalled DNA polymerase. Consequently, long stretches of ssDNA 
within replication forks are exposed. Exposed ssDNA are prone to damage, resulting in 
replication fork breakage (Figure 1.8B). The ATR pathway functions to prevent this by 
protecting exposed ssDNA and repairing the replication obstacle that leads to the slowing or 
stalling of replication fork progression. Exposed ssDNA is rapidly coated with replication 
protein A (RPA), which stabilises the replication fork and protects ssDNA from deleterious 
degradation by cellular endonucleases (Marechal and Zou, 2015).  
The ATR signalling cascade (Figure 1.9A) is initiated by the independent 
recruitment of two complexes to RPA coated ssDNA. The first of these is a heterodimer 
composed of ATR and the ATR-interacting protein (ATRIP). The second is the RAD9-RAD1-
HUS1 (9-1-1) complex. At the exposed ssDNA, the ATR-ATRIP complex binds to RPA, and 
engages with the 9-1-1 complex. Further recruitment of topoisomerase 2-binding protein 1 
(TOPBP1) or Ewing’s tumor-associated antigen 1 (ETAA1) activates ATR by stimulating 
ATR kinase activity (Bass et al., 2016; Cotta-Ramusino et al., 2011; Haahr et al., 2016). 
Functionally active ATR in turn phosphorylates the downstream effector molecule Chk1, and 
other proteins including Werner syndrome ATP-dependent helicase (WRN), Bloom 
syndrome protein (BLM) and SMARCAL1 (Awasthi et al., 2016). 
Through these proteins, ATR promotes replication fork stability and mediates 
replication restart in the event of fork stalling. This is achieved through fork reversal whereby




The ATR signalling pathway.  (A) (1) Exposed ssDNA at the site of replication fork stalling is coated with RPA to stabilise the replication fork. (2) 
ATR/ATRIP binds RPA and (3) engages with the 9-1-1 complex. (4) ATR is activated by the recruitment of TOPBP1 or ETAA1 (not shown). (5) ATR 
phosphorylates Chk1, and ATR/Chk1 engages in the tripartite actions of suppression of replication origin initiation, G2/M cell cycle arrest, and fork 
reversal and restart. (B) Fork reversal involves unwinding of newly synthesised strands, and the sequential annealing of parental and daughter 
strands. Fork reversal is followed by fork restart. Reproduced with modifications from Cimprich & Cortez (2008). ATR: an essential regulator of 
genome integrity. Nat Rev Mol Cell Biol. 9, 616-627, and from Neelsen & Lopes (2015). Replication fork reversal in eukaryotes: from dead end to 
dynamic response. Nat Rev Mol Cell Biol. 16, 207-220. 
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stalled forks reverse their course, and through fork remodelling (Neelsen and Lopes, 2015). 
Helicases such as WRN and BLM, and translocases such as SMARCAL1 and the Fanconi 
anaemia complementation group M protein (FANCM) are thought to play a major role in this 
process (Berti and Vindigni, 2016). Fork reversal, remodelling and restart together ensure 
completion of DNA replication and prevent fork breakage (Figure 1.9B).  
Proteins downstream of ATR also serve additional functions in facilitating fork 
repair, through suppression of new replication origin firing (BLM and FANCM), and 
protection of replication forks from breakage or degradation (WRN) (Berti and Vindigni, 
2016). Furthermore, Chk1 diffuses throughout the nucleus to suppress new replication origin 
initiation (Petermann et al., 2010). Thus, the regulatory activities of ATR signalling are 
amplified and propagated globally throughout the cell nucleus in the event of replication fork 
stalling. This is crucial in curtailing further replication fork stalls, thereby conserving the 
supply of RPA for those replication forks that are already stalled and to ensure that an 
excess supply of RPA is maintained (Fragkos et al., 2015). 
 
1.4.2.3. Regulation of cell cycle progression 
Similar to ATM, ATR also participates in the regulation of cell cycle progression. 
However, in contrast to ATM which controls primarily the G1/S checkpoint, ATR controls 
principally the G2/M checkpoint through the activity of Chk1. Mechanistically, this involves 
inhibiting the phosphatase Cdc25C to prevent it from binding to Cdk1. Cdc25C removes 
inhibitory phosphorylation from Cdk1 that is a prerequisite for mitotic entry. In the presence 
of stalled replication forks, abolition of Cdk1 activity through Chk1-mediated phosphorylation 
of Cdc25C prevents premature entry of replicatively perturbed cells into mitosis, until 
replication stalling is rectified and genomic duplication is complete (Peng et al., 1997; 
Sorensen et al., 2003).  
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1.4.3. ATR as a cancer therapeutic target 
1.4.3.1. Replication stress and DNA damage as consequences of ATR inhibition 
When replication fork progression is disrupted, slowing or stalling of replication forks 
ensues. This results in replication stress, defined as a state of cellular stress which arises 
due to the presence of stalled replication forks and unreplicated DNA (Zeman and Cimprich, 
2014). Replication stress may arise, for instance, from unrepaired DNA damage, which 
obstructs replication fork progression. Such DNA damage may be generated spontaneously 
during DNA metabolism, or by environmental genotoxic agents (Ciccia and Elledge, 2010). 
The ATR signalling pathway ameliorates replication stress through its tripartite role in the 
regulation of DNA replication initiation, the maintenance of replication fork stability, and cell 
cycle regulation, as outlined above. Conversely, inhibition of the ATR pathway is a potent 
inducer of replication stress.   
A consequence of ATR inhibition is the excessive replication origin initiation in an 
unscheduled and uncontrolled manner. This occurs independently of any additional sources 
of replication stress, either endogenous or exogenous. Indeed, studies have shown that the 
number of active replication forks in cancer cells is increased when ATR is inhibited, in the 
absence of DNA damaging agents or other sources of replication stress (Couch et al., 2013). 
Excessive and uncontrolled replication origin initiation as a result of ATR inhibition depletes 
the cellular pool of essential replication factors such as nucleotides and replication proteins. 
This leads to a decrease in the rate of replication fork elongation and stalling of replication 
forks (Petermann et al., 2010; Toledo et al., 2013). This is evidenced by experiments in 
cancer cells showing rapid reduction in inter-origin distance indicating increased replication 
origin initiation, accompanied by reduction in replication fork progression rate, upon inhibition 
of ATR (Couch et al., 2013). These observations are consistent with the induction of 
replication stress.  
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Excessive and uncontrolled initiation of replication origin initiation also generates 
excessive amounts of ssDNA. Exposed ssDNA is normally coated with RPA. However, 
when ATR is inhibited, the excess of ssDNA exhausts the nuclear pool of RPA. Unprotected 
ssDNA is susceptible to fork breakage, thereby precipitating DNA damage (Toledo et al., 
2013). Furthermore, ATR inhibition prevents proper regulation of SMARCAL1, the 
deregulated activities of which promotes excessive replication fork regression and fork 
collapse, resulting in DNA damage (Couch et al., 2013). Together, these mechanisms 
underpin the DNA damage caused by ATR inhibition. 
 
1.4.3.2. Replication stress as a therapeutic vulnerability in cancer cells 
An elevated level of replication stress is a defining feature of malignant cells. 
Although the precise mechanism underlying this remains unclear, it has been hypothesised 
that the accelerated consumption of RPA resulting from unchecked tumour proliferation, 
could be a contributing factor (Toledo et al., 2013). Other potential mechanisms, such as the 
deregulation of replication initiation, have also been postulated (Hills and Diffley, 2014; 
Macheret and Halazonetis, 2015). Given the high constitutive levels of cellular replication 
stress inherent in many tumours, it follows that they are likely to be particularly sensitive to 
replication stress overload instigated by inhibition of ATR.  
Until recently, it has been assumed that ATR is physiologically indispensable and 
not amenable to therapeutic targeting (Brown and Baltimore, 2003). Indeed, human ATR 
mutations are uncommon, even in cancer. Among the few cancer types where ATR 
mutations have been reported, the acquisition of these mutations has been associated with 
tumour progression and poor clinical outcome (Zighelboim et al., 2009). Moreover, 
abrogation of the ATR gene is embryonically lethal, while its deletion in adult mice results in 
rapid aging and stem cell loss (de Klein et al., 2000; Ruzankina et al., 2007). In patients with 
Seckel syndrome in whom ATR signalling is defective due to hypomorphic germline mutation 
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of both ATR alleles, growth retardation, dwarfism, microcephaly and mental impairment are 
typical manifestations (Murga et al., 2009; O'Driscoll et al., 2003).  
Nonetheless, whereas complete or near-complete abolition of ATR activity likely 
results in toxicity to healthy tissues, partial suppression of ATR activity was shown to be 
tolerable in healthy cells but not in tumour cells. In a study by Schoppy and colleagues, 
reduction of ATR in mice to 10% of normal levels, by deleting one ATR allele and replacing 
the other one with a Seckel allele, resulted in minimal adverse effect on healthy 
haematopoietic and intestinal tissues. In contrast, suppression of ATR to this level was 
adequate to severely restrict the growth of fibrosarcomas driven by H-Ras and p53 loss, as 
well as acute myeloid leukaemia driven by N-Ras and the MLL-ENL translocation (Gilad et 
al., 2010). Such a reduction of ATR level likewise prevented the development of Myc driven 
lymphomas and pancreatic tumours featuring high levels of replication stress (Murga et al., 
2011). Therefore, healthy and tumour cells may demonstrate differential sensitivity to ATR 
inhibition, making it a potential cancer therapeutic strategy.  
 
1.4.3.3. ATR pathway addiction and the concept of synthetic lethality 
The substantial functional redundancy within cellular DDR pathways is widely 
recognised, wherein more than one pathway is capable of performing the same role. 
Physiologically this provides protection against disruption of normal DDR mechanisms, 
particularly in cancer where DDR genes are mutated with high frequency. However, when 
one pathway is disrupted, cells become heavily reliant on collateral pathways. Thus, where 
two independent pathways regulate an essential DDR process, the absence of one pathway 
is compatible with cell survival, while the absence of both results in cell death. This gives 
rise to an emerging therapeutic concept known as synthetic lethality, in which collaborating 
pathways are abolished to induce cytotoxicity (McLornan et al., 2014; Shaheen et al., 2011).  
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From the studies highlighted above, it is apparent that tumours with heightened 
levels of replication stress, such as those driven by Myc or Ras, are exquisitely sensitive to 
ATR inhibition. Understanding other circumstances under which tumour cells become 
addicted to ATR is essential to identifying further predictive biomarkers of sensitivity to ATR 
inhibition. There is evidence that such an addiction to ATR may occur in tumours with TP53 
or ATM functional loss.  
   
1.4.3.4. Synthetic lethality with TP53 functional loss 
The loss of the G1/S cell cycle checkpoint due to TP53 functional loss imposes 
upon tumour cells a dependence on the G2/M cell cycle checkpoint controlled primarily 
through ATR via its downstream kinase Chk1. Consequently, ATR inhibition may have 
synthetically lethal properties in TP53 deficient tumours. 
Nghiem and colleagues provided one of the earliest evidence demonstrating 
hypersensitivity of G1/S checkpoint deficient cells to ATR loss. In this study, investigators 
observed that the osteosarcoma cell line U2OS in the absence of ATR function displayed 
premature chromatin condensation, in response to hydroxyurea or ultraviolet radiation 
induced replication stress. Premature chromatin condensation is indicative of mitotic 
catastrophe, a form of cell death occurring during mitosis due to the accumulation of 
catastrophic levels of DNA damage (Castedo et al., 2004). Moreover, repression of p53 
function by overexpression of MDM2, a negative regulator of p53, markedly potentiated the 
lethal effect of ATR inhibition in these cells (Nghiem et al., 2001). These findings were 
recapitulated in a later study showing that a p53 deficient colorectal cell line rendered ATR 
deficient by replacing both wild-type ATR alleles with Seckel alleles, exhibited marked 
sensitivity to hydroxyurea or cisplatin induced replication stress. However, restoration of p53 
function reduced its sensitivity to these agents (Sangster-Guity et al., 2011).     
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These in vitro studies were complemented by in vivo experiments, in which ATR 
knockout murine models were generated from TP53 knockout mice. Mice with concomitant 
loss of both ATR and p53 displayed markedly reduced survival compared to those 
harbouring isolated loss of ATR. In addition, animals carrying a combined loss of ATR and 
p53, but not those with loss of ATR or p53 alone, exhibited high levels of DNA damage 
(Ruzankina et al., 2009). In a further study using xenotransplantation models of both p53 
wild-type and p53 mutant triple-negative breast cancer, Chk1 inhibition potentiated 
chemotherapy-induced apoptosis in p53 mutant xenografts but not in the p53 wild-type 
counterparts. Combining Chk1 inhibition with the topoisomerase inhibitor irinotecan resulted 
in suppression of tumour growth and prolongation of survival in p53 mutant but not wild-type 
xenografts (Ma et al., 2012).  
 
1.4.3.5. Synthetic lethality with ATM functional loss 
ATR inhibition results in the induction of replication stress and DNA damage. In the 
absence of ATR, stalled forks and DNA damage are dependent on ATM for repair. 
Furthermore, as discussed earlier, ATM also plays an important role in cell cycle regulation. 
Thus, ATR may also be synthetically lethal with ATM functional loss.     
Consistent with this, Reaper and colleagues showed that ATR inhibition was 
invariably cytotoxic to ATM defective tumour cell lines. Moreover, ATR inhibition was more 
profoundly synergistic with replication stress inducing genotoxic agents such as cisplatin and 
carboplatin, in tumour cell lines with ATM defects compared to those without, and in cells 
subjected to pharmacological inhibition of ATM compared to cells without ATM inhibition 
(Reaper et al., 2011).  
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1.4.3.6. Small molecule inhibitors of ATR 
As mentioned in section 1.4.1, ATR is a PIKK. As a result of the atypical nature of 
PIKKs relative to other more conventional kinases, the design and development of selective 
ATR kinase inhibitors has not been straightforward. Early inhibitors of ATR were not specific. 
However, more recently, two drug companies have manufactured potent and highly specific 
ATR inhibitors. They are respectively VE-821 and its analogue VX-970 manufactured by 
Vertex Pharmaceuticals, as well as AZ20 and AZD6738 developed by AstraZeneca 
(Charrier et al., 2011; Foote et al., 2013). They are all ATP-competitive ATR kinase 
inhibitors. 
AZ20 is a sulfoximine morpholinopyrimidine with potent and selective activity 
against the ATR kinase. It was generated through an AstraZeneca lead compound discovery 
and optimisation programme, which involved screening a compound library with structural 
similarity to PI3K and PIKK inhibitors, and modification of the identified lead compound 
(Foote et al., 2013). AZD6738 is a newly synthesised analogue of AZ20, with improved 
pharmacodynamic and pharmacokinetic properties, and is suitable for oral administration 
(Foote et al., 2015).  
Both AZD6738 and VX-970 have now entered phase I/II clinical testing. However, 
most of these studies have been initiated recently, and no results have yet been reported. 
As of March 2017, 11 clinical trials on ATR inhibitors are ongoing for a range of 
malignancies. These studies examine the use of the ATR inhibitor either alone or in 
combination with a range of conventional and novel therapeutic agents, including cisplatin, 
carboplatin, gemcitabine, etoposide, irinotecan, the poly (ADP-ribose) polymerase (PARP) 
inhibitors olaparib and veliparib, and the programmed death-ligand 1 (PD-L1) immune 
checkpoint inhibitor durvalumab. 
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1.5. Minimal residual disease in CLL 
 
1.5.1. The concept of post-treatment minimal residual disease 
Post-treatment response assessment in CLL is made in accordance with the IWCLL 
2008 response criteria, in which a CR, which denotes the complete normalisation of blood 
counts and the complete disappearance of symptoms and signs associated with the disease 
(Hallek et al., 2008), is recognised as the therapeutic end-point. However, residual CLL cells 
may still be present after treatment even though no clinically detectable disease remains. 
The residual CLL population remaining after treatment is known as minimal residual disease 
(MRD). The expansion of residual CLL cells may lead to eventual disease relapse with the 
duration of remission dependent on the depth of remission (i.e. the amount of residual CLL 
cells) and the rate of CLL repopulation (i.e. the CLL doubling time). 
In some haematological malignancies, such as CML and acute lymphoblastic 
leukaemia (ALL), periodic monitoring of MRD has become a routine clinical practice. In 
these malignancies, as well as in others where MRD assays are available, the absence of 
detectable MRD is almost always associated with improved clinical outcome. MRD can 
therefore be used as a prognostic biomarker to predict the likelihood of disease relapse 
following treatment. MRD measurements are also increasingly being used to guide 
treatment. For instance, MRD levels at the end of induction therapy for ALL or AML may 
dictate the choice of the subsequent consolidation therapy (Ivey et al., 2016; Vora et al., 
2014; Vora et al., 2013). On the other hand, patients with CML on tyrosine kinase inhibitors 
who no longer have molecularly detectable disease could potentially cease treatment 
(Mahon et al., 2016; Melo and Ross, 2011).  
In CLL, MRD can now be detected, in the bone marrow or peripheral blood, to a 
sensitivity of one CLL cell in 10,000 leukocytes (10-4) using multiparameter flow cytometry or 
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polymerase-chain reaction (PCR) based molecular methods. In addition, treatments are now 
available that can deplete CLL cells to a level below detection by these sensitive methods in 
some patients. However, MRD assays are not in routine clinical use in CLL, and have not 
thus far been used to guide management of CLL patients. The following sections will 
describe methodologies for detecting CLL MRD, as well as the current literature on the 
clinical value of MRD assessment in CLL.  
 
1.5.2. Approaches for measuring MRD 
1.5.2.1. Multiparameter flow cytometry 
As discussed in section 1.1.2, flow cytometry enables a diagnosis of CLL to be 
made based on the unique phenotypic features that distinguish CLL cells from other blood 
cells, including healthy B lymphocytes. On the same basis, MRD can be measured by flow 
cytometric quantification of the cellular population with a CLL phenotype at the end of 
treatment. This is the most widely used approach for MRD analysis.  
The earliest attempt to quantify MRD utilises traditional CLL phenotypic markers: 
CD19 and CD5, together with either κ or λ, depending on the light chain restriction of the 
CLL clone. However, the sensitivity of this method in distinguishing CLL cells from healthy B 
cells was low. In particular, while the proportion of healthy B cells expressing CD5 is 
generally <30%, CD5 expression may be present in up to 90% of healthy B cells in the 
regenerating blood after chemotherapy-containing treatments (Cabezudo et al., 1997). 
Moreover, a proportion of CLL cases may have an atypical phenotype with weak expression 
of CD5 (Romano et al., 2015). In an attempt to design a more sensitive flow cytometry 
based MRD assay, Rawstron and colleagues compared the sensitivity of different 
phenotypic markers in differentiating healthy and neoplastic B cells in patients with CLL 
(Rawstron et al., 2001). Within the peripheral blood, the marker that produces the greatest 
87     
degree of separation between healthy B cells and CLL cells was CD20, followed by CD79a/b 
and CD5. Compared to healthy B cells, CLL cells typically express low levels of CD20 and 
CD79a/b, and high levels of CD5. A four colour MRD flow cytometry assay was developed 
using the CD19/CD5/CD20/CD79b combination, which is capable of detecting CLL cells in 
the peripheral blood to a sensitivity of one CLL cell in 10,000 leukocytes.  
Subsequent attempts have been made by the European Research Initiative in CLL 
to standardise a MRD flow cytometry panel for use across patients receiving different 
treatments, and to harmonise its use across different centres internationally (Rawstron et al., 
2007). This is particularly important for patients who received treatments that incorporate 
rituximab, because CD20 could be downmodulated on CLL as well as healthy B cells by 
rituximab (Jilani et al., 2003). Together with the fact that an atypical CLL phenotype might 
include low CD5 and/or high CD79b expression, and that progenitor B cells do not express 
CD20 and CD79b, the CD19/CD5/CD20/CD79b combination alone might not be sufficient to 
sensitively detect MRD in all CLL patients.  
Therefore, a large number of four-colour combinations of phenotypic markers were 
tested, and three of these showed the lowest inter-laboratory variability and false positive 
rate. These were combinations of CD19/CD5 with CD20/CD38, CD81/CD22 and 
CD43/CD79b respectively. These three 4-colour combinations formed the basis of the 
harmonised MRD panel (Rawstron et al., 2007). Further improvements include efforts to 
consolidate the three 4-colour tubes into two 6-colour tubes, and more recently, by 
eliminating redundant markers to further simplify the assay into a single-tube panel 
consisting of six markers (Rawstron et al., 2013; Rawstron et al., 2016). These six core 
markers are CD19, CD20, CD5, CD43, CD79b and CD81. The use of these 6 markers alone 
could readily differentiate CLL cells from healthy B cells in the majority of CLL patients 
treated with a range of different therapies. The inclusion of CD43 (high in CLL vs healthy B 
cells) could help differentiate CLL cells from healthy B cells in atypical CLL cases with low 
CD5 and/or high CD79b. In addition, the expression of CD5 and CD81 could together 
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distinguish CLL cells from progenitor B cells, because CD5 expression is low and CD81 
expression is high in B cell progenitors, and vice versa in CLL cells. Analysis of the 
sensitivity of this single-tube 6-colour assay shows that a limit of detection of 1 CLL cell in 
100,000 (10−5) leukocytes could be reliably achieved with an acquisition of 2,000,000 events, 
and a limit of detection of 1 CLL cell in 10,000 leukocytes (10−4) could be achieved with 
200,000 events.  
 
1.5.2.2. Quantitative PCR and high-throughout sequencing 
 MRD quantitation by multiparameter flow cytometry is relatively inexpensive and 
rapid. However, its sensitivity is currently limited to 10−4 to 10−5 CLL cells. On the other hand, 
PCR-based molecular methods could be more expensive and time-consuming, but they 
enable higher sensitivity of MRD detection to be achieved. Moreover, DNA samples could be 
stored and analysed retrospectively. 
 PCR-based methods generally exploit the unique IGHV CDR3 sequence of the CLL 
clone to distinguish it from healthy polyclonal B cells. One approach through which this can 
be achieved is by quantitative allele-specific oligonucleotide (ASO) PCR. In this method, the 
IGHV gene of the patient’s CLL is first sequenced prior to the commencement of treatment. 
From the IGHV sequence, ASO primers corresponding to the unique CDR3 sequence of the 
CLL clone is then generated. After the end of treatment, MRD can be monitored by real-time 
quantitative PCR using these CLL-specific primers. The sensitivity of this methodology can 
reach up to 1 CLL cell in 1,000,000 leukocytes (10−6) (Pfitzner et al., 2000; Voena et al., 
1997).  
 More recently, deep sequencing of the IGHV gene has been used to replace 
quantitative PCR for MRD detection (Logan et al., 2013; Rawstron et al., 2016). Deep 
sequencing refers to an NGS approach where a targeted region of the genome is 
sequenced to a high coverage (i.e. >1000 times). This allows sequence variants to be 
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detected and the frequency of the variant quantified within a sample containing different 
cellular populations, such as a mixture of CLL cells and healthy B cells. Like the real-time 
quantitative PCR method, the IGHV gene of the patients’ CLL cells is sequenced before 
treatment, but no subsequent design of CLL-specific primers is required. Detection of MRD 
following the end of treatment utilises deep IGHV sequencing with consensus primers, and 
the results obtained are then compared to the known IGHV sequence of the CLL clone. The 
difference between the IGHV sequences of the CLL cells and healthy B cells allow any 
residual CLL clone to be detected and quantified, to a sensitivity of 10−5 to 10−6. 
 
1.5.3. Clinical significance of MRD in CLL 
1.5.3.1. Treatments capable of achieving MRD negativity 
 In CLL, the current requirement for MRD negativity is less than one CLL cell in 
10,000 leukocytes (10-4), as stipulated in the IWCLL 2008 guidelines (Hallek et al., 2008). 
Historically, the only CLL treatment capable of achieving sustained MRD negativity is 
haematopoietic stem cell transplantation (SCT) (Dreger et al., 2010; Moreno et al., 2006). 
However, the majority of patients requiring treatment for CLL are elderly, frail or have 
multiple co-morbidities. Despite the availability of reduced intensity conditioning (RIC) 
regimens for allogeneic SCT, transplant-related mortality remains substantial for this group 
of elderly individuals. The availability of chemoimmunotherapy has allowed MRD negativity 
to be achievable in a substantial proportion of CLL patients without having to undergo an 
allogeneic SCT. In the German CLL study group CLL8 trial comparing FCR vs FC discussed 
earlier in section 1.3.1.1, MRD negativity at the end of treatment was observed in the 
peripheral blood in 63% of patients who received FCR compared to 35% who received FC, 
and in the bone marrow in 44% of patients who received FCR vs 28% of FC-treated 
patients. Although FCR was superior to FC overall, patients who attained MRD negativity 
had similar clinical outcome regardless of whether they were treated to MRD negativity with 
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FC or FCR. The overall superiority of the FCR arm was due to a higher proportion of 
patients achieving MRD negativity with FCR compared to FC (Bottcher et al., 2012). 
 MRD negativity is also achievable with mAbs alone. For instance, a substantial 
proportion of patients (20%) achieved bone marrow MRD negativity with alemtuzumab in a 
historical clinical trial (Moreton et al., 2005). With regards to novel small molecule inhibitors, 
MRD negativity is uncommon with BCR signalling inhibitors. However, recent reports have 
shown that this is achievable with venetoclax, including among patients having adverse 
biological features such as TP53 mutations (Eichhorst et al., 2015; Ma et al., 2015).  
 
1.5.3.2. Prognostic impact of MRD 
 Numerous studies (Table 1.2) have assessed the prognostic significance of MRD in 
univariate analyses, in which the outcome of MRD-negative patients was compared directly 
to the outcome of MRD positive patients. The majority of these studies were conducted as 
part of a clinical trial evaluating the efficacy of a single (or occasionally two) therapeutic 
agent, either in the frontline or the relapsed/refractory setting. In these studies, attainment of 
MRD negativity was invariably associated with improved PFS and OS. For instance, in 
previously untreated patients receiving FC or FCR as part of the German CLL8 trial, PFS, 
with a 4 year follow-up, was 69, 41 and 15 months respectively for post-treatment MRD 
levels of <10−4, ≥10−4 to ≥10−2 and ≥10−2 (Bottcher et al., 2012). In patients treated with 
combined bendamustine and rituximab, this was not reached, 32 and 12 months 
respectively for the above MRD levels with a median follow-up of 2 years (Fischer et al., 
2012). In relapsed/refractory patients receiving alemtuzumab, the TFS for MRD negative vs 
positive individuals was not reached vs 20 months, and the OS was not reached vs 41 
months with a follow-up of 3 years (Moreton et al., 2005).  
Nevertheless, univariate analyses alone do not provide insight as to whether 
improved clinical outcome is due to the attainment of MRD negativity, or whether MRD 
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FCR 161 BM 
Flow 
cytometry 
2.3 <0.001 0.03 0.006 0.02 











<0.001 - - - 
(Thompson et al., 
2016) 
FCR 170 BM 
ASO IGHV 
qPCR 
12.8 <0.001 - <0.001 - 
 
RELAPSED/REFRACTORY SETTING 
(Wierda et al., 
2005) 
FCR 32 BM 
ASO IGHV 
qPCR 
1.7 n.s. - - - 
(Moreton et al., 
2005) 
Alemtuzumab 34 BM 
Flow 
cytometry 
3.0 <0.001 - <0.001 - 









0.009 - - - 
F, fludarabine; C, cyclophosphamide; M, mitoxantrone; R, rituximab; B, bendamustine; BM, bone marrow; PB, peripheral blood; ASO; allele-specific 
oligonucleotide; PFS; progression-free survival; OS, overall survival. Adapted from Thompson & Weirda (2016). Eliminating minimal residual 
disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 127, 279-286. Modified and updated.  
92     
negativity is a surrogate for other factors that predict for favourable clinical outcome. Such 
an insight can be obtained from multivariate analyses, which take into consideration other 
prognostic factors that could also influence outcome. However, few studies have evaluated 
the impact of MRD within multivariate analyses. In the German CLL8 trial where such an 
analysis was performed, MRD negativity predicted for PFS and OS independently of clinical 
response, del(17p) and IGHV mutational status (Bottcher et al., 2012). On the other hand, 
the independent prognostic significance of MRD outside the frontline chemoimmunotherapy 
setting is unknown. 
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1.6. Aims 
 
 The work described in this thesis aims to generate novel insights into the 
mechanisms behind disease heterogeneity of CLL and improve its treatment. This is 
achieved by focusing on three unique groups of patients: (1) patients with an exceptionally 
good outcome, who have undergone spontaneous disease regression; (2) patients with an 
exceptionally poor outcome, whose CLL harbours TP53 or ATM defects; and (3) patients 
with an exceptionally good response to treatment, who attained MRD negativity. The specific 
aims of each of the three components of this work are outlined below: 
 Features and mechanisms underpinning spontaneous disease regression in 
CLL (Chapter 3).  The biological features and processes underpinning the natural history of 
patients with spontaneous CLL regression are unknown. My aim is to undertake a 
comprehensive phenotypic, functional and genomic study on these patients in order to 
answer three questions: (1) What are the key biological features of spontaneously regressed 
CLL? (2) What are the phenotypic changes during spontaneous CLL regression and the 
potential mechanism underpinning these changes?  (3)  What can we learn about the 
treatment of CLL from these patients? 
 Pre-clinical efficacy and mechanism of ATR inhibition in CLL (Chapter 4). 
Current therapeutic options for CLL, particularly for patients with TP53 or ATM defects, 
remain inadequate. My aim is to undertake a pre-clinical evaluation of the ATR inhibitor 
AZD6738 in CLL in order to answer three questions: (1) What is the therapeutic efficacy of 
ATR inhibition in CLL, particularly in CLL with TP53 or ATM defects? (2) What is the 
mechanism underlying the cytotoxic effects of ATR inhibition in CLL?  (3)  What is the effect 
of combining ATR inhibition with other CLL treatments?   
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 Long-term independent prognostic significance of MRD in CLL (Chapter 5).  
The independent prognostic significance of MRD is unknown in CLL outside the frontline 
chemoimmunotherapy setting. My aim is to undertake a single-centre, retrospective analysis 
of patients who have received MRD assessments after their treatment for CLL, in order to 
answer two questions: (1) What is the long-term prognostic value of MRD in the frontline and 
relapsed/refractory settings respectively? (2) What is the independent prognostic 











MATERIALS & METHODS 
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2.1. Clinical cohorts and CLL samples 
 
2.1.1. Birmingham and Leeds CLL cohorts 
The majority of samples used in the spontaneous CLL regression study (Chapter 3) 
and all samples used in the ATR inhibitor study (Chapter 4) were obtained from patients 
diagnosed with CLL at Queen Elizabeth Hospital Birmingham or at Birmingham Heartlands 
Hospital. The spontaneous CLL regression study also included the use of samples from 
patients diagnosed at St. James’s University Hospital or Pinderfields General Hospital in 
Leeds, or from individuals enrolled within UK multicentre clinical trials. For the retrospective 
MRD study (Chapter 5), all patients enrolled were treated for CLL at St. James’s University 
Hospital in Leeds or at associated hospitals in the Yorkshire region. All research involving 
patients was conducted in accordance with the Declaration of Helsinki, with full approval 
from the local National Health Service (NHS) research ethics committee (REC). These local 
CLL cohorts are described in more detail below: 
Birmingham CLL cohort.  Patients attending CLL clinic were consented for blood 
donation under the REC protocol 10/H1206/58 (West Midlands – Solihull Research Ethics 
Committee). A system has been in place for many years whereby blood samples were 
collected and archived during each clinic visit, resulting in a local biobank of CLL samples 
with different clinical and biological characteristics. These archived samples were used for 
the investigations described in the ATR inhibitor study. For the spontaneous CLL regression 
study, both fresh and archived samples were used, depending on the investigation.   
Spontaneous CLL regression cohort.  Patients with spontaneous CLL regression 
were identified from a review of (1) all patients with a diagnosis of CLL who have attended a 
haematology clinic at Queen Elizabeth Hospital Birmingham or Birmingham Heartlands 
Hospital for the past 5 years; and (2) all patients with CLL who have been enrolled in the 
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Leeds community outreach monitoring programme. The latter scheme allows patients with 
stable disease to be discharged from outpatient follow-up, with regular blood samples being 
sent by their general practitioner to the Haematological Malignancy Diagnostic Service 
(HMDS) laboratory in Leeds for monitoring. Patients identified as meeting the criteria for 
spontaneous disease regression were contacted and invited to attend an outpatient 
appointment where the research study was discussed in detail. Written consent was 
obtained from subjects who agreed to take part, and a blood sample was collected. An 
amendment of the REC protocol 10/H1206/58 was specifically made to allow patients who 
have been discharged from outpatient follow-up to be recalled, and to include Leeds as a 
participating centre.  
 Leeds MRD study cohort.  This cohort includes all patients from Leeds and 
associated regional hospitals who have received an MRD assessment after completion of 
CLL treatment in the 12 year period from 1996 to 2007. These patients all received MRD 
assessments as part of the clinical trials they were enrolled in. Ethical approval for the 
respective trials includes approval for MRD assessments to be carried out and patients to be 
followed up.  
 
2.1.2. Clinical trial cohorts 
Within the CLL spontaneous regression study, a number of investigations involve 
comparison of spontaneous regression cases against progressive as well as indolent cases. 
All indolent cases were derived from the local Birmingham CLL cohort. Progressive samples, 
on the other hand, were taken from patients due to commence treatment as part of a UK 
clinical trial. These trials are described below: 
IcICLLe trial.  This is a phase II trial enrolling 40 patients onto ibrutinib, 20 of whom 
are treatment-naïve and 20 have previously been treated. As part of this study, extended 
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CLL immunophenotypic analysis was carried out on peripheral blood samples taken before 
and at regular intervals during treatment. The pre-treatment immunophenotypic data from 
the entire IcICLLe cohort was used for comparison against the immunophenotypic results 
from the spontaneous CLL regression cohort.  
CLARITY trial.  This is a phase II trial enrolling previously treated patients onto 
venetoclax plus ibrutinib. Because CLL Mcl-1 expression data was not available from the 
IcICLLe cohort, the pre-treatment Mcl-1 expression data from this cohort was used instead 
for comparison against the Mcl-1 expression results from the spontaneous regression 
cohort.  
 
2.1.3. Sample preparation 
Venous blood samples were collected into 9 ml vacutainer tubes coated with 
heparin or ethylenediaminetetraacetic acid (EDTA). They were either used directly for flow 
cytometry experiments, or processed to separate peripheral blood mononuclear cells 
(PBMCs) from other components within the blood sample.  
Isolation of PBMCs from whole blood.  The blood sample was first diluted in 
RPMI-1640 medium (Sigma) supplemented with 10% foetal bovine serum (FBS; Sigma), 
where 10 ml of the medium was added to every 20 ml of whole blood. Up to 30 ml of the 
diluted blood was then layered onto 10 ml of Lymphoprep solution (Axis-Shield) in a 50 ml 
Falcon tube. The tube was then centrifuged at 1700 rpm for 30 minutes with brake off. This 
procedure exploits the differential density of PBMCs relative to erythrocytes and 
granulocytes. Erythrocytes and granulocytes sediment through the Lymphoprep layer to the 
bottom of the Falcon tube, leaving the PBMCs to be collected at the interface between the 
uppermost plasma layer and the Lymphoprep layer at the end of centrifugation. The isolated 
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PBMCs were then washed twice in RPMI-1640 with 10% FBS, and counted using a 
haemocytometer (Kova).  
Cell freezing and storage.  Washed PBMCs were resuspended in a freezing 
medium containing 90% FBS and 10% dimethylsulphoxide (DMSO; Sigma), and transferred 
into 1.5 ml cryovials. Cryovials were then wrapped in cotton wool and placed in a container 
at -80°C to allow gradual cooling of the samples. The samples were subsequently 
transferred to be stored in liquid nitrogen.  
 Cell thawing and revival.   To use archived samples stored in liquid nitrogen, 
samples were first thawed rapidly in a 37°C water bath. The thawed cells were then 
transferred to a universal tube and 10 ml of RPMI-1640 with 10% FBS was added dropwise 
to the cells. The supernatant was quickly removed after centrifugation to avoid prolonged 
exposure to DMSO which may be toxic for the cells.  
 
2.1.4. Cell sorting 
A number of investigations in the spontaneous CLL regression study required the 
use of isolated CD19+ CD5+ CLL cells. The isolation of these cells from PBMCs was carried 
out using a two-step magnetic-activated cell sorting (MACS) process. This involves first 
isolating CD19+ B lymphocytes by depleting all other cell types. The sorted CD19+ B 
lymphocyte population was then enriched for CD19+ CD5+ CLL cells by positive sorting for 
CD5+ cells.  
Isolation of CD19+ B lymphocytes.  CD19+ B lymphocytes were isolated from 
PBMCs using the human B-CLL cell isolation kit (Miltenyl Biotec). First, PBMCs were 
resuspended in MACS buffer containing phosphate-buffered saline (PBS), 0.5% bovine 
serum albumin (BSA) and 2 mM EDTA at pH 7.2. Forty µL of ice-cold MACS buffer was 
used and 10 µL of biotin-antibody cocktail was added per 107 PBMCs, after which cells were 
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incubated for 5 minutes at 4°C. Subsequently, 30 µL of MACS buffer and 20 µL of anti-biotin 
magnetic microbeads were added per 107 PBMCs, and cells were incubated for another 10 
minutes. The antibody cocktail contains biotin-conjugated antibodies directed against CD3 
and CD4 (T cells), CD16 and CD56 (NK cells), CD14 (monocytes), CD15 (granulocytes), 
FcεRIa (basophils), CD34 (haematopoietic progenitor cells), CD61 (platelets) and CD235 
(erythrocytes), which would then become bound to the anti-biotin magnetic beads. Cell types 
other than B lymphocytes would therefore be magnetically labelled. Upon application of the 
cell suspension to a separation column attached to a magnet (LS column; Miltenyl Biotec), 
CD19+ B cells would pass through the column as the elutant, whereas other cell types would 
become adhered to the magnetic column and hence depleted.  
Enrichment for CD19+ CD5+ CLL cells.  Isolated CD19+ cells were resuspended 
in ice-cold MACS buffer at 100 µL per 107 cells. One µL of human CD5-biotin antibody 
(clone UCHT2; Miltenyl Biotec) was added per 107 cells, and cells incubated at 4°C for 5 
minutes. After washing the cells and resuspending them in 80 µL of fresh MACS buffer per 
107 cells, 20 µL of anti-biotin microbeads per 107 cells (Miltenyl Biotec) was added, and cells 
were incubated at 4°C for another 10 minutes. Upon passing through an LS column (Miltenyl 
Biotech) attached to a magnet, the CD5+ CLL cells would adhere to the column whilst the 
remaining CD5 negative B lymphocytes would pass through. The bound CD19+ CD5+ CLL 
cells were then collected after removing the column from the magnet.  
Confirmation of purity of the sorted population.  The sorted cell fraction was 
confirmed to be >93% CD19+ CD5+ by flow cytometry (see section 2.4.4) prior to their use 
in experiments. In the majority of cases this was >95%. Representative flow cytometry plots 




101     





Methodology for the isolation of CD19+ CD5+ CLL cells from PBMCs.  CLL cells were 
isolated from PBMCs using a two-step MACS sorting process. CD19+ B lymphocytes were 
first isolated from PBMCs using human B-CLL cell isolation kit (Miltenyl Biotec) which 
depletes cell types other than B lymphocytes. The sorted population was subsequently 
enriched for CD19+ CD5+ CLL cells using a human CD5-biotin antibody (Miltenyl Biotec). 
The sorted cell fraction was confirmed to be >93% CD19+ CD5+ prior to their use in 
experiments. The sorting of a representative PBMC sample from a patient with spontaneous 
CLL regression was shown.    
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2.1.5. DNA extraction 
DNA was extracted from between 106 and 5 x 106 sorted CD19+ CD5+ CLL cells 
using the DNeasy blood and tissue kit (Qiagen) according to the manufacturer’s instructions. 
Cells were resuspended in 200 µL of PBS. Twenty µL of proteinase K was then added, 
followed by 200 µL of lysis buffer (AL). After vortexing and incubation at 56°C for 10 minutes, 
200 µL of 100% ethanol was added to the sample. Following further vortexing, the sample 
was applied onto the DNeasy Mini spin column and centrifuged at maximum speed (14,000 
rpm) for 1 minute. The flow-through was discarded, 500 µL of wash buffer (AW1) was 
applied onto the spin column, and the column was centrifuged again for 1 minute at 14,000 
rpm. A further wash step with 500 µL of AW2 was carried out after removal of the flow 
through from the previous wash, but on this occasion the column was centrifuged for 3 
minutes at 14,000 rpm. Thereafter, the collection tube was replaced and the DNeasy 
membrane was dried by centrifuging the spin column for a further 3 minutes at 14,000 rpm. 
Finally, 50-100 µL of elution buffer (AE) was added to the spin column, and the elutant was 
collected in a DNase-free eppendorf tube by centrifuging the spin column for 1 minute at 
14,000 rpm.  
DNA samples were quantified and their purity confirmed using a NanoDrop 
spectrophotometer (Thermo Fisher Scientific). The A260/280 ratio was confirmed to be 1.7-
1.9 to ensure minimal protein or phenol contamination, which would result in lower and 
higher readings respectively. For samples subjected to WES, the nucleic acid concentration 
was further verified by a Qubit 2.0 fluorometer (Thermo Fisher Scientific). DNA samples 
were stored at -20°C.  
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2.2. CLL cell lines 
 
2.2.1. Cell lines 
Two CLL cell lines were used in the ATR inhibitor study. Both were obtained from 
Prof. Anders Rosen, Linkoping University, Sweden. The details are as follows: 
The CII cell line was derived from a 47 year old female with CLL who presented 
with lymphadenopathy, hepatosplenomegaly, a white cell count of 152 x 109/L with 88% 
lymphocytes, and increased lymphocytes in the bone marrow. This cell line was established 
by infecting mononuclear cells with the B95-8 strain of Epstein-Barr virus. The CII cell line 
shows expression of mature B cell markers (CD5+, CD19+, CD20+ and CD23+) with 
immunoglobulin production restricted to the IgM λ subtype, similar to the patient CLL clone. 
Moreover, the cell line is characterised by unmutated IGHV1-69/IGHD3-10/IGHJ-6 and 
IGLV1-4/IGLJ-3 gene rearrangements showing CDR3 sequence homology with stereotyped 
CLL subset 5. The CII cell line shows low CD38 but high ZAP-70 levels, and exhibits trisomy 
12, which was also present in the in vivo CLL clone (Fialkow et al., 1978; Karande et al., 
1980; Lanemo Myhrinder et al., 2013).  
The Mec1 cell line was derived from a 58 year old male with CLL in 
prolymphocytoid transformation, clinically characterised by constitutional symptoms, 
lymphadenopathy and splenomegaly. The Mec1 cell line was established by spontaneous 
outgrowth from peripheral blood lymphocytes, taken prior to treatment at a time when the 
white cell count was 39 x 109/L. The Mec1 cell line displays mature B-cell markers (CD19+, 
CD20+ and CD23+) with mutated IGHV4-59/IGHD2-21/IGHJ-4 rearrangement identical to 
that of the patient’s CLL clone. Mec1 cells lack CD5 and express low levels of CD38, with 
absent ZAP70 expression. Mec1 cells possess a deleterious TP53 mutation, which results in 
a truncation at the N-terminus, producing a lower molecular weight protein (approx. 47 kDa 
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compared to wild-type p53 which is 53 kDa) that is non-functional and cannot be induced by 
DNA damaging agents such as fludarabine. Our lab has independently confirmed by TP53 
sequencing the presence of c.950insC insertion with absent wild-type allele in Mec1 cells 
(Almazi et al., 2012; Lanemo Myhrinder et al., 2013; Stacchini et al., 1999).   
 
2.2.2. Generation of isogenic cell lines 
 Isogenic CII and Mec1 cell lines with different expression of ATM or p53 were 
previously generated in our laboratory.   
 Paired ATM-deficient and ATM-proficient CII cell lines.  Isogenic CII cell lines 
were generated by shRNA transfections carried out using RNA oligonucleotide (Dharmacon) 
targeting either green fluorescent protein (GFP) as a negative control (CII-GFPsh), or ATM 
(CII-ATMsh) as described previously (Biton et al., 2006; Weston et al., 2010). In brief, stable 
knockdown of ATM was achieved using two shRNA sequences complementary to a 19 or 21 
nucleotide sequence beginning at positions 912 and 8538 respectively of the ATM transcript. 
The two shRNA sequences were expressed in a retroviral vector. CII cells infected with the 
shRNA-expressing retroviral vector were selected using 1 μg/ml puromycin. The shRNA 
expressed in the vector-infected CII cells would be processed by the endoribonuclease 
Dicer, releasing siRNA sequences that cleave the ATM mRNA at the corresponding 
positions.    
 Paired p53-deficient and p53-proficient CII cell lines.  To re-express wild-type 
TP53 in this TP53 mutant cell line, Mec1 cells were transfected by electroporation (Amaxa 
system; Lonza Biologics) with the vector pcDNA3.1 (kind gift from Dr. A. Turnell, University 
of Birmingham) containing either wild-type TP53 (Mec1-p53-pcDNA3.1), or GFP as control 
(Mec1-GFP-pcDNA3.1). Forty-eight hours after transfection, the culture media was 
supplemented with Geneticin (Life Technologies) to select for the transfected cells.  
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2.3. CLL cell culture 
 
2.3.1. Cell line and primary cell culture 
Cell culture was performed under aseptic technique. CII-GFPsh and CII-ATMsh 
were cultured in RPMI-1640/10% FBS supplemented with 1 μg/ml puromycin to maintain 
selection of cells expressing the corresponding shRNA. The Mec1 cell line and CLL primary 
cells were cultured in RMPI-1640/10% FBS alone. Cells were incubated at 37°C with 5% 
CO2 in an incubator. CII and Mec1 cells were passaged every 4 days. 
 
 2.3.2. Induction of CLL cell proliferation 
 To induce proliferation, primary CLL cells were co-cultured for 4 days in RPMI-
1640/10% FBS with CD40 ligand (CD40L) expressing murine embryonic fibroblasts (MEFs), 
supplemented with IL-21 (eBiosciences) diluted to a final concentration of 25 ng/ml (Pascutti 
et al., 2013). The CD40L expressing MEFs, kindly supplied by Prof. John Gordon (University 
of Birmingham), were generated by transfection of the NIH3T3 MEF cell line with a vector 
expressing CD40L. Prior to their use, the CD40L expressing MEFs were expanded in 
Dulbecco’s Modified Eagle’s Medium (DMEM)/10% FBS culture for two weeks, after which 
they were irradiated with 50 Gy IR to render them non-proliferative. CLL cells and CD40L 
expressing MEFs were cultured in a 10:1 ratio.  
 Following the initial 4-day culture and subsequent drug treatment, CLL cells were 
harvested for analysis. The CLL cells were easily dislodged by gentle pipetting, while the 
MEFs remained adherent to the culture plate or flask. Pilot experiments have shown that 
there was negligible contamination of the harvested CLL cells with MEFs. 
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2.4. Flow cytometry 
 
 Flow cytometry was used within both the spontaneous CLL regression study and 
the ATR inhibitor study. Within the spontaneous CLL regression study, flow cytometry was 
used for peripheral blood immunophenotyping, for phosphoflow analysis of BCR signalling 
and for purity confirmation of cellular populations after MACS sorting. Within the ATR 
inhibitor study, flow cytometry was used for cell cycle analysis, for the measurement of drug-
induced cytotoxicity (section 2.7.2) and for the measurement of tumour load ex vivo (section 
2.10). 
 Flow cytometry enables the detection of both surface and intracellular proteins in 
individual cells. Cells are incubated with fluorochrome-conjugated antibodies that are 
directed against the surface and intracellular proteins of interest. In cases where intracellular 
proteins are investigated, cells are additionally fixed and their cell membrane permeabilised 
to allow antibodies to enter the cell and bind to intracellular proteins. These cells are then 
directed through a single file within the fluidics system, where they pass, one cell at a time, 
through several beams of laser, each with a different frequency. These lasers excite specific 
fluorophore bound to the cell surface or intracellular proteins. Each fluorophore is excited by 
a specific laser and emits fluorescence at a specific wavelength immediately following 
excitation. Each emission is then detected within a specific channel that incorporates a filter 
that permits passage only of emissions within a specific range of wavelengths.  
 
2.4.1. Flow cytometer setup and controls 
As detailed in the sections to follow, different flow cytometers were used for 
different investigations. The flow cytometer used include BD FACSCanto (for peripheral 
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blood immunophenotyping), BD LSRFortessa (for phosphoflow) and BD Accuri C6 (for all 
other investigations). The acquisition and analytical software used was BD FACSDiva, with 
the exception of acquisitions on the BD Accuri C6 which were analysed using the 
accompanying C6 software. All equipment and software were produced by Becton Dickinson 
Biosciences.  
Unstained and compensation controls.  All experiments incorporate an unstained 
control used for setting the voltages of each channel. Unstained controls were prepared in 
exactly the same way as the stained samples, with the exception that no antibody was 
added. Compensation enables the elimination of any spectral overlap, whereby the 
emissions of a fluorophore that is detected by one channel spills over to the adjacent 
channels. Compensation was carried out using anti-mouse immunoglobulin κ/negative 
control compensation particles set (BD Biosciences). A separate polystyrene round-bottom 
tube was prepared for each fluorophore, with each tube containing a mixture of anti-mouse 
immunoglobulin κ beads and negative control beads. The former binds to the κ light chain of 
the mouse antibody, while the latter does not have any antibody-binding capacity. An 
equivalent volume of a single antibody to that used in the samples was added to each tube. 
The tubes were then incubated at room temperature for 30 minutes in darkness. Thereafter 
the compensation beads in each tube were washed in PBS and resuspended in 200 µl of 
PBS for acquisition. This allows the establishment of two distinct populations, one with the 
antibody staining and one without. Using these single stained compensation controls, 
compensation was carried out either manually (for experiments on BD Accuri C6) or 
automatically through the FACSDiva software (for experiments on all other flow cytometers). 
This involves subtracting any spillover from the affected channels such that the median 
fluorescence intensity (MFI) of those channels return to that seen with the unstained control.  
Biological controls and the setting of gates.  To determine the settings of gates 
which demarcate the positive vs negative populations, biological controls were used. For 
many cell surface and intracellular targets, healthy cellular populations known to highly 
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express or not express a particular target protein were used as positive and negative 
controls respectively. For instance, B-progenitor cells were used as a positive control for 
ROR1, and T cells as a negative control. For some target proteins, such as Bcl-2, cell lines 
known to highly express the target were used as positive controls. Isotype controls, which 
are detects non-specific binding of antibodies, were used only where negative biological 
controls were not available. 
Antibody titration.  During the initial setup of the antibody panels, the 
manufacturer recommended antibody volume was used. However, excess antibody may 
bind at low affinity and/or create high levels of non-specific background staining. Therefore, 
antibody volumes used for staining were titrated down to achieve the greatest separation 
between the positive and negative populations.  
 
2.4.2. Peripheral blood immunophenotyping 
 All immunophenotyping experiments carried out as part of the spontaneous CLL 
regression study was performed on fresh blood, with the exception of those experiments 
investigating changes across serial timepoints, in which case immunophenotyping was 
performed on archived PBMCs for all timepoints. To allow comparison of my 
immunophenotypic results from the spontaneous regression and indolent cases with the 
available data from the clinical trial cases, all immunophenotyping experiments were 
performed using the same experimental protocol, antibody panels, flow cytometer and 
analysis template as those used in the clinical trial cases.  
Extracellular antibody staining.  For immunophenotyping on fresh blood samples, 
a blood volume containing 2 x 107 white blood cells were added to 5 ml of ammonium 
chloride solution (8.6 g/L) in a round-bottom polystyrene tube, and incubated at 37°C for 10 
minutes, in order to lyse the red blood cells within the blood sample. Following centrifugation 
109     
and removal of the supernatant, the cells were resuspended in 2.8 ml of FACSFlow (BD 
Biosciences) with 2% BSA. BSA acts as a blocking agent to reduce non-specific binding of 
antibodies to Fc receptors expressed on monocytes, dendritic cells and B lymphocytes, 
which could otherwise yield false positive results. Two hundred µl of the cell suspension 
(equivalent of 106 cells) was then applied to each well within a round-bottom 96-well plate, 
the number of wells applied being dependent on the number of antibody panels being used. 
For archived samples, 106 cells were applied to each well after cell thawing and revival 
(section 2.1.3). After centrifugation of the plate, removal of the supernatant and 
resuspension of the cells, cells were washed once with FACSFlow/BSA, and extracellular 
antibodies added to the appropriate wells. Cells were incubated with these antibodies for 30 
minutes at 4°C, after which they were washed twice with FACSFlow/BSA, resuspended in 
180 µl of FACSFlow, and transferred to a polystyrene tube for acquisition on a FACSCanto.  
Intracellular antibody staining.  For antibody panels where intracellular markers 
were included, 100 µl of Intrasure reagent A (BD Biosciences) was added immediately after 
the first wash step following extracellular antibody incubation, in order to fix the cells. After 5 
minutes of incubation at room temperature with Intrasure A, the plate was centrifuged, the 
supernatant removed and 200 µl of FACSLyse reagent (BD Biosciences) was applied to the 
resuspended sample to remove any residual red blood cells. Following 10 minutes of 
incubation with FACSLyse at room temperature, and subsequent centrifugation and removal 
of the supernatant, 50 µl of Intrasure B reagent (BD Biosciences) was added to permeabilise 
the cells. Thereafter, intracellular antibodies were applied, and the plates were then 
incubated at 4°C for 15 minutes to allow for intracellular antibody binding. The cells were 
then washed twice with FACSFlow/BSA, and resuspended in FACSFlow for acquisition. 
Antibody panels.   For all antibody staining, master mixes were prepared to ensure 
staining consistency. Up to 8 different fluorophores (colours) per antibody panel is used. 
Example of an extracellular antibody panel, and an extracellular and intracellular antibody 
panel, is shown in Figure 2.2. A list of all antibodies used is provided in Appendix 1. 
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Figure 2.2 
Example of an extracellular antibody panel 
 
Antigen Source Catalogue No. Excitation laser Filter Volume (µl)/10 samples 
BV421 CD23 BD Biosciences 562707 Violet (405 nm) 450 nm 10 
BV510 CD43 BD Biosciences 563377 Violet (405 nm) 525 nm 10 
FITC CD81 BD Biosciences 551108 Blue (488 nm) 530 nm 50 
PE CD79b Coulter IM1612 Blue (488 nm) 575 nm 50 
PerCP-Cy5.5 CD19 BD Biosciences 332780 Yellow-Green (561 nm) 695 nm 50 
PE-Cy7 CD5 BD Biosciences 348810 Yellow-Green (561 nm) 780 nm 10 
APC ROR1 Miltenyi Biotec 130-098-320 Red (640 nm) 660 nm 50 
APC-H7 CD20 BD Biosciences 641414 Red (640 nm) 780 nm 50 
Buffer (FACSFlow/2% BSA) 120 
 
 
Example of an antibody panel comprising extracellular and intracellular antibodies 
 Antigen Source 
Catalogue 
No. 
Excitation laser Filter 
Volume (µl)/10 samples 
Extracellular Ab mix Intracellular Ab mix 
BV421 CD95/FasR BD Biosciences 562616 Violet (405 nm) 450 nm 10 - 
BV510 CD49d BD Biosciences 563204 Violet (405 nm) 525 nm 10 - 
FITC [Ki67] BD Biosciences 558616 Blue (488 nm) 530 nm - 50 
PE [ZAP70] BD Biosciences 344635 Blue (488 nm) 575 nm - 200 
PerCP-Cy5.5 CD19 BD Biosciences 332780 Yellow-Green (561 nm) 695 nm 50 - 
PE-Cy7 CD5 BD Biosciences 348810 Yellow-Green (561 nm) 780 nm 10 - 
APC [BCL2] BD Biosciences 563600 Red (640 nm) 660 nm - 10 
APC-H7 CD20 BD Biosciences 641414 Red (640 nm) 780 nm 50 - 
Buffer (FACSFlow/2% BSA) 270 140 
 
 
Examples of antibody panels used for peripheral blood immunophenotyping. The volume of each antibody and buffer required to produce 
master mixes for 10 samples are shown (400 µl). Forty µl of antibody master mix is dispensed to each sample. Events were acquired by a LSR 
Fortessa flow cytometer. In the tables, intracellular antibodies are displayed in boldface within brackets.   
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Data analysis (Figure 2.3). Following the setting of voltage and spectral 
compensation (section 2.4.1), different cellular populations were identified on the forward 
scatter (FSC) vs side scatter (SSC) plot by their relative position. The granulocyte population 
would have higher granularity and therefore higher SSC than mononuclear cells. On the 
other hand, apoptotic cells and cellular debris would have lower FSC and/or higher SSC 
than the mononuclear cell population. This allowed a gate (P1) to be applied on the FSC vs 
SSC plot to include the mononuclear cell population (shown in black), but exclude 
granulocytes, dead cells and debris (shown in green) (Figure 2.3A). The positioning of this 
gate was confirmed by displaying the P1 gated events on a CD19 vs CD20 plot. The CD19+ 
population would represent the B lymphocytes, whereas the CD19− CD20− population 
would comprise other mononuclear cells. Any events that were CD20+ but CD19− would be 
considered possibly to be apoptotic or degenerate cells, and would prompt re-adjustment of 
the P1 gate to exclude those events. Such a gating strategy has been confirmed to exclude 
>98% of propidium iodide (PI) positive cells.  
The P1 gated events were then displayed on a FSC-area (FSC-A) vs FSC-height 
(FSC-H) plot. A second gate (P2) was then applied to include singlets but exclude doublets, 
on the basis that doublets would have double the area as singlets while the height would 
remain the same (Figure 2.3B).  
For CLL immunophenotyping, events were displayed on a CD19 vs CD20 plot. 
CD20 provides the single best discriminator between the CLL cells and normal B cells 
(Rawstron et al., 2001). A third gate (P3) was applied to include all CD19+ CD20-low CLL 
cells, but exclude normal B cells that would be CD19+ CD20-high (Figure 2.3C). For T cell 
immunophenotyping, events were displayed on a CD3 vs SSC plot, and the third gate was 
applied on the CD3+ T cell population, with further gating to differentiate between CD3+ 
CD4+ and CD3+ CD8+ T cells (Figure 2.3E). The P1 + P2 + P3 gated singlet CLL or T cell 
population was then analysed for the expression of a variety of markers (Figure 2.3D-E). A 
minimum of 200,000 events were acquired for each sample. 


















Gate settings in peripheral blood immunophenotyping experiments. (A) First, the viable 
mononuclear cell population is gated (P1) based on its position on the FSC vs SSC plot. (B) 
The P1 gated events are subjected to further gating to include singlets but exclude doublets 
(P2). (C) For immunophenotypic analysis of CLL cells, events are displayed on a CD19 vs 
CD20 plot, and a third gate (P3) applied to include CLL cells but exclude non-malignant B 
cells and CD19-negative mononuclear cells. The P1 + P2 + P3 gated events are displayed 
in black, while the P1 + P2 gated events that have fallen outside the P3 gate are displayed in 
grey. (D) The gated CLL singlet population (in black) is then analysed for the expression of 
various markers (e.g. ZAP-70 and Ki-67). (E) For immunophenotypic analysis of T cells, 
further gates (P3, and Q1-Q4) are applied to identify the singlet CD3+ CD4+ (P1 + P2 + P3 
+ Q1, in dark green) and the CD3+ CD8+ (P1 + P2 + P3 + Q4, in red) populations. These 
populations are then analysed for the expression of various markers (e.g. CD27 and 
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2.4.3. Phosphoflow analysis of BCR signalling 
 All phosphoflow analysis was performed on fresh blood samples. The experimental 
setup consists of four tubes per CLL sample, labelled as: (A) no IgM or IgD stimulation; (B) 
IgM stimulation only; (C) IgD stimulation only; and (D) IgM and IgD stimulation. A blood 
volume containing 106 white blood cells was applied to each tube, and PBS was added such 
that the total volume in each tube was 189 µl. Thereafter, a master mix containing the 
following extracellular antibodies (BD Biosciences) were made and dispensed to each tube: 
 CD20  APC-H7   5 µl per tube 
 CD19  PE-Cy7   1 µl per tube 
 CD5  PerCP-Cy5.5  5 µl per tube 
The tubes were incubated in darkness at room temperature for 30 minutes, following which 
the cells in each tube were stimulated with 8 µl (to produce a final concentration of 20 
µg/mL) of either anti-human IgM F(ab’)2 (Southern Biotech; tube B), anti-human IgD F(ab’)2 
(Southern Biotech; tube C) or both (tube D), for 2 minutes in a 37°C water bath. Immediately 
after the 2 minute incubation, cells were fixed by adding 1 ml of pre-warmed Lyse/Fix buffer 
(BD Biosciences) and incubated in the water bath for a further 10 minutes. This incubation 
duration was adopted based on time course experiments showing that maximal effect of 
IgM/IgD stimulation was reached at 2 minutes.  
After centrifugation to remove the fixative, cells were washed in 1ml PBS, and then 
permeabilised by adding 1 ml of Perm/Wash buffer (BD Biosciences), followed by 15 
minutes’ of incubation at room temperature. Cells were then washed again in Perm/Wash, 
after which a master mix containing the following intracellular phosphoantibodies (BD 
Biosciences) were made and dispensed to each tube: 
 Akt (pS473)   BV421   3 µl per tube 
 Syk (pY348)   PE   20 µl per tube 
 Erk 1/2 (pT202/pY204)  Alexa Fluor 488  20 µl per tube  
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Following incubation with these antibodies in darkness at room temperature, cells were 
washed with FACSFlow/BSA, and resuspended in 200 µl of FACSFlow for acquisition on an 
LSR Fortessa. A minimum of 200,000 events were recorded.  
 Data Analysis (Figure 3.10A).  Cells were gated on the live, singlet, CD19+ 
CD20-low CLL population using the methodology outlined in section 2.4.2. Histograms 
corresponding to each phosphoprotein were then constructed. For each phosphoprotein, the 
positive vs negative gate was set such that 99% of unstimulated (tube A) cells would fall 
within the negative gate. The CD19− CD5+ T cell population was used as an internal 
negative control.  
 
2.4.4. Purity confirmation of sorted cellular populations 
 This was carried out on the BD Accuri C6 flow cytometer using a combination of 
CD19 PE-Cy7, CD5 FITC and CD3 APC antibodies (all from eBiosciences). Antibody 
staining, acquisition and exclusion of dead cells, cellular debris and doublets were 
performed as described in section 2.4.2. The purity of the sorted CLL population was 
determined from the proportion of the remaining cells that were CD19+ CD5+. An illustrative 
example is provided in Figure 2.1. 
 
2.4.5. Cell cycle analysis 
 Cell cycle analysis in response to drug treatment was performed as part of the ATR 
inhibitor study. Harvested cells were fixed and permeabilised in ice-cold 80% ethanol and 
stored overnight at −20°C. On the following day, the cells were washed in PBS, and then 
resuspended in 100 µl PBS. Thereafter a mastermix was prepared containing 2 µl of 1 
mg/mL PI stock solution (Sigma) and 5 µl of 20 mg/mL PureLink RNase A (Invitrogen) per 
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sample. Seven µl of the mastermix was added to each sample, such that the final 
concentration of PI was 20 µg/mL and the final concentration of RNase A was 1 mg/mL. PI 
binds to cellular DNA, and therefore measurement of its level reflects the position of a cell 
within the cell cycle (i.e. G0/G1 phase: 2N; S phase: 2N-4N; G2/M phase: 4N). RNase A 
was added to prevent any binding of PI to double-stranded RNA. The samples were 
incubated in darkness at room temperature for 15 minutes, prior to acquisition on an Accuri 
C6 flow cytometer.  
 A minimum of 100,000 events were analysed. Following the exclusion of doublets 
and cellular debris, the events were displayed on a PI histogram for analysis. All cell cycle 
experiments were performed in triplicates.  
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2.5. DNA and genomic analysis 
 
2.5.1. SNP array analysis 
 SNP array genotyping was provided by University College London (UCL) 
Genomics. Ten µl of DNA per sample at 50 ng/µl was submitted to UCL Genomics for 
genotyping on a HumanCoreExome BeadChip array (Illumina). The array contains 
oligonucleotide probes corresponding to >500,000 SNP-containing DNA sequences 
throughout the genome. The preparation of the array was carried out according to the 
Infinium High Throughput Screening (HTS) Assay protocol (Illumina).  
Briefly, in a deep well plate 200 ng of DNA was whole genome amplified overnight 
(at 37°C for 20-24 hours), then fragmented (at 37ºC for 1 hour and 15 minutes in a 
hybridisation oven), precipitated and resuspended in hybridisation buffer. Using a liquid 
handling robot (Freedom Evo, Tecan Ltd), samples were hybridised onto the array 
containing oligonucleotide probes and incubated at 48°C for 16-24 hours. Unhybridised and 
non-specifically hybridised DNA was washed away. Using the captured DNA as a template, 
a single base, conjugated to a fluorophore, was then added to the end of the DNA-bound 
oligonucleotide probes on the array. Finally, the array was scanned using an iScan scanner 
with autoloader (Illumina). This involves using a laser to excite the fluorophore of the single-
base extension on the oligonucleotide probes, and the image of light emitted from the 
fluorophores was captured and recorded by the scanner. This process allows the genotype 
to be determined for each of the markers contained within the array.  
  Raw data was sent by UCL Genomics for analysis using the GenomeStudio 
software Genotyping Module v.3.1 (Illumina) and OncoSNP v2.1. Log R ratio and B allele 
frequency values were generated across all 23 chromosome pairs. The log R ratio reflects 
the intensity of the signal observed at a particular SNP, compared to the expected intensity. 
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The log R ratio is normally zero, and any deviation above or below this reflects genomic 
duplication or deletion respectively at that particular position. The B allele frequency, on the 
other hand, reflects the ratio of the intensity of the two alleles (A and B) at the specific SNP. 
This is normally 0.5, and deviations from this value would be seen in duplications or 
deletions. However, such deviations in B allele frequency may also be seen in the presence 
of a normal log R ratio, in cases where there is copy-neutral loss of heterozygosity (Figure 
2.4).  
 
2.5.2. IGH sequencing 
 Initial PCR.  The rearranged IGH gene was amplified from genomic DNA extracted 
from MACS-sorted CLL cells (section 2.1.5) using the BIOMED-2 framework region 1 (FR1) 
multiplexed primers (Sigma) and a JH consensus primer (Sigma) (van Krieken et al., 2007): 
JH consensus   5' CTT ACC TGA GGA GAC GGT GAC C 3' 
FR1 VH1  5' GGCCTCAGTGAAGGTCTCCTGCAAG 3' 
FR1 VH2  5' GTCTGGTCCTACGCTGGTGAAACCC 3' 
FR1 VH3  5' CTGGGGGGTCCCTGAGACTCTCCTG 3' 
FR1 VH4  5' CTTCGGAGACCCTGTCCCTCACCTG 3' 
FR1 VH5  5' CGGGGAGTCTCTGAAGATCTCCTGT 3' 
FR1 VH6  5' TCGCAGACCCTCTCACTCACCTGTG 3'  
A PCR mastermix was made containing: 1x PCR buffer, magnesium chloride (2 mM), 
deoxyribonucleotide (dNTP; 0.125 mM) and Taq polymerase (1 unit), all from Applied 
Biosystems, and 20 mM of each forward primer (FR1) and the reverse (JH) primer. Twenty-
four µl of the mastermix was dispensed to each PCR tube, following which 1 µl of DNA at 
20-100 ng/µl was added. PCR was performed on a Veriti thermal cycler (Applied 
Biosystems) using the following settings: 95°C for 4 minutes, then 95°C for 30 seconds,
  






Copy number alterations detectable by SNP array analysis.  Examples of copy 
alterations detectable by SNP array analysis are shown. These include hemizygous deletion 
(top left), homozygous deletion (top right), hemizygous duplication (bottom left) and copy-
neutral loss of heterozygosity (cnLOH, bottom right). Intraclonal heterogeneity is evident in 
these examples with only a proportion of tumour cells harbouring deletion or duplication.   
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58°C for 30 seconds and 72°C for 45 seconds repeated 37 times, and finally 72°C for 7 
minutes.  
 Gel electrophoresis and extraction.  Three µl of the PCR product was mixed with 
3 µl of a 1:5000 dilution of the SYBR Green nucleic acid gel stain (Invitrogen). The mixture 
was ran on 1% agarose gel (prepared by dissolving 1 g of agarose in 100 ml of 
Tris/Borate/EDTA (TBE) buffer) at 130V for 30 minutes, with a DNA ladder (Invitrogen). The 
PCR products were then visualised in an ultraviolet transilluminator, and the band with the 
appropriate product size was excised from the gel. DNA was extracted from the excised gel 
using a QIAquick gel extraction kit (Qiagen) according to the manufacturer’s instructions. 
Briefly, buffer QG was added to the gel and the sample incubated at 50°C for 10 minutes to 
dissolve the gel. Isopropanol was then added to the sample and the mixture transferred to a 
QIAquick spin column. The flow through was discarded after centrifugation of the spin 
column and further QG buffer was applied. Thereafter the spin column was washed with 
buffer PE, and the DNA was eluted in 50 µl of buffer EB.  
 Sequencing.  Gel extracted PCR products were then subjected to a sequencing 
PCR reaction using a BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems). 
The BigDye reagent consists of a mixture of dNTPs, fluorescently labelled 
dideoxynucleotides (ddNTPs) and Taq polymerase. In this PCR reaction, sequence 
extension by the addition of dNTPs proceeds as usual until the DNA polymerase inserts a 
fluorescently labelled ddNTP, which stops the chain elongation process. This generates 
DNA sequences with one of four coloured ddNTPs. A BigDye mastermix was produced 
containing the BigDye reagent, 1x PCR buffer and the JH primer (at 0.06 µM). One µl of the 
gel extraction product was added to 19 µl of the mastermix, and BigDye PCR was performed 
on a Veriti thermal cycler: 96°C for 2 minutes, followed by 96°C for 10 seconds, 50°C for 5 
seconds and 60°C for 4 minutes repeated 29 times.  
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Following the PCR reaction, the fluorescently labelled DNA product was 
precipitated with 50 µl of 100% ethanol and 2 µl of 3M sodium acetate at room temperature 
for 30 minutes, and then centrifuged at 2000 rpm for 20 minutes. This removes any 
unwanted products, such as residual primers, dNTPs and ddNTPs, form the sequencing 
reaction. Finally, the DNA product was washed twice in 70% ethanol, and allowed to air dry 
for 30 minutes, before being Sanger sequenced on an ABI 3500 capillary sequencer 
(Applied Biosystems). Prior to loading onto the sequencer, 10 µl of HiDi-Formamide (Applied 
Biosystems) was added to the samples, which were then denatured by heating to 95°C for 5 
minutes. Capillary electrophoresis allows separation of the different-sized DNA fragments 
within the sample. Base calling was made on the basis of the specific fluorescence 
emissions detected from the ddNTP ends of each DNA fragment, upon laser excitation.   
 For the spontaneous CLL regression cases, all IGH sequencing results generated 
by myself were independently validated by Dr Paul Evans (HMDS, Leeds) using VH leader 
peptide primers combined with a consensus JH primer (Rosenquist et al., 2017). The IGHV 
sequences were aligned and analysed using the international immunogenetics information 
(IGMT) online database and analytical platform. These sequences were also checked for 
IGHV stereotypy using the online ARResT/AssignSubsets tool (Bystry et al., 2015).   
 
2.5.3. Whole exome sequencing 
 Qubit-quantified DNA from sorted CD19+ CD5+ CLL cells or the granulocyte-
containing fraction isolated during Lymphoprep (as germline controls) was used to produce 
paired-end libraries for WES. Library preparation was carried out using the Nextera Rapid 
Capture Exome Kit (Illumina) according to the instructions detailed in the Nextera Rapid 
Capture guide (Illumina). DNA from each sample was first diluted in 10 mM Tris-Cl buffer 
(pH 8.5) to produce a final volume of 10 µl at 5 ng/µl. The diluted DNA sample was then 
subjected to the following steps in sequential order (Figure 2.5): 




Library preparation workflow for whole exome sequencing.  Reproduced with minor 
modification from the Nextera Rapid Capture Guide (Illumina, February 2013).   
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 Tagmentation.  Tagmentation is a process through which the genomic DNA is 
fragmented and adapter sequences added to the ends of the DNA fragment, thereby 
allowing primer binding during subsequent PCR amplification. Twenty five µl and 15 µl 
respectively of tagment DNA buffer and tagment DNA enzyme was added to the DNA 
sample in a deep-well plate. The plate was then heated for 10 minutes at 58°C, following 
which 15 µl of stop tagment buffer was added and the sample incubated for another 4 
minutes. Thereafter, the tagmented DNA was purified from the tagment enzyme in a clean-
up process. This involves adding sample purification beads which bind to the tagmented 
DNA, and washing each well of the plate with 80% ethanol with the plate placed on a 
magnetic stand. The tagmented DNA was then resuspended in 22.5 µl of resuspension 
buffer, and the sample purification beads were removed.  
 First PCR Amplification.  In this step, the tagmented DNA is PCR amplified. 
During the PCR amplification process, an index is added to the DNA to identify the sample, 
and common adaptors are added to facilitate subsequent cluster generation and 
sequencing. Five µl each of the corresponding index 1 and index 2 primers, and 20 µl of the 
Nextera library amplification mix were added to the purified tagmented DNA. PCR was 
performed on a Veriti thermal cycler according to the following programme: 72°C for 3 
minutes and 98°C for 30 seconds, then 98°C for 10 seconds, 60°C for 30 seconds and 72°C 
for 30 seconds repeated 10 times, and finally 72°C for 5 minutes. Thereafter, the PCR 
amplified DNA sample was purified in a clean-up process using sample purification beads as 
described above. The PCR-amplified sample, now known as a DNA library, was then 
quantified using Qubit. Finally, 500 ng of DNA each from 8 DNA libraries with different 
indices were combined into a volume totalling 40 µL.  
 Hybridisation and capture.   Probes that target specific coding DNA regions bind 
to the DNA library in a process known as hybridisation. The probe-hybridised DNA is then 
selectively captured, allowing enrichment of the DNA library for coding exomes. Ten µl of 
coding exome oligos and 50 µl of enrichment hybridisation buffer were added to the pooled 
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DNA libraries. The pooled libraries were then hybridised to the oligos in a Veriti thermal 
cycler using the following programme: 95°C for 10 minutes, followed by 18 cycles of 1 
minute incubations, starting at 94°C, and decreasing 2°C each cycle. Next, 250 µl of 
streptavidin magnetic beads were added to the probe-hybridised libraries. Following 25 
minutes of incubation which allowed capture of the probe-hybridised libraries by the 
streptavidin magnetic beads, the supernatant was removed with the sample placed on a 
magnetic stand. Two hundred µl of enrichment wash solution was subsequently added to the 
bead-captured libraries and incubated at 50°C for 30 minutes, after which the sample was 
returned to the magnetic stand and the wash solution was removed. This process was 
repeated for a total of two washes. Finally, the exome-enriched libraries were separated 
from the streptavidin beads by the addition of enrichment elution buffer to the sample, and 
by the subsequent removal of the supernatant containing the exome-enriched libraries while 
the sample was placed on a magnetic stand.  
 This hybridisation and capture process was repeated a second time using the 
eluted DNA library from the first enrichment. This allowed enhanced exome enrichment, thus 
ensuring that the libraries contained specifically the coding DNA regions. Prior to the second 
PCR amplification, the sample containing exome-enriched libraries was purified in a clean-
up process using sample purification beads as described above.  
 Second PCR amplification.  This final PCR step amplifies the exome-enriched 
libraries. Five µl of the PCR primer cocktail and 20 µl of the Nextera library amplification mix 
were added to the sample containing exome-enriched libraries. PCR was performed on a 
Veriti thermal cycler according to the following programme: 98°C for 30 seconds, then 98°C 
for 10 seconds, 60°C for 30 seconds and 72°C for 30 seconds repeated 10 times, and finally 
72°C for 5 minutes. Thereafter, the sample was purified in a clean-up process using sample 
purification beads described above, and quantified using Qubit. In addition, the sample was 
assessed for quality using TapeStation 2200 (Agilent Technologies). A distribution of DNA 
fragments ranging from 200 to 1000 base pairs was considered acceptable (Figure 2.6A). 







Quality checks following library preparation and sequencing.  (A) TapeStation trace 
showing the majority of DNA fragments in the sequencing library falling within the 200 to 1000 
base pairs (bp) range.  (B) The Phred quality score (Q score) after the sequencing run 
showing a Q score of >30 for the majority of bases.   
A 
B 
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 Exome sequencing.   The prepared WES library pool from 8 DNA libraries was 
submitted to the University of Birmingham genomics facility for sequencing using the 
NextSeq 500/550 High Output Kit v2 (Illumina). The sequencing process involved loading 
the pooled library onto the reagent cartridge which then flows through the lanes of the flow 
cell. The flow cell is filled with a lawn of oligonucleotides, which binds to the adaptor region 
of the DNA fragments in the library. Using the DNA fragment as a template, the DNA 
polymerase then adds complementary bases to the end of the oligonucleotide, thus creating 
a sequence that is complementary to the DNA fragment. The double-stranded DNA 
produced is then denatured with the original DNA fragment being washed away, leaving 
behind the newly created complementary strand. The strand is then amplified through bridge 
amplification, in which the strand bends over before being duplicated through the activity of 
the DNA polymerase. This process is repeated simultaneously throughout the flow cell, 
generating clusters of strands, and resulting in the amplification of all DNA fragments within 
the library pool. These amplified strands in turn serve as a template for a process known as 
sequencing by synthesis. In this process, fluorescently-tagged bases complementary to the 
template are added to the elongating DNA chain. After the addition of each nucleotide, the 
strands are excited by a light source, resulting in emissions from the base-specific 
fluorophores which are then detected by the sequencer. A base is assigned according to the 
specific emissions from the fluorophore. Each time a strand is sequenced is known as a 
read. This sequencing process occurs simultaneously in all clusters throughout the flow cell, 
and is repeated numerous times, resulting in all DNA fragments being sequenced. 
Altogether 8 DNA samples were sequenced within a single flow cell, allowing an average of 
50 million reads per sample.     
 Following each sequencing run, a Phred quality score (Q score) was generated by 
the sequencer which reflects the probability of a base calling error (Figure 2.6B). A score of 
30 or above, which indicates a base calling accuracy of 99.9%, for the majority of reads 
would be considered acceptable. The sequencing output (FASTQ) files were downloaded 
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from my BaseSpace (Illumina) account, and uploaded to a shared folder within the 
University of Birmingham Linux-based high performance computing cluster known as 
BlueBEAR for bioinformatics analysis.  
 
2.5.4. Bioinformatics analysis of whole exome sequencing data 
 Bioinformatics analysis of WES data was carried out by Dr Anshita Goel, Dr 
Archana Sharma-Oates and Prof. Jean-Baptiste Cazier. The major steps are briefly 
summarised here and illustrated in Figure 2.7A.  
Raw FASTQ files were first processed using FastQC which makes diagnostic plots 
for indicators such as base quality distribution, GC content, sequence length distribution and 
adapter content. Trimmomatic was then used to remove adaptors and trim low quality bases 
from sequence end. Reads were aligned and mapped to the human reference genome 
(GRCh37) using Burrows-Wheeler Aligner (BWA). Picard tools was used to coordinate sort 
the aligned reads, mark PCR duplicates and create the BAM file (a text file containing the 
sequence alignment data) that would be used as input to the Genome Analysis Tool Kit 
(GATK). Local realignment and base quality score recalibration was performed to refine the 
alignments around known variations (indels and SNPs) using GATK. Subsequently, somatic 
mutations were identified independently through two separate programmes, MuTect and 
Platypus, by comparing paired tumour (i.e. CLL) and germline (i.e. granulocyte) samples. 
The somatic mutations identified were annotated using Variant Effect Predictor (VEP), SIFT 
and Polyphen, and only variants that were predicted to be of high or moderate impact by 
VEP and functionally deleterious by SIFT and Polyphen were retained. Finally, MutSigCV 
was used to identify genes with statistically significant mutation occurrence in the CLL whole 
exome sequencing dataset. A p value threshold of <0.05 was used to identify significantly 
mutated genes.  






         
 
Bioinformatics analysis of whole exome sequencing data.  (A) Schematic diagram 
showing the major steps involved in the processing of raw exome sequencing data. MuTect 
utilises a scoring system that takes into account of whether a variant is present in the 
COSMIC database of known somatic mutations or the dbSNP database of known 
polymorphisms. The former confers a positive score whereas the latter a negative score. 
Thus, polymorphisms that are unlikely to be genuine mutations are filtered out. Reproduced 
with modification from Best Practices for Somatic SNPs in Whole Genomes and Exomes, 
GATK website, Broad Institute, https://software.broadinstitute.org/gatk/best-practices. (B) 
Diagram showing the mean depth of coverage of the CLL samples to be approximately 50x.  
A 
B 
128     
2.6. Analysis of telomeres and cellular senescence 
 
2.6.1. Telomere length analysis 
 Allele-specific single telomere length analysis (STELA) was carried out at the 
University of Cardiff by Prof. Duncan Baird and his team, as previously described (Lin et al., 
2010). This is a single molecule PCR technique that analyses the length of specific telomere 
repeat regions in individual single cells. The technique employs an adaptor that attaches to 
the telomeric ends, as well as PCR primers that bind to the adaptor and to a known DNA 
sequence in the sub-telomeric region of chromosome arms Xp and Yp. In brief, multiple 
PCR steps were carried out on 10 ng of DNA in the presence of Taq (ABGene) and Pwo 
polymerase (Roche), the Telorette2 linker (adaptor), the sub-telomeric primer XpYpE2 and 
the Teltail primer which binds to the Telorette2 linker. The PCR products were resolved by 
agarose gel electrophoresis, and detected by Southern blot hybridisations using α-33P–
labelled TTAGGG repeat probes (GE Healthcare), sub-telomeric probes and probes 
recognising the molecular weight markers (Bio-rad). The Southern blot hybridisations were 
visualised by a phosphoimager (GE Healthcare), with each single band on the blot 
representing a single telomeric molecule. Hence, the molecular weight of a band reflects the 
telomere length of Xp/Yp in a cell.  
 
2.6.2. Analysis of telomerase activity 
 Analysis of telomerase activity was carried out using the TeloTAGGG telomerase 
PCR enzyme-linked immunosorbent assay (ELISA) kit (Roche), which incorporates a 
telomeric repeat amplification protocol (TRAP) followed by detection of the PCR amplified 
telomerase-mediated elongation products using ELISA. The assay was performed according 
to the manufacturer’s instructions, as outlined below: 
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 DNA elongation and PCR amplification.  The addition of telomeric repeats 
(TTAGGG) to telomeric ends is dependent on the activity of telomerase. Therefore, the 
amount of TTAGGG added to a telomerase substrate would reflect the level of telomerase 
activity. A total of 106 MACS-sorted CD19+ CD5+ CLL cells were used for each sample. 
These cells were pelleted and washed in PBS. The pelleted cells were then lysed in 200 µl 
of lysis reagent, and incubated on ice for 30 minutes. The lysate was centrifuged at 14,000 
rpm following which the supernatant was collected and used for the TRAP reaction. The 
TRAP reaction mixture contains the biotin labelled telomerase substrate P1-TS (5'-Biotin-
AATCCGTCGAGCAGAGTT-3'), the reverse P2 primer (5’-CCCTTACCCTTACCCTTAC 
CCTAA-3’), nucleotides and Taq polymerase. Three µl of the cell lysate was added to 25 µl 
of the TRAP reaction mixture in a PCR tube, and sterile water added to a final volume of 50 
µl. The sample was first incubated at 25°C for 30 minutes in a Veriti thermal cycler to allow 
the addition of telomeric repeats to the 3’ end of P1-TS by the telomerase present in the 
sample. Thereafter, the sample was heated to 94°C for 5 minutes to inactivate the 
telomerase. Finally, PCR amplification was performed, with 30 cycles of 94°C for 30 
seconds, 50°C for 30 seconds and 72°C for 90 seconds, followed by 72°C for 10 minutes. 
Cell lysates that were heat-treated for 10 minutes at 85°C, which inactivates the telomerase, 
were used as negative controls. The positive control cell extract supplied with the kit, and the 
Mec1 cell line, were used as positive controls.  
 Hybridisation and ELISA.  Five µl of the PCR product per sample was denatured 
by incubating with 20 µl of denaturation reagent at room temperature for 10 minutes. 
Hybridisation buffer (225 µl) was then added and 100 µl of the mixture was transferred to a 
streptavidin-coated microplate well, which was incubated at 37°C in a shaker (300 rpm) for 2 
hours. This allows the biotin-labelled elongation products to adhere to streptavidin, and the 
digoxigenin-labelled telomeric repeat detection probe, contained within the hybridisation 
buffer, to bind to the TTAGGG repeats. Subsequently, the hybridisation buffer was removed 
and the wells on the microplate were washed three times with washing buffer. The 
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immobilised PCR product was then detected by the addition of 100 µl of a peroxidase-
conjugated antibody against digoxigenin. Following 30 minutes’ incubation and further 
washing steps, the elongation products were visualised by the addition of 
tetramethylbenzidine which was converted to a coloured product by peroxidase. A stop 
reagent was added after 10 minutes, and the absorbance of the samples were detected at 
450 nm using an iMark microplate absorbance reader (Bio-rad). The mean absorbance of 
the blank wells were subtracted form all other wells, and the mean absorbance of the 
negative controls were subtracted form those of the samples. Absorbance values of <0.25 
and >1.5 were considered acceptable for the negative and positive controls respectively.  
 
2.6.3. β-galactosidase assay 
 β-galactosidase expression and activity at pH 6 is a characteristic unique to 
senescent cells (Dimri et al., 1995). β-galactosidase hydrolyses β-D-galactosides (e.g. X-
gal) that may yield products emitting a specific colour (e.g. a blue precipitate), and can 
therefore be detected. A senescence β-galactosidase staining kit (Cell Signaling 
Technology) was used for this purpose. MACS-sorted CD19+ CD5+ CLL cells were plated 
onto a 96-well plate at 105 cells per well. The cells were then fixed in fixative solution for 15 
minutes at room temperature. During this time, the β-galactosidase staining solution was 
prepared by combining X-gal stock solution and other staining solutions as per the supplier’s 
instructions, and adjusted to a pH of 6. The plate was washed two times with PBS, following 
which 200 µl of the prepared galactosidase staining solution was added to each well. The 
plate was incubated at 37°C in a dry incubator overnight, in the absence of CO2 which might 
alter the pH of the staining solution. Thereafter, with the staining solution still in place, the 
cells were examined under an inverted microscope (Nikon) for the development of a blue 
colour. 
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2.7. Cytotoxicity assays 
 
 For the assessment of drug-induced cytotoxicity carried out as part of the ATR 
inhibitor study, two different methodologies were employed: the CellTiter-Glo luminescent 
cell viability assay (Promega), and a flow cytometric method using PI. The former is a high-
throughput, albeit indirect, method of assessing the number of viable cells in multiple 
samples, and was used in all experiments involving cell lines. However, due to the presence 
of CD40L-expressing MEFs within the primary CLL co-culture system, the CellTiter-Glo 
assay could not be used in experiments involving primary CLL cells. Therefore, for these 
experiments, the flow cytometric method was employed.  
 
2.7.1. CellTiter-Glo luminescent cell viability assay 
 The CellTiter-Glo luminescent cell viability assay utilises a thermostable luciferase, 
which catalyses a reaction involving the mono-oxygenation of luciferin, producing a 
luminescent signal in this process. This reaction is dependent on adenosine triphosphate 
(ATP), and the intensity of the luminescent signal is directly proportional to the amount of 
ATP present. Since the absolute quantity of ATP within a sample is directly proportional to 
the number of viable, metabolically active cells, it follows that the luminescent signal 
intensity must also be proportional to the number of viable cells in the sample.  
 Cell density.  Cells were plated on a flat-bottomed, opaque-walled 96-well 
microplate, with each well capable of holding a maximum volume of 200 µl. The plating 
density of the CII and Mec1 cell line was tested in a pilot experiment using a variety of 
plating densities, and the optimal plating density for both CII and Mec1 cells was found to be 
104 cells per well. When analysed after 4 days of incubation, such a plating density produced 
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the maximum luminescent signal, whereas increasing the plating density beyond this did not 
improve the signal. A plating density of 104 cells per well was therefore adopted for all 
subsequent experiments. Cells were resuspended in RPMI-1640/10% FBS at 105 cells/mL, 
and 100 µl of cells were dispensed into each well using a multichannel pipette. The 
exception to this was the outer wells forming the perimeter of the microplate, which were 
filled instead with 200 µl of culture medium. The purpose of this was to reduce evaporation 
from the sample wells during culture which could otherwise affect result interpretation.  
 Drug dilutions.  For experiments involving a single drug, a doubling dilution of 9 
drug doses was used to construct the dose response curve. A stock solution containing 
twice the highest drug concentration was prepared by dissolving the appropriate amount of 
drug in RPMI-1640/10% FBS. A two-fold serial dilution in RPMI-1640/10% FBS was then 
carried out starting with the stock solution. Therefore, for each dose, a solution containing 
twice the desired drug concentration was made. One hundred µl of the 2x drug solution was 
dispensed and mixed with the 100 µl of cells in each well, such that the final drug 
concentration was 1x. Triplicate wells were used for each drug dose, and triplicate wells 
containing untreated cells were included as negative control.  
 For experiments involving a combination of two drugs, a solution containing four-
fold the desired drug concentration was made for each dose of the two drugs. Fifty µl of the 
4x solution of each drug was added to 100 µl of cells in each well, such that the final 
concentration of each drug was 1x. Triplicate wells were used for each dose combination. In 
addition, single-agent treated wells and untreated negative controls were included. An 
example microplate setup for experiments involving a single drug and drug combinations are 
displayed in Figure 2.8A and Figure 2.8B respectively.  
    Plate reading and analysis.  The microplate was incubated at 37°C with 5% CO2 
for 4 days, after which the plate was equilibrated at room temperature for 30 minutes.
  






Example microplate setups for CellTiter-Glo luminescent cell viability assay.  (A) An 
example microplate setup involving a single drug. Isogenic CLL cell lines (CII-ATMsh and 
CII-GFPsh) were incubated in doubling dilutions of AZD6738. (B) An example microplate 
setup involving drug combinations. A single cell line was incubated with various doses of 
fludarabine or 4HC, with and without AZD6738 (1 µM). Triplicate wells were included for 
each drug dose or dose combination. Blank wells contained culture medium only.    
A 
B 
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Twenty µl of the CellTiter-Glo reagent was dispensed to each well using a multichannel 
pipette. The microplate was placed on an orbital shaker for 2 minutes to lyse the cells, after 
which it was incubated for 10 minutes at room temperature to stabilise the luminescent 
signal. Finally, the microplate was read in a luminescent plate reader (Bio-Tek). The mean 
luminescence of the medium-only wells were subtracted form all other wells, and the relative 
survival fraction at each drug dose was calculated through dividing the mean luminescence 
corresponding to the drug dose by the mean luminescence of the untreated controls.  
 
2.7.2. Flow cytometric assessment of cell viability 
 Cytotoxicity assessments in primary CLL cells involved several experimental 
procedures carried out in succession. These were: (1) carboxyflourescein succinindyl ester 
(CFSE) labelling of CLL cells; (2) induction of CLL cell proliferation; (3) addition of drug or 
drug combination; (4) cell harvesting and labelling; and (5) flow cytometric analysis.  
 CFSE labelling.  CLL cells were labelled with 5 μM CFSE (Cell Technologies). 
CFSE is a fluorescent dye that covalently binds to intracellular molecules. CFSE fluorescent 
intensity would be expected to halve with each cell division, and can therefore be used to 
confirm proliferation. To perform CFSE labelling, cells were first washed with serum-free 
PBS and up to 108 cells were resuspended in 1 ml serum-free PBS. Five μl of 1 mM CFSE 
was added to produce a final concentration of 5 μM, after which the cell suspension was 
incubated for 5 minutes at room temperature with gentle swerving. Following this, the 
labelling was stopped by adding 10 ml of RMPI-1640/10% FBS. Cells were then washed 
with RMPI-1640/10% FBS to remove unlabelled CFSE.    
 Induction of CLL cell proliferation.  CFSE-labelled primary CLL cells were 
induced to proliferate in transparent flat-bottomed 96-well microplates using the CD40L/IL-21 
co-culture system described in section 2.3.2. In pilot experiments, the optimal plating density 
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was found to be 105 CLL cells and 104 MEFs per well (Figure 2.9A). Increasing the plating 
density or the ratio of MEFs to CLL cells did not improve CLL cell viability or the number of 
viable CLL cells. An 8-day co-culture period was used, and shortening this to 6 days in pilot 
experiments did not improve CLL cell viability. Hence, all subsequent experiments adopted a 
plating density of 105 CLL cells and 104 MEFs, and a co-culture period of 8 days. This 
includes 4 days to allow CLL cells to proliferate before the addition of drugs, and 4 days after 
drug treatment. Similar to the setup for CellTiter-Glo experiments, the outer wells forming the 
perimeter of the microplate were not plated with cells, but rather were filled with 200 µl of 
culture medium.    
 Addition of drug or drug combination.  Following 4 days of CLL cell culture 
within the CD40L/IL-21 co-culture system, the microplates were examined under an inverted 
microscope to confirm CLL proliferation. Proliferating CLL cells appeared as cells of varying 
sizes congregating around the adherent fibroblasts. One hundred μl of culture medium was 
removed from each well without disrupting the CLL cells. This was replaced by 100 μl of 
drug or drug combination, prepared in the same way as for the CellTiter-Glo experiments 
described in section 2.8.1 (Figure 2.9B). Similar to the CellTiter-Glo experiments, triplicate 
wells were used for each drug dose or dose combination, and untreated controls were 
included. The CellTiter-Glo experimental layouts shown in Figure 2.8 are also reflective of 
the microplate layout used for drug studies involving primary CLL cells. Following drug 
treatment, the cells were incubated at 37°C with 5% CO2 for 4 further days.  
 Cell harvesting and labelling.  CLL cells were harvested after a total of 8 days of 
culture. CLL cells were dislodged by gentle pipetting as described in section 2.3.2, and 
transferred to a new 96-well round-bottom microplate using a multichannel pipette. These 
cells were washed in PBS with 2% BSA, after which they were incubated in CD19 APC 
antibody (eBiosciences) for 30 minutes at 4°C. After a further wash in PBS/BSA, 10 µl of 10 
μg/mL PI solution (Sigma) was dispensed to each well, and the microplate was immediately 
loaded onto the plate handler for automated acquisition using an Accuri C6 flow cytometer.







Drug cytotoxicity assays on primary CLL cells.  (A)  Results of optimisation experiments 
in 96-well microtitre plates showing the total viable CLL cell number per well (left panel) and 
the proportion of dead CLL cells (right panel) at the end of the culture period, with different 
initial plating densities, incubation durations (8 days vs 6 days) and ratios of CD40L-
expressing MEFs to CLL cells (10:1 vs 5:1). A plating density was 105 CLL cells and 104 
MEFs per well, and a total culture period of 8 days was found to be optimal. (B)  Schematic 
diagram showing the key steps involved in the experimental setup for the assessment of 
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Flow cytometric analysis (Figure 2.10).  The flow cytometer was set up as 
described in section 2.4.1. A mixture of CFSE-labelled and unlabelled CLL cells was used as 
the compensation control for CFSE, whereas a mixture of fludarabine treated and untreated 
PI-labelled CLL cells was used as the compensation control for PI. Prior to sample 
acquisition, the flow cytometer was pre-programmed to acquire 20,000 gated events for 
each sample. Following the exclusion of doublets and debris (which had lower FSC and 
SSC compared to live cells), but not dead cells (which had lower FSC but similar or higher 
SSC compared to live cells) (Figure 2.10A-B), the acquired events were displayed in a 
CFSE histogram. The rightmost peak represents non-cycling cells. Each cell division was 
accompanied by reduction in CFSE fluorescence intensity indicated by a shift of the peaks to 
its left. Cellular proliferation could therefore be confirmed using by the CFSE histogram 
which demonstrates successive reduction in CFSE fluorescence intensity (Figure 2.10C). 
The CD19+ population that had undergone at least one round of cell division was gated in a 
CFSE vs CD19 plot (Figure 2.10D), and the gated events were analysed on a PI histogram 
(Figure 2.10E). The viability of each sample is calculated by: Viability = 1 – (% of PI positive 
events). The relative surviving fraction at each drug dose was calculated through dividing the 
mean viability corresponding to the drug dose by the mean viability of the untreated controls.   
 
2.7.3. Calculation of drug combination indices 
 Drug doses which would produce 50% cell killing (EC50) and drug combination 
indices (CI) were calculated using Calcusyn (Biosoft), which employs a mathematical 
modelling algorithm known as the median effect method (Chou and Talalay, 1984). 
Synergism was observed when the combined use of two drugs produced an effect 
exceeding the use of the two drugs separately (i.e. 1 + 1 > 2). Antagonism, on the other 
hand, was reported when the combined use of two drugs was less effective than either of  
  
























Gate settings in flow cytometric assessments of cell viability.  (A) First, events on the 
FSC vs SSC plot are gated (P1) to exclude cellular debris.  (B) The P1 gated events are 
subjected to further gating to include singlets but exclude doublets (P2).  (C) Cellular 
proliferation can be confirmed on a CFSE histogram. Only P1 + P2 gated events are 
displayed. The rightmost peak represents non-cycling cells. Each cell division is 
accompanied by reduction in CFSE fluorescence intensity indicated by a shift of the peaks to 
its left. Each peak represents cells that have undergone a particular number of cell divisions, 
indicated on the top of the histogram (in red).  (D) The P1 + P2 gated events are displayed in 
a CFSE vs CD19 plot, which is used to identify CLL cells (CD19+) that have undergone at 
least one round of cell division (P3).  (E) The viability of the gated P3 population is analysed 
on a PI histogram. The PI positive events (dead cells) fall within the M1 gate and viability is 
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the two agents (i.e. 1+1 < 1) (Bijnsdorp et al., 2011). A list of CI values and their indications 
is provided below:  
CI   <0.1  +++++  Very strong synergism 
 CI   0.1-0.3  ++++  Strong synergism 
 CI   0.3-0.7  +++  Synergism 
 CI   0.7-0.85  ++  Moderate synergism 
 CI   0.9-1.1  +   Slight synergism 
 CI   0.9-1.1  ±  Additive 
 CI   1.1-1.2  −  Slight antagonism 
 CI   1.2-1.45  −−  Moderate antagonism 
 CI   1.45-3.3  −−−  Antagonism 
 CI   3.3-10  −−−−  Strong antagonism 
 CI   >10   −−−−−  Very strong antagonism 
 
 
2.7.4. Drugs and inhibitors 
 Drug and inhibitors used in the cytotoxicity assays and other experiments within the 
ATR inhibitor study are summarised here. AZD6738, hydroxyurea (Sigma), chlorambucil 
(Sigma), fludarabine (Teva), bendamustine (Sigma) and ibrutinib (Seleckchem) were 
dissolved in DMSO and used at the specified concentration. In vitro studies involving 
cyclophosphamide were conducted using 4-hydroperoxycyclophosphamide (Niomech). 
Pharmacological inhibition of ATM, DNA protein kinase (DNA-PK) and caspases was carried 
out respectively using the ATM inhibitor KU-55933 (Calbiochem), the DNA-PK inhibitor 
NU7441 (Seleckchem) and Z-VAD-FMK (Enzo).  
 
  
140     
2.8. Western blotting 
 
2.8.1. Sample preparation and protein quantification 
 Harvested cells were lysed and protein extracted in urea/Tris buffer (UTB), 
prepared by dissolving urea, Tris and 2-mercaptoethanol in distilled water to a concentration 
of 9 M urea, 75 mM Tris and 150 mM 2-mercaptoethanol, and then adjusting the pH to 7.5. 
Cells were washed with PBS and pelleted at 4°C in a universal tube, after which 50 µl of ice-
cold UTB buffer was added and mixed with the cells. Cells were then sonicated twice in UTB 
buffer for 15 seconds each, in order to ensure complete cell lysis and to reduce sample 
viscosity by shearing the DNA. Sonicated samples were transferred to an eppendorf, and 
centrifuged at 14,000 rpm for 20 minutes at 4°C. The supernatant containing the extracted 
proteins was then transferred to a new eppendorf, and the pellet remaining in the previous 
eppendorf was discarded.  
Protein determination was then carried out in a colorimetric assay using the 
Bradford dye binding method (Bradford, 1976). This method utilises a Coomassie Brilliant 
Blue dye, which changes from red to blue upon binding to protein. A set of 6 concentrations 
of BSA (0, 100, 200, 300, 400 and 500 µg/ml) was prepared by diluting a 1 mg/ml BSA stock 
solution with distilled water. This was used as the protein standard. Ten µl of each BSA 
standard and 10 µl of a 1:10 dilution (in distilled water) of each sample was added in 
triplicates to a transparent, flat-bottomed 96-well microplate, after which 200 µl of a 1:5 
dilution (in distilled water) of the Bradford reagent (Biorad) was dispensed to each well. The 
microplate was allowed to equilibrate for 5 minutes before absorbance was measured at 595 
nm by an iMark microplate reader (Bio-rad). A linear standard curve was constructed by 
plotting the absorbance readings against known concentrations of the BSA standard. The 
standard curve was then used to convert absorbance readings of the samples to protein 
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concentrations. The actual protein concentration of each sample was calculated by 
multiplying the value obtained from the standard curve by 10.    
 
2.8.2. Gel electrophoresis and transfer 
 A polyacrylamide gel was used to resolve the proteins in each sample. Gels can be 
made with different acrylamide percentages. A 10% gel was used if the proteins of interest 
were <50 kDa; otherwise, a 6% gel was used. The gels were made according to the 
following recipe: 
      6% gel  10% gel   
 Distilled water    27.4 ml  19.4 ml 
 1M Tris     4 ml  4 ml 
 30% acrylamide    8 ml  13.4 ml 
 10% sodium dodecyl sulphate (SDS) 400 µl  400 µl 
 Tetramethylethylenediamine (TEMED) 80 µl  80 µl 
 10% ammonium persulphate (APS) 200 µl  200 µl 
TEMED and APS were used to catalyse the polymerisation of acrylamide to form the gel. 
SDS was used to denature the proteins such that the mobility during gel electrophoresis 
would depend primarily on its molecular size.  
The gel was cast and allowed to set for 2 hours. Thereafter, 20 µg of each protein 
sample, prepared in loading buffer (made with bromophenol blue, 2-mercaptoethanol, SDS 
and glycerol in Tris buffer, pH 6.8), was denatured by heating to 99°C for 5 minutes, and 
loaded into individual wells. A multicolour broad range protein ladder (Thermo Fischer 
Scientific) was also loaded. The gel was run at 25 mA for 5 hours in gel running buffer 
(prepared by adding 50 ml of 1M Tris and 5 ml of 10% SDS to 445 ml of distilled water).      
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The resolved proteins were then transferred onto a nitrocellulose membrane 
(Thermo Fischer Scientific). First, the transfer buffer was made by dissolving 1.4 L of 
methanol, 203 g of glycine and 40.6 g of Tris in 7 L of distilled water. Next, the transfer 
cassette was assembled by placing the gel and the nitrocellulose membrane in between two 
sponges and filter papers soaked in transfer buffer, with the membrane facing the cathode 
and the gel facing the anode. The assembled cassette was then placed in a tank filled with 
transfer buffer, and the transfer was run for 18 hours at 200 mA.  
 
2.8.3. Antibody staining and visualisation 
 Following protein transfer, the nitrocellulose membrane was rinsed in water and 
stained with Ponceau S solution (Sigma) to visualise and confirm equal loading of proteins. 
Using the protein ladder and Ponceau staining as a guide, the membrane was then 
separated into several strips, each containing a single protein of interest. The membrane 
strips were washed in TBST (50 mM Tris, 150 mM NaCl and 0.1% Tween 20, at pH 7.5) to 
remove the Ponceau stain, and blocked in 5% non-fat dry milk (20 g of milk powder 
dissolved in 400 ml of TBST) for 2 hours to reduce subsequent non-specific antibody 
binding. After a further wash in TBST, the membrane strips were incubated overnight at 4°C 
with their respective primary antibody made up in TBST with 5% BSA. A list of antibodies 
used is provided in Appendix 2. Antibodies were generally used at dilutions recommended 
by the supplier, with optimisation required only for a minority of antibodies.  
 Following three further wash in TBST, the membrane strips were incubated for 1 
hour at room temperature with an anti-mouse, anti-goat or anti-rabbit antibody (Dako) 
conjugated to horseradish peroxidase (HRP), depending on the animal species from which 
the primary antibody was raised. Thereafter, the membrane strips were washed for three 
times in TBST before the addition of the enhanced chemiluminescence (ECL) reagent 
(Thermo Fischer Scientific). The ECL reagent is a substrate for HRP, and emits signals that 
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can be detected on an X-ray film. The membrane strips were incubated in ECL reagent for 1 
minute, following which excess ECL reagent was removed. The strips were wrapped in cling 
film and placed in a cassette with the protein side facing up. X-ray films (Thermo Fischer 
Scientific) were placed on top of the membrane in a dark room for exposures of varying 
durations. These films were then developed in a dark room.  
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2.9. Immunofluorescence microscopy 
 
2.9.1. Analysis of DNA damage foci 
 Slide preparation.  Harvested cells were pelleted in a universal tube, washed once 
with PBS and resuspended in PBS at a concentration of 106 cells/mL. Multispot glass slides 
(4 spots/slide; Hendley-Essex) were prepared the previous day by immersing in 70% ethanol 
with 1% hydrochloric acid for 1 hour, rinsing with distilled water and drying overnight in a 
37°C incubator. A blob of poly-L-lysine (Sigma) was added to each spot on the slide, and left 
for 20 minutes at room temperature. The poly-L-lysine was then removed and each spot was 
washed with a blob of distilled water. The slide was left to dry at room temperature for 30 
minutes, after which 100 µl of cells (containing 105 cells) was applied to each spot.  
 Extraction, fixing and blocking.  The cells were left to adhere onto the glass slide 
for 30 minutes, and fixed in ice cold 4% paraformaldehyde for 5 minutes in a coplin jar. 
Thereafter, extraction buffer (containing 10 mM piperazine-N,N′-bis(2-ethanesulfonic acid), 
300 mM sucrose, 20 mM sodium chloride, 3 mM magnesium chloride and 0.5% Triton X-
100) was applied to each spot, in order to permeabilise the cell membrane to allow 
subsequent antibody entry and binding. Slides were then washed three times in PBS at 
room temperature, after which blocking was carried out by immersing the slides in PBS with 
10% FBS for 1 hour. This prevents subsequent non-specific antibody binding.  
 Antibody labelling and microscopy.  Following blocking, the slides were washed 
three times in PBS, and labelled with primary antibody. The primary antibodies used include 
those against γH2AX (Millipore), 53BP1 (Santa Cruz), lamin B (Santa Cruz) and 
phosphohistone H3 serine 10 (pH3; Cell Signaling). All antibodies were used at the 
supplier’s recommended dilution, and dilutions were made in PBS with 1% FBS. One 
hundred µl of the primary antibody dilution was added to each spot. The slides were then 
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incubated at 4°C in a moist chamber overnight. After three further washes in PBS, 100 µl of 
the secondary antibody dilution, made in PBS with 1% FBS, was applied to each spot. A 
fluorophore-conjugated anti-mouse or anti-rabbit antibody (Dako) was used as the 
secondary antibody, depending on the animal species from which the primary antibody was 
raised. The slides were incubated with the secondary antibody for 1 hour at room 
temperature in darkness. Thereafter, three further washing steps were performed, and the 
slides were mounted in Vectashield mounting medium with 4',6-diamidino-2-phenylindole 
(DAPI; Vector Laboratories) which stains the cellular DNA content. The slides were 
examined under an immunofluorescence microscope (Nikon) using a x60 lens and analysed 
using the Volocity software (Perkin Elmer). 
 
2.9.2. DNA fibre analysis 
 DNA fibre analysis performed as part of the ATR inhibitor study was carried out by 
Dr Eva Petermann (University of Birmingham).  
First, cells were pulse-labelled sequentially with thymidine analogues 5-chloro-2’-
deoxyuridine (CidU; Sigma) and 5-iodo-2’-deoxyuridine (IdU; Sigma) as previously described 
(Jackson and Pombo, 1998; Petermann et al., 2010). This involved incubating the cells with 
25 μM of CidU for 20 minutes, and then 250 μM of IdU for the next 20 minutes, such that 
CidU and IdU was incorporated into newly synthesised DNA during the first and second 20 
minutes respectively. Cells were then lysed and DNA molecules were stretched and fixed 
onto a microscope slide. Thereafter, the slide was stained with antibodies directed against 
CiDU and IdU respectively.  
DNA replication tracts were examined using an immunofluorescence microscope. 
Replication rates in kb/min were obtained by measuring DNA fibre length in microscopy 
images. Fibre length in μm was converted into kb using the factor 2.59 kb/μm as determined 
by spreading and staining viral genomes of a defined length (Jackson and Pombo, 1998).  
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2.10. Animal experimentation 
 
 All animal experimentation conducted as part of the ATR inhibitor study was carried 
out by Dr Nicholas Davies (University of Birmingham) under a UK Home Office animal 
license (PPL 70/8151).  
Generation of primary CLL xenografts.  Primary CLL xenografts were generated 
by injecting 2-5 x 107 CLL cells intravenously into irradiated (1.25 Gy X-ray) NOD/Shi-
scid/IL-2Rγ (NOG) mice, alongside 105 autologous T lymphocytes. Autologous T 
lymphocytes were stimulated for 3-7 days prior to inoculation into mice with CD3/CD28 
Dynal beads (Life Technologies) in the presence of human IL-2 (30 units/ml; Peprotec, 
London, UK) in accordance with a published protocol (Patten et al., 2011). Engraftment was 
ascertained by the presence of ≥1% human CD45+ CD19+ cells in peripheral blood, 
assessed using flow cytometry.  
Drug treatment.  Animals were treated with AZD6738 (12.5 mg/kg orally 5 days per 
week for 2 weeks) and/or chlorambucil (16mg/kg on day 1 and 5mg/kg on day 3, 
intraperitoneally), or vehicle, and sacrificed 3 weeks following the initiation of treatment. 
Assessment of tumour load and cytogenetics.  Tumour load was assessed by 
flow cytometric quantification of murine CD45−, human CD45+ CD19+ cells in infiltrated 
murine spleens. FISH was carried out on these murine CD45−, human CD45+ CD19+ cells 
using 11q FISH probes (Abbott Molecular).   
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2.11. Statistical analysis 
 
 All statistical analysis was carried out using the GraphPad Prism software, with the 
exception of survival analysis which was performed using SPSS Statistics (IBM 
Corporation). The range of values which has a 95% probability of containing the true value 
was determined by the 95% confidence interval (CI), and p values of <0.05 were considered 
statistically significant. The specific statistical tests used are described below: 
 Student’s t-test.  This test was applied to compare a single variable between two 
groups. Paired t-tests were used to compare the same patients or samples between two 
timepoints, whereas unpaired t-tests were used for comparisons between two distinct groups 
of patients or samples.   
Analysis of variance (ANOVA).  This test was employed for comparison of a 
single variable across more than two groups. The one-way ANOVA and the two-way 
ANOVA were used for comparisons across three or more distinct groups of patients or 
samples, defined by a single factor and by two different factors, respectively. In all ANOVA 
tests, a Bonferroni post-hoc analysis was additionally performed to generate a significance 
value for all possible pairwise comparisons, where the results of each group was compared 
to the results of each of the remaining groups.  
Kaplan-Meier analysis.  This methodology was used to estimate the PFS and OS 
of specific groups of patients. Such estimation of PFS and OS was based on the last known 
clinical status (i.e. remission vs progression for PFS; alive vs dead for OS) and time to event 
for each individual within a group, calculated from the date of end of treatment to clinical 
progression or death respectively. Events were censored at the time of the last clinic 
appointment for patients who remained untreated or were lost to follow up. These statistics 
were used to construct survival curves, in which the proportion of patients who remained 
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progression-free or alive was plotted against time. In these curves, each downward step or 
deflection represents one or more progression or death events, whereas a tick reflects a 
censored event.  
Log-rank test.  The univariate log-rank test was employed to compare the survival 
outcomes of two distinct groups of patients. For each comparison, the statistical significance 
and hazard ratio were reported. The hazard ratio (HR) refers to the ratio of the rate of 
progression (for PFS) or death (OS) in one group of patients compared to the other group. 
For instance, an HR of 2 would indicate that the rate of death in one group was twice that of 
the other group.  
Cox proportional hazards model.  This multivariate Cox regression analysis was 
used to assess the relative impact of and the relationship between several different co-
variates which, as a single variable, had demonstrable impact on clinical outcome. Similar to 
the log-rank test, the statistical significance and HR were reported. A significant result from 
this test indicates that the variable under consideration has clinical impact independent of all 
the other co-variables analysed. 
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Understanding the features and probable mechanism of spontaneous disease 
regression could inform the therapeutic management of CLL. Multiple lines of evidence now 
suggest that the clinical course of individual patients is shaped both by the biological 
properties of their CLL clone and by the dynamics of its interaction with the 
microenvironment. Disease progression in CLL is often accompanied by increased CLL cell 
trafficking to proliferation centres, BCR positive signalling, and proliferation (Herishanu et al., 
2011; Messmer et al., 2005; Stevenson et al., 2011). Moreover, the emergence of driver 
mutations and genomic complexity may result in the outgrowth of CLL cells with greater 
proliferative and survival advantage (Landau et al., 2013; Landau et al., 2015; Puente et al., 
2015). These changes, facilitated by impaired tumor immunity and a microenvironment 
conducive to CLL proliferation and apoptotic evasion (Burger, 2011; Forconi and Moss, 
2015; Herishanu et al., 2011; Nunes et al., 2012; Ramsay et al., 2008; Riches et al., 2013), 
may shift the balance of CLL turnover in favour of clonal expansion (Messmer et al., 2005). I 
therefore postulated that, conversely, spontaneous CLL regression may occur under some 
or all of the following conditions: low CLL BCR signalling and proliferative capacity, high 
susceptibility of CLL cells to apoptosis, low tumour mutational burden and improved 
immunity. 
To evaluate this hypothesis, and to identify features underpinning spontaneous CLL 
regression, I conducted an integrative analysis using phenotypic, functional and genomic 
approaches on peripheral blood samples from 19 subjects who have undergone 
spontaneous CLL regression. The analysis revealed unique features that were seen 
consistently across these subjects, providing novel insights into spontaneous disease 
regression in CLL.  
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3.1. Results 
 
 I reviewed the clinical records of all patients with untreated CLL from 4 UK 
haematology centres who either attended a CLL clinic or participated in the community 
monitoring program between 2010 and 2016. Subjects with complete spontaneous disease 
regression were identified on the basis of a sustained reduction in lymphocyte count (ALC) 
to below 4 x 109/L, with complete resolution of CLL-related symptoms, anaemia (<100 g/L), 
thrombocytopenia (<100 x 109/L) or clinically detectable lymphadenopathy or 
hepatosplenomegaly that may be present at diagnosis. Subjects with partial spontaneous 
disease regression were identified based on evidence of sustained reduction of 
lymphocytosis by ≥ 50% from the peak level with regressing nodal disease. Individuals with 
an alternative explanation for the disease regression were excluded. These comprise 
patients with concurrent infections or second malignancies and those receiving treatment 
with cytotoxic or immunosuppressive drugs, including long-term or high-dose corticosteroids, 
immediately preceding or coinciding with the onset of CLL regression. Subjects diagnosed 
with a second malignancy following the onset of spontaneous CLL regression were not 
excluded, but were considered within a separate category if the subsequent malignancy was 
diagnosed within 5 years of the onset of CLL regression. These patients were categorised 
separately from other spontaneous regressors because pro-inflammatory responses could 
potentially be developed against the second malignancy, and these responses could have 
potential anti-tumour effects that might have impacted on the initial CLL.  
For comparison purposes, untreated CLL cases with indolent disease were 
recruited locally, while progressive cases were sourced from UK multicentre clinical trials, as 
detailed in Table 3.1. Indolent CLL was defined as Binet stage A disease with a lymphocyte 
doubling time of ≥ 2 years monitored over ≥ 5 years. For progressive cases, a sample
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Table 3.1.   Demographic and clinical features of patient cohorts in this study.  
 
(A) Patient cohorts used in section 3.2.3  (phenotypic analysis) 
 
  
Spontaneous regression Indolent Progressive 
Cohort size N 17 54 40 
Age Median 77.4 71.3 61.5 
 
Range 44-86 45-89 42-83 
Binet stage 
 
A A B/C 
Previous treatment % treated 0 0 50 
IGHV mutational status % U-CLL 0 8 70 
Source 
 
Local hospitals Local hospitals UK IciCLLe trial 
 
 
(B) Patient cohorts used in section 3.2.5  (BCR signalling analysis)  
 
  
Spontaneous regression Indolent mutated Indolent unmutated 
Cohort size N 14 35 4 
Age Median 78.6 71.3 70.5 
 
Range 67-86 45-89 66-80 
Binet stage 
 
A A A 
Previous treatment % treated 0 0 0 
IGHV mutational status % U-CLL 0 0 100 
Source 
 
Local hospitals Local hospitals Local hospitals 
 
 
 (C) Patient cohorts used in section 3.2.7  (T cell analysis) 
  
Healthy controls Spontaneous regression Indolent 
Cohort size N 6 16 31 
Age Median 62.0 76.6 71.3 
 
Range 47-70 44-86 60-89 
Binet stage 
 
- A A 




50.0 68.8 67.7 
Source 
 
Local donors Local hospitals Local hospitals 
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obtained immediately before treatment was used. Details of patient recruitment and the 
clinical trial cohorts used in this study were provided in section 2.1.1 and 2.1.2. 
 
3.1.1. Spontaneous disease regression occurs at a frequency of 1.4% in 
CLL 
Twenty individuals who fulfilled the criteria for spontaneous disease regression 
were identified from a review of 1425 patients with CLL. The prevalence of spontaneous CLL 
regression in this cohort was 1.4%, which approximates the frequency reported in earlier 
studies (Del Giudice et al., 2009; Thomas et al., 2002). The clinical details of these 20 
individuals are described in Figure 3.1 and Table 3.2. These 20 individuals include 11 
subjects who underwent complete spontaneous regression (Category A; CLL01 to CLL11); 6 
who experienced partial spontaneous regression (Category B; CLL12 to CLL17); 2 whose 
onset of CLL regression preceded the diagnosis of a second malignancy by ≤ 5 years, and 
thus may potentially be related to the concurrent malignancy (Category C, CLL 18 and 
CLL19); and 1 who experienced spontaneous regression over a 14-year period, but whose 
ALC has recently increased (Category D, CLL20). In the absence of a reactive cause, the 
latter may represent CLL relapse following spontaneous regression.  
Subjects were followed for a median of 15.2 years (range 3.6-30 years). Among the 
complete spontaneous regressors, CLL regression occurred over a median of 8.6 years 
(range 5.3-26.2 years). At the time of the study, lymphocytosis and CLL-related clinical 
features have been absent for a median of 2.7 years for the complete spontaneous 
regressors (range 0.9-11.8 years). Lymphopenia is a rare, idiosyncratic effect of certain 
drugs (e.g. levetiracetam); however, no temporal relationship was apparent between the 
initiation of these drugs and spontaneous CLL regression. Therefore, CLL regression in 
individuals other than CLL18 and CLL19 could not be explained by their medical or drug 
history (Table 3.2).  
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Clinical features of 20 spontaneous CLL regression cases.  Spontaneous CLL regression cases were categorised into 4 groups: complete 
spontaneous regression (Category A; represented by red-coloured curves), partial spontaneous regression (Category B; blue-coloured curves), 
spontaneous regression potentially associated with a second malignancy (Category C; green-coloured curves) and relapsed spontaneous 
regression (Category D; purple-coloured curves). The absolute lymphocyte count for each patient is plotted against the time elapsed from the 
date of diagnosis. Clinical features are annotated, and the time of peripheral blood sampling is displayed at the bottom each chart. T0 
represents the diagnostic timepoint, whereas T1 and T2 represent the regression timepoints, except in CLL20 where T2 represents the relapse 
timepoint. LN, lymphadenopathy (the measurement that follows denote the size of the largest palpable node); Tx, treatment.   
Figure 3.1 
  (cont’d) 
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Year Age Peak Current Site Diagnosis 
Complete spontaneous regression  (Category A) 













CLL03 1996 66 M 32.7 1.5 
Ischaemic heart disease, 
peripheral vascular disease, 
diabetes mellitus, 







CLL04 1994 58 M 10.5 1.7 






CLL05 2000 56 M 25.7 2.6 
Previous rectal polyp (non-
malignant), diabetes mellitus 
- - Metformin 
CLL06 1997 61 M 27.4 3.5 
Diabetes mellitus, 
hypertension 
- - Metformin, furosemide 
CLL07 2002 83 M 23.2 3.6 
Hypothyroidism, diabetes 







CLL08 2002 72 F 6.7 2.4 




- - Bisoprolol 
CLL09 1990 46 M 20.2 3.1 
Hypertension, 
Hypercholesterolaemia 
- - Ramipril, simvastatin 
CLL10 2008 70 M 13.8 3.2 
Hypertension, abdominal 












Partial spontaneous regression  (Category B) 
CLL12 2000 66 M 40.6 5.6 







CLL13 2013 73 M 161.0 11.3 





CLL14 2002 73 F 44.5 8.5 













CLL16 2007 36 F 19.6 7.0 Eczema, mild depression - - Nil 
CLL17 2009 81 M 42.4 16.9 
Lewy body dementia, previous 





Spontaneous regression associated with second malignancy  (Category C) 












Relapsed spontaneous regression  (Category D) 
CLL20 1993 38 M 52.4 20.0 
Hypercholesterolaemia, 






ALC, absolute lymphocyte count; TIA, transient ischaemic attack; COPD, chronic obstructive 
pulmonary disease; SCC, squamous cell carcinoma; BCC, basal cell carcinoma.  
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3.1.2. Spontaneously regressed CLL tumours utilise mutated IGVH3 and 
IGVH4 genes 
All subjects except one (CLL07) were alive at the time of analysis. CLL07 died from 
complications of sepsis, arising from an ascending urinary tract infection associated with an 
indwelling urinary catheter. The cause of death was therefore not directly related to CLL. 
Peripheral blood samples were available at the time of CLL regression from 19 individuals 
(T1/T2 timepoint), and at the time of diagnosis in 6 individuals (T0 timepoint). The blood 
sampling timepoints for each subject is displayed in Figure 3.1 beneath their respective 
lymphocyte count charts.  
In all cases, a residual monoclonal B lymphocyte population with CLL phenotype 
(CD19, CD5, CD23 and CD43 positive, CD20, CD79b and CD81 weak, CD10 negative and 
Igκ/λ-restricted) could be identified by multiparameter flow cytometry in the regression blood 
sample (T1 timepoint). These cases were therefore genuine cases of CLL. Furthermore, the 
residual CLL population could be distinguished from the normal B cell population and 
quantified based on several cell surface markers. Both normal B cells and CLL cells are 
CD19 positive; however, whereas normal B cells have high expression levels of CD20, 
CD79b and CD81 and low expression levels of CD43, CLL cells typically have high 
expression levels of CD43 and low expression levels of CD20, CD79b and CD81, as shown 
in Figure 3.2A (Rawstron et al., 2016). On this basis, it could be determined that residual 
CLL cells accounted for a median of 92.5% of B cells (range 71.6-99.8%) at the time of 
regression (Table 3.3). Furthermore, by taking into account of the lymphocyte count and 
determining the proportion of lymphocytes that were B cells (CD19+), T cells (CD3+) or NK 
cells (CD3− CD4− CD16+), as shown in Figure 3.2B, the B cell, T cell, NK cell and residual 
CLL cell count could be estimated for each case (Table 3.3). At the time of regression, the 
median residual CLL count was 1.8 x 109/L (range 0.4-6.5 x 109/L), and these residual
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Gating strategies to differentiate various lymphocyte populations in CLL patients.  In 
both (A) and (B), singlet mononuclear cells are first selected using the gating strategy shown 
in Figure 2.3A-B. (A) A CD19 gate is then applied to select for CD19+ B lymphocytes (not 
shown). The CLL population (shown in red) is distinguished from the non-malignant B 
lymphocyte population (shown in green) by their immunophenotype. CLL cells have high 
CD5 and CD43 expression and low CD20, CD79b and CD81 expression. Non-malignant B 
lymphocytes and progenitors have high CD20, CD79b and/or CD81 expression.  (B)  
Different mononuclear cell populations are distinguished based on their CD3, CD4 and 
CD16 expression. B lymphocytes (in purple) are CD3−CD4−CD16−, CD4 T lymphocytes (in 
green) are CD3+CD4+CD16−, CD8 T lymphocytes (in orange) are CD3+CD4−CD16−, NK 
cells (in red) are CD3−CD4−CD16+, and monocytes (in blue) are CD3−CD4+ with variable 
CD16 expression.   
A 
B 
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Table 3.3.   Lymphocyte count and characteristics of the IGH gene in 















































VH DH JH 
CLL01 1.0 0.9 92.0 28.8 3-30 4-17 4 95.5 1.9 1.2 0.7 0.3 
CLL02 2.1 2.1 99.0 63.6 3-53 2-21 4 93.7 1.0 0.6 0.4 0.2 
CLL03 0.4 0.4 91.6 23.8 1-69 5-12 3 91.7 0.8 0.4 0.4 0.3 
CLL04 0.5 0.5 91.5 28.0 3-48 5-18 1 95.5 1.0 0.7 0.3 0.2 
CLL05 1.4 1.0 71.6 38.5 2-5 2-15 4 96.3 1.1 0.5 0.4 0.1 
CLL06 1.7 1.7 98.8 48.0 4-34 6-13 4 87.9 1.7 0.6 1.0 0.1 
CLL07 2.2 2.2 98.0 59.9 3-23 6-19 3 93.1 1.2 0.7 0.5 0.2 
CLL08 - - 86.1 - 3-15 1-1 3 89.1 - - - - 
CLL09 2.0 1.8 92.2 58.0 4-39 2-8 5 91.8 0.7 0.5 0.2 0.4 
CLL10 1.3 1.2 92.5 37.6 3-13 3-16 6 92.6 1.8 1.0 0.7 0.1 
CLL11 0.7 0.7 98.3 57.3 4-4 3-22 4 94.8 0.4 0.3 0.2 0.1 
CLL12 1.6 1.2 75.0 21.4 3-30 3-10 4 91.7 3.9 1.0 2.7 0.1 
CLL13 5.3 5.3 99.8 46.8 3-74 2-21 5 88.9 4.4 3.6 0.6 1.6 
CLL14 6.6 6.5 98.2 76.2 
4-39 1-26 4 95.9 
1.6 0.8 0.6 0.3 
3-23 6-6 2 89.9 
CLL15 3.4 3.4 99.2 61.3 3-30 1-1 3 97.6 1.8 0.9 0.9 0.3 
CLL16 6.1 5.9 96.4 84.0 3-23 4-17 5 92.7 0.6 0.3 0.3 0.3 
CLL18 1.9 1.8 92.4 58.5 3-23 6-19 5 93.1 0.9 0.4 0.4 0.3 
CLL19 6.7 6.2 92.0 80.0 4-34 5-18 6 95.1 0.7 0.4 0.3 0.3 
CLL20 - - - - 4-34 6-19 3 94.7 - - - - 
 
B-cell, CD4+ T cell, CD8+ T cell and NK cell count were derived from the ALC taking into 
consideration the proportion of lymphocytes that were CD19+, CD3+CD4+, CD3+CD8+ and 
CD16+CD3−CD4− respectively. The CLL count was derived from the B-cell count taking into 
account of the proportion of CLL cells in the B lymphocyte population, determined using the 
methodology illustrated in Figure 3.2. IGH sequencing was performed on DNA from sorted CLL 
cells. Gene usage and % homology to the germline IGHV sequence was determined using the 
international immunogenetics information (IGMT) platform.  
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CLL cells accounted for a median of 57.3% of circulating lymphocytes (range 21.4-84%).  
Analysis of the CLL IGH gene locus by Sanger sequencing revealed that every 
spontaneous regression case possessed mutated IGHV, consistent with findings from the 
Italian spontaneous CLL regression study (Del Giudice et al., 2009). There was usage of 
IGVH3 genes in 12 cases. In addition to the use of IGVH3 genes, IGVH4 gene usage was 
also observed in 6 cases in the present cohort, and a single case each of IGVH1 and IGVH2 
usage was seen (Table 3.3). None exhibited stereotyped BCR usage. Importantly, in all 6 
individuals with sequential samples, the IGH sequence of the diagnostic (T0) and regression 
(T1/T2) samples were indistinguishable, indicating that the CLL cells at the diagnostic and 
regression timepoints belonged to the same CLL clone. 
 
3.1.3. Spontaneously regressed CLL tumours exhibit specific 
phenotypic features 
To identify biological features within the CLL clone among spontaneous regressors, 
a comprehensive immunophenotypic analysis was performed comparing regressors (n=17) 
at the regression (T1) timepoint against non-regressing indolent (n=54) and progressive CLL 
cases (n=40). Gated CLL cells (Figure 2.3) were analysed for molecules of relevance to 
CLL pathogenesis, including the proliferation marker Ki-67, key CLL prognostic biomarkers 
(CD38, ZAP-70) (Crespo et al., 2003; Del Poeta et al., 2001; Ibrahim et al., 2001), adhesion 
molecules (CD49d, CD62L/L-selectin) (Brachtl et al., 2014; Bulian et al., 2014), chemokine 
receptors (CXCR4, CXCR5, CCR6, CCR7) (Burkle et al., 2007; Krzysiek et al., 2000; Mohle 
et al., 1999; Till et al., 2002; Vlad et al., 2009), antiapoptotic proteins (Bcl-2, Mcl-1), 




CLL cells from regression cases had uniformly low Ki-67 expression. Indeed, Ki-67 
was positive in <1% of CLL cells in all spontaneous regression cases, with Ki-67 <0.5% in 
the majority, indicating absent or negligible CLL proliferation (Figure 3.3A). Spontaneously 
regressed CLL tumours were generally CD38 and ZAP-70 negative, but these markers did 
not distinguish regressors from non-regressing indolent cases, with the majority of 
regression and indolent cases being negative for both CD38 and ZAP-70 (<30% positivity), 
whereas a substantial proportion of the progressive cases were CD38 and/or ZAP-70 
positive using a 30% cut-off (Figure 3.3B).  
Adhesion molecules, particularly CD49d, are important for the homing of CLL cells 
from the peripheral blood to the lymph nodes where CLL proliferation takes place. CD49d 
expression was significantly lower among spontaneous CLL regression cases compared to 
both indolent and progressive cases, with less than 2% of CLL cells being CD49d positive in 
the majority of the spontaneous CLL regression cases (Figure 3.4A). On the other hand, 
there was no significant difference in CD62L expression across the comparator groups 
(Figure 3.4B).  
The interaction between chemokine and chemokine receptors also plays a crucial 
role in CLL cell trafficking between the proliferative compartment and the peripheral blood. 
As discussed in section 1.2.3.1, the interaction between the chemokine CXCL12 and the 
chemokine receptor CXCR4 on CLL cells is of particular biological significance. Newly 
proliferated CLL cells downregulate cell surface CXCR4 expression to allow their exit from 
lymph nodes into the peripheral circulation (Vlad et al., 2009). Over time, these CLL cells 
recover their CXCR4 expression (Calissano et al., 2011). Hence, CLL cells with low CXCR4 
expression are those that have recently proliferated and emerged from the lymph nodes 
(Coelho et al., 2013). CXCR4 expression was found to be significantly higher in the 
spontaneous regression cases compared to the indolent and progressive cases (Figure 
3.4C). Indeed, >95% of CLL cells were CXCR4 positive in the majority of the spontaneous 
CLL regression cases, indicating that very few have recently proliferated. On the other hand,
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Figure 3.3    
 
 




Spontaneously regressed CLL tumours have low Ki-67, CD38 and ZAP-70 expression. 
CLL cells were gated on the basis of their expression of CD19 and CD20 (CD19+ CD20-
low), as shown in Figure 2.3. The gated CLL population was analysed for the expression of 
the respective markers shown in each panel. For all comparisons, the regression (T1) 
samples from 17 spontaneous regression cases were compared against 54 indolent and 40 
progressive CLL cases. Complete spontaneous regression cases, partial spontaneous 
regression cases and regression cases associated with second malignancy were 
represented by red, blue and green dots respectively as shown by the key. Statistical 
significance was determined using one-way ANOVA with Bonferroni post-hoc analysis. 
Statistical significance is indicated by *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001; n.s. 
denotes comparisons that are not statistically significant.   
A 
B C 
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Figure 3.4    
            
             
            
Spontaneously regressed CLL tumours have low CD49d and high CXCR4 expression. 
The gated CLL population was analysed for the expression of the respective markers shown 
in each panel. For all comparisons, 17 spontaneous regression cases were compared 
against 54 indolent and 40 progressive CLL cases. Complete spontaneous regression 
cases, partial spontaneous regression cases and regression cases associated with second 
malignancy were represented by red, blue and green dots respectively as shown by the key 
in Figure 3.3. Statistical significance was determined using one-way ANOVA with Bonferroni 
post-hoc analysis. Statistical significance is indicated by *p<0.05, **p<0.01, ***p<0.001 and 
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there was no significant difference in CXCR5, CCR6 or CCR7 expression between the 
spontaneous regression and indolent groups (Figure 3.4D-F). However, progressive cases 
had comparatively lower expression of all four chemokine receptors. Lower CXCR4, CXCR5 
and CCR6 levels may reflect a higher proportion of recently proliferated CLL cells that have 
undergone BCR signalling among the progressive cases (Calissano et al., 2011; Krzysiek et 
al., 2000; Saint-Georges et al., 2016; Vlad et al., 2009). 
With regards to anti-apoptotic proteins, there was no difference in Bcl-2 or Mcl-1 
expression levels between regression and indolent CLL, but Mcl-1 levels were higher in 
progressive CLL cases (Figure 3.5A-B). It is of particular importance to highlight the 
observation that CLL cells from spontaneous regressing patients retained high levels of 
Bcl-2 expression. On the other hand, spontaneously regressed CLL tumours had 
significantly higher CD95/FasR expression compared to both indolent and progressive CLL 
cases (Figure 3.5C), implicating a potential role of the extrinsic apoptotic pathway in 
spontaneous CLL regression.  
Finally, ROR1 has generated considerable interest recently because of its high 
expression in many CLL cells. Functionally, ROR1 is a tyrosine kinase receptor that binds 
Wnt5a, and enhances chemokine-mediated CLL cell migration and CD40L-induced 
proliferation through the activation of RhoA and Rac1 respectively which forms part of the 
non-canonical Wnt signalling pathway (Yu et al., 2016). A recent study has demonstrated 
that high expression level of ROR1 is associated with accelerated disease progression in 
CLL (Cui et al., 2016).  Although not significant, I found that there was a trend towards lower 
ROR1 expression in spontaneously regressed CLL tumours compared to indolent CLL 
cases (Figure 3.5D). No significant difference was observed with respect to the expression 
of each of the phenotypic markers studied among the different categories of spontaneous 
regression (i.e. Category A-D as detailed in section 3.2.1 and Table 3.2).  
 To determine whether the phenotypic features among spontaneous regressors 
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Figure 3.5    
                
 




Spontaneously regressed CLL tumours retain high Bcl-2 expression, and have 
increased FasR and reduced ROR1 expression. The gated CLL population was analysed 
for the expression of the respective markers shown in each panel. For all comparisons 
except Mcl-1, 17 spontaneous regression cases were compared against 54 indolent and 40 
progressive CLL cases. For Mcl-1, 11 spontaneous regression cases were compared 
against 20 indolent and 29 progressive cases. Complete spontaneous regression cases, 
partial spontaneous regression cases and regression cases associated with second 
malignancy were represented by red, blue and green dots respectively as shown by the key. 
Statistical significance was determined using one-way ANOVA with Bonferroni post-hoc 
analysis. Statistical significance is indicated by *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001; n.s. denotes comparisons that are not statistically significant.  
A B 
C D 
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were pre-existing or were acquired during the course of regression, I compared samples 
from the diagnostic (T0) and regression (T1) timepoints in up to 5 spontaneous CLL  
regression cases (Figure 3.6). A reduction in Ki-67 positivity was observed across all 5 
cases. In addition, there was a trend towards an increase in CXCR4 expression and a 
reduction in CD38 expression. These changes were consistent with reduced CLL 
proliferation over time. They were accompanied by a trend towards a reduction in cell 
surface CD49d expression, and an increase in CD95/FasR expression. Collectively, these 
results on sequential samples suggest that these unique phenotypic features in spontaneous 
regressors were acquired during course of disease regression.  
     
3.1.4. Reduction in CLL proliferation during spontaneous regression is 
not due to cellular senescence 
Since the major finding emerging from the phenotypic analysis has been that of 
decreased CLL proliferation in spontaneous disease regression, I next investigated its 
potential cause and underlying mechanism.  
To examine the proliferation history of CLL cells from individuals with spontaneous 
disease regression, single-cell telomere length analysis was performed on DNA from sorted 
CLL cells, through collaboration with Prof. Duncan Baird (Cardiff University) and his team as 
detailed in section 2.6.1. Indolent CLL cases displayed variable telomere lengths. This 
observation is likely to reflect the clinical heterogeneity of this group of indolent CLL patients, 
with variable lymphocyte doubling times ranging from 3 years to not reached. Importantly, 
the mean telomere length of the spontaneous regressing cases was not longer than that of 
the indolent cases. Indeed, the mean telomere length among spontaneous regressors was 
generally <5 kb, indicating that the regressed CLL clone was likely to have proliferated at 
some point during its natural history (Figure 3.7). In most spontaneous regression cases, a 
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Figure 3.6 
                     
                 
 
 
CLL proliferation and cell surface CD49d expression are reduced and CD95/FasR 
expression is increased during spontaneous regression. Expression of Ki-67, CD38, 
CD49d, CXCR4 and CD95/FasR were compared between two sequential timepoints in 
individual spontaneous regression cases. T0 represents the diagnostic timepoint, whereas 
T1 represents the regression timepoint. Each coloured line represents a specific case, as 
indicated by the key.   
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  Figure 3.7 
 
        
 
 
       
 
 
Telomere lengths of spontaneously regressed and non-regressing indolent CLL 
tumours are comparable. (A) STELA was performed to assess the telomere length of 
chromosomes Xp and Yp of the CLL cells in each case. The Southern blot shows the 
telomere length distribution of typical indolent and spontaneous regression cases.  (B) The 
telomere length distribution of the CLL Xp and Yp chromosomes in all of the analysed 
indolent and spontaneous regression cases is summarised. (C) The mean CLL XpYp 
telomere length was compared between the spontaneous regression and indolent cases. 
Complete spontaneous regression cases and partial spontaneous regression cases were 
represented by red and blue dots respectively as shown by the key. Statistical significance 
was determined using Student’s T test; n.s. denotes comparisons that are not statistically 
significant.     
A 
B C 
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range of telomere lengths was seen within individual samples, suggesting intraclonal 
heterogeneity. When the telomere length of the diagnostic (T0) and regression (T1/T2) 
samples in individual regression cases were compared, the telomere length distributions 
were found to be largely similar across timepoints, suggesting the presence of the same CLL 
clone (Figure 3.8). Thus, this finding corroborates the IGH sequencing results detailed in 
section 3.1.2 showing identical IGH sequence across timepoints within individual 
spontaneous CLL regression cases.  
Given the rather short CLL telomere length in some of the spontaneous regression 
cases, I questioned whether the reduction in proliferation seen during spontaneous 
regression was due to the CLL cells becoming senescent. To address this, I first measured 
the telomerase activity of the CLL cells from each regression (T1) sample using 
methodology outlined in section 2.7.2, and compared that with samples from indolent CLL 
cases. Interestingly, and contrary to expectation, high CLL telomerase activity was observed 
among the spontaneous regressors compared to patients with indolent disease (Figure 
3.9A). I next proceeded to stain the CLL cells from patients who have undergone 
spontaneous disease regression with beta-galactosidase, a marker of cellular senescence. 
The CLL cells from these patients were negative for beta-galactosidase staining (Figure 
3.9B). Collectively, these results exclude cellular senescence as a cause of decreased CLL 
proliferation during spontaneous regression. 
     
3.1.5. Spontaneously regressed CLL tumours are unresponsive to IgM 
and IgD BCR stimulation   
BCR positive signalling is the major driver of CLL proliferation (Herishanu et al., 
2011; Stevenson et al., 2011). Having excluded cellular senescence as a cause of 
decreased CLL proliferation in spontaneous regression, I asked whether this could be due 
  




Telomere length distributions are similar across sequential timepoints in 
spontaneous CLL regression cases. STELA was performed to assess the telomere length 
of chromosomes Xp and Yp of CLL cells from sequential samples in 4 spontaneous 
regression case. T0 represents the diagnostic timepoint, whereas T1/T2 represents the 
regression timepoint(s). The Southern blot shows the telomere length distribution of each 
sample.    






      
 
Reduction in CLL proliferation during spontaneous regression is not due to cellular 
senescence. (A) Telomerase activity of sorted CLL cells was assessed using the 
TeloTAGGG telomerase PCR enzyme-linked immunosorbent assay kit. The absorbance at 
450 nm, which is proportional to the telomerase activity, was compared between the 
spontaneous regression and indolent cases. Complete spontaneous regression cases and 
partial spontaneous regression cases were represented by red and blue dots respectively as 
shown by the key. Statistical significance was determined using Student’s T test. Statistical 
significance is indicated by ***p<0.001.  (B) Sorted CLL cells were assessed for β-
galactosidase staining. The staining pattern of a typical spontaneous regression case 
(CLL02) was shown in comparison with the positive control (murine embryonic fibroblasts 




IR-treated murine fibroblasts CLL02 
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to the attenuation of CLL BCR signalling responses in patients with spontaneous CLL 
regression. 
 I therefore assessed BCR signalling response by phosphoflow analysis on gated 
CLL cells, comparing spontaneous regression cases at the regression (T1) timepoint against 
IGHV mutated and unmutated indolent cases (Figure 3.10). The combined effect of IgM and 
IgD stimulation was first examined, which reflects BCR stimulation in vivo. Indolent M-CLLs 
displayed variable BCR signalling response to combined stimulation with anti-IgM and anti-
IgD F(ab)2 antibodies, with many cases showing substantial response as evidenced by high 
levels of Syk, Erk and Akt phosphorylation. On the contrary, the response to combined IgM 
and IgD BCR stimulation was uniformly low among spontaneous regressors, as evidenced 
by <10% of CLL cells in these cases displaying p-Syk, p-Erk and p-Akt positivity following 
BCR stimulation. No significant difference in BCR signalling response was apparent 
between individuals with complete spontaneous regression and those with partial 
spontaneous regression.  
In order to dissect the relative contribution of IgM and IgD response to the overall 
BCR signalling response in each comparator group, I next stimulated the CLL cells in each 
sample separately with anti-IgM or anti-IgD F(ab)2 antibodies. As expected, there was a 
marked difference in IgM response between indolent M-CLL and UM-CLL, with much greater 
IgM response in UM-CLL. This was consistent with data presented in several previously 
published studies (Guarini et al., 2008; Lanham et al., 2003; Mockridge et al., 2007).  In 
addition, there was a smaller but significant difference in IgM response between the 
regression group and the indolent M-CLL group, such that whereas all the regression cases 
were unresponsive to IgM BCR stimulation, many indolent M-CLL cases retained a low level 
of response. Moreover, the IgD response was both significantly and substantially lower in 
the regression group compared to the indolent M-CLL group (Figure 3.11). This was 
reflected in the differential expression of CLL cell surface immunoglobulins across the three 






              
Spontaneously regressed CLL tumours are unresponsive to combined IgM and IgD 
BCR stimulation.  (A) BCR signalling responses to IgM and IgD stimulation can be assessed 
by phosphoflow. Cells were stimulated with anti-human IgM and IgD F(ab’)2 antibodies prior to 
acquisition on a flow cytometer. Left panel: The CD19− CD5+ T-cell population (shown in blue) 
was used as the internal negative control, and the CD19+ CD5+ CLL population (shown in 
red) was gated and analysed for the phosphorylation of Syk, Erk and Akt. The positive vs 
negative gate for p-Syk, p-Erk and p-Akt was set such that 99% of unstimulated cells would fall 
within the negative gate. Right panel: Example histograms showing results of a typical indolent 
M-CLL case and a spontaneous regression case. While many M-CLL cases were responsive 
to IgM/IgD stimulation (>10% p-Syk, p-Erk and p-Akt positivity), spontaneous regression cases 
were not. (B) Phosphoprotein levels of spontaneous regression cases (n=14) in response to 
combined IgM and IgD stimulation were compared against indolent M-CLL (n=35) and UM-
CLL (n=4) cases. Complete spontaneous regression cases and partial spontaneous 
regression cases were represented by red and blue dots respectively as shown by the key in 
Figure 3.9A.  Statistical significance was determined using one-way ANOVA with Bonferroni 
post-hoc analysis. Statistical significance is indicated by *p<0.05, **p<0.01 and ****p<0.0001; 
n.s. denotes comparisons that are not statistically significant.   
B 
A 
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Figure 3.11 
             
 
              
 
             
 
Spontaneously regressed CLL tumours are unresponsive to separate IgM BCR 
stimulation and IgD BCR stimulation.  Phosphoprotein levels of spontaneous regression 
cases (n=14) in response to separate stimulation with anti-human IgM or IgD F(ab’)2 
antibody stimulation were compared against indolent M-CLL (n=35) and UM-CLL (n=4) 
cases. Complete spontaneous regression cases and partial spontaneous regression cases 
were represented by red and blue dots respectively as shown by the key. Statistical 
significance was determined using one-way ANOVA with Bonferroni post-hoc analysis. 
Statistical significance is indicated by *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001; n.s. 
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comparator groups, i.e. spontaneous regression, indolent M-CLL and indolent UM-CLL. 
Spontaneous regression cases had low CLL surface IgM (sIgM) and modest surface IgD 
(sIgD) expression. However, whereas indolent M-CLLs also had low sIgM expression 
compared to UM-CLL cases, many of these cases retained high sIgD expression that was 
comparable to their UM-CLL counterpart and significantly higher than that of spontaneous 
CLL regressors (Figure 3.12). Because low sIgM and sIgD expression in CLL can 
sometimes be due to class-switch recombination, I examined the expression of IgG in all 
cases. All samples had negligible IgG expression with the exception of a single spontaneous 
regression case and an indolent M-CLL case.  
The unresponsiveness to BCR stimulation seen in CLL cells from spontaneously 
regressing CLL cases, coupled with low cell surface immunoglobulin expression, are 
hallmark features of B cell anergy (Packham et al., 2014). I therefore proceeded to evaluate, 
by flow cytometry, the spontaneous CLL regression cases for constitutive Erk 
phosphorylation and the expression of the B cell inhibitory receptor LAIR1 that could 
corroborate these features (Muzio et al., 2008; Packham et al., 2014; Perbellini et al., 2014). 
High levels of constitutive Erk phosphorylation, but not constitutive Akt phosphorylation, was 
apparent in CLL cells from the spontaneous regression cases, particularly when compared 
to the indolent M-CLL and UM-CLL cases (Figure 3.13A-B). In addition, CLL cells from 
spontaneous regressors displayed higher levels of expression of LAIR1, a B cell inhibitory 
receptor, on their cell surface compared to both indolent M-CLL and UM-CLL cases (Figure 
3.13C). Taken together, these results indicate CLL anergy as a mechanism accounting for 
the reduction in CLL proliferation during spontaneous regression.  
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Figure 3.12 
 




Spontaneously regressed CLL tumours have low cell surface IgM and IgD expression. 
CLL cells were gated on the basis of their expression of CD19 and CD20 (CD19+ CD20-
low), as shown in Figure 2.3. The gated CLL population was analysed for the expression of 
cell surface IgM (sIgM; A) and IgD (sIgD; B). Spontaneous regression cases (n=14) were 
compared against indolent M-CLL (n=35) and UM-CLL (n=4) cases. Complete spontaneous 
regression cases and partial spontaneous regression cases were represented by red and 
blue dots respectively as shown by the key. Statistical significance was determined using 
one-way ANOVA with Bonferroni post-hoc analysis. Statistical significance is indicated by 
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Figure 3.13 
 




Spontaneously regressed CLL tumours have high levels of constitutive Erk 
phosphorylation and LAIR1 expression. The gated CLL population was analysed for 
basal Erk and Akt phosphorylation (A-B) and cell surface LAIR1 expression (B). 
Spontaneous regression cases (n=14) were compared against indolent M-CLL (n=35) and 
UM-CLL (n=4) cases. Basal Erk and Akt phosphorylation in CLL cells was normalised to B 
cells from 3 age-matched healthy donors, and was expressed as fold change compared to 
these controls. Complete spontaneous regression cases and partial spontaneous regression 
cases were represented by red and blue dots respectively as shown by the key. Statistical 
significance was determined using one-way ANOVA with Bonferroni post-hoc analysis. 
Statistical significance is indicated by *p<0.05 and ****p<0.0001; n.s. denotes comparisons 
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3.1.6. The genomic landscape of spontaneously regressed CLL 
tumours  
 The genomic landscape of CLL in general is well characterised, with several major 
WES or WGS studies published over recent years. However, these studies focused on 
indolent CLL cases (Kasar et al., 2015; Puente et al., 2015) or progressive cases (Landau et 
al., 2015; Puente et al., 2015). On the other hand, the genomic landscape of spontaneously 
regressing CLL is unknown.  
To elucidate the genomic landscape of this group of CLL patients, I undertook SNP 
array analysis and WES on 19 spontaneous regression cases, using a CLL sample from the 
regression (T1) timepoint and a germline sample (either the granulocyte or the T cell 
fraction, as outlined in section 2.5) for each case. SNP array analysis revealed a median of 1 
somatic copy number aberrations (CNAs; range 0-3) per case that were not present in the 
germline DNA. These are listed in Table 3.4 for each spontaneous CLL regression case. A 
summary of the recurrent and/or functionally important CNAs is provided in Figure 3.14, 
alongside the recurrent single nucleotide variations (SNVs) for each case.  
The most frequent CNA was 13q14.2-3 deletion, seen in 12 of 19 cases (63%), with 
all deletions encompassing the minimally deleted region involving the DLEU2/miR-15a/16-1 
cluster. Most 13q14 deletions also encompassed both DLEU7 and RNASEH2B genes that 
are adjacent to DLEU2. In addition, 2 cases (10%; CLL14 and CLL16) carried a larger 13q14 
deletion that included the retinoblastoma (RB1) gene (Table 3.4). Two of these 13q14 
deletions were homozygous (CLL05 and CLL06), whereas others were hemizygous.   
Consistent with acquisition of del(13q14) being an early genomic event, in the majority (10 of 
12) of cases del(13q14) was clonal, and was present in all CLL cells. The frequency of 
del(13q14) in this spontaneous regression cohort was comparable to a typical non-
regressing CLL cohort. There was no recurrent CNAs in the spontaneous regression cohort  
179     





CLL01 8q24.13 del (x1; TRIB1; NSMCE2); 13q14.2- q14.3 del (x1; miR15a/16-1, DLEU7; RNASEH2B) 
CLL02 10q26.3 gain (x3); 13q14.2- q14.3 del (x1; miR15a/16-1, DLEU7; RNASEH2B) 
CLL03 13q14.2- q14.3 del (x1; miR15a/16-1, DLEU7) 
CLL04 2q13 del (x1); 3p24.2-p24.3 gain (x3; NKIRAS1) 
CLL05 13q14.2- q14.3 del (x0;  miR15a/16-1, DLEU7) 
CLL06 3q23 gain (x3); 13q14.2-q14.3 del (x0; miR15a/16-1, DLEU7; RNASEH2B) 
CLL07 3q11.1-q11.2 gain  (x3) ; 4q28.3 gain (x3); 11p13-p14.1 gain (x3; WT1)   
CLL08 No detectable CNV 
CLL09 7q11.23 del (x1) 
CLL10 7q31.33-q32.1 gain (x3; POT1); 13q14.2- q14.3 del (x1; miR15a/16-1, DLEU7; RNASEH2B) 
CLL11 13q14.2-q14.3 del (x1; miR15a/16-1, DLEU7) 
CLL12 2p16.1 del (x1) 
CLL13 8p del (x1; TNFRSF10A); 13q14.2-q14.3 del  (x1; miR15a/16-1, DLEU7); 17p del (x1; TP53)  
CLL14 
10q21.2 gain (x3); 13q14.2-q14.3, q21-q22 del (x1; miR15a/16-1, DLEU7, RNASEH2B; RB1);  
20q11.21-11.22, q13.31-q13.32 gain (x3) 
CLL15 
12q21.2-q31 gain (x3; PAWR); 13q14.2-q14.3 del (x1; miR15a/16-1, DLEU7; RNASEH2B);  
16q11.2-q12.1 gain (x3) 
CLL16 13q14.2-q14.3 del (x1; miR15a/16-1, RNASEH2B; RB1) 
CLL18 6p22.3 gain (x3) 
CLL19 7p12.1 gain (x3) 
CLL20 13q14.2-q14.3 del (x1; miR15a/16-1, DLEU7; RNASEH2B) 
 
Shown in brackets following each CNV are the copy number within the cytoband, followed by 
any genes within the cytoband that could potentially be functionally significant. Highlighted in 
bold are CNVs that have not been previously reported in major CLL genomic studies. 
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other than del(13q14), although additional CNAs were found in isolated cases. One 
spontaneous regression case (CLL13) harboured clonal del(17p) and del(8p), which are  
well-described genomic aberrations in CLL, in addition to del(13q14). Other CNAs of 
potential functional significance include deletion of 8q24 (clonal), as well as duplications of 
3p24, 7q31, 11p13-14 and 12q21-31 (all clonal) as shown in Table 3.4. 
  In addition to CNAs, a number of SNVs which include missense, nonsense, stop 
loss and splice donor site mutations were detected by WES across the spontaneous CLL 
regression cohort. Included in Figure 3.14 are all SNVs that were identified by MuTect 
and/or Platypus, found to be significantly mutated by MuSigCV, and predicted to have a 
functional impact by VEP, SIFT and Polyphen. All were validated independently by Sanger 
sequencing or allele-specific PCR. The mutational burden as revealed by WES was 
generally low in spontaneously regressed CLLs, with a median of 2 SNVs per case (range 0-
5) and no significant indels identified in any case. Recurrent SNVs were seen in only 3 
genes: TP53 (occurring in 3 cases), PCMTD1 (in 3 cases) and NAV3 (in 2 cases). Mutations 
within known putative CLL drivers were found in 5 spontaneous regression cases (26%). In 
addition to TP53 mutations, MYD88 and HIST1H1B mutations were each observed in one 
case. All TP53 and MYD88 mutations were previously described and reported in the 
Catalogue of Somatic Mutations in Cancer (COSMIC), whereas the HIST1H1B mutation 
identified was novel. Of note, CLL13 harboured a biallelic TP53 defect, consisting of a 17p 
deletion and a c.484A>T TP53 mutation. With the exception of the TP53 mutation in CLL13 
which was clonal with variant allelic frequency (VAF) of 100%, all driver mutations were 
subclonal with VAF of 12-44%. These results collectively demonstrate that spontaneous CLL 
regression can occur in the presence of mutations in putative CLL drivers. 
    Among SNVs that were identified in genes not known to be CLL drivers, all have 
previously been reported in cancer, but only 19 of 30 (63%) have previously been reported 
in CLL. The majority were subclonal and occur in isolated spontaneous regression cases.       
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Figure 3.14 
 
The genomic landscape of 19 spontaneously regressed CLL tumours. The CNV data of each spontaneous regression case was combined 
with their respective SNV data obtained from WES. Different types of genomic events are represented by different colours, with the colour code 
displayed next to the table. The frequency of each genomic event is represented in the bar chart beneath the table. CNV, copy number 
variation; SNV, single nucleotide variation; VAF, variant allelic fraction.  
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3.1.7. Spontaneous CLL regression leads to partial recovery of normal 
immune phenotype 
CLL is associated with immune dysfunction. In T cells this is manifested in the 
accumulation of terminally differentiated memory T cells, leading to expanded T cell 
numbers, as well as T cell exhaustion (Forconi and Moss, 2015; Nunes et al., 2012; Ramsay 
et al., 2008; Riches et al., 2013). Likewise, NK cells numbers are expanded in CLL, and NK 
cell function is defective (Huergo-Zapico et al., 2014). To determine whether the defective 
immune phenotype is reversed in spontaneous CLL regression, I analysed T cell and NK cell 
number, as well as the T cell phenotype, in patients with spontaneous CLL regression and 
compared this to non-regressing indolent CLL patients.  
Spontaneous CLL regression was associated with a reduction in CD4+ and CD8+ T 
cell number, both when compared to non-regressing indolent cases (Figure 3.15A, left 
panel), and when compared across sequential timepoints in individual regression cases 
(Figure 3.15B). CD4+ and CD8+ T cells can be further differentiated into four subsets on the 
basis of their CD27 and CD45RA expression. These are namely naïve (CD27+ CD45RA+), 
central memory (CM; CD27+ CD45RA−), effector memory (EM; CD27− CD45RA−) and 
effector memory RA (EMRA; CD27− CD45RA+) T cell subsets. Patients who have 
undergone spontaneous CLL regression had lower CD4 and CD8 T cell number compared 
to patients with non-regressing indolent CLL across all T cell subsets (Figure 3.15A, left 
panel), and no difference was observed in T cell subset distribution between spontaneous 
regression and indolent CLL groups (Figure 3.15A, right panel).  
As explained in section 1.2.1.4, the inversion of CD4:CD8 ratio (CD4:CD8 < 1) is an 
abnormality seen in some CLL patients. Inversion of CD4:CD8 ratio was found to persist in 
several subjects who have undergone spontaneous CLL regression (Figure 3.15C). On the 
other hand, spontaneous regression was associated with a significant reduction in the 
expression of the T cell exhaustion marker PD-1 in CD8+ but not CD4+ T cells (Figure 




           
Spontaneous CLL regression is accompanied by a reduction in T cell number. (A) 
Subsets of CD4+ and CD8+ T cells were defined by the markers CD27 and CD45RA, with 
naïve cells being CD27+ CD45RA+, central memory (CM) cells being CD27+CD45RA−, 
effector memory (EM) cells being CD27−CD45RA−, and effector memory RA (EMRA) cells 
being CD27−CD45RA+. The number of T cells within each subset was determined from the 
CD4 or CD8 count by taking into consideration of the subset distribution within the CD4+ or 
CD8+ T cell population respectively. Spontaneous regression cases were compared to 
indolent cases, and statistical significance was determined using Student’s T test. Statistical 
significance is indicated by *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001; n.s. denotes 
comparisons that are not statistically significant.  (B) The CD4+ and CD8+ T cell number 
was compared between the diagnostic (T0) and the regression (T1) timepoint in 3 individuals 
with spontaneous CLL regression.  (C) The CD4:CD8 ratio in spontaneous regression cases 
(REG; n=16) were compared against indolent cases (INDOL; n=31) and age-matched 
healthy controls (CTRL; n=6). Complete spontaneous regression cases, partial spontaneous 
regression cases and regression cases associated with second malignancy were 
represented by red, blue and green dots respectively as shown by the key in Figure 3.5.   
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Figure 3.16 
      
             
          
 
Spontaneous CLL regression is accompanied by decreased PD-1 expression and 
increased T cell proliferation.  (A) PD-1 expression in CD4+ and CD8+ T cells in 
spontaneous regression cases (REG; n=16) were compared against indolent cases (INDOL; 
n=31) and age-matched healthy controls (CTRL; n=6).  (B)  PD-1 expression in CD4+ and 
CD8+ T cells was compared between the diagnostic (T0) and the regression (T1) timepoint 
in 3 individuals with spontaneous CLL regression.  (C) Ki-67 expression in T cells in 
spontaneous regression cases (CTRL; n=16) were compared against indolent cases 
(INDOL; n=31) and age-matched healthy controls (CTRL; n=6).  (D)  Ki-67 expression in T 
cells was compared between the diagnostic (T0) and the regression (T1) timepoint in 3 
individual subjects with spontaneous CLL regression. In (A) and (C), complete spontaneous 
regression cases, partial spontaneous regression cases and regression cases associated 
with second malignancy were represented by red, blue and green dots respectively as 
shown by the key in Figure 3.5. Statistical significance is indicated by *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001; n.s. denotes comparisons that are not statistically significant.   
B 
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3.16A-B), and a recovery of T cell proliferation (Figure 3.16C-D). This was demonstrated by 
comparing spontaneous regression cases against indolent CLL cases, and by comparing 
results across sequential timepoints in patients who have undergone spontaneous CLL 
regression. The recovery of T cell proliferation was particularly marked among patients who 
have undergone complete spontaneous CLL regression (Figure 3.16C). However, the 
reduction of PD-1 expression on CD8+ T cells and the recovery of T cell proliferation was 
only partial, and a significant difference in these parameters between spontaneously 
regressed CLL cases and age-matched healthy controls remained (Figure 3.16A,C). 
A reduction in NK cell number was also evident in spontaneous CLL regression 
from a comparison of spontaneous CLL regression cases with non-regressing indolent 
cases (Figure 3.17A) and from an analysis of individual spontaneous regression cases 
across sequential timepoints (Figure 3.17B). Collectively, these data on T cells and NK cells 
suggest that there may be a partial recovery of immune dysfunction in spontaneous CLL 
regression. However, a degree of immune defect remains apparent in the majority of 
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Figure 3.17 
 
               
 
Spontaneous CLL regression is accompanied by a reduction in NK cell number. NK 
cells were identified from the gated mononuclear cell population on the basis of expression 
of cell surface markers (CD16+CD3−CD4−), as shown in Figure 3.2B. The NK cell count 
was derived from the ALC taking into consideration the proportion of lymphocytes that were 
NK cells (CD16+CD3−CD4−). (A) NK cell numbers in spontaneous regression cases (REG; 
n=16) were compared against indolent cases (INDOL; n=31). Statistical significance was 
determined using Student’s T test. Statistical significance is indicated by ****p<0.0001.  (B) 
The NK cell number was compared between the diagnostic (T0) and the regression (T1) 
timepoint in 3 individuals with spontaneous CLL regression.     
  
A B 
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3.2. Discussion 
 
3.2.1. Competing models of CLL clonality in spontaneous disease 
regression 
In this study, I collated clinical data and performed biological study on a substantial 
spontaneous CLL regression cohort, including analysis of sequential samples taken before 
and after regression. However, the interpretation of all experimental results requires an 
understanding of the changes, if any, in CLL clonality before and after the onset of 
regression. Is the CLL clone at the time of diagnosis the same as the CLL clone at the time 
of regression in an individual patient? This question is important because, owing to limitation 
in sample availability at earlier timepoints, many of the experimentation and analyses in this 
study were carried out on samples taken at the regression timepoint. 
As illustrated in Figure 3.18, there are two possible scenarios that could occur 
during spontaneous CLL regression. The first scenario (Model 1) involves a single CLL 
clone, which has initially proliferated and subsequently regressed but not completely 
disappeared. The second scenario (Model 2) involves two CLL clones, one of which (Clone 
1) has initially proliferated but subsequently regressed and disappeared, leaving behind a 
second CLL clone (Clone 2) that has always been dormant and never proliferated. If the 
second model (Model B) was correct, then one would expect two CLL clones to be present 
at the time of diagnosis, but only one would remain at the time of regression.  
However, Model B was not consistent with the experimental data presented in the 
previous section. Using spontaneous CLL regression cases with sequential samples, I 
confirmed that CLL cells at the diagnostic and regression timepoints belonged to the same 
CLL clone based on identical IGH sequence and similar telomere length patterns







Two possible models of CLL clonality in spontaneous CLL regression.  In the above 
schematic diagram, the absolute lymphocyte count (ALC) is displayed against time. Two 
possible scenarios (Model 1 and Model 2) are shown. Both scenarios involve an initial 
proliferative phase followed by a spontaneous regression phase, with residual disease 
remaining following spontaneous regression. However, Model 1 involves a single CLL clone 
that that has initially proliferated, then regressed but not completely disappeared, whereas 
Model 2 involves two clones, one of which (Clone 1) has proliferated but subsequently 
regressed and disappeared, leaving behind a second clone (Clone 2) that has always been 
dormant.  Experimental data from this study (IGH sequence and telomere length distribution 
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(Figure 3.8), consistent with Model 1. This was the case in all the paired diagnostic and 
regression samples analysed as part of this study. These results therefore indicate that the 
residual CLL cells in the regression blood samples (T1/T2 timepoints) were likely to be 
derived from the CLL clone that has regressed.  
 
3.2.2. Phenotypic features of spontaneously regressed CLL tumours 
In the ensuing investigations, I compared the phenotype of spontaneously 
regressed CLL tumours against non-regressing indolent CLLs or untreated progressive 
CLLs, focusing on molecules of particular relevance to CLL pathogenesis. This permits the 
identification of specific phenotypic features among individuals who have undergone 
spontaneous CLL regression. These phenotypic features include low or absent CLL 
proliferation and a lack of recently proliferated CLL cells. as evidenced by low or negligible 
Ki-67 and high CXCR4 expression respectively in the CLL cells from spontaneous 
regression cases (Figure 3.3A and Figure 3.4C) (Calissano et al., 2009; Calissano et al., 
2011; Coelho et al., 2013). My analysis also identified low cell surface CD49d expression as 
a consistent feature of spontaneously regressed CLL tumours (Figure 3.4A), as well as 
comparatively higher CD95/FasR expression (Figure 3.5C) and a trend towards lower CLL 
cell surface ROR1 expression (Figure 3.5D) in these tumours. Finally, spontaneous 
regression CLL cases were exclusively IGHV mutated, and exhibited low expression of cell 
surface IgM and IgD and high expression of LAIR1, but none displayed stereotyped BCR 
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3.2.3. Potential mechanisms underpinning spontaneous disease 
regression in CLL 
Analysis of the phenotype in spontaneous regression CLL cases revealed evidence 
of phenotypic changes across sequential timepoints, particularly a reduction in Ki-67 and 
CD38 expression, and an increase in CXCR4 expression (Figure 3.6). Moreover, the 
telomere length of the CLL clone in many of the spontaneous regression cases was rather 
short. Telomere erosion typically occurs at an average rate of 111 base pairs (bp)/year in 
M-CLLs (Damle et al., 2004). While many of spontaneous regression cases in the present 
cohort have telomere lengths that would fall within the short (1.9-2.9 kb) or intermediate (2.9-
3.6 kb) categories based on the UK CLL4 trial data (Strefford et al., 2015) (Figure 3.7), the 
telomere length distribution data of these cases remains largely similar between the time of 
diagnosis and regression, with minimal telomere length erosion at <50 bp/year between 
these two timepoints in all cases examined (Figure 3.8). Although the latter may reflect 
telomerase activity in regressing CLL tumours, the above observations collectively support 
the presence of an initial proliferation phase and the subsequent reduction in CLL 
proliferation during spontaneous regression.  
Initially, I hypothesised that the reduction in CLL proliferation might be due to CLL 
cellular senescence; however, the high telomerase activity and negative beta-galactosidase 
staining in these cells were incompatible with such a hypothesis (Figure 3.9). The higher 
telomerase activity in the spontaneous regression cases compared to the indolent cases is 
interesting but difficult to explain. One hypothesis could be that the regressing CLL clone 
could be composed of cells with different telomerase activity, and the subclonal population 
with lower telomerase activity might have preferentially regressed over the population with 
higher telomerase activity. If this was the case, one might expect changes in the telomere 
length distribution pattern over time to reflect the subclonal selection of cells with shorter 
telomeres, which are associated with higher telomerase activity (Damle et al., 2004). 
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However, there was minimal change in the telomere length patterns over time across the 
spontaneous regression subjects (Figure 3.8). In any case, the difference in telomerase 
activity between the spontaneous regression and indolent groups should be interpreted with 
caution. This is because this data was derived from CLL cells that are quiescent. CLL cells 
upregulate telomerase activity when they are induced to proliferate, such as when stimulated 
by BCR agonists (Damle et al., 2012). Unpublished data from our group also shows that 
telomerase activity in CLL cells is upregulated when co-cultured with CD40L/IL-21. It is 
therefore of interest to compare the extent to which spontaneous regression and indolent 
CLL tumours upregulate telomerase activity when induced to cycle.  
 Strikingly, spontaneously regressing CLL tumours displayed a consistent 
unresponsiveness to BCR stimulation and low surface immunoglobulin expression (Figure 
3.10, Figure 3.12) that are characteristic of CLL anergy (Packham et al., 2014). These CLL 
cells also exhibited high levels of basal Erk phosphorylation, which is another B cell anergic 
feature (Figure 3.13) (Muzio et al., 2008). Collectively, these findings suggest clonal anergy 
as a mechanism underpinning reduced CLL proliferation in spontaneous regression. LAIR1 
is a BCR inhibitory receptor that binds extracellular matrix collagen and the complement 
protein C1q (Perbellini et al., 2014), and its high expression levels may potentially contribute 
to clonal anergy in spontaneously regressing CLL tumours. Further experiments to 
demonstrate features of anergy in these tumours could include measuring constitutive 
SHIP1 phosphorylation levels and assessing proliferative responses to CD40L and IL-4 or 
IL-21. It would also be important to compare BCR signalling responses across diagnostic 
and regression timepoints in the spontaneous CLL regression cases where samples are 
available. This is currently being carried out in collaboration with Dr Francesco Forconi 
(Southampton), and preliminary data in two cases suggest that there was indeed a reduction 
in BCR signalling response over time as measured by calcium flux.  
192     
Consistent with previous studies, I found that the majority of indolent M-CLL cases 
retained high CLL IgD expression and IgD response (Figure 3.11) (D'Avola et al., 2016; 
Mockridge et al., 2007). Interestingly, and in contrast to the indolent cases, CLL cells from 
spontaneous regressing individuals expressed low sIgM and sIgD (Figure 3.12), and 
displayed unresponsiveness to both IgM and IgD triggering (Figure 3.11). At present, the 
functional significance of IgD BCR signalling in CLL is unclear. Two previous studies from 
the same group demonstrated that IgD BCR stimulation can promote the survival of CLL 
cells. In one study, the exposure of CLL cells to anti-IgD but not anti-IgM antibodies 
prolonged the survival of these cells when cultured in vitro for up to 10 days (Zupo et al., 
2000). In the second study, analysis of the CLL IgD BCR responses in a group of Binet 
stage A CLL patients showed that IgD BCR triggering by anti-IgD antibodies can lead to 
inhibition of spontaneous apoptosis in some cases (33 of 106 cases; 31.1%), but not in 
others (Morabito et al., 2010). A recent study however suggested that, in contrast to IgM 
BCR signalling that results in prolonged downstream activation (e.g. Erk phosphorylation), 
the more transient downstream responses elicited through IgD signalling do not support CLL 
survival in vitro (Ten Hacken et al., 2016). On the other hand, my phosphoflow data herein 
indicate the possibility that IgD signalling may contribute to in vivo disease persistence in 
highly indolent M-CLLs, whereas absence of IgD and IgM signalling together may lead to 
spontaneous disease regression (Figure 3.11).  
In addition to anergy leading to decreased CLL proliferation, there may be other 
potential mechanisms that could contribute to spontaneous CLL regression. Firstly, the low 
CD49d +/- low ROR1 expression on CLL cells from spontaneous regression cases (Figure 
3.4A, Figure 3.5D) could potentially contribute to reduced CLL proliferation through reduced 
CLL cell migration to proliferation centres. This potential mechanism could be studied further 
in vitro by assessing transwell migration responses of CLL cells to chemokines such as 
CXCL12. Secondly, increased apoptosis might also play a role in spontaneous CLL 
regression through increased levels of CD95/FasR expression on regressing CLL tumours 
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(Figure 3.5C). However, CLL cells are known to be resistant to Fas-mediated apoptosis 
(Greaney et al., 2006; Panayiotidis et al., 1995), in part through overexpression of TOSO. 
Upon activation of FasR by Fas ligand, FADD is recruited to the FasR which leads to 
cleavage and activation of procaspase 8. TOSO binds to FADD and inhibits procaspase 8 
activation (Proto-Siqueira et al., 2008). On the other hand, CD40L-activated CLL cells are 
highly susceptible to Fas-mediated apoptosis by cells expressing Fas ligand such as T cells 
and NK cells. This is mediated through upregulation of FADD and downregulation of FLIP, 
the latter of which is another inhibitor of the Fas signalling pathway that binds to FADD and 
inhibits procaspase 8 activation (Chu et al., 2002). Additionally, CD40L-activated CLL cells 
also upregulate TRAIL receptor, which acts together with FasR in mediating apoptosis 
through the extrinsic apoptotic pathway (Dicker et al., 2005). It is therefore of relevance to 
examine the expression of molecules such as FADD, FLIP, TOSO and TRAIL receptor 
(DR4/DR5) in spontaneously regressing CLL tumours, and to determine their sensitivity to 
FasR agonists compared to non-regressing CLL tumours. It is possible that spontaneously 
regressing CLL tumours may have an intrinsic sensitivity to Fas-mediated apoptosis. 
Additionally, clonal anergy and a lack of IgM and IgD BCR signalling may potentially 
contribute to increased CD95/Fas expression and/or sensitivity to Fas-mediated apoptosis 
during the course of spontaneous CLL regression. Indeed, Fas-mediated cell death plays an 
important role in the elimination of anergic non-malignant B cells (Rathmell et al., 1995). In 
CLL, the transcription factor NFAT has been shown to be a crucial mediator of clonal anergy 
(Marklin et al., 2017), and one important action of NFAT is the induction of Fas ligand 
upregulation (Rengarajan et al., 2000). It remains to be ascertained whether anergy-
associated NFAT activation also leads to FasR upregulation, or whether alternative 
mechanisms are involved.      
A limitation of phenotypic analysis by flow cytometry is the restricted number of 
markers that can be assessed. To comprehensively elucidate the features and potential 
mechanisms underpinning spontaneous CLL regression, an unbiased approach is 
194     
preferable. I have therefore carried out RNA sequencing (RNA-seq) and initiated 
transcriptomic analysis on spontaneously regressing CLL tumours (n=15) comparing them to 
indolent (n=17) and untreated progressive (n=12) M-CLLs, as well as normal B cells from 
healthy donors (n=3). Preliminary data from this analysis shows that the transcriptomic 
profile from spontaneous regression cases were distinct from those of healthy controls and 
the majority of indolent and progressive case. In particular, consistent with reduced 
proliferation in spontaneously regressing tumours, RNA-seq data showed downregulation of 
cell cycle genes, as well as pathways involved in cell proliferation, RNA processing and 
cellular metabolism in these tumours compared to indolent and progressive M-CLLs. 
Corroborating my flow cytometry data, ITGA4 (CD49d) and FAS (FasR) expression was also 
downregulated in spontaneously regressed CLL tumours. In addition, gene set enrichment 
analysis showed downregulation of MYC and Myc target genes in spontaneous regression 
cases compared to their non-regressing indolent M-CLL counterpart, and analysis is 
currently underway to determine if a signature of B cell anergy is present in the RNA-seq 
data of spontaneous regressing CLLs.  Finally, genes involved in DNA repair and telomere 
maintenance were upregulated in spontaneous regressing CLL cases. The upregulation of 
these processes could reduce the level of genomic instability and may potentially play a role 
in spontaneous regression. 
Finally, analysis of the immune compartment revealed that spontaneous CLL 
regression is associated with a partial reversal of T-cell defects that are ubiquitous in 
patients with CLL (Figure 3.15, Figure 3.16). It is therefore plausible that enhanced T-cell 
immunosurveillance could contribute to the later stages of CLL regression and the 
maintenance of regressed state following spontaneous regression, but is unlikely be a major 
mediator of early regression when substantial T-cell dysfunction exists. Furthermore, it is 
possible that spontaneous regressing CLL tumours are more immunogenic than their non-
regressing counterparts, and are therefore more capable of inducing an adaptive immune 
response. The determinants of CLL immunogenicity is unclear and is an area that warrants 
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further investigation. It is possible that the genomic and epigenomic landscape could 
influence expression of immunogenic antigens on individual CLL tumours. In addition, the 
levels of HLA expression on tumour cells, and the presence or otherwise of 
immunosuppressive mechanisms such as tumour PD-L1 expression and regulatory T cell 
recruitment, are also likely to influence tumour immunogenicity (Blankenstein et al., 2012).    
 
3.2.4. Genomic features of spontaneously regressed CLL tumours 
The 13q14 deletion seen among spontaneously regressing CLL tumours is mostly 
clonal and is likely to be the main genomic event driving the initial proliferative phase before 
the onset of spontaneous disease regression. This is likely to be mediated primarily through 
loss of the DLEU2/miR-15a/16-1 cluster. However, there are other genes in 13q14 that were 
co-deleted with DLEU2/miR-15a/16-1, including DLEU1, DLEU5, DLEU7, KCNRG and 
RNASEH2B. The function of DLEU1, DLEU5, RNASEH2B and KCNRG is unknown in CLL 
(Lia et al., 2012), but DLEU7 has been shown in a single study to have inhibitory effect on 
the transcription activatory activity of NF-kB and NFAT (Palamarchuk et al., 2010). In 
addition, in two of the cases del(13q14) involved loss of the RB1 gene which encodes for the 
retinoblastoma protein that negatively regulates cell cycle entry (Lia et al., 2012). RB1 
deletion could therefore co-operate with miR-15a/16-1 deletion in promoting CLL 
proliferation during the initial proliferative phase.  
There are a number of other clonal CNVs that may have arisen early during disease 
development in this cohort. Of particular interest are duplications of 3p24 (NKIRAS1), 
12q21-31 (PAWR), 7q31-32 (POT1) and 11p13-14 (WT1), where the duplications 
encompass respective genes of functional significance (shown in brackets). NKIRAS1 
encodes for a Ras-like protein that is known to inhibit NF-kB signalling by preventing the 
degradation of the NF-kB inhibitory molecule IkB-β (Fenwick et al., 2000). PAWR encodes 
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for Par-4, which has been shown to also have an inhibitory effect on NF-kB signalling and 
additionally causes tumour regression in prostate cancer by enhancing the cell membrane 
trafficking of FasR and Fas ligand, and activating Fas-mediated apoptosis (Chakraborty et 
al., 2001). POT1 encodes for a protein that forms part of the shelterin complex, which is 
important in maintaining telomere length and genome integrity (Maciejowski and de Lange, 
2017), and indeed POT1 loss-of-function mutations are known to cause telomere 
dysfunction in CLL (Ramsay et al., 2013). Finally, WT1 encodes for a transcription factor that 
has both oncogenic and tumour suppressor activities (Yang et al., 2007). It is unclear 
whether these gene duplications have any effect in mediating subsequent spontaneous 
tumour regression. It is important to highlight the fact that these duplications were found only 
in isolated spontaneous regression cases. Moreover, it remains to be determined whether 
these gene duplications translate into increased gene expression, and if so whether this 
leads to any functional consequences.  
Exome sequencing revealed the presence of mutations in known putative CLL 
drivers in several spontaneous regression cases. These include mutations in TP53, MYD88 
and HIST1H1B. The functional role of TP53 has been described in detail in sections 1.2.4.2 
and 1.4.1. MYD88 encodes for an intracellular adaptor protein involved in the TLR signalling 
pathway. The MYD88 mutation in CLL14 occurs at L265 of MYD88, which leads to 
increased downstream activation of TLR signalling through enhanced binding of MYD88 to 
IRAK1, resulting in increased activation of targets such as NF-kB (Fabbri and Dalla-Favera, 
2016). HIST1H1B, on the other hand, encodes for a histone that is involved in chromatin 
remodelling by packaging and organising DNA into nucleosomes (Landau et al., 2015). The 
presence of these mutations, together with del(13q14) found in the majority of 
spontaneously regressed tumours, suggest that the forces underpinning disease regression 
must have been sufficient to overcome the growth advantage conferred by these genomic 
aberrations. This is particular the case with CLL13, which harboured multiple clonal genomic 
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aberrations including del(8p) involving the TRAIL receptor gene and biallelic TP53 defects, 
in addition to del(13q14).   
Of the two recurrent SNVs that were not known CLL driver mutations, one involved 
PCMTD1, which encodes for a component of a methyltransferase, and the other NAV3, 
which may have some T cell regulatory function (Karenko et al., 2005). There were also a 
substantial number of significantly mutated genes occurring in isolated spontaneous 
regression cases. Examples of genes with potential functional significance include MDC1 
(involved in DNA damage response), PCM1 (involved in centrosome assembly and 
function), as well as FAT1 and CDH2 (which encodes for cadherins that may be involved in 
cell migration and adhesion). Most of these mutations were subclonal and it is likely that the 
majority would be passenger mutations. It would be of interest to investigate whether there is 
any clonal selection or evolution during the course of spontaneous CLL regression, and work 
is currently under way to compare CNVs and SNVs in spontaneous regression cases where 
paired diagnosis and regression samples are available.  
 
3.2.5. Limitations of the current study and a mechanistic model of 
spontaneous CLL regression 
A limitation of this study is the lack of CT imaging and bone marrow samples; 
hence, it was not possible to determine the full extent of residual nodal and marrow disease, 
if any, after spontaneous regression. Notwithstanding this limitation, there is strong evidence 
in our subjects for spontaneous regression, at least of peripheral CLL. Moreover, CLL cells 
from complete and partial spontaneous regressors displayed similar phenotypic features, 
suggesting that partial regressors were merely at an earlier stage of regression, and with 
time, complete regression of CLL clinical features could become apparent.  
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A further limitation is the unavailability of samples from the initial proliferative phase, prior to 
CLL diagnosis and the onset of spontaneous regression. It is therefore not possible to 
establish the biological features of these cases during the early stages of their natural 
history. Nevertheless, a possible model for spontaneous CLL regression can be inferred 
from the literature and from the available data within this study (Figure 3.19). Initially, 
antigenic BCR stimulation in the presence of co-stimulatory signals may account for CLL 
proliferation. With increasing proliferation, the demand for co-stimulation may also increase 
(Bagnara et al., 2011; Os et al., 2013). Concomitantly, T cells may become more 
dysfunctional as CLL progresses (Palma et al., 2017), with reduced ability to provide the 
required co-stimulation (Packham et al., 2014). Continued chronic antigenic BCR 
stimulation, in the absence of adequate co-stimulation, results in CLL anergy (Cambier et al., 
2007; Gauld et al., 2005). In non-regressing indolent CLLs, the consequences of anergy 
could potentially be counteracted by high ROR1 and Bcl-2 levels, CD49d expression and 
IgD BCR signalling, resulting in disease persistence. In the rare scenarios where CLL 
anergy occurs in the absence of both IgM and IgD BCR signalling, reduced CD49d and 
ROR1 expression, high FasR levels and/or enhanced tumour immunosurveillance, 
spontaneous CLL regression ensues.  
It is important to emphasise that the above remains largely a hypothetical model. To 
provide further evidence to support this model, experimental work will need to be conducted 
to demonstrate impaired in vitro signalling and proliferative response to BCR stimulation that 
can be reversed with CD40L/IL-4 co-stimulation, and that impaired in vivo engraftment in 
immunodeficient mice of CLL cells from spontaneous regressors can be reversed by 
suppression of inhibitory BCR signalling, re-expression of CD49d and ROR1, and/or 
inhibition of Fas-mediated signalling.  
 
  





A possible mechanistic model of spontaneous CLL regression.  The features pertaining 
to the spontaneous regression phase (shown in bold) are supported by experiential evidence 
from this study. Due to the unavailability of samples, the features pertaining to the initial 
proliferative phase (shown in italics) are speculative. Disease regression may occur when 
the balance of cell turnover is shifted in favour of cell death rather than cell proliferation. 
ALC, absolute lymphocyte count; Prolif, CLL proliferation; Apop, CLL cell death.   
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3.2.6. Clinical implications of this study 
My experimental findings from this study support the continued use of BCR 
signalling inhibitors for the treatment of CLL. The finding of decreased CD49d and ROR1 
and increased FasR expression on CLL cells in patients with spontaneous disease 
regression suggests approaches to downregulate CD49d and ROR1 expression and 
upregulate FasR expression may also potentially be useful for the treatment of CLL in 
combination with BCR signalling inhibition. At present, gene therapy for the treatment of 
cancer is still in its infancy, and delivery systems that are selective for tumour cells are 
limited to platforms such as those that utilises oncolytic adenoviruses (Choi et al., 2012) and 
lipid nanoparticles conjugated to monoclonal antibodies, which allows delivery of antisense 
oligonucleotides targeting a specific mRNA (Petrilli et al., 2014). Alternatively, combined use 
of ROR1 mAb and BCR signalling inhibitor may show promise (Yu et al., 2016). 
Finally, it is important to highlight the substantial level of minimal residual disease in 
all of the spontaneous regression cases in this study, and its potential clinical significance.  
Firstly, since T cell dysfunction arises from their interaction with CLL cells, it is plausible that 
residual disease may contribute to persistent T cell defects seen among CLL patients even 
after spontaneous disease regression (Figure 3.15 and Figure 3.16) (Gorgun et al., 2005; 
Ramsay et al., 2008). Indeed, the partial normalisation of T cell numbers and phenotype 
seen in spontaneous CLL regressors is reminiscent of that observed in patients treated with 
BCR signalling inhibitors such as ibrutinib (Niemann et al., 2016). It is possible that complete 
immune recovery in CLL might require disease eradication (i.e. MRD negativity); this 
hypothesis will necessitate investigation in future studies. Moreover, as my experimental 
data indicates, residual CLL cells remaining after spontaneous regression are quiescent and 
anergic rather than senescent. Quiescence and anergy are reversible (Mockridge et al., 
2007; Nossal, 1996), as exemplified by CLL20 in this cohort, where the patient experienced 
disease relapse following complete spontaneous regression. Therefore, there remains the 
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case for disease eradication rather than merely disease control, especially for CLL with 
poor-risk features such as TP53 defects. This will be the focus of the next two chapters of 
this thesis.  
 





PRE-CLINICAL EFFICACY AND 
MECHANISM OF 








This chapter has been published as: 
Kwok M, et al. (2016). ATR inhibition induces synthetic lethality and overcomes 
chemoresistance in TP53 or ATM defective chronic lymphocytic leukemia cells.  Blood. 127, 
582-595.  
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ATR regulates replication initiation, preventing aberrant or excessive replication 
origin initiation that depletes the cellular pool of nucleotides and replication proteins. 
Inhibition of ATR therefore induces replication stress, manifested by the accumulation of 
slowed and stalled replication forks with unprotected ssDNA that inevitably collapses into 
DSBs. Specifically, the breakage of ssDNA results in the formation of partially replicated 
DNA fragments with DNA double-stranded ends. ATR also mediates the response to 
replication stress, delaying cell cycle progression, as well as stabilising and repairing DNA 
replication forks (Couch et al., 2013; Toledo et al., 2013; Zeman and Cimprich, 2014). If ATR 
is inhibited, maintenance of genome integrity becomes dependent upon functional ATM and 
p53, with ATM being essential for HRR to repair DSBs and hence restore the original 
structure of the replication fork, and both ATM and p53 for arresting cell cycle progression to 
permit repair. ATR therefore represents an attractive synthetically lethal target for p53 or 
ATM deficiency. Evidence for this synthetically lethal interaction has previously been 
provided by the deletion of ATR in p53-deficient mice (Ruzankina et al., 2009) and by 
inhibition of ATR in tumour cell lines which resulted in selective killing of cells harbouring p53 
or ATM defects (Nghiem et al., 2001; Reaper et al., 2011; Sangster-Guity et al., 2011). 
These studies have been outlined in section 1.4. 
On the other hand, no study to date has addressed the impact of ATR inhibition on 
primary tumour samples of CLL or other haematological malignancies in which DDR defects 
are present. In this study, I utilised AZD6738 (AstraZeneca), a novel, highly specific and 
orally bioavailable ATR kinase inhibitor to examine the effect of ATR inhibition in CLL cell 
lines, primary CLL cells and primary CLL xenotransplantation models. The study 
demonstrated synthetic lethality and selective cytotoxicity of the ATR inhibitor AZD6738 in 
CLL cells with TP53 or ATM defects, as well as the sensitisation of these cells to 
chemotherapeutic agents and ibrutinib by ATR inhibition. 
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4.1. Results 
 
 To investigate the therapeutic efficacy and mechanism of action of AZD6738 in CLL 
cells, I employed two pairs of isogenic cell lines: CII-GFPsh (ATM wild-type) and CII-ATMsh 
(ATM deficient), as well as Mec1-p53-pcDNA3.1 (p53 mutant) and Mec1-GFP-pcDNA3.1 
(p53 wild-type). These two cell line pairs were previously established in our laboratory as 
outlined in section 2.2.2.  
In addition to cell lines, primary CLL PBMC samples from a panel of previously 
characterised CLL cases (n=36) were utilised. These 36 CLL cases include patients of a 
variety of age, disease stage, treatment status, as well as IGHV mutational status, as shown 
in Table 4.1. The panel comprises 18 CLL cases with wild-type ATM and TP53, 10 cases 
with an ATM defect and 8 cases a TP53 defect. All ATM defective or TP53 defective cases 
harboured del(11q) and del(17p) respectively in ≥80% of CLL cells, as assessed by FISH. 
Moreover, the majority of ATM defective or TP53 defective cases also harboured ATM or 
TP53 mutations of varying allelic frequencies.  
In all cases, the functional status of ATM and p53 had been previously ascertained 
by Western blotting. Two strategies were used to determine ATM/p53 function. This first 
strategy assessed p53 and p21 expression in response to IR. The absence of p53 and p21 
induction is a feature common to both ATM and p53 functional loss; however, p53 mutation 
may be accompanied by a high p53 basal level (Figure 4.1A). The second strategy 
assessed the phosphorylation of ATM targets, including ATM, SMC1 and p53, in response 
to IR. ATM functional loss results in defective phosphorylation response to all three ATM 
targets, whereas p53 functional loss results in defective phosphorylation of only p53 (Figure 
4.1B). Each of the 18 ATM defective or TP53 defective cases was associated with an ATM 
 
  

















Determination of DNA damage response (DDR) in primary CLL samples. Two strategies 
were used to assess DDR in primary CLL samples and the impact of the identified mutations 
in the ATM or TP53 gene. (A) Cellular lysates were obtained from CLL cells before and 8 
hours following in vitro treatment with 5 Gy IR. Subsequent assessment of the levels of p53 
and its target p21 allowed identification of defective p53 function in CLL29 and defective 
ATM function in CLL26. Both samples are characterised by the absence of IR-induced p53 
and p21 levels, but in the p53 mutant CLL29 this is coupled with a high p53 basal level. (B) 
Analysis of IR-induced ATM targets (phosphorylated ATM/p53 and SMC1) 45 minutes after 
5 Gy IR allows detection of normal ATM function in CLL07, CLL11, CLL15 and CLL09 and 
defective p53 function in CLL34 where p53 cannot be phosphorylated, despite normal SMC1 
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or p53 functional defect. Due to limited sample availability, not every case was used for each 
experiment. The samples used for each experiment are listed in Table 4.1. 
Using these CLL cell lines and primary CLL samples, a pre-clinical study of 
AZD6738 was carried out to address: (1) the inhibitory activity of AZD6738 on the ATR 
pathway; (2) the single-agent efficacy of AZD6738; (3) the mechanism underpinning the 
cytotoxic effect of ATR inhibition; and (4) the effect of combining AZD6738 with 
chemotherapy and ibrutinib.  
 
4.1.1. ATR signalling is active in proliferating CLL cells and is inhibited 
by AZD6738 
The ATR pathway has previously been shown to be suppressed in quiescent 
lymphocytes in both healthy individuals and patients with CLL. This was evidenced by the 
absence of detectable ATR protein expression in non-proliferating CLL cells or healthy 
PBMCs, and by a lack of p53 induction and phosphorylation upon exposure of quiescent 
lymphocytes to ultraviolet radiation, a known activator of ATR (Jones et al., 2004).  
Consistent with this, I found, using Western blotting, that ATR protein expression was low in 
quiescent CLL PBMCs obtained from peripheral blood sampling of patients with CLL. 
However, ATR expression was induced when cells were stimulated to proliferate by co-
culturing for 4 days with CD40L/IL-21, a method described in section 2.3.2. This was 
consistently observed across all 12 CLL cases tested, irrespective of the presence, or 
otherwise, of p53 or ATM defects (Figure 4.2A; showing the results of 8 of these 12 cases).  
Next, I used phosphorylation of the checkpoint kinases Chk1 (at Ser345) and Chk2 
(at Thr68), which are downstream targets of ATR and ATM respectively, as surrogate 
markers for ATR and ATM pathway activation. Primary CLL cells were cultured for 4 days 
with CD40L/IL-21 to induce proliferation, or for 1 day in RPMI-1640 without CD40/IL-21.  
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Table 4.1.  Clinical and biological characteristics of primary CLL samples 
 











Cytogenetics ATM mutation TP53 mutation 












CLL01 66 M A 0 No nk Normal No No - nk No 66.8 Figure 4.2, 4.8 
CLL02 73 M C 2 Yes U Normal No No - Normal NOTCH1 38.9 Figure 4.2, 4.8, 4.9 
CLL03 74 F B 1 Yes M Normal No No - Normal No - Figure 4.2 
CLL04 58 F A 0 No M Normal No No - Normal No 9.3 Figure 4.2, 4.8 
CLL05 70 M A 0 No nk Normal No No - nk No 19.6 Figure 4.8 
CLL06 67 M A 2 No U Normal No No - Normal No 21.2 Figure 4.2, 4.8, 4.9 
CLL07 72 F C 1 No M del13q, trisomy12 No No - Normal No 25.6 Figure 4.2, 4.8, 4.9 
CLL08 80 M C 1 No nk del13q No No - Normal No 67.4 Figure 4.8 
CLL09 57 F A 0 No M Normal No No - Normal No 40.2 Figure 4.8 
CLL10 66 F A 0 No M del13q No No - Normal No 26.8 Figure 4.8 
CLL11 70 M B 2 No M Normal No No - Normal No 45.0 Figure 4.8 
CLL12 61 M A 2 No nk Normal No No - nk No 29.4 Figure 4.8 
CLL13 51 F A 0 No M Normal No No - Normal No 33.2 Figure 4.8 
CLL14 65 M A 0 No U del13q No No - Normal No 76.0 Figure 4.8 
CLL15 69 F C 1 No M Normal No No - Normal No 44.1 Figure 4.8 
CLL16 35 F A 1 No nk trisomy12 No No - nk No 22.9 Figure 4.8 
CLL17 77 F A 4 No M Normal No No - nk No 52.2 Figure 4.8 
CLL18 55 F A 1 No M Normal No No - Normal No 32.9 Figure 4.8 
CLL19 70 M A 1 No U del11q, trisomy12 
c.5224G>C,  
p.A1724P 
No nk Defective No 7.1 Figure 4.8 
CLL20 70 M A 1 No nk del11q c.2282delCT, p.761fs No nk Defective No 9.2 Figure 4.8 
CLL21 79 M A 0 No U del11q 
c.2466+2T>G,  
splicing site 
No nk Defective No 18.5 Figure 4.2, 4.8 
CLL22 88 M A 0 No M del11q c.222T>A, p.C74X No 41.7 Defective No 5.8 Figure 4.2, 4.8, 4.21 
CLL23 61 F A 1 No M del13q c.1229T>C, p.V410A No 48.0 Defective No 5.1 
Figure 4.2, 4.8, 4.21, 
4.9 
 
208     
Table 4.1.   (cont’d) 
 
 











Cytogenetics ATM mutation TP53 mutation 












CLL24 61 M A 1 No M Normal c.6067G>A, p.G2023R    No 56.4 Defective No 6.3 Figure 4.8, 4.21 
CLL25 78 F C 2 No nk 
del11q, del6q, 
trisomy12 
c.4220T>C, p.I1407T    No nk Defective 
BIRC3, 
NOTCH1 
- Figure 4.10, 4.25 
CLL26 74 M B 1 No U del11q c.9038T>A, p.L3013Q    No 65.0 Defective No - Figure 4.10 
CLL27 65 F A 3 No U del11q, trisomy12 
c.4220T>C,  
p.I1407T 
No 76.0 Defective BIRC3 - Figure 4.9 
CLL28 80 M A 0 No M del11q, trisomy12 
c.6966C>G,  
p.S2322R 
No 46.6 Defective No - Figure 4.9 
CLL29 56 M C 2 Yes U del17p, trisomy12 No c.752T>G, p.I251S 27.2 Defective BIRC3 16.0 
Figure 4.8, 4.10, 4.21, 
4.9 
CLL30 55 F C 4 Yes U del17p c.968T>A, p.I323K No 30.1 Defective No 15.7 Figure 4.8
†
 
CLL31 78 F C 2 Yes M 
del17p, del13q, 
trisomy12 
No c.711G>A, p.M237I 98.2 Defective No 2.8 Figure 4.8, 4.10, 4.21 
CLL32 65 M A 1 Yes M del17p, del13q No c.377A>G, p.Y126C 75.3 Defective No 2.9 Figure 4.2, 4.8, 4.21 
CLL33 77 M A 1 No M del17p No No 50.8 nk SF3B1 - Figure 4.2 
CLL34 74 F C 2 No U Normal No 
c.849_850insC, 
p.T284fs 
54.7 Defective No 5.6 Figure 4.8, 4.9 
CLL35 86 F B 2 No nk Normal No 
c.626_627del, 
p.209_209del 
90.3 Defective No 15.7 Figure 4.8, 4.9 
CLL36 60 M B 3 No M del17p, del13q No c.743G>A, p.R248Q 53.5 Defective SF3B1 7.0 Figure 4.8, 4.9 
 
ID, sample identifier; Flud refractory, fludarabine refractory; IGHV mut status, IGHV mutational status; U, unmutated; M, mutated; nk, not known  
* DNA damage response (ATM and p53 function) was assessed using methodology specified in Figure 4.1.  
† 
This sample was originally used in the experiment presented in Figure 4.8 but subsequently was excluded from analysis, as it contained both ATM and TP53 defects.
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Thereafter, hydroxyurea (HU), a known inducer of replication stress, was added. 
Cells were then harvested for analysis following 1, 5 and 24 hours of HU exposure. Upon 
treatment with HU, ATR-dependent Chk1 phosphorylation was observed in proliferating 
(Figure 4.2B; lanes 2-3, 10) but not quiescent CLL cells (lanes 6 & 8). Indeed, in 
proliferating CLL cells, Chk1 phosphorylation was observed as early as 1 hour (lane 2) after 
exposure to HU, with maximal Chk1 phosphorylation being seen at 5 hours (lane 3). The 
background Chk2 phosphorylation in quiescent cells (lanes 5-6) likely reflected the 
accumulation of cellular stress in cryopreserved primary CLL samples when resuspended 
and cultured in RPMI medium for 1 day, without access to survival signals afforded by the 
CD40L/IL-21 co-culture system. Such background Chk2 phosphorylation was absent when 
the experiment was repeated using CLL PBMCs isolated from fresh peripheral blood 
samples without prior culture (lanes 7-8).  
It has been reported that prolonged incubation with replication inhibitors, including 
ATR inhibitors, can lead to S phase checkpoint adaptation, a process in which Chk1 
phosphorylation is lost despite persistent replication stress. The underlying mechanism is 
likely to be attributable to ubiquitin-mediated degradation of the Chk1 adaptor protein 
Claspin, which is required for recruiting Chk1 and mediating Chk1 phosphorylation 
(Syljuasen, 2007; Yoo et al., 2004). Because 24-hour HU treatments (lane 4) appeared to be 
associated with S phase checkpoint adaptation, in which Chk1 phosphorylation was lost 
despite persistent replication stress, 24-hour HU treatments do not provide optimal 
conditions for the assessment of ATR activity. Therefore, 5-hour HU treatments were 
adopted for all subsequent experiments. The specificity of Chk1 as a marker for ATR 
activation was evident by minimal Chk1 phosphorylation following IR. Specifically, exposure 
to IR generates DNA DSBs and activates the ATM pathway rather than ATR, hence leading 
to ATM and Chk2 phosphorylation at Ser1981 and Thr68 respectively, rather than Chk1 
phosphorylation (Figure 4.3, lanes 8-11).  
  







ATR signalling is activated in response to replication stress in proliferating primary 
CLL cells. (A) Stimulation of primary CLL cell proliferation by co-culture with CD40L-
expressing murine embryonic fibroblasts in the presence of IL-21 (CD40L/IL-21) for 4 days 
resulted in induction of ATR expression in primary CLL cells irrespective of ATM or TP53 
status. Cyclin A expression is a marker of proliferating cells. Actin is the loading control. (B) 
Cryopreserved or fresh primary CLL cells cultured with or without CD40L/IL-21 (lanes 1-4 
and 9-10, and lanes 5-8 respectively) were treated with HU. Cryopreserved samples not co-
cultured with CD40L/IL-21 were resuspended and pre-incubated in culture media for 24 
hours prior to treatment (lanes 5-6), whereas fresh cells were treated immediately upon 
isolation from peripheral blood without pre-incubation (lanes 7-8). Exposure to HU (1 mM) 
which induces replication stress led to Chk1 phosphorylation in primary CLL cells co-
cultured with CD40L/IL-21 (lanes 2-3, 10).   
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To investigate the effect of AZD6738 on ATR and ATM pathways, TP53/ATM wild-
type primary CLL cells induced to proliferate within the CD40/IL-21 co-culture system 
(Figure 4.3), as well as the CII-GFPsh and CII-ATMsh isogenic cell lines (Figure 4.4), were 
employed. The ATM functional status of these cell lines were confirmed by their response to 
IR. In the CII-GFPsh cell line, exposure to 6 Gy of IR led to activation of the ATM pathway, 
as evidenced by the phosphorylation of ATM and Chk2 (Figure 4.4, lane 5). This was not 
seen in the CII-ATMsh cell line, indicating that the ATM response was defective in this cell 
line (Figure 4.4, lane 11).  
Proliferating primary CLL cells and cell lines were treated with 1 μM of AZD6738 
and/or 10 μM of the ATM inhibitor KU-55933 for 2 hours prior to HU or IR exposure. These 
drug doses and treatment durations were chosen with reference to both published studies 
(Reaper et al., 2011) and unpublished data (AZD6738 Investigator’s Brochure, AstraZeneca, 
2013) of these inhibitors on tumour cell lines, and on the basis of the results of my pilot 
experiments. Pilot experiments showed that treatment at these doses and for these 
durations produced the desired inhibition of the ATR or ATM pathway, without incurring any 
substantial impact on CLL cell viability. Moreover, the maximal inhibitory effect on these 
pathways was reached at 2 hours, with no observable difference in inhibitory effect when the 
treatment duration was extended from 2 hours to 24 hours.  
AZD6738 treatment led to the suppression of ATR signalling as indicated by a 
reduction in HU-induced Chk1 phosphorylation, independent of ATM functional status 
(Figure 4.3, lane 4 vs 6, 5 vs 7; Figure 4.4, lanes 3 vs 4, 9 vs 10). Complete abolition of HU-
induced Chk1 phosphorylation was evident at AZD6738 doses ≥3 μM (Figure 4.5A). The 
specificity of AZD6738 for ATR inhibition was demonstrated by its lack of effect on IR-
induced ATM/Chk2 phosphorylation (Figure 4.3, lane 8 vs 10; Figure 4.4, lane 5 vs 6). 
Instead, ATM/Chk2 phosphorylation was suppressed by the ATM inhibitor (Figure 4.3, lane 
8 vs 10; Figure 4.4, lane 5 vs 6). Importantly, in ATM-proficient primary CLL cells and cell 
line, AZD6738 treatment resulted in ATM activation as evidenced by ATM phosphorylation





ATR signalling in primary CLL cells is inhibited by AZD6738. ATM/p53-wild type (wt) 
primary CLL cells co-cultured with CD40L/IL-21 were treated with AZD6738 (1 μM) and/or 
the ATM inhibitor KU-55933 (ATMi; 10 μM) for 2 hours, or left untreated, prior to exposure to 
HU (1 mM) or IR (6 Gy) for a further 5 hours. AZD6738 treatment inhibited ATR signalling as 
indicated by a reduction in HU-induced Chk1 phosphorylation (lane 4 vs 6). In ATM-
proficient CLL cells this also led to ATM activation as evidenced by ATM phosphorylation 
and Chk2 phosphorylation (lane 4 vs 6). Representative blots from experiments on 3 CLL 
samples are shown.  





ATR signalling in CLL cell lines is inhibited by AZD6738. CII cells, both CII-GFPsh and 
CII-ATMsh, were treated with AZD6738 (1 μM) and/or the ATM inhibitor KU-55933 (ATMi; 10 
μM) for 2 hours, or left untreated, prior to exposure to HU (1 mM) or IR (6 Gy) for a further 5 
hours. AZD6738 treatment inhibited ATR signalling as indicated by a reduction in HU-
induced Chk1 phosphorylation (lanes 3 vs 4, and 9 vs 10). In ATM-proficient CLL cells this 
also led to ATM activation as evidenced by ATM phosphorylation and Chk2 phosphorylation 
(lane 3 vs 4).   
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and HU-induced Chk2 phosphorylation (Figure 4.3, lane 4 vs 6; Figure 4.4, lane 1 vs 2 and 
3 vs 4). This indicated activation of the ATM pathway in the absence of functional ATR.  
DNA-dependent protein kinase (DNA-PK) is a protein that functions alongside ATM 
to mediate the repair of DSBs. Whereas ATM repairs DSBs through HRR and NHEJ, 
DNA-PK is capable of repairing DSBs solely through NHEJ. Recently, DNA-PK was reported 
to possess some redundant activity with ATR. In one study, DNA-PK was shown to play a 
role in regulating Claspin expression, maintaining Chk1 stability and promoting Chk1 
phosphorylation in cervical and colorectal cancer cell lines in response to replications stress. 
This was evidenced from the knockdown of DNA-PK in these cells, which led to decreased 
Claspin expression, Chk1 protein levels, as well as Chk1 phosphorylation in response to HU 
(Lin et al., 2014). In view of this, I assessed the impact of DNA-PK inhibition in primary CLL 
cells co-cultured with CD40L/IL-21, using the DNA-PK inhibitor NU7441. Cells were pre-
treated with NU7441 and/or AZD6738, or neither, for 1 hour. Thereafter, cells were exposed 
to HU or IR, and incubated for a further 5 hours prior to protein extraction and analysis using 
Western blotting. The results are displayed in Figure 4.5B. Treatment with 10 μM NU7441 
resulted in a reduction of IR-induc ed DNA-PK phosphorylation by >60% (lane 5 vs 6). 
However, treatment with 10 μM NU7441, either alone (lane 1 vs 2) or in combination with 
low dose AZD6738 (lane 3 vs 4), did not produce any observable impact on HU-induced 
Chk1 phosphorylation in primary CLL cells. The lack of impact on HU-induced Chk1 
phosphorylation upon treatment with the DNA-PK inhibitor suggests a possibility that such a 
functional redundancy between ATR and DNA-PK may not be present in CLL cells. 
 
4.1.2. ATR inhibition is selectively cytotoxic to TP53 or ATM defective 
CLL cells in vitro and in vivo 
To assess the therapeutic potential of ATR inhibition for DDR-defective CLL, I 
investigated the cytotoxic effects of AZD6738 on CLL cells. The cytotoxic effect of AZD6738 















Complete abolition of Chk1 activity can be achieved with higher doses of AZD6738 
and is not dependent on DNA-PK activity. (A) Primary CLL cells were treated with 
escalating doses of AZD6738 for 1 hour prior to exposure to HU. Complete elimination of 
HU-induced Chk1 phosphorylation was observed at 3 μM AZD6738 or above (lanes 7-8). (B) 
Cells were pre-treated with the DNA-PK inhibitor NU7441 and/or AZD6738, or neither, for 1 
hour, exposed to HU or IR, and incubated for a further 5 hours before analysis. Treatment 
with 10 μM NU7441 resulted in >60% reduction of IR-induced DNA-PK phosphorylation 
(lane 5 vs 6). However, treatment with NU7441, either alone (lane 1 vs 2) or in combination 
with 1 μM AZD6738 (lane 3 vs 4) did not produce a detectable impact on HU-induced Chk1 






Lanes:    1      2     3      4     5      6     7     8 
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was first assessed in CLL cell lines. The ATM-deficient CII-ATMsh cell line and the p53-
mutant Mec1 cell line displayed significantly greater AZD6738 sensitivity (EC50 1.6 μM and 
1.1 μM respectively) following 96 hours of drug treatment compared to the ATM/p53-
proficient CII-GFPsh cell line (EC50 8.4 μM; Figure 4.6), as assessed by CellTiter-Glo 
luminescent cell viability assay. The differential sensitivity of the CII-ATMsh and Mec1 cell 
lines relative to the CII-GFPsh cell line to AZD6738 was apparent across a range of 
AZD6738 doses. 
 Although Mec1 CLL cells lack p53 function, they are not isogenic with the p53-
proficient Cll cell lines. Therefore, observations regarding the effects of AZD6738 based 
solely on comparisons between these cell lines may not be conclusive. Therefore, I 
performed additional experimentation on separate paired cell lines that are either proficient 
or deficient in p53. To achieve this, I utilised Mec1 cells that were transfected by 
electroporation with the vector pcDNA3.1 containing either wild-type TP53, or GFP as 
control, as outlined in section 2.2.2. The expression of the wild-type TP53 was confirmed on 
Western blot by the presence of a 53 kDa wild-type p53 protein, located above the smaller 
47 kDa truncated mutant p53 protein, as shown in Figure 4.7A. The expression of wild-type 
p53 significantly reduced the sensitivity of Mec1 cells to AZD6738 (EC50 3.2 μM vs 1.0 μM; 
Figure 4.7B), as assessed by CellTiter-Glo luminescent cell viability assay.  
Having demonstrated, using cell lines, the selectivity of ATR inhibition for ATM or 
p53 defective CLL cells, I then proceeded to confirm this in a panel of 29 primary CLL 
samples. As outlined in section 2.8.2, CFSE-labelled CLL PBMCs from each patient were 
co-cultured with CD40L/IL-21 for 4 days to induce proliferation, following which cells were 
treated for 4 days with AZD6738. Viability was measured by PI exclusion of the proliferating 
CLL population identified by CD19 positivity and a reduction in CFSE fluorescence intensity
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Figure 4.6 
 
               
 
ATR inhibition is selectively cytotoxic to both ATM-deficient and TP53-deficient CLL 
cell lines. CII-GFPsh, CII-ATMsh (ATM-deficient) and Mec1 (p53-defective) cells were 
treated with AZD6738 for 4 days and viability measured using the CellTiter-Glo assay. 
Surviving fraction is expressed relative to untreated controls. AZD6738 induced significantly 
greater dose-dependent cytotoxicity with significantly lower AZD6738 EC50 in CII-ATMsh and 
Mec1 cells compared to CII-GFPsh cells. All data is displayed as mean ± SEM. Statistical 
significance was determined using two-way ANOVA with Bonferroni post-hoc analysis (left 
panel) or one-way ANOVA (right panel). Statistical significance is indicated by *p<0.05, 
**p<0.01 and ***p<0.001.  
  











                 
 
Reintroduction of wild-type TP53 in Mec1 cells decreased their sensitivity to ATR 
inhibition. (A) Western blotting shows expression of wild type p53 (wt-p53) in p53-
pcDNA3.1 transfected Mec1 cells. Irradiated CII cells were loaded as control for wt-p53 and 
the position of the mutant p53 (mut-p53) expressed by Mec1 cells is indicated. Actin was 
used for loading control. (B) Mec1 cells transfected with either wild-type TP53 (Mec1-p53-
pcDNA3.1) or GFP (Mec1-GFP-pcDNA3.1, as control) were treated with AZD6738 for 4 
days and viability measured using the CellTiter-Glo assay. Surviving fraction is expressed 
relative to untreated controls. AZD6738-induced cytotoxicity was reduced with significantly 
higher AZD6738 EC50 in Mec1-p53-pcDNA3.1 cells compared to Mec1-GFP-pcDNA3.1 
cells. All data is displayed as mean ± SEM. Statistical significance was determined using 
two-way ANOVA with Bonferroni post-hoc analysis (left panel) or Student’s t-test (right 
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(Figure 2.11). Selective cytotoxicity towards CLLs with DDR defects was evidenced by a 
significantly lower EC50 in ATM-defective (8.7 μM; 95% CI 3.4-13.9 μM; n=6) and TP53-
defective CLL samples (8.2 μM; 95% CI 3.5-12.9 μM; n=6) compared to either ATM/TP53-
wild-type CLLs (38.3 μM; 95% CI 28.8-47.8 μM; n=17) or healthy donor PBMCs (87.6 μM; 
95% CI 50.0-125.3 μM; n=4). As with CLL cell lines, the differential sensitivity of ATM-
defective or TP53-defective CLL samples to AZD6738, relative to the ATM/TP53-wild-type 
CLL samples and healthy donor PBMCs, was seen across a range of AZD6738 doses. 
These results are displayed in Figure 4.8A-B, and individual results are included in Table 
4.1.  
No significant difference in AZD6738 sensitivity was found when these samples 
were analysed according to clinical stage, prior treatment or IGHV mutational status (Figure 
4.8C). As discussed earlier, all of the ATM/TP53-defective cases harboured del(11q) or 
del(17p) in the majority of CLL cells. No significant correlation was found between the 
mutant allelic frequency of the remaining ATM or TP53 allele, and sensitivity to AZD6738 
(Table 4.1). The lack of such correlation may be due to the small sample size of CLL cases 
with ATM or TP53 defect. Finally, as expected from a loss of the G1/S checkpoint, there was 
a trend towards a higher level of proliferation among CLL samples carrying ATM or TP53 
defects, as estimated from the proportion of cells that have cycled ≥1 and ≥4 times during 
the 8-day culture period. However, the differences were not statistically significant, indicating 
that ATM or TP53 defective CLL cells possess intrinsic sensitivity to ATR inhibition, rather 
than increased sensitivity simply because of a higher proliferation rate.   
To investigate the effect of ATR inhibition in quiescent CLL cells, I treated 10 
primary CLL samples (3 TP53/ATM-wild type, 3 ATM-defective and 4 TP53-defective 
samples) with escalating doses of AZD6738 without CD40L/IL-21 co-culture, and measured 
cytotoxicity at 24 hours and 96 hours using PI labelling and flow cytometric analysis. As 
expected, AZD6738 had little, if any, cytotoxic effect on cells cultured without CD40L/IL-21, 
regardless of TP53 or ATM status (Figure 4.9). This is consistent with my earlier finding that







             
                    
 
ATR inhibition is selectively cytotoxic to both ATM-defective and TP53-defective CLL 
primary cells. (A) CFSE-labelled primary CLL cells with or without ATM/TP53 defects and 
healthy donor PBMCs co-cultured with CD40L/IL-21 were treated with AZD6738 for 4 days. 
Viability was measured by propidium iodide exclusion of the proliferating cell population that 
was identified by reduction in CFSE fluorescence intensity. Surviving fraction is expressed 
relative to untreated controls. AZD6738 induced significantly greater dose-dependent 
cytotoxicity in ATM/TP53-defective CLL cells than either ATM/TP53-wild type CLL cells or 
healthy donor PBMCs. (B) The EC50 of AZD6738 was significantly lower for ATM/TP53-
defective primary CLL samples than both ATM/TP53-wild type samples and healthy donor 
PBMCs. A list of CLL samples assessed and their respective EC50 are provided in Table 
4.1. (C) There was no significant difference in the EC50 of AZD6738 between subgroups of 
CLL samples stratified according to Binet stage, prior treatment and IGHV mutational status. 
All data is displayed as mean ± SEM. Statistical significance was determined using two-way 
ANOVA with Bonferroni post-hoc analysis (A), one-way ANOVA (B) or Student’s t-test (C). 
Statistical significance vs ATM/TP53-wild type samples (*) or healthy donor PBMCs (†) 
(C,D), or vehicle (F-H) is indicated by *,†p<0.05, **,††p<0.01 and ***,†††p<0.001. Non-
significant results are denoted by n.s.   
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The cytotoxic effect of AZD6738 monotherapy is dependent on CLL cell proliferation. 
Primary CLL samples [n=10, including 3 TP53/ATM-wild type (CLL02, CLL06 and CLL07), 3 
ATM-defective (CLL23, CLL27 and CLL28), and 4 TP53-defective samples (CLL29, CLL34, 
CLL35 and CLL36)] were treated with escalating doses of AZD6738 without co-culture with 
CD40L/IL-21. Cytotoxicity was assessed using flow cytometric measurement of PI uptake. 
Surviving fraction was expressed as a percentage of untreated controls. In the absence of 
cycling induced by CD40L/IL-21, AZD6738 had little impact on the viability of CLL cells, 
regardless of TP53 or ATM status. 
No CD40L/IL-21 (24 hours) 
No CD40L/IL-21 (96 hours) 
A 
B 
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the ATR pathway in CLL cells is active only upon induction of cell cycling (Figure 4.2). 
Therefore, AZD6738, when used as a single agent, specifically targets the proliferating CLL 
population. 
To assess the effectiveness of ATR inhibition in vivo, primary CLL xenografts were 
employed. In a set of experiments carried out by Dr Nicholas Davies, four representative 
primary CLL samples carrying either del(17p) and a TP53 mutation (p.I251S or p.M237I) or 
del(11q) and an ATM mutation (p.I1407T or p.L3013Q) were engrafted into NOD/Shi-scid/IL-
2Rγnull mice. Following treatment with AZD6738 (n=10) or vehicle (n=11) for two weeks, 
tumour load was significantly reduced in AZD6738-treated animals compared to vehicle-
treated controls (Figure 4.10A). When analysed separately according to genotype, both 
TP53 and ATM defective AZD6738-treated xenografts showed significant reduction in 
tumour load (Figure 4.10B). Furthermore, in the CLL26 xenograft where tumour cell 
recovery allowed monitoring of del(11q) cells, a significant reduction in the percentage of 
cells with del(11q) (37% vs 100%) was observed in AZD6738-treated animals compared to 
vehicle-treated controls (Figure 4.10C). Taken together, the in vitro and in vivo data 
demonstrates efficacy and specificity of AZD6738 for TP53 or ATM defective CLL.  
 
4.1.3. ATR inhibition induces DNA damage and mitotic catastrophe in 
TP53 or ATM defective CLL cells 
As discussed in section 1.4.2.1, suppression of aberrant or excessive replication 
origin initiation is an important mechanism whereby ATR protects DNA replication forks from 
collapse and breakage (Couch et al., 2013; Toledo et al., 2013; Zeman and Cimprich, 2014). 
I therefore hypothesised that ATR inhibition in CLL cells would result in increased replication 
origin initiation. To verify this, I first determined the impact of ATR inhibition on DNA 
replication in CII-ATMsh and Mec1 cells. I collaborated with Dr Eva Petermann, who 
performed, on these cells, DNA fibre analysis that visualises origins of replication and
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Figure 4.10 
 
                 
                            
ATR inhibition is selectively cytotoxic to both ATM-defective and TP53-defective CLL 
cells in vivo. (A) Primary CLL samples (CLL29, CLL31, CLL25, CLL26) with biallelic TP53 
or ATM defects were engrafted into NOD/Shi-scid/IL-2Rγnull mice and treated with vehicle 
(n=11) or AZD6738 (n=10). Treatments were carried out according to the schedule outlined 
in section 2.10. Collectively, AZD6738 treatment significantly reduced tumour load compared 
to vehicle treatment in TP53/ATM-defective xenografts. (B) When analysed separately, both 
TP53 and ATM defective xenografts showed significant reduction in tumour load following 
AZD6738 treatment compared to vehicle-treated controls. (C) FISH probes for 11q were 
applied on human CD45+ CD19+ cells collected from the spleens of CLL26 xenografts 
(harbouring del(11q) and L3013Q ATM mutation) treated with AZD6738 (n=3) or vehicle 
(n=3). Two hundred cells were analysed per mouse. The proportion of CLL cells with 
del(11q) was significantly reduced following AZD6738 treatment compared to vehicle-treated 
controls. All data is displayed as mean ± SEM. Statistical significance was determined using 
two-way ANOVA with Bonferroni post-hoc analysis (B) or Student’s t-test (A,C). Statistical 
significance is indicated by *p<0.05, **p<0.01 and ***p<0.001.  
A 
B C 
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replication fork progression (Figure 4.11). One hour after treatment with AZD6738, 
increased replication origin initiation was observed as indicated by decreased inter-origin 
distance (Figure 4.11A-B). Decreased DNA fibre length and hence decreased replication 
fork progression rates was also observed (Figure 4.11A, C), consistent with fork slowing or 
stalling and therefore increased replication stress upon ATR inhibition (Couch et al., 2013; 
Petermann et al., 2010; Toledo et al., 2013).  
Next, I assessed the impact of ATR inhibition on cell cycle progression. I performed 
cell cycle analyses on CII-GFPsh, CII-ATMsh and Mec1 cells following 24-hour and 48-hour 
treatment with either AZD6738 (1 μM or 3 μM) or RPMI-1640 medium. A representative cell 
cycle profile is displayed in Figure 4.12, and data from three independent experiments are 
presented in Figure 4.13. In response to AZD6738, CII-GFPsh cells accumulated in G0/G1 
consistent with G1/S cell cycle arrest. Specifically, there was a significant increase in the 
proportion of G0/G1 cells by a magnitude of 10-13% following treatment with AZD6738, 
seen both at the 24-hour and the 48-hour timepoint (Figure 4.12; Figure 4.13A). In contrast, 
neither G1/S nor G2/M arrest was evident in CII-ATMsh and Mec1 cells despite replication 
stress. Indeed, AZD6738 treatment in the Mec1 cell line resulted in a reduction in the 
proportion of G0/G1 cells with a corresponding increase in the proportion of cells in S phase, 
indicating that the G0/G1 checkpoint was bypassed in these cells. This was accompanied by 
an accumulation of dead cells, represented by an increase of cells in the sub-G phase, 
particularly with 3 μM of AZD6738 and at the 48-hour timepoint (Figure 4.12; Figure 4.13B-
C). Together, these results indicate that CLL cells depend on ATM and p53 for cell cycle 
regulation in the absence of ATR function.  
ATR inhibition results in the collapse of stalled replication forks into DNA fragments 
with double-stranded ends (Couch et al., 2013; Toledo et al., 2013), for which effective 
resolution requires ATM-mediated HRR and ATM/p53-dependent cell cycle checkpoint 
activation (Bieging et al., 2014; Shiloh and Ziv, 2013). This was reflected by ATM/Chk2 
phosphorylation upon ATR inhibition (Figure 4.3; Figure 4.4). Therefore, I reasoned that 





ATR inhibition leads to increased replication stress in CLL cells. (A) AZD6738 (1 μM) 
treatment for 1 hour led to increased replication stress in Mec1 (p53-defective) and CII-
ATMsh (ATM-deficient) cells as demonstrated by DNA fibre analysis. Replicating DNA in 
cycling cells was sequentially labelled with CldU and IdU for 20 min each, after which DNA 
fibres were analysed by immunofluorescence microscopy. Representative images are 
displayed. (B-C) AZD6738 (1 μM) treatment for 1 hour significantly reduced (B) inter-origin 
distance and (C) fork progression rate in Mec1 and CII-ATMsh cells.  Statistical significance 
was determined using Student’s t-test (B) or Mann Whitney U test (C). In (B), statistical 
significance vs DMSO-treated controls is indicated by **p<0.01.  
  















The effect of ATR inhibition on the cell cycle profiles of CLL cells with defective ATM or p53. CII-GFPsh, CII-ATMsh and Mec1 cells 
were analysed 24 (A) or 48 (B) hours after treatment with either AZD6738 (1 μM or 3 μM) or RPMI media. AZD6738 treatment induced G1/S 
cell cycle arrest in CII-GFPsh cells but not in CII-ATMsh or Mec1 cells. Representative cell cycle profiles from 3 independent experiments are 
displayed. The percentages shown represent the proportion of cells within each phase of the cell cycle.      




ATR inhibition leads to ATM/p53 dependent G1/S cell cycle arrest in CLL cells. Cell 
cycle analysis on (A) CII-GFPsh, (B) CII-ATMsh and (C) Mec1 cells were carried out 
following 24 or 48 hour treatment with either AZD6738 (1 μM or 3 μM) or RPMI media. 
AZD6738 treatment induced G1/S cell cycle arrest in CII-GFPsh cells but not CII-ATMsh or 
Mec1 cells. Data is displayed as mean ± SEM of triplicate experiments. Statistical 
significance was determined using two-way ANOVA with Bonferroni post-hoc analysis. 
Statistical significance vs untreated controls is indicated by *p<0.05 and **p<0.01.  
  
228     
ATR inhibition should produce more fragmented DNA in ATM/p53-defective CLL cells. To 
assess the amount of DNA damage accrued through ATR inhibition, I utilised CII cells pre-
treated for 2 hours with 10 μM of ATM inhibitor, CII cells without ATM inhibitor pre-treatment, 
and Mec1 cells. I treated these cells with 1 μM of AZD6738 for 24 or 48 hours, after which 
the cells were harvested, labelled with anti-γH2AX and anti-53BP1 antibodies and the 
appropriate secondary antibodies, and analysed by immunofluorescence microscopy. As 
discussed in section 1.4.1, ATM can phosphorylate histone H2AX to produce γH2AX. 
However, H2AX can also be phosphorylated by numerous other DDR proteins, such as ATR 
and DNA-PK, leading to their accumulation at sites of DNA DSBs, even in the absence of 
ATM (Rothkamm et al., 2015). Likewise, 53BP1 accumulates at sites of DSBs. The 
aggregation of these proteins at damaged sites can be visualised as DNA damage foci. 
These foci serve as biomarkers of DNA damage, or more specifically of DSBs. Consistent 
with the above hypothesis that ATM/p53-defective CLL cells should preferentially 
accumulate DNA fragments arising from collapsed replication forks, I observed accumulation 
of these markers of DSBs, namely γH2AX and 53BP1 foci, in Mec1 and ATMi pre-treated CII 
cells but not in CII cells without ATMi pre-treatment, 24 and 48 hours respectively following 
exposure to 1 μM of AZD6738 (Figure 4.14A-C; Figure 4.15A-C).  
To assess the amount of DNA damage specifically in CLL cells that are undergoing 
mitosis, I co-labelled these cells with anti-γH2AX antibody and an antibody against 
phosphohistone H3 ser-10 (pH3). The phosphorylation of histone H3 at Ser10 (as well as 
Ser28 and Thr11) is associated with chromosome condensation that occurs during mitosis. 
Hence, pH3 serves as a specific marker for mitosis. Co-labelling for γH2AX and pH3 
revealed dual positivity for these markers following 24-hour incubation with 1 μM AZD6738 
in Mec1 and ATMi pre-treated CII cells. Indeed, among Mec1 and ATMi pre-treated CII cells, 
a substantial proportion of cells undergoing mitosis was γH2AX positive (Figure 4.14A-B, 
D). Therefore, consistent with the loss of both G1/S and G2/M checkpoints in the absence of 
functional ATM/p53 and ATR, Mec1 and ATMi pre-treated CII cells, when treated with 
AZD6738, progressed into mitosis despite carrying unrepaired DNA damage. 






















ATR inhibition results in accumulation of γH2AX foci in CLL cells with ATM or p53 
deficiency. (A) Co-labelling of CLL cells with γH2AX and pH3 allows identification of both 
mitotic (pH3-positive) and non-mitotic (pH3-negative) cells that have accumulated DNA 
damage (γH2AX). Images were captured using a 60x lens. (B) Cells treated with AZD6738 
(1 μM) for 24 hours were co-labelled with anti-γH2AX and anti-pH3 antibodies, and analysed 
by immunofluorescence microscopy. A cell was considered γH2AX positive if more than five 
γH2AX foci were present. At least 200 cells were analysed in each sample. AZD6738 
induced γH2AX foci in Mec1 and ATMi pre-treated CII cells, but not in CII cells without ATMi 
pre-treatment. (C-D) The effect of AZD6738 (1 µM) treatment on the proportion of mitotic 
and non-mitotic γH2AX-positive CLL cells. Data is displayed as mean ± SEM of triplicate 
results from a representative experiment. Statistical significance compared to untreated 
controls, assessed by Student’s t-test, is indicated by *p<0.05.  
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ATR inhibition results in replication stress, which leads to replication fork slowing 
and stalling and hence increasing the amount of incompletely replicated regions within the 
genome (Zeman and Cimprich, 2014). As outlined in section 1.4.2.3, ATR-mediated G2/M 
arrest would normally occur in the presence of replication stress, allowing resolution of 
stalled forks and completion of DNA replication prior to entry into mitosis. In the absence of 
functional ATR, some cells could enter mitosis despite incomplete genomic duplication. 
During the metaphase stage of mitosis, chromosomes align at the equatorial region of the 
cell. The sister chromatids of each duplicated chromosome are held together by protein 
complexes called cohesins, which are cleaved before the chromatids separate during 
anaphase, and by DNA catenanes. DNA catenanes are two DNA strands located within 
each of the two sister chromatids that become intertwined and entangled with each other. 
DNA catenanes can arise during normal DNA replication but these are normally resolved, by 
a hitherto unknown mechanism, prior to chromatid separation. In contrast, DNA catenanes 
that arises from partially replicated DNA, as a result of replication stress during the previous 
S phase, remain unresolved (Mankouri et al., 2013). As the sister chromatids try to separate 
during anaphase, these catenated regions of DNA result in ultra-fine DNA bridges, which are 
chromatin that remain connected to both chromatids (Liu et al., 2014). As the sister 
chromatids continue to separate, these ultra-fine DNA bridges often break and are 
transmitted to daughter cells at the following G1. These lesions are sequestered within 
nuclear compartments called 53BP1 nuclear bodies which serve to protect DNA from 
endonuclease degradation during G1, and facilitate their repair during the subsequent S 
phase (Harrigan et al., 2011; Lukas et al., 2011).  
53BP1 foci appear as discrete dots or points on immunofluorescence microscopy. 
On the contrary, 53BP1 nuclear bodies are characterised by robust, block-like staining 
(Harrigan et al., 2011; Lukas et al., 2011). As shown in Figure 4.15A, 53BP1 foci reflect 
unrepaired DSBs, whereas 53BP1 bodies represent under-replicated DNA. As expected, I 
observed an accumulation of 53BP1 bodies in ATM/p53-proficient CII cells following 48
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Figure 4.15 
                  
 
                   
        
 
ATR inhibition results in accumulation of 53BP1 foci in CLL cells with ATM or p53 
deficiency. (A) The pattern of 53BP1 labelling distinguishes 53BP1 bodies from 53BP1 foci. 
53BP1 bodies are characterised by robust block-like staining, and indicate under-replicated 
DNA. 53BP1 foci are characterised by discrete punctate staining, and indicate DNA damage. 
A cell was considered 53BP1 foci positive if more than five 53BP1 foci were present. (B-D) 
Cells treated with AZD6738 (1 μM) for 48 hours were labelled with anti-53BP1 antibodies, 
and at least 200 cells were then analysed in each sample using a 60x lens. AZD6738 
treatment led to an accumulation of 53BP1 foci in Mec1 and ATMi pre-treated CII cells, and 
an accumulation of 53BP1 bodies in CII cells without ATMi pre-treatment. Data is displayed 
as mean ± SEM of triplicate results from a representative experiment. Statistical significance 
compared to untreated controls, assessed by Student’s t-test, is indicated by *p<0.05, 




232     
hours of AZD6738 treatment (Figure 4.15A-B, D). In contrast, this was not seen in 
ATM/p53-defective CLL cells, suggesting that formation of 53BP1 bodies was dependent on 
the ATM pathway as previously demonstrated using rapidly dividing fibroblast cell lines 
(Harrigan et al., 2011). Failure to initiate this protective mechanism could precipitate further 
DNA damage in ATM/p53-defective CLL cells.  
Based on the results so far, I postulated that the abolition of both G1/S and G2/M 
cell cycle checkpoints due to the combined loss of functional ATM/p53 and ATR would 
permit entry into mitosis despite the accumulation of unrepaired DNA DSBs and partially 
replicated DNA fragments, resulting in mitotic catastrophe. Mitotic catastrophe is a form of 
cell death occurring during mitosis, as DNA damaged cells engage in an aberrant attempt at 
chromosomal segregation. Mitotic catastrophe is characterised by premature chromatin 
condensation, and the formation of micronuclei, which are distinct, oval-shaped DNA mass 
positioned next to the nucleus within the cytoplasm, and arise from failure of DNA or DNA 
fragments to incorporate into the daughter nuclei during mitosis. The exact mechanism of 
cell death occurring during mitotic catastrophe is, however, unclear (Vitale et al., 2011).    
Experimentally, cells undergoing mitotic catastrophe can be distinguished from 
those undergoing apoptosis by immunofluorescence labelling of pH3 and lamin B (Weston et 
al., 2010). Lamin B is a nuclear membrane protein. Cells undergoing normal mitosis stain 
positive for pH3 but lose lamin B staining, because of dissolution of the nuclear membrane 
during mitosis. In contrast, cells undergoing mitotic catastrophe do not stain for pH3 but 
retain lamin B staining due to failed nuclear membrane disassembly. In addition, cells 
undergoing mitotic catastrophe can be identified and distinguished from quiescent cells by 
multiple micronuclei that are visible with DAPI staining. On the other hand, the expression of 
both pH3 and lamin B is lost when cells undergo apoptosis, because the nuclear membrane 
is targeted by caspases for proteolytic degradation. Apoptotic cells can also be recognised 
by their characteristic appearance upon DAPI staining, consistent with apoptosis-associated 
nuclear fragmentation (Figure 4.16A). Therefore, in order to confirm the cytotoxic




              
 
       
ATR inhibition results in mitotic catastrophe in CLL cells with ATM or p53 deficiency. 
(A) Co-labelling with anti-lamin B and anti-pH3 antibodies allows apoptotic CLL cells to be 
distinguished from cells undergoing mitotic catastrophe. At least 200 cells were analysed in 
each sample. (B) AZD6738 exposure for 72 hours resulted in significantly elevated levels of 
mitotic catastrophe in Mec1 and ATMi pre-treated CII cells. Data is displayed as mean ± 
SEM of triplicate results from a representative experiment. Statistical significance was 
determined using Student’s t-test. Statistical significance compared to untreated controls, 
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mechanism underpinning ATR inhibition, I probed CLL cells for pH3 and lamin B. I found 
significant levels of mitotic catastrophe 72 hours following 1 μM AZD6738 in Mec1 and ATMi 
pre-treated CII cells, but not in CII cells without ATMi pre-treatment (Figure 4.16B).  
It has been reported in a previous study that mitotic catastrophe could be 
accompanied by an accumulation of tetraploid cells (4N, corresponding to the G2/M 
population) that have failed to complete mitosis (Huang et al., 2005). However, I did not 
observe this in CLL cells treated with AZD6738. A potential explanation relates to the effect 
of ATR inhibition on DNA replication. As alluded to previously, cells subjected to ATR 
inhibition enter mitosis having undergone incomplete DNA replication. They are therefore 
expected to have DNA content between 2N and 4N, rather than 4N. Therefore, mitotic arrest 
would be manifested by the accumulation of cells with DNA content between 2N and 4N 
(corresponding to S phase) rather than 4N, as observed from the changes in the Mec1 cell 
cycle profile in response to AZD6738 (Figure 4.12; Figure 4.13C).  
In ATM/p53-proficient CII cells, I detected low level apoptotic activity after AZD6738 
treatment by both immunofluorescence microscopy (Figure 4.16C) and Western blotting, 
where I used PARP and caspase 7 cleavage as markers of apoptosis. AZD6738 induced a 
modest reduction in full-length caspase 7, as well as an increase in cleaved PARP (Figure 
4.17A). The modest change in the levels of these markers is indicative of a low level of 
apoptotic activity being induced by AZD6738. In these ATM/p53-proficient CLL cells, the 
apoptotic activity is likely to be a result of p53 activation in response to replication stress. 
Mec1 cells also exhibited low levels of apoptotic markers PARP and caspase cleavage 
(Figure 4.17B), but such levels were unlikely to account for their differential sensitivity to 
ATR inhibition compared to DDR-proficient cells. Indeed, in response to AZD6738, similar 
levels of apoptotic induction was seen across Mec1 cells and CII cells with and without ATM 
inhibitor pre-treatment (Figure 4.16C). Moreover, the negligible impact of pan-caspase 
inhibitor Z-VAD-FMK on the viability of AZD6738-treated Mec1 cells supports this notion 
(Figure 4.17C). 
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ATR inhibition induces a low-level of apoptotic activity in both DDR-proficient and 
DDR-deficient CLL cells. (A) CII-GFPsh (DDR-proficient) and (B) Mec1 (DDR-deficient) 
cells treated with AZD6738 (0, 1 or 3 μM) for 24-72 hours or 20 Gy IR as a positive control 
were analysed by Western blotting. AZD6738 induced a small reduction in full-length PARP 
and full-length caspase 7, as well as an increase in cleaved PARP. Taken together the 
minimal changes in the levels of these markers are indicative of a low level of apoptotic 
activity being induced. SMC1 was the loading control. (C) Mec1 cells were treated with 
AZD6738 in the presence or absence of the pan-caspase inhibitor Z-VAD-FMK (30 μM). 
Following 96 hours of incubation cells were analysed using the CellTiter-Glo assay. Z-VAD-
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4.1.4. ATR inhibition sensitises TP53 or ATM defective CLL cells to 
chemotherapy and ibrutinib 
I reasoned that the synthetically lethal effects of ATR inhibition on ATM or TP53 
defective CLL cells could sensitise these chemoresistant cells to chemotherapeutic agents 
through potentiation of DNA damage. I therefore assessed the impact of combining 
AZD6738 with chemotherapy in CLL cell lines and primary CLL PBMCs. The 
chemotherapeutic agents chosen to combine with AZD6738 reflect the range of agents 
currently used in clinical practice: the alkylating agents chlorambucil, cyclophosphamide and 
bendamustine, and the purine analogue fludarabine. Cyclophosphamide is a pro-drug that 
requires metabolic activation in vivo by liver cytochrome P450. Therefore, its active form, 4-
hydroperoxycyclophosphamide (4HC), was used in all in vitro experiments.  
Since the goal of drug combination is to reduce the drug dose required to achieve 
the desired therapeutic effect, a low dose of AZD6738, at 1 μM, was used for the in vitro 
drug combination studies. At 1 μM, AZD6738 produced a cytotoxic effect that approximates 
the EC25 (the dose that produces 25% cell killing): slightly above the EC25 in ATM/TP53-
defective CLL cell lines, and slightly below the EC25 in ATM/TP53-defective primary CLL 
cells (Figure 4.6; Figure 4.8). On the other hand, the choice of drug doses for 
chemotherapeutic agents was made with reference to their physiologically achievable dose 
range, calculated based on the maximal plasma concentrations (Cmax) obtained from 
patients treated with conventional doses of the drug in published in vivo pharmacokinetics 
studies. These are 5.7 µM, 5.4 µM, 0.6 µM / 11 µM (depending on the dose and route of 
administration) and 25 µM respectively for chlorambucil (Silvennoinen et al., 2000), 
fludarabine (Foran et al., 1999), 4HC (Anderson et al., 1996; Struck et al., 1987) and 
bendamustine (Ogura et al., 2011). Because these Cmax values were derived from a single 
drug dose and do not take into account the effect of repeat or continuous dosing, I have 
included several chemotherapy doses that are slightly higher than the Cmax (<4x Cmax). 
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While resistance to chlorambucil, fludarabine, 4HC or bendamustine monotherapy 
was evident in the ATM defective CII-ATMsh cells and the TP53 defective Mec1 cells even 
at the highest chemotherapy dose, I discovered significant sensitisation to a range of doses 
of these agents upon addition of 1 μM AZD6738. This is evidenced by marked dose-
dependent response of these cells to all four chemotherapeutic agents upon the addition of 
1 μM AZD6738, as assessed by CellTiter-Glo luminescent cell viability assay after 4 days of 
treatment (Figure 4.18). Additive effect was seen in several dose combinations involving 
lower doses of fludarabine and bendamustine. However, highly synergistic interaction was 
evident with dose combinations involving higher chemotherapy doses that produce 50% cell 
killing or above, across all four drug combinations (Figure 4.19; Table 4.2). Of note, CII-
GFPsh cells were sensitive to chemotherapy. However, addition of AZD6738 to 
chemotherapeutic agents led to further sensitisation (Figure 4.20A). AZD6738 was 
synergistic with chlorambucil, 4HC and bendamustine but mostly additive with fludarabine in 
CII-GFPsh CLL cells (Figure 4.20B; Table 4.3).  
I then proceeded to evaluate these findings in DDR-defective primary CLL cells co-
cultured with CD40L/IL-21. AZD6738 (at 1 μM) enhanced sensitivity to (Figure 4.21) and 
synergised with (Figure 4.22; Table 4.4) chlorambucil, fludarabine and 4HC in primary CLL 
samples with defective ATM or TP53 (n=6) across a range of chemotherapy doses, as 
assessed by flow cytometric analysis of cell viability on the proliferating CLL cell population. 
However, due to pro-survival properties of the co-culture system the sensitisation effect in 
primary CLL cells (Figure 4.21) was less profound than in CLL cell lines (Figure 4.18). In 
order to assess the interaction of AZD6738 with chemotherapeutic agents across a broader 
range of cytotoxic effect, I additionally carried out combination experiments with 3 µM 
AZD6738 on these CLL samples. The interaction was highly synergistic for these drug 
combinations (Table 4.4).  
Interestingly, in these primary CLL samples I also found additive to synergistic 
interaction between AZD6738 and cytotoxic doses of ibrutinib (Herman et al., 2011), as 
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Figure 4.18 















ATR inhibition sensitises CII-ATMsh and Mec1 CLL cells to cytotoxic chemotherapy. 
(A) CII-shATM and (B) Mec1 cells were treated with chlorambucil, fludarabine, 4-
hydroperoxycyclophosphamide (4HC) or bendamustine with or without co-administration of 
AZD6738 (1 μM). Viability was assessed 96 hours later by the CellTiter-Glo assay. Surviving 
fraction is expressed relative to untreated controls for chemotherapy treatment alone (no 
AZD6738) and relative to 1 μM AZD6738 monotherapy for the co-treated samples. Addition 
of AZD6738 significantly enhanced sensitivity of CII-shATM and Mec1 cells to cytotoxic 
chemotherapeutic agents. Data is displayed as mean ± SEM of triplicate experiments. 
Statistical significance was determined using two-way ANOVA with Bonferroni post-hoc 
analysis. Statistical significance vs no AZD6738 is indicated by *p<0.05, **p<0.01 and 
***p<0.001.   






















ATR inhibition synergises with cytotoxic chemotherapy in CII-ATMsh and Mec1 CLL 
cells. AZD6738 is synergistic with chlorambucil, fludarabine, 4HC and bendamustine in (A) 
CII-shATM and (B) Mec1 cells across a range of effective drug doses. Combination indices 
(CI) were calculated using the median-effect method. Each point represents the mean CI 
value obtained from 3 independent experiments plotted against the corresponding affected 
fraction that is expressed relative to untreated controls. CI < 0.9 represents synergism, CI 
0.9-1.1 represents additive effect, and CI > 1.1 represents antagonism. The actual values 
are presented in Table 4.2.    
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Table 4.2.  Combination indices of AZD6738 (1 µM) with cytotoxic chemotherapy in CII-ATMsh and Mec1 cells 
 















(mean ± SEM) 
Synergism 
Chlorambucil 
1 0.43 0.45 ± 0.16 +++ 0.51 0.75 ± 0.16 ++ 
2.5 0.54 0.48 ± 0.09 +++ 0.61 0.49 ± 0.11 +++ 
5 0.73 0.27 ± 0.14 ++++ 0.71 0.29 ± 0.03 ++++ 
10 0.89 0.16 ± 0.08 ++++ 0.76 0.26 ± 0.03 ++++ 
Fludarabine 
1 0.35 0.89 ± 0.29 + 0.44 1.06 ± 0.14 ± 
2.5 0.37 0.93 ± 0.28 ± 0.55 0.69 ± 0.14 +++ 
5 0.51 0.69 ± 0.17 +++ 0.61 0.56 ± 0.18 +++ 
10 0.71 0.55 ± 0.13 +++ 0.72 0.34 ± 0.07 +++ 
4-hydroperoxy-
cyclophosphamide 
0.25 0.40 0.75 ± 0.33 ++ 0.48 0.97 ± 0.30 ± 
0.5 0.56 0.53 ± 0.26 +++ 0.57 0.69 ± 0.28 +++ 
1 0.73 0.36 ± 0.15 +++ 0.68 0.42 ± 0.14 +++ 
2 0.89 0.30 ± 0.07 ++++ 0.78 0.26 ± 0.10 ++++ 
Bendamustine 
10 0.24 1.08 ± 0.15 ± 0.39 1.10 ± 0.08 ± 
25 0.31 0.86 ± 0.15 + 0.49 0.89 ± 0.29 + 
50 0.40 0.66 ± 0.15 +++ 0.52 0.76 ± 0.18 ++ 
100 0.65 0.34 ± 0.11 +++ 0.66 0.41 ± 0.01 +++ 
 
++++, strong synergism; +++, synergism; ++, moderate synergism; +, slight synergism; ±, additive 
  




















AZD6738 is synergistic with chlorambucil, 4-hydroperoxycyclophosphamide and 
bendamustine in CII-GFPsh CLL cells. (A) CII-shGFP cells were treated with 
chlorambucil, fludarabine, 4-hydroperoxycyclophosphamide (4HC) or bendamustine with or 
without co-administration of AZD6738 (1 μM). Viability was assessed 96 hours later by the 
CellTiter-Glo assay. Surviving fraction is expressed relative to untreated controls for 
chemotherapy treatment alone (no AZD6738) and relative to 1 μM AZD6738 monotherapy 
for the co-treated samples. Addition of AZD6738 significantly enhanced the sensitivity of CII-
shGFP cells to cytotoxic chemotherapeutic agents. Data is displayed as mean ± SEM of 
triplicate experiments. Statistical significance was determined using two-way ANOVA with 
Bonferroni post-hoc analysis. Statistical significance vs no AZD6738 is indicated by *p<0.05, 
**p<0.01 and ***p<0.001. (B) AZD6738 is synergistic with chlorambucil, 4HC and 
bendamustine and mostly additive with fludarabine in CII-GFPsh cells. Combination indices 
(CI) were calculated using the median-effect method. Each point represents the mean CI 
value obtained from 3 independent experiments plotted against the corresponding affected 
fraction that is expressed relative to untreated controls. CI < 0.9 represents synergism, CI 
0.9-1.1 represents additive effect, and CI > 1.1 represents antagonism. The actual values 
are presented in Table 4.3.  
A 
B 
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Table 4.3.  Combination indices of AZD6738 (1 µM) with cytotoxic 











(mean ± SEM) 
Synergism 
Chlorambucil 
1 0.33 0.74 ± 0.42 ++ 
2.5 0.53 0.46 ± 0.14 +++ 
5 0.70 0.40 ± 0.03 +++ 
10 0.85 0.34 ± 0.03 +++ 
Fludarabine 
1 0.20 0.98 ± 0.24 ± 
2.5 0.28 1.10 ± 0.27 ± 
5 0.39 1.29 ± 0.36 −− 
10 0.64 1.09 ± 0.33 ± 
4-hydroperoxy-
cyclophosphamide 
0.25 0.29 0.67 ± 0.10 +++ 
0.5 0.37 0.78 ± 0.10 ++ 
1 0.53 0.92 ± 0.22 ± 
2 0.83 0.79 ± 0.04 ++ 
Bendamustine 
10 0.26 0.41 ± 0.09 +++ 
25 0.32 0.45 ± 0.10 +++ 
50 0.42 0.45 ± 0.10 +++ 
100 0.60 0.36 ± 0.04 +++ 
 





















ATR inhibition sensitises both in ATM-defective and TP53-defective primary CLL cells 
to existing therapeutic agents. CFSE-labelled primary CLL cells with (A) ATM (CLL22, 
CLL23, CLL24) or (B) TP53 defect (CLL29, CLL31, CLL32) co-cultured with CD40L/IL-21 
were treated with chlorambucil, fludarabine, 4-hydroperoxycyclophosphamide (4HC) or 
ibrutinib with or without co-administration of AZD6738 (1 μM). Viability was assessed after 
96 hours by propidium iodide exclusion of the proliferating cell population as identified by 
reduction in CFSE fluorescence intensity. Surviving fraction is expressed relative to 
untreated controls for chemotherapy treatment alone (no AZD6738) and relative to 1 μM 
AZD6738 monotherapy for the co-treated samples. Addition of AZD6738 significantly 
enhanced sensitivity of ATM-defective primary CLL samples to chlorambucil and 4HC, and 
TP53-defective primary CLL samples to these therapies and also to fludarabine and ibrutinib 
at ≥1 dose combination. Data is displayed as mean ± SEM. Statistical significance was 
determined using two-way ANOVA with Bonferroni post-hoc analysis. Statistical significance 








      
 
        
 
ATR inhibition synergises with existing therapeutic agents both in ATM-defective and 
TP53-defective primary CLL cells. AZD6738 is synergistic with chlorambucil, fludarabine, 
4HC and ibrutinib in primary CLL samples with (A) ATM or (B) TP53 defect across a range 
of effective drug doses. CI values were calculated using the median-effect method. Each 
point represents the mean CI value of 3 samples plotted against the corresponding mean 
affected fraction that is expressed relative to untreated controls. CI < 0.9 represents 
synergism, CI 0.9-1.1 represents additive effect and CI > 1.1 represents antagonism. The 
actual values are presented in Table 4.4. 
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Table 4.4.  Combination indices of AZD6738 (1 or 3 µM) with cytotoxic chemotherapy or BCR signalling inhibitor in ATM 
or TP53 defective primary CLL cells co-cultured with CD40L/IL-21 
 
 


















(mean ± SEM) 
Synergism 
Chlorambucil 
4 1 0.37 0.30 ± 0.05 ++++ 0.27 0.47 ± 0.20 +++ 
16 1 0.45 0.34 ± 0.04 +++ 0.35 0.38 ± 0.17 +++ 
16 3 0.50 0.78 ± 0.29 ++ 0.59 0.34 ± 0.08 +++ 
Fludarabine 
1 1 0.22 0.83 ± 0.29 ++ 0.18 0.81 ± 0.24 ++ 
4 1 0.29 0.77 ± 0.27 ++ 0.27 0.56 ± 0.16 +++ 
16 1 0.44 0.71 ± 0.21 ++ 0.49 0.37 ± 0.05 +++ 
4-hydroperoxy-
cyclophosphamide 
1 1 0.39 0.32 ± 0.11 +++ 0.29 0.36 ± 0.11 +++ 
4 1 0.49 0.33 ± 0.10 +++ 0.40 0.34 ± 0.13 +++ 
4 3 0.60 0.12 ± 0.02 ++++ 0.71 0.22 ± 0.07 ++++ 
Ibrutinib 
1 1 0.37 0.36 ± 0.00 +++ 0.20 0.84 ± 0.27 ++ 
4 1 0.47 0.46 ± 0.04 +++ 0.27 0.83 ± 0.20 ++ 
16 1 0.60 1.00 ± 0.13 ± 0.44 1.05 ± 0.17 ± 
 
All abbreviations are explained in Table 4.2.  
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shown in Figure 4.21, Figure 4.22 and Table 4.4. I addressed mechanisms behind the 
AZD6738-ibrutinib interaction. At higher doses, I postulated that this could be due to the off-
target effects of ibrutinib on the ATR pathway, and, vice versa, to the off-target effects of 
AZD6738 on BCR signalling. I therefore assessed the impact of ibrutinib on Chk1 
phosphorylation and the impact of AZD6738 on Erk and Syk phosphorylation in primary CLL 
cells. I found a dose-dependent reduction in HU-induced Chk1 phosphorylation with ibrutinib 
(Figure 4.23A), as well as a modest dose-dependent reduction in Erk and Syk 
phosphorylation with AZD6738 (Figure 4.23B). The former is supported by documented 
data showing 24% inhibition of Chk1 kinase activity with 0.1 µM ibrutinib (Medical Research 
Council International Centre for Kinase Profiling; Kinase Profiling Inhibitor Database 
http://www.kinase-screen.mrc.ac.uk/screening-compounds/349403). These findings are 
consistent with the above hypothesis, suggesting that the off-target effects of AZD6738 and 
ibrutinib may account for the potentiating effect at higher dose combinations involving 4 μM 
or 16 μM ibrutinib.  
I also assessed whether distinct CLL populations were targeted by AZD6738 and 
ibrutinib respectively. I induced CFSE-labelled primary CLL cells to proliferate and treated 
them with AZD6738 or ibrutinib for 4 days prior to flow cytometric analysis. Viable (PI 
negative) CLL cells were gated and analysed for their CFSE content. I found that AZD6738 
targeted primarily cycling CLL cells for killing, indicated by a dose-dependent reduction in 
the cycling population as a percentage of the remaining viable cells. Ibrutinib, on the other 
hand, targeted both the cycling and non-cycling populations as evidenced by minimal dose-
dependent change in the composition of the viable population (Figure 4.24). Thus, the 
potentiating interaction between AZD6738 and ibrutinib at lower dose combinations involving 
1 μM ibrutinib could possibly be accounted for by the limited overlap in the cellular 
populations targeted by these two agents.    
Finally, the AZD6738-chlorambucil combination was assessed in a patient-derived 
CLL murine xenotransplantation model with del(11q) and ATM mutation p.I407T (CLL25). In 
























The additive to synergistic interaction between AZD6738 and ibrutinib at higher dose 
combinations may be attributable to the off-target effect of ibrutinib on the ATR 
pathway and to the off-target effect of AZD6738 on BCR signalling. (A) Primary CLL 
cells were pre-treated with escalating doses of ibrutinib for 1 hour before exposure to HU, 
and incubated for a further 5 hours prior to cell lysis and analysis using Western blotting. At 
ibrutinib doses >3 μM, there was a dose-dependent reduction in HU-induced Chk1 
phosphorylation with ibrutinib. Cyclin A expression is a marker of proliferating cells. (B) 
Primary CLL cells were treated with escalating doses of AZD6738 for 5 hours prior to cell 
lysis. A small, dose-dependent reduction in Erk and Syk phosphorylation was seen with 
AZD6738. EGF; epidermal growth factor.  
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AZD6738 targets specifically cycling CLL cells while ibrutinib targets both cycling and non-cycling populations. CFSE-labelled primary 
CLL cells were induced to proliferate and treated with AZD6738 or ibrutinib for 96 hours prior to flow cytometric analysis. Viable (PI negative) 
cells were gated and analysed for their CFSE content. Results from a representative sample (CLL36) are displayed. On the flow cytometric 
plots, cells to the left of the dotted line represent the cycling population whereas those to the right were non-cycling. Relative ratios of cycling 
and non-cycling cells are provided at the bottom of the flow cytometric plots and summarized in stacked column graphs. AZD6738 targeted 
cycling CLL cells for killing, indicated by a dose-dependent reduction in the cycling population as a percentage of the remaining viable cells. 
Ibrutinib targeted both the cycling and non-cycling populations as evidenced by minimal dose-dependent change in the composition of the 
viable population. SSC, side scatter.  
AZD6738 (μM) 
Ibrutinib (μM) 
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experiments carried out by Dr Nicholas Davies, twenty engrafted mice were randomised into 
4 treatment arms: AZD6738, chlorambucil, the AZD6738-chlorambucil combination or 
vehicle (n=5 in each arm). AZD6738 monotherapy resulted in significant reduction in tumour 
load. Moreover, combination treatment yielded significantly greater reductions in tumour load 
than chlorambucil monotherapy (Figure 4.25). Collectively, these results support the 
combined use of ATR inhibitor with a range of existing therapeutic agents for CLL. 
 
  










ATR inhibition potentiates chlorambucil in ATM-defective primary CLL xenograft 
models. A primary CLL xenograft (CLL25) with a biallelic ATM defect (del(11q) and 1407I>T 
ATM mutation) was randomised into four treatment arms (n=5 each): AZD6738, 
chlorambucil, AZD6738-chlorambucil co-treatment and vehicle. AZD6738 treatment alone or 
in combination with chlorambucil significantly reduced tumour load relative to vehicle, and 
the addition of AZD6738 to chlorambucil led to a significantly greater reduction in tumour 
load relative to chlorambucil monotherapy. The relative number of CLL cells in (B) was 
normalised to vehicle-treated controls. Data is displayed as mean ± SEM. Statistical 
significance was determined using two-way ANOVA with Bonferroni post-hoc analysis, and 
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4.2. Discussion 
 
4.2.1. Cytotoxic mechanism underpinning ATR inhibition in CLL  
As discussed earlier, cellular DDR is regulated by several pathways, involving 
proteins such as ATM, ATR and DNA-PK. Tumorigenesis is associated with a pervasive 
corruption of one or more of these pathways, often through mutation or deletion of key DNA 
repair or regulatory proteins, conferring on malignant cells a survival advantage, avoidance 
of apoptosis and chemoresistance (Jackson and Bartek, 2009). However, the subversion of 
normal DDR mechanisms can render tumour cells susceptible to further DNA insults, the 
accumulation of which may become incompatible with survival and results in mitotic 
catastrophe (Castedo et al., 2004; Vitale et al., 2011). Moreover, the disruption of a DNA 
repair pathway constrains tumour cells to rely on collateral repair pathways to maintain 
genome stability, thereby exposing them to a vulnerability that can be amenable to 
therapeutic targeting (O'Connor, 2015). 
In this study, I produced experimental data demonstrating the pre-clinical efficacy of 
ATR inhibition in CLL with TP53 or ATM defects. While a number of novel agents exhibit 
considerable activity against TP53 defective CLL, ATR inhibition is unique in its ability to 
provide specific targeting of TP53 defective and ATM defective CLL cells. Results detailed in 
the preceding section provide insight into the cytotoxic mechanism underpinning ATR 
inhibition in CLL, which is consistent with our current understanding of the role of ATR in 
resolving replication stress (Figure 4.26A; section 1.4.2). When ATR function is abolished, 
stalled replication forks with persistent ssDNA are susceptible to fork breakage and collapse 
resulting in the accumulation of partially replicated DNA fragments with double-stranded 
ends that have become disengaged from the replication template (Figure 4.26B). These 
DNA fragments require ATM-mediated HRR for repair and re-engagement with the
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Figure 7. A model for synthetic lethality in CLL cells with ATM or p53 deficiency by inhibition of ATR. ATM and ATR are master regulators of 
DDR, with ATM being activated in response to DNA double-strand breaks, and ATR in response to replication stress. (A) Activation of the ATR 
pathway leads to cell cycle arrest mediated primarily through the G2/M checkpoint, and repair of stalled replication forks. This leads to the resolution 
of replication stress. (B-C) Inhibition of ATR by AZD6738 directly induces replication stress by slowing and stalling replication forks. The inability of 
CLL cells to resolve stalled forks as a result of suppressed ATR signalling leads to collapse of stalled replication forks into fragmented, partially-
replicated sister chromatids with free DNA double-stranded ends (DSEs) that necessitate repair through the ATM/p53 pathway. This involves cell 
cycle arrest mediated primarily through the G1/S checkpoint and HRR. (D) In cells with defective ATM or p53, inhibition of ATR by AZD6738 results in 
an intolerable accumulation of unrepaired DNA damage. This arises from impaired HRR due to defective ATM and/or impaired cell cycle regulation 
resulting from combined loss of functional ATR and ATM/p53.  
253               
replication template. Additionally, because the G2/M checkpoint is lost as a consequence of 
ATR inhibition, functional p53 and ATM becomes required for G1/S cell cycle arrest to permit 
HRR-directed repair of collapsed forks (Figure 4.26C). In the absence of functional ATM, 
NHEJ mediated by DNA-PK can ligate the double-stranded ends of two DNA fragments. 
However, unlike HRR which is a high fidelity repair process, NHEJ is a low fidelity and error-
prone repair mechanism. Therefore, in ATM defective CLL cells, NHEJ repair of collapsed 
forks occur at the expense of potential sequence deletions and aberrant chromosomal 
translocations that may arise during the repair process. Hence, CLL cells with defective p53 
or ATM accumulate collapsed forks and damaged DNA, manifested by an accumulation of 
DNA proteins γH2AX and 53BP1 which appear as foci. The loss of both the G1/S and G2/M 
cell cycle checkpoints in turn permits subsequent unrestricted entry into mitosis, resulting in 
mitotic catastrophe (Figure 4.26D).   
This mechanistic model accounts for the selective cytotoxicity of ATR inhibition for 
CLL cells with TP53 or ATM defects. It is noteworthy to highlight the mechanistic difference 
between ATR inhibitor therapy and conventional chemotherapy. Both therapeutic modalities 
exert their cytotoxic effect through the induction of DNA damage, but ATR inhibition 
additionally inhibit the repair and regulatory processes that TP53 and ATM defective cells 
are exceptionally dependent on, thus rendering these cells exquisitely sensitive to DNA 
damage. 
 
4.2.2. Impact of ATR inhibition on proliferating vs quiescent CLL cells 
Importantly, experimental results from this study show that ATR inhibition is capable 
of circumventing the protective effect of the microenvironment, which often hinders effective 
clearance of genomically unstable, proliferating CLL populations. This is evidenced by the 
ability of AZD6738 to overcome the pro-survival signals provided by the CD40L/IL-21 co-
culture system that mimics interaction of CLL cells with T cells in proliferation centres 
254     
(Figure 4.8), and, in xenograft experiments, by the loss of tumour burden in murine spleens 
upon treatment with AZD6738 (Figure 4.10).  
It is also important to note that ATR inhibition targets specifically the proliferating 
CLL population (Figure 4.8; Figure 4.9). At any one time only a fraction of CLL cells are 
proliferating in vivo. However, aggressive CLL associated with relapsed/refractory disease, 
for which the use of ATR inhibition is the most appropriate, are typically associated with 
higher proliferation rates. For instance, in relapsed/refractory cases up to 68% of CLL cells 
were found to be newly synthesised over an 84 day period within in vivo isotope labelling 
studies, equivalent to a proliferation rate of 1.76% per day (Messmer et al., 2005). Isotope 
labelling studies also showed that cell proliferation is ongoing in cells recently released into 
the circulation and as such they are also susceptible to ATR inhibition (Calissano et al., 
2009). Furthermore, although only a proportion of CLL cells are proliferating at any given 
time, it is the proliferating CLL population that is the most genomically unstable, because 
new genomic changes arise during DNA replication. Expansion of novel, deleterious variants 
could result in clonal evolution. This argues for the need to target specifically the proliferating 
population, particularly given that this population is protected by the pro-survival 
microenvironmental signals as mentioned above. Finally, as studies with BCR signalling 
inhibitors have demonstrated, CLL cells that are driven out of proliferating centres contribute 
to a redistribution lymphocytosis of quiescent cells that is of no major clinical significance 
(Woyach et al., 2014b). CLL cells in peripheral circulation that re-enter the proliferative 
compartment would again be targetable by ATR inhibition. 
 
4.2.3. Markers of sensitivity to ATR inhibitor in CLL 
Interestingly, whereas TP53 or ATM defective primary CLL PBMCs were uniformly 
and substantially more sensitive to ATR inhibition than healthy donor PBMCs, TP53/ATM-
255     
wild-type primary CLL cells displayed variable sensitivity towards ATR inhibition (Figure 
4.8). There are several potential explanations for this finding.  
 Firstly, the acquisition of alternative DDR defects that were unknown or not 
specifically characterised in this study could render some CLL patients sensitive to ATR 
inhibition even in the absence of defective TP53 or ATM. For instance, cyclin E promotes 
G1/S cell cycle progression and hence contributes to a heighted level of cellular replication 
stress. Cyclin E is expressed at a higher level in CLL cells, particularly the ZAP-70 positive 
ones, compared to non-malignant B lymphocytes (Bogner et al., 2006; Decker et al., 2004). 
Its overexpression has been reported to exacerbate the effects of ATR inhibition (Toledo et 
al., 2011).  
In addition, several studies have demonstrated synthetic lethality between ATR 
inhibition and other DDR defects. ATR inhibition was lethal in ovarian cancer cell lines with 
Breast cancer type 1 susceptibility protein (BRCA) or Rad51 deficiency, both of which are 
essential HRR proteins (Krajewska et al., 2015; Middleton et al., 2015; Yazinski et al., 2017). 
Deficiency in the DNA repair proteins XRCC1, ERCC1, POLD1, PRIM1 and the nucleosome 
remodelling protein AT-rich interaction domain 1A (ARID1A) has also been shown to 
enhance sensitivity to ATR inhibition (Hocke et al., 2016; Mohni et al., 2014; Sultana et al., 
2013). XRCC1 is a protein involved in base excision repair and the single strand break 
repair pathway, whereas ERCC1 mediates the repair of several types of DNA lesions 
including bulky adducts, DSBs and inter-strand crosslinks, and facilitates the separation of 
sister chromatids during anaphase. POLD1 and PRIM1, on the other hand, are involved in 
DNA replication synthesis. Finally, ARID1A deficiency leads to disrupted topoisomerase 
localisation and cell cycle progression, thus imposing on cancer cells a dependence on the 
ATR signalling pathway (Williamson et al., 2016). Recurrent mutations in ARID1A have been 
reported in CLL, and loss of function mutations may lead to ARID1A deficiency (Puente et 
al., 2015). Although not recognised as CLL genomic drivers, mutations of all other 
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aforementioned genes have been reported in individual CLL cases (Landau et al., 2015; 
Puente et al., 2015).  
Secondly, the variability in sensitivity to ATR inhibition could be due to different 
amounts of endogenous DNA damage in each sample, reflecting varying degrees of 
genomic instability. For instance, Myc, a major driver of replication stress (Cottini et al., 
2015; Murga et al., 2011), is variably expressed in CLL, and higher levels correlate with 
progressive disease (Zhang et al., 2010). ATR inhibition may therefore potentially be most 
useful in heavily pre-treated relapsed/refractory patients, where higher levels of genomic 
instability could be due, in part, to enhanced replication stress. It remains to be established 
whether replication stress is associated with karyotypic and genomic complexity, as well as 
the emergence of subclonal driver mutations and clonal evolution in CLL.  
Finally, Flynn et al has recently reported on the hypersensitivity to ATR inhibition of 
cancer cells that are reliant on a mechanism of telomere maintenance known as alternative 
lengthening of telomeres (ALT), whereby telomeres are elongated through recombination 
(Flynn et al., 2015). The absence of ATR leads to abrogation of ALT, compromising 
telomere stability in ALT-dependent cancer cells. This results in DNA damage, telomere loss 
as well as selective lethality of these cells. Alternative lengthening of telomeres has been 
reported in CLL cells (Damle et al., 2005), and could possibly provide an additional 
mechanism accounting for their sensitivity to ATR inhibition.  
Further work is required to explore these hypotheses and identify markers of 
sensitivity to ATR inhibition in CLL other than TP53 or ATM defects. With respect to TP53 or 
ATM defects, the specificity of ATR inhibition for these lesions could allow alteration of the 
subclonal landscape in favour of less genomically unstable DDR-proficient subclones, which 
are less susceptible to clonal evolution, thus reducing the likelihood of therapeutic resistance 
or disease relapse. The specificity of ATR inhibition for TP53-defective CLL cells may 
possibly also reduce the likelihood of Richter’s transformation, since TP53 defects, 
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alongside Myc and CDKN2A abnormalities, as well as NOTCH mutations and trisomy 12, 
have been implicated in this process (Chigrinova et al., 2013; Fabbri et al., 2013; Rossi et 
al., 2011). 
 
4.2.4. Potential toxicity and tolerability of ATR inhibition 
Although the in vivo toxicity profile and long-term effects of AZD6738 remain to be 
established in a clinical setting, it is important to note the lack of detrimental effect on normal 
tissues reported in mice subjected to ATR suppression to 10% of its normal levels (Schoppy 
et al., 2012). Corroborating this report, the AZD6738 dose used in the current study to 
achieve effective tumour load reduction in TP53/ATM-defective xenografts was well 
tolerated. Indeed, considerable cytotoxic activity was observed in TP53/ATM-defective CLL 
cell lines and primary cells at AZD6738 doses below 3 μM which produce only partial 
inhibition of HU-induced Chk1 phosphorylation (Figure 4.2; Figure 4.3; Figure 4.4), 
suggesting that complete abolition of ATR activity may not necessarily be required to 
achieve therapeutic efficacy. In addition, the discrepancy between sensitivity of TP53/ATM-
defective CLL cells and healthy donor PBMCs to AZD6738 argues for the existence of a 
substantial therapeutic window making it suitable for clinical use (Figure 4.8).  
Nevertheless, the long-term effects and toxicity of ATR and Chk1 inhibition are 
unknown. Targeting a process of such importance to genome integrity can be potentially 
dangerous, if it also affects healthy cells. Moreover, sublethal targeting of tumour cells with 
ATR inhibitors can inadvertently promote tumorigenesis and clonal evolution, as these cells 
accumulate replication stress and DNA damage, but escape death (Gilad et al., 2010). It is 
therefore of paramount importance that patients are selected for ATR inhibitor treatment 
according to their CLL characteristics: whether they possess features that make them 
differentially sensitive to ATR inhibition. By selecting patients whose CLL is hypersensitive to 
these inhibitors, CLL killing can be maximised while minimising treatment duration, thereby 
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reducing both toxicity to healthy tissues and the risk of CLL evolution and therapeutic 
resistance. The experimental data from my work support the use of ATR inhibition 
specifically in CLL patients with TP53 or ATM defects, where there is distinct reliance on 
ATR and sensitivity to ATR inhibition.  
In the ongoing clinical trial of AZD6738 for relapsed/refractory solid tumours 
(PATRIOT; NCT02223923), the ATR inhibitor is given daily for an indefinite period, unless 
disease progression or toxicity occurs (Prof. Kevin Harrington, Institute of Cancer Research, 
London, personal communication). In the case of CLL, however, given its primary clinical 
utility will be for the treatment of patients with aggressive, relapsed/refractory disease with 
relatively high proliferation rates, and taking into account its potent cytotoxic effect on 
proliferating CLL cells with TP53 or ATM defects, it is anticipated that prolonged treatment 
may not be necessary for the majority of patients with TP53/ATM-defective CLL. Daily 
administration of AZD6738 until the attainment of a maximum response can be envisaged, 
which could potentially be profound and achievable over weeks to months. This is especially 
the case if AZD6738 is used in combination with chemotherapy or other targeted therapies, 
as discussed below.   
 
4.2.5. Combination of ATR inhibitor with chemotherapy and ibrutinib 
Inhibitors of ATR such as AZD6738 could potentially augment current therapies for 
TP53 or ATM defective CLL. This is likely to be due to potentiation by chemotherapeutic 
agents of AZD6738-induced replication stress to which TP53 or ATM defective cells are 
distinctively susceptible (Figure 4.18; Figure 4.21). Combination of ATR inhibitor with 
cytotoxic chemotherapy could provide a realistic salvage option for TP53 or ATM defective 
patients relapsing from BCR signalling inhibitors. The synergism of AZD6738 with 
chlorambucil and bendamustine (Figure 4.19; Figure 4.22; Table 4.2; Table 4.4) is 
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particularly attractive given their milder toxicity profiles, making these combinations 
potentially suitable for older or frailer CLL patients. 
As expected, TP53/ATM wild-type CLL cells were substantially more sensitive to 
chemotherapeutic agents (chlorambucil, fludarabine, 4HC and bendamustine) compared to 
TP53/ATM defective CLL cells (Figure 4.18; Figure 4.20). Of note, similar to TP53/ATM 
defective cells, AZD6738 was highly synergistic with chemotherapeutic agents in TP53/ATM 
wild-type CLL cells, with the exception of fludarabine, where an additive effect was seen 
(Figure 4.20; Table 4.3). As with their DDR defective counterparts, the synergistic 
interaction between AZD6738 and chemotherapy in TP53/ATM wild-type cells may be due to 
the potentiation of AZD6738 induced replication stress by chemotherapeutic agents. In the 
presence of high levels of replication stress and DNA damage following combined treatment, 
the likely sequelae in these cells would be the induction of p53-mediated apoptosis rather 
than cell cycle arrest. All in all, the addition of AZD6738 renders ATM/p53 proficient and 
deficient cells equally sensitive to chemotherapeutic agents, as reflected by a similar fraction 
of cells affected (<10% difference among CII-GFPsh, CII-ATMsh and Mec1 cells) at the 
higher dose combinations (Figure 4.18; Figure 4.20).  
Unexpectedly, I found, depending on the dose, additivity or synergism between 
AZD6738 and ibrutinib in TP53/ATM defective primary CLL cells (Figure 4.22; Table 4.4). 
The underlying mechanism of the potentiating interaction at higher dose combinations may 
involve off-target effects of AZD6738 and ibrutinib (Figure 4.23). At clinically relevant doses 
(with ≤ 1 μM ibrutinib), however, this is likely to be accounted for by the limited overlap in the 
cellular populations that are targeted by these two compounds (Figure 4.24). Should 
AZD6738 be used in combination with BCR signalling inhibitors, consideration needs to be 
given to the sequence of treatment, since signalling inhibitors, which evict CLL cells from 
proliferation centres, may render them quiescent and no longer sensitive to ATR inhibition 
(Byrd et al., 2013). Combination with chemotherapy or other targeted therapies would allow 
simultaneous targeting of both the proliferating and non-proliferating populations, and both 
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DDR proficient and deficient subclones. When combined with ibrutinib, AZD6738 should be 
initiated first, with ibrutinib added subsequently and dual therapy continued until maximum 
response is attained.   
 
4.2.6. Potential mechanisms of resistance to ATR inhibition 
A fundamental assumption underpinning models of synthetic lethality is that there 
are only two major pathways regulating a specific process. Therefore, if one pathway is 
defective, cellular demise is assured when the other pathway is blocked. However, this 
notion is inevitably an over-simplification of the myriad of collateral pathways regulating a 
cellular process, many of which are hitherto under-appreciated or unknown. When one 
collateral pathway is therapeutically inhibited, tumour cells may upregulate an alternative 
collateral pathway to mitigate the effects of the initial block, thereby resulting in therapeutic 
resistance.  
As discussed previously, there have been reports pointing to a possible functional 
redundancy between ATR and DNA-PK in regulating downstream Chk1 activity (Lin et al., 
2014). More recently, Buisson et al demonstrated the existence of a DNA-PK-Chk1 backup 
pathway that can mediate resistance to ATR inhibitors. In this model, ATR inhibition is 
cytotoxic to a proportion of tumour cells with the highest levels of replication stress, but 
those with moderate levels are protected through the backup pathway (Buisson et al., 2015). 
Although DNA-PK inhibition did not appear to have substantial impact on HU-induced Chk1 
phosphorylation in CLL, such a DNA-PK-Chk1 backup pathway could still potentially mediate 
therapeutic resistance in vivo. Simultaneous targeting of ATR and Chk1 or DNA-PK could 
possibly overcome this. Indeed, a potentiating interaction between ATR and Chk1 inhibitors 
has been reported, suggesting that the combined use of these inhibitors could be more 
efficacious than either agent alone (Sanjiv et al., 2016). However, the potential toxicities and 
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adverse effects of any combined use of ATR and Chk1 inhibitors will need to be properly 
assessed.  
Finally, both ATR and Chk1 inhibitors are kinase inhibitors. As observed from the 
small molecule kinase inhibitors currently in clinical use, point mutations in the target kinase 
can develop. This constitutes another potential source of therapeutic resistance that 
physicians and investigators will need to anticipate and overcome.  
 
4.2.7. Clinical applicability of ATR inhibitors 
In addition to CLL, TP53 and ATM defects are poor prognostic markers in other 
haematological malignancies including mantle cell lymphoma (Schaffner et al., 2000), T-
prolymphocytic leukaemia (Stilgenbauer et al., 1997; Stoppa-Lyonnet et al., 1998), acute 
myeloid leukaemia (Rucker et al., 2012; Seifert et al., 2009), myelodysplastic syndrome 
(Jadersten et al., 2011), multiple myeloma (Chng et al., 2007; Drach et al., 1998) and diffuse 
large B-cell lymphoma (Xu-Monette et al., 2012). The current work on CLL provides a model 
of how ATR inhibition could selectively target TP53 or ATM defective cells, and its use in 
these malignancies could be explored in future studies.  
The ATR kinase inhibitors AZD6738, as well as VX-970, have now entered Phase 
I/II clinical testing. However, most of these studies have been initiated recently, and no 
results have yet been reported. As of March 2017, 11 clinical trials on ATR inhibitors are 
ongoing for a range of solid tumours. These studies examine the use of the ATR inhibitor 
either alone or in combination with a range of conventional and novel therapeutic agents, 
including cisplatin, carboplatin, gemcitabine, etoposide, irinotecan, the PARP inhibitors 
olaparib and veliparib, and the anti-PD-L1 immune checkpoint inhibitor durvalumab. No 
clinical study of ATR inhibition has yet been initiated in haematological malignancies. 
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However, the pre-clinical data presented herein provides a basis for such investigations in 
refractory TP53/ATM defective CLL. 
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With the advent of chemoimmunotherapy and other novel therapeutic approaches, 
it has been possible, over the past two decades, to achieve MRD eradication in CLL to 
below 10-4. As detailed in section 1.5, clinical trials that have incorporated MRD 
assessments have shown consistent correlation between post-treatment MRD level and 
therapeutic outcome (Abrisqueta et al., 2013; Bosch et al., 2008; Bottcher et al., 2012; 
Dreger et al., 2010; Fischer et al., 2012; Goede et al., 2014; Moreno et al., 2006; Moreton et 
al., 2005; Pettitt et al., 2012; Santacruz et al., 2014; Strati et al., 2014), with MRD status 
demonstrating independent prognostic significance in patients treated upfront with 
chemoimmunotherapy (Bottcher et al., 2012; Santacruz et al., 2014; Strati et al., 2014).. 
However, the independent prognostic relevance and long-term benefit of MRD negativity in 
other therapeutic settings and patient populations, such as with chemotherapy-free 
treatments and among relapsed/refractory patients, remain unclear. Moreover, a direct 
comparison of the clinical impact of MRD negativity between frontline and 
relapsed/refractory settings has not hitherto been undertaken.  
For the past 20 years, MRD evaluation by flow cytometry has been an integral part 
of the response assessment for multiple UK CLL clinical trials led by Prof. Peter Hillmen. 
This resulted in the availability of patients at different disease stages and with different 
biological features, who have received various treatments. The MRD status of each 
individual following the end of treatment is known. Moreover, given that the clinical trials 
were initiated many years ago, the majority of these patients have extended follow-up. I 
therefore undertook a retrospective analysis of this historical cohort which addresses the 
long-term independent prognostic value of MRD status across different therapeutic settings 
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5.1. Results 
 
5.1.1. Study criteria and cohort demographics  
I retrospectively analysed all patients who completed treatment for CLL at St 
James’s University Hospital in Leeds or associated regional hospitals in West and North 
Yorkshire during 1996 to 2007, achieved at least a partial response (PR), and received an 
MRD assessment from a bone marrow aspirate specimen taken within 6 months of 
treatment completion. These individuals were identified from computerised records at the 
HMDS laboratory in Leeds, where MRD analysis was undertaken. Patients who failed to 
respond or died before treatment completion were excluded, as were those who received 
allogeneic stem cell transplantation, because ongoing graft-versus-leukaemia effect can lead 
to continued depletion of residual disease. Also excluded were patients who subsequently 
received alemtuzumab for consolidation as part of the National Cancer Research Institute 
(NCRI) CLL207 trial, which prospectively evaluated the effect of MRD eradication in patients 
who remained MRD positive after chemotherapy (Varghese et al., 2017). For individuals who 
received multiple treatments, the first therapy completed between 1996 and 2007 was used 
for analysis.  
Altogether 536 patients were assessed at the HMDS laboratory during the study 
period, of whom 173 received treatment in Leeds and other associated hospitals in the 
region. MRD assessments were carried out using multiparameter flow cytometry according 
to the international harmonised approach (Rawstron et al., 2013; Rawstron et al., 2016; 
Rawstron et al., 2007). Specifically, MRD was assessed using CD19 and CD20, in 
combination with CD5, CD79b, CD81 and CD43. Earlier MRD assessments, performed 
before 2003, did not necessarily contain all the reported markers. Indeed, MRD assays 
carried out during that period typically contained only four markers: CD19, CD20, CD5 and 
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CD79b. However, data was included only if it was ascertained from the pre-treatment 
material that a limit of detection of ≤10-4 CLL cells could be achieved with the available 
markers. MRD negativity was defined as the absence of detectable CLL cells using a 
detection threshold of 10-4 CLL cells. 
Of these 173 patients, 23 were excluded due to a lack of CR/PR, 10 due to the 
assessment of blood rather than bone marrow MRD, 3 because of treatment with allogeneic 
stem cell transplantation and 4 as a result of subsequent enrolment into a consolidation trial 
(NCRI CLL207). Among the 133 who fulfilled the inclusion criteria, 67 received combination 
chemotherapy or chemoimmunotherapy, 31 received single-agent chemotherapy, 7 
underwent autologous stem cell transplantation, and 28 were treated with chemotherapy-
free regimens, mostly with monoclonal antibody therapy (Figure 5.1A). The median age of 
the cohort at the start of treatment was 62 (range, 38-83). One hundred and four patients 
(77%) were male. Fifty-seven (43%) received no previous CLL treatment, with the remainder 
having 1 to 7 prior therapies. The demographic details are summarised respectively in Table 
5.1. 
Clinical response assessments were made in accordance with the IWCLL response 
criteria. As explained in section 1.5.1, a CR requires the complete normalisation of blood 
counts and the complete disappearance of symptoms and signs associated with CLL. 
Patients with persistent cytopenias due to incomplete recovery of haematopoietic function 
following myelosuppressive treatments, but otherwise fulfil the criteria for a CR, were staged 
as CR with incomplete marrow recovery (CRi). On the other hand, those who otherwise fulfil 
the criteria for a CR, but have residual nodular aggregates in the bone marrow trephine 
composed of CLL cells as verified by immunohistochemistry, were staged as nodular PR 
(nPR). Patients not meeting the criteria for a CR, CRi or nPR, but achieved ≥50% reduction 
in lymphocytosis together with ≥50% regression of organomegaly, were considered as 
having had a PR. Lymphadenopathy and hepatosplenomegaly was evaluated in most cases





Treatment details (A) and IWCLL and MRD response (B) of patients enrolled in the 
current MRD study. In (B), the proportion patients with CR, CRi, nPR and PR who were 
also MRD-negative is displayed beneath the chart. A higher proportion of patients with 
CR/CRi were MRD-negative (66%) compared to patients with PR/nPR (14%).    
A   
B   
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(CLL > 1%) 




Age, years        
< 60 51 27 52.9% 14 27.5% 10 19.6% 
≥ 60 82 28 34.1% 21 25.6% 33 40.2% 
Sex        
Female 29 11 37.9% 7 24.1% 11 37.9% 
Male 104 44 42.3% 28 26.9% 32 30.8% 
Binet stage        
A/B 70 33 47.1% 24 34.3% 13 18.6% 
C 60 20 33.3% 10 16.7% 30 50.0% 
Lymphadenopathy        
None 34 19 55.9% 4 11.8% 11 32.4% 
Largest node < 5 cm 84 29 34.5% 29 34.5% 26 31.0% 
Largest node ≥ 5cm 8 3 37.5% 1 12.5% 4 50.0% 
Splenomegaly        
Absent 81 36 44.4% 21 25.9% 24 29.6% 
Present 52 19 36.5% 14 26.9% 19 36.5% 
Hepatomegaly        
Absent 128 53 41.4% 34 26.6% 41 32.0% 
Present 5 2 40.0% 1 20.0% 2 40.0% 
B-symptoms        
Absent 112 44 39.3% 28 25.0% 40 35.7% 
Present 21 11 52.4% 7 33.3% 3 14.3% 
White Cell Count        
< 30 x 10
9
/L 58 31 53.4% 13 22.4% 14 24.1% 
≥ 30 x 10
9
/L 72 22 30.6% 21 29.2% 29 40.3% 
Cytopenias        
Haemoglobin < 110 g/L 42 15 35.7% 10 23.8% 17 40.5% 
Haemoglobin ≥ 110 g/L 88 38 43.2% 24 27.3% 26 29.5% 
Platelet < 100 x 10
9
/L 44 14 31.8% 10 22.7% 20 45.5% 
Platelet ≥ 100 x 10
9
/L 86 39 45.3% 24 27.9% 23 26.7% 
Del(17p)        
Absent 84 36 42.9% 23 27.4% 26 30.1% 
Present 9 3 33.3% 4 44.4% 2 22.2% 
Del(11q)        
Absent 81 30 37.0% 24 29.6% 27 33.3% 
Present 15 6 40.0% 4 26.7% 5 33.3% 
Del(13q)        
Absent  45 20 44.4% 12 26.7% 13 28.9% 
Present 56 18 32.1% 17 30.4% 21 37.5% 
Trisomy 12        
Absent 87 36 41.4% 25 28.7% 26 29.9% 
Present 18 4 22.2% 6 33.3% 8 44.4% 
IGHV        
Mutated  26 18 69.2% 3 11.5% 5 19.2% 
Unmutated 15 5 33.3% 4 26.7% 6 40.0% 
Number of prior therapy       
0 57 24 42.1% 17 29.8% 16 28.1% 
1 27 11 40.7% 5 18.5% 11 40.7% 
2 24 12 50.0% 5 20.8% 7 29.2% 
3 18 8 44.4% 3 16.7% 7 38.9% 
≥ 4 7 2 28.6% 3 42.9% 2 28.6% 
Prior Fludarabine        
No prior fludarabine 84 29 34.5% 23 27.4% 32 38.1% 
Fludarabine responsive 30 17 56.7% 6 20.0% 7 23.3% 
Fludarabine refractory 19 9 47.4% 6 31.6% 4 21.1% 
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(78%) by CT imaging. Of the 133 patients in the cohort, 46 achieved a CR, 24 achieved a 
CRi, 27 achieved an nPR and 36 achieved a PR.  
Altogether 55 patients (41%) were MRD-negative post-treatment, including 46 with 
CR/CRi and 9 with PR/nPR (Figure 5.1B). A much greater proportion of patients with a CR 
or CRi were MRD-negative (67%) compared to those with a PR or nPR (16%). All patients 
with a MRD-negative PR had morphologically clear bone marrow but residual adenopathy. 
Among the 24 previously untreated individuals who attained MRD negativity following 
treatment, all received fludarabine-based combination therapy (FC: n=21 or FCR: n=1), with 
the exception of one individual who was treated with chlorambucil and one who received 
autologous stem cell transplantation. Of the 33 relapsed or refractory patients who became 
MRD negative, the majority received alemtuzumab (n=15) or fludarabine-based regimens 
(n=13). Of the 9 fludarabine-refractory patients who achieved MRD negativity, seven were 
treated with alemtuzumab and two with autologous stem cell transplantation. The proportion 
of patients achieving MRD negativity following each treatment type is shown in Table 5.2.       
 
5.1.2. MRD negativity predicts for long-term PFS and OS independent of 
the type and line of therapy  
To assess the impact of MRD status on clinical outcome, I performed Kaplan-Meier 
analysis, as well as univariate and multivariate statistical analyses, as described in section 
2.12.  Progression evaluations were made blinded to MRD status, and MRD status did not 
influence treatment duration, except for individuals receiving alemtuzumab who were treated 
until maximum IWCLL and MRD response was attained. For multivariate analyses, all 
prognostic variables that were routinely assessed and available for ≥70% of patients were 
included.
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(CLL < 0.01%) 
MRD-positive  
 (CLL 0.01-1%) 
MRD-positive  
(CLL > 1%) 
Number % Number % Number % 
Alemtuzumab 26 15 57.7% 8 30.8% 3 11.5% 
Autologous SCT 7 5 71.4% 0 0.0% 2 28.6% 
Chlorambucil 13 1 7.7% 2 15.4% 10 76.9% 
CHOP + Rituximab 2 1 50.0% 1 50.0% 0 0.0% 
Cyclophosphamide 1 0 0.0% 0 0.0% 1 100% 
FC 57 26 45.6% 17 29.8% 14 24.6% 
FCM 2 1 50.0% 0 0.0% 1 50.0% 
FCR 4 3 75.0% 1 25.0% 0 0.0% 
Fludarabine 17 2 11.8% 5 29.4% 10 58.8% 
Fludarabine + 
Alemtuzumab 
2 1 50.0% 1 50.0% 0 0.0% 
Methylprednisolone 1 0 0.0% 0 0.0% 1 100% 
Ofatumumab 1 0 0.0% 0 0.0% 1 100% 
 
SCT: stem cell transplantation; CHOP: cyclophosphamide, doxorubicin, vincristine and 
prednisolone; FC: fludarabine and cyclophosphamide; FCM: fludarabine, cyclophosphamide 
and mitoxantrone; FCR: fludarabine, cyclophosphamide and rituximab.   
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With a median follow-up of 10.1 years (range 7.8-18.6) among surviving patients, 
the median PFS in MRD-negative (<0.01%) individuals was 7.6 years, compared to 3.3 and 
2 years respectively in individuals with positive MRD at 0.01-1% and >1% (Figure 5.2A). 
The median OS was likewise prolonged in MRD-negative patients (10.6 years) compared to 
MRD-positive patients (5.3 and 3.6 years respectively for 0.01-1% and >1% MRD; Figure 
5.2B).  
When both IWCLL and MRD status were taken into account, the best PFS and OS 
outcomes were seen in patients with a CR/CRi who were MRD-negative (Figure 5.3). 
Among patients with a CR/CRi, there was a significant difference in both PFS and OS 
between the MRD-negative (n=46) and MRD-positive groups (n=24). Among the patients 
with a PR/nPR, there was a statistically significant difference in PFS between the MRD-
negative (n=9) and positive groups (n=54), but not in OS. On the other hand, there was no 
statistically significant difference between CR and PR populations with the same MRD status 
(i.e. between MRD-negative CR vs MRD-negative PR, and between MRD-positive CR vs 
MRD-positive PR).     
Patients with MRD-negative PR appeared to have outcomes intermediate between 
patients with MRD-negative CR and those with MRD-positive CR/PR (Figure 5.3). The nine 
patients with MRD-negative PR comprised six who were treated with chemotherapy-based 
combinations and two who were treated with single-agent alemtuzumab. These patients had 
residual disease in their lymph nodes and/or spleen, despite evidence of disease clearance 
from the bone marrow. This could potentially account for the inferior outcome, albeit not 
statistically significant, of the MRD-negative PR group relative to the MRD-negative CR 
group.   
Finally, I considered MRD response in a multivariate analysis together with 
established prognostic factors including age, Binet stage, cytopenias (haemoglobin <110 g/L 
and platelet <100 x 109/L), prior treatment and adverse cytogenetics, either del(17p) or





PFS (A) and OS (B) according to level of detectable disease at the end of treatment. 
Post-treatment MRD levels were obtained within 6 months following the end of treatment by 
multiparameter flow cytometry to a sensitivity of 10-4 (0.01%). A patient was considered 
MRD negative if the MRD level was below the level of detection (i.e. <0.01%). The log-rank 
p value is displayed, and p<0.05 is considered statistically significant. Presence of residual 
disease at the end of treatment predicts for long-term PFS and OS.    
A   
B   



















PFS (A) and OS (B) according to both the MRD and the IWCLL response status at the 
end of treatment. Among the patients with a CR, there was a statistically significant 
difference in both PFS and OS between the MRD-negative and MRD-positive groups. 
Among the patients with a PR, there was a statistically significant difference in PFS between 
the MRD-negative and MRD-positive groups, but not in OS. On the other hand, there was no 
statistically significant difference between CR and PR populations with the same MRD 
status. The PFS and OS curves for the MRD-negative PR group lie between that of the 
MRD-negative CR group and the MRD-positive CR/PR groups respectively.  
A   
B   
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del(11q), evaluated by metaphase FISH at the time of treatment, as well as treatment 
modality and IWCLL response. Only MRD response and adverse cytogenetics were 
significant for PFS, and only MRD response, age, stage and prior treatment were significant 
for OS on multivariate analysis (Table 5.3). IWCLL response was found not to be an 
independent predictor for either PFS or OS. IGHV mutational status, available in 41 patients 
(31%), was significant in univariate analysis for both PFS (p=0.016) and OS (p=0.014). 
However, due to the limited number of cases with IGHV data in this cohort, this parameter 
was not included in the multivariate analysis. 
 
5.1.3. MRD negativity confers the greatest prognostic benefit when 
achieved in the frontline setting  
Next, I analysed the treatment-naïve and previously treated patients separately, in 
order to compare the relative impact of MRD between frontline and relapsed/refractory 
settings. I found that patients receiving both frontline and subsequent treatments derived 
significant PFS and OS benefit from attaining MRD negativity (Figure 5.4). However, greater 
long-term benefit was seen when MRD negativity was achieved upfront, with 10-year PFS of 
65% vs 10% and 10-year OS of 70% vs 30% for MRD-negative vs positive patients. In 
comparison, in the relapsed/refractory setting, the 10-year PFS was 30% vs 0% and the 10-
year OS was 47% vs 11% for MRD-negative vs positive patients.  
The PFS curve for the 23 patients who achieved MRD negativity upfront appears to 
plateau at 7.7 years, beyond which no clinical relapse was observed among the 12 (52%) 
who remained in remission (Figure 5.4A). This is similar to the PFS plateau previously 
reported in the IGHV mutated MRD-negative patients from the MD Anderson Cancer Center 
fludarabine, cyclophosphamide and rituximab (FCR) trial (Thompson et al., 2016). However, 
in the present cohort, 1 out of 9 patients with known IGHV mutational status in remission 
beyond 7.7 years had unmutated IGHV. 
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Table 5.3.  Univariate and multivariate analysis of post-treatment MRD levels 























Age* (60 years) 0.513 
 
 0.001 0.001 
2.41 
(1.45-4.00) 





Platelet* (100 x 10
9
/L) 0.001 0.983  0.034 0.168  




Prior treatment (Y/N) 0.003 0.159  0.003 <0.001 
2.61 
(1.61-4.23) 
Treatment type <0.001 0.265  0.004 0.886  
IWCLL Response <0.001 0.545  0.001 0.585  
MRD level 
(< 0.01 / 0.01-0.1 / 
















* Age, haemoglobin and platelet count, Binet stage and cytogenetics were assessed at the 
time of treatment initiation.  
 
† Cytogenetic aberrations [del(17p) and/or del(11q)] were evaluated by metaphase 
fluorescence in-situ hybridization (FISH). 
  
CLL level at  
end of 






PFS (A) and OS (B) according to prior treatment and MRD status at the end of 
treatment.  Presence of residual disease at the end of treatment predicts for long-term PFS 
and OS independent of prior treatment. MRD-neg, MRD-negative; MRD-pos, MRD-positive.   
B   
A   
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5.1.4. Attainment of MRD negativity partially overcomes the adverse 
prognostic impact of del(17p) and del(11q)  
As mentioned in previous chapters, the adverse cytogenetic aberrations del(17p) 
and del(11q) are well-known prognostic factors in CLL. Furthermore, adverse cytogenetics, 
together with MRD status, are the two parameters found to possess independent prognostic 
significance for PFS in the present patient series. I therefore analysed PFS and OS 
according to both the presence of MRD and adverse cytogenetics (Figure 5.5). The best 
outcome was seen in MRD-negative patients without adverse cytogenetic features, whose 
median PFS was not reached and median OS was 10.1 years. In patients with del(17p) or 
del(11q), achievement of MRD negativity appeared to partially overcome the poor prognosis 
associated with their cytogenetic aberrations. Within this group of patients the median PFS 
and OS for MRD-negative vs MRD-positive subjects were significantly different: 4.9 vs 1.3 
years for PFS (Figure 5.5A) and 6.5 vs 2.7 years for OS (Figure 5.5B). This suggests that 
achieving MRD negativity may potentially be of value in this group of CLL patients with 
deletion of TP53 or ATM. 
 
  




PFS (A) and OS (B) according to del(17p) or del(11q) and the MRD status at the end of 
treatment. Cytogenetic aberrations were evaluated by FISH. The balance of patients with 
del(17p) and del(11q) respectively was comparable between the MRD-negative and MRD-
positive groups. In the MRD-negative del(17p/11q) group, 3/9 patients (33%) had del(17p) 
while 6/9 patients (67%) had del(11q). In the MRD-positive del(17p/11q) group, 6/15 patients 
(40%) had del(17p) while 9/15 patients (60%) had del(11q). Presence of residual disease at 
the end of treatment predicts for long-term PFS and OS independent of cytogenetics.  MRD-
neg, MRD-negative; MRD-pos, MRD-positive.   
A   
B   
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5.2. Discussion 
 
5.2.1. Clinical significance of the findings from this study 
As detailed in section 1.5.3.2, MRD has previously been shown to correlate with 
prognosis in a number of prospective clinical trials. However, the results I have generated 
from the current study provide several important additions to the existing literature on MRD 
as a prognostic variable in CLL.  
Firstly, the duration of follow-up in most of the published CLL MRD studies has 
been relatively short. For instance, the median follow-up duration was 4.3 years within the 
published MRD study on the German CLL group CLL8 cohort (Bottcher et al., 2012). It is 
thus unclear whether MRD remains prognostically relevant with extended follow-up. In this 
present cohort, subjects were followed for a median of 10.1 years among surviving patients, 
and up to a maximum of 18.6 years. This has allowed confirmation of the 10-year prognostic 
impact of MRD status in CLL. Importantly, my results shows that the PFS and OS curves of 
the MRD-negative and MRD-positive groups do not converge for up to 18 years after the 
end of treatment. 
Secondly, the independent prognostic importance of MRD in CLL has thus far been 
demonstrated only in patients treated upfront with chemotherapy-based combination 
therapeutic regimens. This is the first study to incorporate different treatment settings and 
therapeutic modalities into a single multivariable model to evaluate the clinical impact of 
post-treatment MRD status in CLL. Importantly, the results from this analysis confirm the 
independent predictive value of MRD not only in the frontline but also in the 
relapsed/refractory setting, and not only with chemoimmunotherapy but also with 
chemotherapy-free treatments (Table 5.3). Indeed, the median PFS of the MRD-negative 
and MRD-positive patients in this cohort treated with chemotherapy-free regimens was 
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significantly different at 4.9 and 1.3 years respectively (p=0.002). At present, MRD negativity 
is achieved predominantly through chemotherapy-containing regimens with considerable 
toxicity, such as FCR, thus precluding its use in frailer or older CLL patients, who are likely 
to be less tolerant to such therapies. Newer agents such as venetoclax can also produce 
MRD negativity in substantial proportions of CLL patients, including in individuals with 
del(17p) (Eichhorst et al., 2015; Ma et al., 2015). With the availability of new targeted 
therapies and therapeutic combinations for CLL, there will likely be a trend towards reduced 
reliance on chemotherapy, and therefore evidence to support the independent prognostic 
power of MRD status in the chemotherapy-free setting is of particular relevance. 
Finally, the current study provides a direct comparison of the relative value of 
achieving MRD negativity in the first and subsequent treatments. My results highlight the 
distinct PFS benefit of attaining MRD negativity in the upfront setting (Figure 5.4A). An 
explanation for the importance of achieving MRD negativity upfront could be that poor 
survival is associated with the development of a resistant genotype (e.g. TP53 mutation), 
which arises or is enriched within residual disease post-therapy. Indeed, the emergence and 
expansion of resistant subclones during and after treatment has been described in CLL 
patient series (Landau et al., 2015; Nadeu et al., 2016; Rossi et al., 2014) as well as in 
animal models (Davies et al., 2017). This is also the reason why the durability of remissions 
tends to decrease with each subsequent treatment, regardless of the therapeutic modality. 
In patients with profound remissions (i.e. MRD negativity) there will inevitably be a smaller 
pool of residual cells in which such resistance can occur.  My findings therefore underscore 
the importance of achieving the best possible response with first-line therapy. 
 
5.2.2. Limitations of this study and other considerations 
Due to the historical nature of the cohort in this study, IGHV mutational status was 
available only in a proportion of CLL patients. Therefore, in the multivariate analysis, IGHV 
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mutational status was not included. Likewise, due to data unavailability, other established 
prognostic variables, such as CD38 and ZAP-70 positivity, as well as putative prognostic 
markers such as NOTCH1 and SF3B1 mutational status, were not incorporated into the 
multivariate analysis. Moreover, some therapies used in the current cohort, such as 
chlorambucil, single-agent fludarabine and FC, were historical and are no longer CLL 
treatments of choice except in the palliative setting. However, the significance of this study 
lies in the demonstration that the clinical benefit of MRD negativity was independent of the 
type or line of therapy through which this was achieved.  
This study is also limited by its retrospective nature. One topic of particular interest 
in the area of CLL MRD assessment is whether MRD could be used as a surrogate marker 
for PFS, and therefore potentially replacing PFS as a primary endpoint in CLL clinical trials. 
Such an idea is attractive because the prolonged PFS with FCR-like therapy and novel 
agents such as venetoclax, especially in the frontline setting, means that clinical trials aiming 
to improve outcome are inevitably very prolonged and require a very large sample size to 
observe a significant PFS difference. This greatly restricts the development of novel drugs 
and drug combinations for patients with CLL. Therefore, using MRD as a clinical trial 
endpoint may accelerate clinical drug development in CLL.  
However, the results from this study do not provide a definitive proof of surrogacy of 
MRD for PFS and OS because of the retrospective nature of this study. Although MRD was 
demonstrated to be an independent predictor for both PFS and OS in this cohort, it is 
unlikely that this was the only factor that influences PFS and OS. Other factors such as prior 
treatment and adverse cytogenetics might also independently affect PFS and OS, as shown 
in the multivariate analysis. As highlighted in an editorial accompanying the published 
manuscript of this study, in order to use MRD as a surrogate for PFS and OS, it is incumbent 
on investigators to prospectively compare, within randomised clinical trials, the impact of 
each individual treatment on MRD, and whether the magnitude of effect on MRD 
corresponds to the magnitude of effect on PFS or OS (Little and McShane, 2016). As such, 
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the clinical importance of MRD with each treatment needs to be prospectively validated in 
the context of randomised clinical trials.  
In the current study, bone marrow rather than peripheral blood MRD was evaluated. 
While work is still ongoing internationally to determine the comparability between bone 
marrow and peripheral blood MRD assessments, previously published data shows that bone 
marrow is a more sensitive site for MRD detection than peripheral blood when assessed at 
three months after the end of treatment or earlier. This is particularly the case in patients 
treated with single-agent monoclonal antibodies such as rituximab or alemtuzumab, where 
clearance of peripheral blood CLL cells occurs earlier than the clearance of infiltrated bone 
marrow CLL cells. Therefore, there could be more than 10-fold discrepancy between 
residual disease levels in the bone marrow and peripheral blood while on treatment and 
early after treatment completion (Rawstron et al., 2007). For this reason, the standard 
practice at many institutions is to use bone marrow aspirate samples for MRD quantification 
at the time of response assessment, in line with recommendations from the IWCLL 2008 
guidelines (Hallek et al., 2008).  
Finally, it is of relevance to provide a discussion of MRD-negative PR. Recently, an 
analysis of the German CLL group CLL8 trial by both IWCLL and MRD response status 
shows that patients with MRD-negative PR had significantly superior PFS compared to both 
the MRD-positive CR and PR groups. On the other hand, compared to the MRD-negative 
CR group, MRD-negative PR patients with residual splenomegaly had equally good PFS, 
whereas patients MRD-negative PR with residual lymphadenopathy had inferior PFS 
(Kovacs et al., 2016). As explained in the results section of this chapter, patients with MRD-
negative PR in the current study had outcomes intermediate between patients with MRD-
negative CR and those with MRD-positive CR/PR (Figure 5.3), consistent with findings from 
the German CLL8 study.  However, the lack of statistically significant difference between the 
MRD-negative PR group in relation to the MRD-negative or the MRD-positive CR groups 
might be due to the small number of patients in the current study with MRD-negative PR 
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(n=9), and to the fact that more patients had residual splenomegaly than residual 
lymphadenopathy.  
 
5.2.3. MRD negativity as a therapeutic goal in CLL 
In this study, I demonstrated that long-term treatment-free remissions are 
associated with MRD negativity, particularly when MRD negativity is attained upfront. Hence, 
my findings support MRD as a prognostic marker for long-term PFS. However, whether 
MRD negativity should be a therapeutic goal in CLL remains a subject of intense debate.  
With the therapeutic options available at present, MRD negativity is an appropriate 
therapeutic goal for only a minority of CLL patients. Specifically, they are younger, physically 
fitter individuals who are more likely to tolerate an aggressive treatment approach involving 
combination chemoimmunotherapy, which is at present the only widely available treatment 
that can produce MRD negativity in substantial proportions of patients. As mentioned earlier, 
these treatments can be associated with significant toxicity, and are therefore unsuitable for 
many CLL patients who are at an advanced age, are frail or have multiple co-morbidities. It 
is therefore imperative that therapeutic approaches aiming at disease control or palliation 
are not dismissed in favour of MRD negativity. In CLL, new targeted therapies such as BCR 
signalling inhibitors have important clinical utility, despite the lack of deep remissions and 
MRD negativity. This is particularly the case for older and frailer patients, in the absence of 
other more efficacious and curative, but equally tolerable, treatments. Therefore, MRD 
evaluations should not be used to screen out novel therapies that do not yield MRD-negative 
responses. 
With regards to the clinical deployment of novel therapies, a number of factors 
needs to be taken into consideration, such as toxicity and tolerability, in addition to efficacy. 
In the context of an early-phase trial, MRD negativity might be an indication of efficacy, and 
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could support further clinical investigation of the treatment, as exemplified by the case of 
venetoclax in CLL (Eichhorst et al., 2015; Ma et al., 2015). Moreover, there are ongoing 
studies to examine the role of consolidation therapy aiming to convert patients with residual 
disease at the end of treatment to MRD negativity. Results from UK CLL207 study, which 
assessed alemtuzumab consolidation in patients with MRD after chemotherapy, showed that 
subjects who were MRD-negative after consolidation had improved survival outcomes that 
were comparable with those who were MRD-negative after initial chemotherapy (Varghese 
et al., 2017).   
At present, due to the limited number of well-tolerated treatments that can yield 
MRD negativity, MRD negativity is an appropriate therapeutic goal only for a subgroup of 
relatively young and fit CLL patients. However, MRD is clearly a powerful prognostic marker 
for long term clinical outcome, and its assessment can be incorporated into clinical trials. 
There is an ongoing effort by myself (Chapter 4) and others to develop new chemotherapy-
free treatments that may produce deep, MRD-negative remissions. In future, chemotherapy-
free combinations may potentially allow MRD eradication with minimal toxicity, making MRD 
negativity a feasible therapeutic goal, including for patients with adverse biological features 
such as del(17p) or TP53/ATM mutations.   
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6.1. Novel insights into the clinical heterogeneity of CLL 
 
 This thesis sets out to generate novel insights into the clinical heterogeneity and 
treatment of CLL through a series of investigations that focus on three distinct groups of CLL 
patients: (1) patients who have undergone spontaneous disease regression; (2) patients with 
poor-risk CLL carrying TP53 or ATM defects in need of novel therapies; and (3) patients who 
have achieved MRD negativity after treatment.  
 CLL is characterised by substantial clinical heterogeneity, and patients with CLL 
could have disparate clinical outcomes. While several biological processes have been found 
to influence disease heterogeneity in CLL, as outlined in section 1.2, and numerous 
prognostic biomarkers for disease progression and survival have been uncovered, there 
remains a knowledge gap in our understanding of the biological features of patients with 
spontaneous CLL regression and the potential mechanisms underpinning this process. 
Moreover, although MRD has been shown in multiple studies to have predictive value on the 
clinical outcome of patients after CLL treatment, it remains unclear whether MRD has 
independent prognostic value outside the frontline chemoimmunotherapy setting. It is also 
unclear whether MRD negativity confers long-term prognostic benefit.   
 Through analysis of 19 individuals with spontaneous CLL regression, both on 
residual circulating CLL cells, as well as on stored cells where available, I identified a range 
of novel features in this group of patients. CLL tumours that have undergone spontaneous 
disease regression express somatically mutated immunoglobulin genes, demonstrate short 
telomeres, and have a phenotype of B cell anergy with unresponsiveness to both IgM and 
IgD BCR stimulation. This phenotypic profile suggests a model in which the CLL clone 
undergoes an initial phase of proliferation which subsequently subside into a state of clonal 
anergy and low proliferation. In addition, other features such as reduced tumour expression 
287     
of CD49d and ROR1, and increased FasR expression, could potentially also contribute to 
spontaneous disease regression in CLL. Finally, through characterisation of the genomic 
landscape in these individuals, I found that in some cases spontaneous CLL regression 
occurred in the presence of known CLL genetic aberrations, including TP53 mutations.   
 In addition, through analysis of 133 patients with CLL who have received a bone 
marrow MRD assessment after treatment, I identified MRD, as evaluated by standardised 
multiparameter flow cytometry, as an independent predictor for long-term PFS and OS. 
Moreover, while the prognostic benefit of achieving MRD negativity was independent of the 
type and line of treatment, with patients receiving both frontline and subsequent treatments 
deriving benefit from MRD negativity, a greater PFS and OS benefit with MRD negativity 
was seen in patients receiving their first CLL treatment.  
 These findings provide novel insights into the biological properties and potential 
mechanisms underpinning spontaneous CLL regression, as well as the long-term 
independent prognostic role of MRD in CLL. These results have implications for the 
treatment of CLL, as highlighted in subsequent sections.  
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6.2. Novel insights into the treatment of CLL 
 
 The treatment of CLL has historically relied upon cytotoxic chemotherapy, which 
has limited efficacy when used as a single therapeutic agent and is associated with 
substantial toxicity and side effects. Subsequently monoclonal antibodies targeting CLL 
surface antigens have become widely available, and more recently, small molecule inhibitors 
of the BCR signalling pathway and Bcl-2 have revolutionised the treatment of CLL. However, 
despite these therapeutic advances, there remains a need to develop novel therapeutic 
approaches and therapeutic combinations for CLL, because effective treatment options 
remain limited for multiply relapsed CLL, particularly in patients with poor-risk features such 
as TP53 and ATM defects.  
 The unique phenotypic characteristics identified from the analysis of patients with 
spontaneous disease regression provide several insights into the treatment of CLL. Firstly, 
the finding that spontaneously regressed CLL tumours were unresponsive to BCR 
stimulation supports the use of BCR signalling inhibitors in CLL. Secondly, the findings from 
this study suggest that therapies that target ROR1, or those that upregulate FasR and 
downregulate CD49d and ROR1 expression in CLL cells may also have therapeutic 
potential.  
Despite the therapeutic success of BCR signalling inhibitors in CLL, patients with 
poor-risk CLL, particularly those with TP53 or ATM defects, can relapse from BCR signalling 
inhibitors. In addition, some may become intolerant to these agents. Only a proportion of 
patients with CLL relapsing from BCR signalling inhibitors respond to alternative kinase 
inhibitors, highlighting the need for novel therapeutic approaches (Jain et al., 2015; Mato et 
al., 2016). In the work presented in this thesis, I evaluated the pre-clinical efficacy and 
mechanism of ATR inhibition in CLL. Through the use of a novel and highly-specific ATR 
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inhibitor AZD6738, I demonstrated that ATR inhibition was selectively cytotoxic to CLL cells 
with TP53 or ATM defects arising from deletions and/or mutations of these genes. This was 
accomplished through the suppression of the ATR pathway that is essential for the 
resolution of replication stress in CLL cells with compromised ATM/p53 function, resulting in 
the accumulation of DNA damage and mitotic catastrophe in these cells. The specificity of 
ATR inhibition for TP53 and ATM defects allows selective targeting of genomically unstable 
DDR-defective CLL cells, therefore potentially helping to avert clonal evolution, a major 
cause of treatment refractoriness and disease relapse. Furthermore, ATR inhibitor was 
synergistic in combination with chemotherapeutic agents, and has a synergistic or additive 
effect in combination with the BCR signalling inhibitor ibrutinib.  
 The presence of residual disease provides a reservoir for eventual disease relapse, 
especially in DDR-defective CLL with high levels of genomic instability. In my study 
investigating the long-term impact of MRD on clinical outcome, I confirmed that the 
long-term survival benefit of achieving MRD negativity extends to poor-risk CLL patients with 
TP53 or ATM deletions. Indeed, my findings suggest that the attainment of MRD negativity 
partially overcomes the poor prognosis associated with these DDR defects. Therefore, 
therapies eliciting deep remissions may provide enhanced benefit for del(17p) or del(11q) 
CLL.  
At present, therapies capable of producing MRD negativity in TP53 defective CLL 
are lacking. As evidenced from several patients within my MRD study cohort, alemtuzumab 
can occasionally yield MRD-negative responses. However, alemtuzumab is no longer 
routinely available for the treatment of CLL. More recently, venetoclax has been shown to be 
capable of producing MRD-negative remissions in up to 17% of patients TP53 defective CLL 
(Eichhorst et al., 2015), which represents a small fraction of these patients. Given the potent 
cytotoxic effect of ATR inhibition against proliferating TP53 defective CLL cells as 
demonstrated in my pre-clinical study, and the relatively high proliferation rate associated 
with these CLL cells, particularly in the context of clinically aggressive, relapsed/refractory 
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disease (Messmer et al., 2005), it is anticipated that depth of response to ATR inhibitor could 
be profound. However, this will require confirmation within well-designed clinical trials. 
 In summary, the phenotypic features evident from the analysis of patients with 
spontaneous disease regression support the use of BCR signalling inhibitors for the 
treatment of CLL. The findings from this thesis also provide demonstration of the pre-clinical 
efficacy of ATR inhibition against TP53 or ATM defective CLL, and support the clinical 
evaluation of this therapeutic strategy.  
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6.3. A stratified approach for the treatment of CLL 
 
 The BCR signalling inhibitor ibrutinib is an example of a treatment that achieves 
disease control but not disease eradication. The direct cytotoxic effect of ibrutinib on CLL 
cells is modest at clinically achievable doses, as evidenced from the results of my drug 
combination experiments described section 4.1.4 and from other published studies (Herman 
et al., 2011). Moreover, detectable MRD remains in the vast majority of patients on ibrutinib 
monotherapy. Despite this, BCR signalling inhibitors have shown remarkable efficacy in CLL 
in improving clinical outcomes despite the lack of disease eradication. Moreover, the finding 
in this thesis of curtailed proliferation associated with clonal anergy in CLL cells from 
patients with spontaneous disease regression, including from three spontaneous regression 
cases with TP53 defects, lends further support for such a therapeutic approach. On the 
other hand, it is widely recognised that MRD eradication leads to improved clinical outcome, 
and this is further supported by results from my study on the impact of MRD on long-term 
outcomes. How can this apparent contradiction be reconciled? Should the treatment strategy 
in CLL be that of disease control or disease eradication? 
For many patients with CLL requiring treatment, a disease control approach could 
be sufficient to produce durable remissions. This is evidenced from studies that showed 
durable response (e.g. remissions > 3 years) in patients treated with ibrutinib, particularly 
among patients who were treated upfront and those without poor-risk features such as 
adverse cytogenetic aberrations and complex karyotype (Burger et al., 2015; Byrd et al., 
2015). In this regard, spontaneous regressing CLL tumours all possessed mutated IGHV 
and most had low genomic complexity. Although three of the spontaneous regression cases 
in my study harboured TP53 mutation, this may possibly be countered by features such as 
clonal anergy with unresponsiveness to both IgM and IgD BCR triggering, low CD49d and 
ROR1 expression, as well as high CD95/FasR expression that are uncommon in non-
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regressing TP53 mutant CLL. On the other hand, patients progressing on ibrutinib tend to be 
those with TP53 or ATM aberrations or genomic complexity (Burger et al., 2016; Maddocks 
et al., 2015; Woyach et al., 2014a).  
It is plausible, therefore, that this group of patients with relapsed/refractory disease 
who carry poor-risk features are the ones who are most likely to benefit from therapeutic 
approaches that are aimed at disease eradication rather than merely disease control. This is 
because, owing to their genomic instability, these tumours are prone to the acquisition of 
further genomic events that could lead to the development of resistance mechanisms (e.g. 
BTK or PLCγ2 mutations in the case of ibrutinib) and clonal evolution. The outgrowth of 
resistant CLL clones in turn leads to disease relapse. Although well-tolerated therapies that 
can produce MRD-negative remissions in this group of poor-risk patients remain severely 
limited at present, combination of different targeted treatment approaches are likely to be of 
promise, and the pre-clinical and clinical investigation of various combinations of small 
molecule inhibitors is likely to be an important future research focus.  
The progressive selection and accrual of resistant CLL subclones, which eventually 
become the dominant ones, is reflected in the observation that remission durations dwindle 
with increasing numbers of therapies given (Kutsch et al., 2014; Zenz et al., 2010b). This is 
perhaps the reason why some would advocate for empirical treatments against clonal 
targets (i.e. “trunk” lesions) rather than subclonal lesions (i.e. “branches”), as has been 
suggested in a recent review (Landau and Wu, 2013). However, one limitation with such an 
approach is it does not recognise that some subclones are inherently more genomically 
unstable and prone to the evolution of resistant mechanisms than others, the Darwinian 
selection of which may lead to the eventual emergence of a more aggressive disease. This 
could explain, for instance, why therapeutic resistance to ibrutinib remains more common in 
CLL patients with TP53 aberrations or genomic complexity, as highlighted above. This is 
also why it might be more appropriate to adopt a “trunk-plus-branch” approach, where, in 
addition to reducing tumour burden with generic agents that target “trunk” lesions, there is 
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active effort made to target the most aggressive or genomically unstable ”branches”, in order 
to reduce the likelihood of treatment failure or disease relapse. In this regard, therapeutic 
strategies such as ATR inhibition that specifically target TP53 or ATM defective CLL 
subclones are likely to be important in the treatment of patients with poor-risk CLL.  
For all the above reasons, it is of relevance to consider a stratified treatment 
approach for CLL. So far, prognostic stratification based on IGHV mutational status and 
genomic lesions have not translated into therapeutic stratification, with the exception of 
patients with del(17q) or TP53 mutations, who would be diverted away from 
chemotherapeutic agents to treatments that bypass p53-dependent apoptosis, such as BCR 
signalling inhibitors. With the development of novel therapies against different CLL lesions, 
such as γ-secretase inhibitors (NOTCH1) (Lopez-Guerra et al., 2015), spliceosome inhibitors 
(SF3B1) (Larrayoz et al., 2016), selective inhibitors of nuclear export (XPO1) (Lapalombella 
et al., 2012), PARP inhibitor (ATM) (Weston et al., 2010) and ATR inhibitor (ATM and TP53), 
it is likely that therapeutic stratification of CLL based on the biological properties of the CLL 
clone in individual patients would be achievable in the near future. Indeed, the forthcoming 
UK-wide phase III CLL trial (CLL11) currently being planned will involve the stratification of 
patients into different sub-trials based on the biological properties of their CLL determined at 
the time of trial entry by extended immunophenotyping and NGS.   
Finally, in the assessment of new therapeutic agents it will be important to delineate 
how the novel agent impacts upon subclonal composition. In vivo models that reflect 
subclonal heterogeneity and could recapitulate subclonal dynamics, such as the CLL 
xenograft models developed by our group and used in my ATR inhibitor study, are 
particularly useful for this purpose (Davies et al., 2017). Likewise, sequential assessment of 
the CLL subclonal composition may be a useful component within future clinical trials.  
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6.4. Unanswered questions and future work 
 
 The findings described in this thesis generate several interesting questions which 
provide several ideas for future work.  
 Firstly, my analysis of the spontaneous regression CLL cohort show that 
spontaneous regression was associated with only partial recovery of normal T cell 
phenotype, with patients who have undergone spontaneous CLL regression still exhibiting 
features such as CD4:CD8 inversion and high T cell PD-1 expression compared to age-
matched healthy controls. Likewise, although treatment with BCR signalling inhibitors such 
as ibrutinib result in improvement in T cell phenotype and function, most of the published 
studies do not include healthy controls as comparators (Long et al., 2017; Niemann et al., 
2016), and therefore it cannot be ascertained whether this represents a complete or partial 
normalisation. It is likely that the persistence of T cell dysfunction could be related to the 
persistence of CLL MRD, given the direct effect CLL cells exert on autologous T cells 
(Gorgun et al., 2005; Ramsay et al., 2008). It will be of interest to determine whether the 
eradication of MRD leads to normalisation of T cell phenotype and function.  
 Secondly, results from the spontaneous CLL regression study suggest a model in 
which clonal anergy, reduced CLL cell trafficking and possibly also the extrinsic apoptotic 
pathway co-operates in mediating disease regression. Further functional analyses, 
highlighted in sections 3.2.3 and 3.2.5, will be required to confirm this model. In addition, 
there may be other, as yet unidentified, features and potential mechanisms underpinning 
spontaneous regression in CLL. The transcriptomic analysis, currently underway, can 
potentially identify other pathways or processes that may be implicated in spontaneous CLL 
regression. Alternatively, there may be differences between spontaneous regression and 
non-regressing CLL cases at an epigenetic level that could potentially be investigated.  
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 Thirdly, TP53/ATM wild-type CLL exhibit variable sensitivity to ATR inhibition, with 
several cases displaying sensitivity levels that were similar to that of TP53/ATM defective 
CLL. It is likely that there are markers of sensitivity to ATR inhibition in CLL other than TP53 
or ATM defects. It will be of interest, for instance, to explore whether sensitivity of CLL cells 
to ATR inhibition correlate with the level of endogenous replication stress, as assessed by 
the level of 53BP1 bodies or by DNA fibre analysis, and whether this also correlate with the 
level of Myc expression. The effect of mutations such as those affecting ARID1A on 
sensitivity to ATR inhibition could also be explored. Moreover, the combination of ATR 
inhibition with other therapeutic modalities such as PARP inhibitor or venetoclax has not 
been investigated in the current study, and could be an important area for future work. 
Additionally, there are currently plans to initiate early-phase trials of AZD6738 on patients 
with TP53 or ATM defective CLL. It will be important to incorporate correlative biological 
studies within these trials. For instance, the mutant allele frequency of TP53 or ATM in these 
patients should be monitored during the course of AZD6738 treatment.  
 Finally, although my study confirmed the long-term independent prognostic 
significance of MRD in CLL, the significance of MRD with novel targeted therapies such as 
venetoclax is unclear. It will be of importance to assess the prognostic impact of MRD with 
each novel therapeutic agent, be it venetoclax or any other novel treatment that is being 











Appendix 1:     List of antibodies used for flow cytometry 
 
Antibody Clone Source Catalogue No Vol per sample/µl 
Bcl2 Bcl-2/100 BD Biosciences 563600 1 
CD10 HI10a BD Biosciences 332777 5 
CD184/CXCR4 12G5 BD Biosciences 562448 1 
CD185/CXCR5 RF8B2  BD Biosciences 563105 1 
CD19 SJ25C1 BD Biosciences 332780 5 
CD196/CCR6 11A9 BD Biosciences 562515 1 
CD197/CCR7 3D12 BD Biosciences 563449 1 
CD20 L27 BD Biosciences 641414 5 
CD27 M-T271 BD Biosciences 560609 1 
CD3 HIT3a Biolegend 300330 3 
CD305/LAIR1 DX26 BD Biosciences 550811 5 
CD38 HB7 BD Biosciences 335825 1 
CD4 SK3 BD Biosciences 332772 5 
CD43 1G10 BD Biosciences 563377 1 
CD45RA HI100 BD Biosciences 562298 5 
CD49d 44H6 Abd Serotec MCA923F 5 
CD5 L17F12 BD Biosciences 348810 1 
CD62L DREG-56 BD Biosciences 555544 5 
CD79b CB3-1 Coulter IM1612 5 
CD8 SK1  BD Biosciences 560179 5 
CD81 JS-81  BD Biosciences 551108 5 
CD95 DX2 BD Biosciences 562616 1 
IgD IA6-2 BD Biosciences 555779 5 
IgG G18-145 BD Biosciences 555786 5 
IgM G20-127 BD Biosciences 551062 7.5 
Ki-67 B56 BD Biosciences 558616 5 
Mcl-1 Y37  Abcam AB197035 1 
PD-1 EH12.2H7 Biolegend 329952 3 
ROR1 2A2 Miltenyi Biotec 130-098-320 5 




Appendix 2:     List of antibodies used for Western Blotting 
 
Antibody Source Catalogue No Animal Dilution Size/kDa 
Actin Sigma A2228 Mouse 1:50000 42 
ATM P-Ser1981 R&D AF1655 Rabbit 1:250 350 
ATM Total Abcam ab78 Mouse 1:1000 350 
ATR Total Santa Cruz sc-1887 Goat 1:1000 250 
Caspase 7 Cell Signaling 9494 Mouse 1:1000 35/30 
Chk1 P-Ser345 Cell Signaling 2341 Rabbit 1:1000 56 
Chk1 Total Santa Cruz sc-8408 Mouse 1:1000 56 
Chk2 P-Thr68 Cell Signaling 2661 Rabbit 1:1000 56 
Chk2 Total Cell Signaling sc-5278 Rabbit 1:1000 62 
Cyclin A Thermo Scientific MS-1061 Mouse 1:1000 60 
Erk P-Thr202/204 Cell Signaling 9101 Rabbit 1:1000 42/44 
Erk Total Cell Signaling 9102 Rabbit 1:1000 42/44 
p53 In-house n/a Mouse 1:10 53 
PARP Cell Signaling 9532 Rabbit 1:1000 116/89 
SMC1 Bethyl A300-055A Rabbit 1:1000 160 
Syk P-Tyr525/526 Cell Signaling 2711 Rabbit 1:1000 72 




Appendix 3:  List of antibodies used for immunofluorescence   
microscopy 
 
Antibody Source Catalogue No Animal Dilution 
γH2AX Millipore 05-636 Mouse 1:1000 
53BP1 Santa-Cruz sc-22760 Rabbit 1:1000 
Cyclin A Santa-Cruz sc-596-G Goat 1:50 
Lamin B Santa-Cruz sc-6216 Goat 1:200 
P-Histone H3 Ser-10 Cell Signaling 9701 Rabbit 1:100 
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Key Points
• ATR inhibition is synthetically
lethal to TP53- or ATM-
defective CLL cells.
• ATR targeting induces
selective cytotoxicity and
chemosensitization in TP53-
or ATM-defective CLL cells
in vitro and in vivo.
TP53 and ataxia telangiectasia mutated (ATM) defects are associated with genomic
instability, clonal evolution, and chemoresistance in chronic lymphocytic leukemia
(CLL). Currently, therapies capable of providing durable remissions in relapsed/
refractory TP53- or ATM-defective CLL are lacking. Ataxia telangiectasia and Rad3-
related (ATR) mediates response to replication stress, the absence of which leads to
collapse of stalled replication forks into chromatid fragments that require resolution
through the ATM/p53 pathway. Here, using AZD6738, a novel ATR kinase inhibitor, we
investigated ATR inhibition as a synthetically lethal strategy to target CLL cells with
TP53 or ATM defects. Irrespective of TP53 or ATM status, induction of CLL cell
proliferation upregulated ATR protein, which then became activated in response to
replication stress. In TP53- or ATM-defective CLL cells, inhibition of ATR signaling
by AZD6738 led to an accumulation of unrepaired DNA damage, which was carried
through into mitosis because of defective cell cycle checkpoints, resulting in cell death by mitotic catastrophe. Consequently,
AZD6738 was selectively cytotoxic to both TP53- and ATM-defective CLL cell lines and primary cells. This was confirmed in vivo
using primary xenograft models of TP53- or ATM-defective CLL, where treatment with AZD6738 resulted in decreased tumor load
and reduction in the proportion of CLL cells with such defects. Moreover, AZD6738 sensitized TP53- or ATM-defective primary
CLL cells to chemotherapy and ibrutinib. Our findings suggest that ATR is a promising therapeutic target for TP53- or ATM-
defective CLL that warrants clinical investigation. (Blood. 2016;127(5):582-595)
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Key Points
• MRD negativity is a predictor
for long-term progression-
free and overall survival
independent of the type
and line of therapy.
• MRD negativity confers the
greatest prognostic benefit
when achieved in the frontline
setting.
Minimal residual disease (MRD) negativity, defined as <1 chronic lymphocytic leukemia
(CLL) cell detectable per 10 000 leukocytes, has been shown to independently predict for
clinical outcome in patients receiving combination chemoimmunotherapy in the frontline
setting. However, the long-term prognostic value of MRD status in other therapeutic
settings remainsunclear.Here,we retrospectivelyanalyzed,withup to18years follow-up,
all patients at our institution who achieved at least a partial response (PR) with various
therapies between 1996 and 2007, and received a bone marrow MRD assessment at the
end of treatment according to the international harmonized approach. MRD negativity
correlated with both progression-free survival (PFS) and overall survival (OS) in-
dependent of the type and line of treatment, as well as known prognostic factors
including adverse cytogenetics. The greatest impact of achieving MRD negativity was
seen inpatients receiving frontline treatment,with 10-yearPFSof 65%vs10%and10-year
OS of 70% vs 30% for MRD-negative vs MRD-positive patients, respectively. Our results
demonstrate the long-term benefit of achieving MRD negativity, regardless of the therapeutic setting and treatment modality, and
support its use as a prognostic marker for long-term PFS and as a potential therapeutic goal in CLL. (Blood. 2016;128(24):2770-2773)
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Key Points
• USP7 is overexpressed and
regulates HRR in CLL cells.
• USP7 inhibition is selectively
cytotoxic to CLL cells
independently of ATM and
p53 and synergizes with
chemotherapy.
The role of deubiquitylase ubiquitin-specific protease 7 (USP7) in the regulation of the
p53-dependent DNA damage response (DDR) pathway is well established. Whereas
previous studies havemostly focused on themechanisms underlying howUSP7 directly
controls p53 stability, we recently showed that USP7 modulates the stability of the DNA
damage responsive E3 ubiquitin ligase RAD18. This suggests that targeting USP7 may
have therapeutic potential even in tumors with defective p53 or ibrutinib resistance. To
test this hypothesis, we studied the effect of USP7 inhibition in chronic lymphocytic
leukemia (CLL)where theataxia telangiectasiamutated (ATM)–p53pathway is inactivated
with relatively high frequency, leading to treatment resistance and poor clinical outcome.
We demonstrate that USP7 is upregulated in CLL cells, and its loss or inhibition disrupts
homologous recombination repair (HRR). Consequently, USP7 inhibition induces significant tumor-cell killing independently of
ATM and p53 through the accumulation of genotoxic levels of DNA damage. Moreover, USP7 inhibition sensitized p53-defective,
chemotherapy-resistant CLL cells to clinically achievable doses of HRR-inducing chemotherapeutic agents in vitro and in vivo in a
murine xenograft model. Together, these results identify USP7 as a promising therapeutic target for the treatment of hematological
malignancies with DDR defects, where ATM/p53-dependent apoptosis is compromised. (Blood. 2017;130(2):156-166)
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Dynamic changes in clonal cytogenetic architecture during 
progression of chronic lymphocytic leukemia in patients and 
patient-derived murine xenografts
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ABSTRACT
Subclonal heterogeneity and clonal selection influences disease progression 
in chronic lymphocytic leukemia (CLL). It is therefore important that therapeutic 
decisions are made based on an understanding of the CLL clonal architecture and its 
dynamics in individual patients. Identification of cytogenetic abnormalities by FISH 
remains the cornerstone of contemporary clinical practice and provides a simple 
means for prognostic stratification. Here, we demonstrate that multiplexed-FISH can 
enhance recognition of CLL subclonal repertoire and its dynamics during disease 
progression, both in patients and CLL patient-derived xenografts (PDX). We applied 
a combination of patient-specific FISH probes to 24 CLL cases before treatment and 
at relapse, and determined putative ancestral relationships between subpopulations 
with different cytogenetic features. We subsequently established 7 CLL PDX models 
in NOD/Shi-SCID/IL-2Rγctm1sug/Jic (NOG) mice. Application of multiplexed-FISH to 
these models demonstrated that all of the identified cytogenetic subpopulations 
had leukemia propagating activity and that changes in their representation during 
disease progression could be spontaneous, accelerated by treatment or treatment-
induced. We conclude that multiplexed-FISH in combination with PDX models have the 
potential to distinguish between spontaneous and treatment-induced clonal selection, 
and therefore provide a valuable tool for the pre-clinical evaluation of novel therapies.
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